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 i 
Abstract 
 
In the UK, more than 30 000 men are diagnosed annually with prostate cancer (PCa) and 
about 10 000 men die from it each year. Although several molecular markers have been 
associated with prostate cancer development and/ or progression, only few of them are used in 
diagnostic pathology. The current standard tests include serum PSA test, digital rectal 
examination and histology of prostate biopsy. Recently the PCA-3 molecular test was 
approved in the European Union, and it is now used in many laboratories. But these tests are 
not sufficient to molecularly characterise the behaviour of prostate cancer in many patients.  
 
Through extensive literature review, a panel of sixteen molecular markers were selected for 
further evaluation in prostate cancer cases. They included KLK2, KLK3, MCM2, MCM5, 
TP53, Bcl-2, CD44, CDH1, AURKA, AURKB, and AURKC; ESRα, ESRβ, AR, FASN, 
TMPRSS2: ERG, and TMPRSS2:ETV1. The aim was to examine the link between 
development/progression of prostate cancer and the production of diagnostic/prognostic 
biomarkers. An in vitro model consisting of PC-3 and PNTIA, MDA PCa 2b prostate cell 
lines were used to investigate the influence of steroid hormones on these biomarkers using 
molecular and proteomic techniques. All the three cell lines expressed AR, ESRα, ESRβ and 
PSA at mRNA and protein levels. The AR expressed in PC-3 and MDA PCA 2b cells was 60 
kDa while the PNT1A expressed a 90 kDa AR protein. The ESRβ was over-expressed in the 
MDA PCA 2b cells, and was also significantly up-regulated by 17β oestradiol treatment. At a 
concentration of 4.92 and 33.96µM 17β oestradiol inhibited the growth of 10 to 50% of 
PNT1A cell line and increased the doubling time three folds. Although the PC-3 cells 
expressed AR, it was still androgen insensitive and could not produce PSA in culture 
supernatants. AR and PSA were up-regulated in PNT1A cells in response to testosterone and 
dihydrotesterone treatment but were reduced in response to 17β oestradiol and Hydrocortisone 
treatment. All the molecular markers except the TMPRSS2: ERG and TMPRSS2:ETV1 were 
expressed in the cell lines. The MCM2 and MCM5 were not differentially expressed in 
response to hormonal treatment. However, the Aurora kinases A, B and C were up-regulated 
in response to steroid modulation. The KLK2 was only up-regulated by the androgens. Three 
candidate control genes: ABL1, GUS and G6PD were also evaluated in the cell lines and 
clinical samples; the ABL1 gene emerged as the most stably expressed house keeping gene 
and was subsequently used in the normalization of real time PCR assays (RQ-PCR). 
 
Analysis of the sixteen biomarkers in prostate tissues and exfoliated urine cells of benign, 
prostate cancer and non-involved cases (n = 228) showed that seven of the molecular markers 
were significantly strongly associated with prostate cancer progression (P<0.05). The Aurora 
 ii 
kinases A and B were consistently significantly over-expressed in prostate cancer cases. The 
CD44 was also over-expressed in prostate cancer, and was associated with Gleason score. The 
TMPRSS2 fusion genes were detected in 15.6% of the prostate cancer cases. The TP53 was 
also over-expressed in prostate cancer, and significantly associated with tumour grade. The 
ESRβ was over-expressed in prostate cancer, and was significantly associated with high 
tumour grade. This implied a proliferative role for the ESRβ in prostate cancer progression, 
because the ESRα was not differentially expressed among the sample groups. Concomitantly, 
the AR was also over-expressed in same pattern with ESRβ. The combination of these 
biomarkers: AR, ESRβ, CD44, TP53, TMPRSS2 fusion genes, AURKA and AURKB could 
molecularly characterise most prostate cancers. Therefore 2 sets of pentaplex RQ-PCR assays 
including ABL1 for normalization would provide a cost-effective, flexibly high throughput 
assay for molecular grading of tissue sections in diagnostic pathology. 
 
In addition to the gene expression studies, the genetic variation in KLK2 gene was further 
investigated by direct DNA sequencing, pyrosequencing and TaqMan allelic discrimination 
assay. Two SNPs in the gene were found significantly associated with prostate diseases. The 
T/T allele of rs198977 predicted the presence of prostate cancer at biopsy and was associated 
with high tumour grade. The A/A variant of rs2664155 was also significantly associated with 
the presence of benign nodular hyperplasia.  
 
The combination of gene expression and genetic variation using real time PCR applications 
would provide an accurate, reproducible and cheap method for molecular profiling of prostate 
cancer patients. 
   
An exploratory study of organic volatiles in urine of one prostate cancer patient and eight 
BPH patients using thermal desorption GC-MS showed that Ethanethiol, Dimethyl sulfide, 
Propyn-1-ol acetate, Nitro-2-propanone, pentane, Hydrazine and Nitrous oxide were 
differentially over-expressed in the prostate cancer patient compared to the benign cases. 
Further studies would be required to rule out possible contamination and drug metabolites. 
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Chapter 1- Introduction and Literature Review 
 
1.1 Introduction to Molecular basis of Prostate Cancer 
 
1.1.1 Prostate Cancer statistics 
Globally, the incidence of prostate cancer has been on the increase in recent years. The World 
health organization (WHO) reported a steady increase in prostate cancer incidence which 
resulted in 239,000 deaths in 1998, 255,000 deaths in 1999 and 269,000 deaths in 2002 
{WHO, 2004}.The mortality rate for prostate cancer, standardized to the world population, 
ranged from 1.3 to 22.1 per 100,000 men {Dijkman  & Debruyne ,1996}. 
 
It is estimated that 13% of all cancer deaths result from prostate cancer in most western 
countries {Droller, 1997}. The incidence and death rates for prostate cancer by country in the 
European Union in 1998 is shown in Table 1.1. In the United Kingdom, it is reported that 
more than 30,000 men are diagnosed annually with prostate cancer and about 10,000 men die 
from it each year; showing that prostate cancer has replaced lung cancer as the most common 
cancer in men {The Institute of Cancer Research UK, 2006}. In the United States of America, 
Prostate cancer (PCa) is the second most common type of malignancy and cause of death due 
to cancer among men {The Cancer Net, 2004}. In 2004 in the US, it was estimated that more 
than 200,000 males were diagnosed with prostate cancer, joining approximately 1.4 million 
men already diagnosed and about 30,000 died from it {Rodney et al, 2006}. For the Sub-
Saharan Africa in 2002, a total of 26,800 new cases were estimated, comprising 10.6% of 
cancers of men {Dean et al, 2006}. 
 
Most of the patients diagnosed with PCa have early-stage disease that is confined to the 
prostate gland, with less than 6% presenting with advanced, metastatic disease {Wilding et al, 
2006}. Prostate cancer incidence increases with age more rapidly than any other type of 
cancer; less than 1% of it are diagnosed in men below 50 years of age {Isaac, 1997}. Ninety-
five percent of cases of PCa are diagnosed in men between 45 and 89 years of age, with a 
median age at diagnosis of 72 years {Meikle & Smith, 1990}. It is often described as the 
disease of old age in men. However, it is presumed that PCa in younger men are often 
diagnosed in the metastatic stage at the time of clinical presentation, but there is no strong 
evidence to support this {Wilding et al, 2006}.  
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Table 1.1 Incidence and death rates from prostate cancer by country in EU in 1998. 
(Source: Health Evidence Network, WHO Regional office for Europe 2004). 
Population Cases Age-standardized 
Rate (per 100 
000) 
Deaths Age-standardized 
rate(per 100 000) 
European Union 144504 67.55 56035 25.55 
Austria 3667 89.49 1139 27.21 
Belgium 5566 95.34 1846 30.59 
Denmark 1627 53.89 1009 32.11 
Finland 3087 121.84 777 31.02 
France 28 135 87.10 9239 27.08 
Germany 30 911 77.21 11417 26.65 
Greece 2823 41.00 1208 17.22 
Ireland 1138 69.57 514 30.68 
Italy 19 258 52.78 7109 19.12 
Luxembourg 163 78.53 49 24.42 
The Netherlands 6594 85.74 2383 30.25 
Portugal 3210 55.23 1653 27.92 
Spain 10659 45.33 5742 23.76 
Sweden 6610 114.95 2480 37.71 
United 
Kingdom 
21056 60.97 9470 26.41 
 
Racially, blacks have the highest prostate cancer incidence rates in the world compared to 
whites and Asians for all age groups {Meikle & Smith. 1990}. The lowest incidence rates 
observed in Asian populations in their native countries seem to change following migration to 
western countries {Dijkman & Debruyne, 1996}. 
 
However, some reports have suggested under-estimation of prostate cancer incidence as the 
cause of purported low incidence rate in Asian population rather than a ‘true natural low 
incidence’ {Hong-Wen et al, 2005}. In the western countries, men of African descent still 
have the highest incidence and mortality rates in prostate cancer. The 5-year survival rate for 
prostate cancer diagnosed in the United States between 1974 and 1985 was 62% for African-
Americans as compared with 72% for American whites. The racial/ethnic variations on 
incidence, mortality and survival rates of PCa may be contingent on socioeconomic status and 
health care delivery systems rather than genetic causes {Freedland & Isaacs, 2005}.The risk 
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factors of prostate cancer, which include age, environment, race, diet, family history and life 
style, are discussed in Section 1.2.3. 
 
Even though the disease burden of prostate cancer is very significant in most countries, there 
are a few controversies in prostate cancer statistics. Prostate cancer incidence does not clearly 
correlate with its mortality. Until recent reports {Ling Zhang et al, 2009}, it was traditionally 
believed that the Chinese have the lowest prostate cancer incidence even though many cases 
were discovered at autopsy. But, the mortality to incidence rate (MR/IR) was 0.63 in the 
Chinese population, much higher than that of North America (MR/IR = 0.13) that has a 
higher incidence rate. Diagnostic strategy in China was deemed inadequate, many cases 
presented late at advanced stage and some died of it without diagnosis {Ling Zhang et al, 
2009}. Another factor is that not all patients with prostate cancer die from it nor suffer 
symptoms from it during their life time. Some are not even diagnosed except during autopsy. 
But incidence rates are calculated from the numbers of patients who have a histologic 
diagnosis of the disease with or without any clinical or biologic significance {Meikle & 
Smith, 1990}. The age specific prevalence of histological prostate cancer, that is PCa 
diagnosed at autopsy and biopsy (accidental during TRUS resection), is uniform world-wide, 
and this frequency is many times greater than would be expected from the incidence and 
mortality of clinical prostate cancer {Dijkman & Debruyne, 1996}.  
 
Screening and diagnostic criteria also vary among countries. In some countries, annual mass 
screening of men aged 50 years and above has been introduced; which is capable of detecting 
more cases of PCa (increase incidence rate up to 22%) {Andriole  et al, 2009}. It is advocated 
in the United States that men with a positive family history of prostate cancer, after the age of 
40 years, should undergo a digital rectal examination (DRE) and PSA monitoring yearly 
{Dijkman & Debruyne, 1996}. Results of the European Randomized study of Screening for 
Prostate Cancer (the largest screening of its kind) showed that mass screening using PSA test 
and DRE, followed by prostate biopsy for men with PSA > 3.0ng/ml yielded a 20% reduction 
in mortality from PCa (http://www.erspc-media.org/release090318.php ). This result 
underpins the rationale why some countries are more aggressive in screening than others, 
leading to differential detection rates among countries. Furthermore, as the life expectancy of 
the male population increases over time, the incidence of clinical prostate cancer will also 
increase {Isaac. 1997}. It has been argued that the increase in incidence of PCa in many 
countries could be attributed to the availability of more frequent and better diagnostic tests, an 
aging population and increased awareness for both patients and physicians, and not 
necessarily a true rise in incidence {Andriole  et al, 2009}. Another aspect of the controversy 
is the difficulty in accurately reporting mortality rates due to PCa because some prostatic 
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cancer patients die from other causes of death. Prostate cancer is a disease of old men, more 
of whom die with the disease than from the disease. This might explain the preference of 
incidence rate to mortality rates in reporting PCa cases. 
 
1.1.2 Cellular and Molecular Basis of Cancer 
 
The term cancer is synonymous with neoplasm and tumour. Human cancer is not a single 
disease rather a myriad collection of diseases with as many different manifestations as there 
are tissues and cell types in the body, involving numerous internal and /or external causative 
agents, and various disease mechanisms {Coleman  & Tsongalis, 2002}. Willis (1967) 
defined a neoplasm as a mass, the growth of which is incoordinate with the surrounding 
normal tissues and that persists in the absence of the inciting stimulus {McKinnell RG, 
2006}. At cellular level, neoplasm is characterized by unregulated cell growth, impaired 
differentiation, invasiveness (increased cell mobility and loss of contact inhibition) and 
metastatic potential (ability to spread to distant organs). These biological traits of neoplastic 
cells enable them to exert nutritional, spatial, signal and mobility pressures on normal 
neighbouring cells. The neoplastic cells also, in many cases, form structures and patterns that 
morphologically distinguish them from normal cells. The transformation process is accrual. 
 
Neoplasms can be benign or malignant. Depending on cell and tissue of origin, the main 
classes (nomenclature) of neoplasm are:  
i. Carcinoma which is the malignant form of cancer arising from the skin and epithelial 
lining of internal organs and surfaces. The benign tumours of epithelial origin have 
various names (depending on basic cell type) such as papilloma (from skin and 
urinary bladder), adenoma (solid epithelial organs, epithelia of gonads and bronchial 
epithelium), melanoma (skin pigments) and teratoma (germ cells);  
ii. Sarcoma, which is malignant cancer of the mesenchyme (bone, fibrous tissue, fat, 
cartilage, muscle, blood vessels and lymph vessels) and shades of names for the 
benign forms (Osteoma, Fibroma, Lipoma, Chondroma, Leiomyoma and 
Haemangioma); 
iii. Blastoma for the malignant cancers of the nervous system (neuroblastoma for nerve 
cells, Astrocytoma for astrocytes and Oligodendrocytoma for oligodendrocytes) while 
benign forms for meningeal cells are called Meningioma. 
iv. Leukaemia for white blood cells, Erythroleukaemia for red blood cells, Lymphoma for 
the lymph nodes and reticulo-endothelial system. Cancer of the embryonic type 
tissues are known as teratocarcinoma {Franks & Teich, 2001}. 
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At molecular level, it is conceived that the accumulation of multiple mutations within genes 
of a single cell drive neoplastic transformation leading to cancer development {Coleman & 
Tsongalis, 2002}.Several agents cause these mutations including viruses, chemicals 
(carcinogens); radiations, bacterial and fungal activities, and the ageing process. In its 
simplest form, the human cancer is a genetic corruption of a normal cell. The multiple 
transforming mutations confer selective growth advantage to a cell by affecting three major 
classes of genes: proto-oncogenes, tumour-suppressor genes and DNA repair genes. These 
classes of genes are altered (activated and/ or inactivated) by a series of cellular and 
molecular events which include deletions, insertions, translocations (rearrangements), 
mutations, loss of heterozygosity, amplification (increase copy number), epigenetic changes 
and genomic instability (chromosomal instability and microsatellite instability){Lengaur  et 
al, 1999}. These events result in aberrant genes encoding for oncoproteins and/ or abnormally 
expressed normal proteins, which drive neoplastic transformation; and the inability of the 
repair system to safeguard the genomic DNA. Therefore, the development of human cancers 
almost always includes certain patterns of abnormality: i) autonomy of cell proliferation-
through loss of the normal extracellular regulatory activity and acquisition of dysregulated 
internal drive for proliferation, ii) escape from apoptosis, iii) evasion of senescence and iv) 
gain of angiogenesis {Hanahan & Weinberg, 2000; Wylie, 2008}. 
 
Oncogenes are activated (frequently mutated) alleles of normally functioning wild-type genes 
(proto-oncogenes) that function in cell-cycle progression and cellular proliferation. Examples 
of oncogenes are the c-myc family, c-erbB family, the c-ras family, the c-abl; growth factors 
and their receptors: PDGF family, EGF family, Wnt family, the interleukins and the 
serine/tyrosine/threonine kinases (c-raf family, Protein Kinase C family, akt). Activated or 
mutated proto-oncogenes promote unregulated cell-cycle progression and cell proliferation, 
leading to cancer development {Coleman & Tsongalis, 2002}.  
 
The tumour- suppressor genes encode proteins that inhibit, constrain or suppress cell 
proliferation. The tumour-suppressor (T-S) proteins function in parallel with the protein 
products of proto-oncogenes, but work instead to suppress cell proliferation through the 
regulation of signal transduction and nuclear transcription. Mutations in the T-S proteins 
(Table 1.2) lead to altered cellular morphology, loss of normal intracellular-signaling 
pathways and loss of normal intercellular interactions, all of which are features of neoplastic 
cells {Weinberg, 1991}. The loss of function of T-S proteins is as important as the gain in 
function of proto-oncogenes in the development of human cancers {Levine, 1993}.  
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Normal cells have the ability to repair damaged DNA; a process that helps to prevent 
permanent mutations during DNA replication. DNA repair systems involve four main 
processes: 
 
i) recognition and removal of altered portion of a damaged DNA by DNA repair nucleases, ii) 
binding of DNA Polymerase to the 3’-OH end of the cut DNA to fill the gap by making a 
complementary copy of the information stored in the residual template strand, iii) proof 
reading of new DNA strands during replication by the 3’-5’ exonuclease activity of DNA 
Polymerase and iv) post replication or mismatch repair {Coleman & Tsongalis, 2002}. 
Alterations of any these DNA –repair processes can result in a large increase in spontaneous 
mutations and predisposition to cancer development. Therefore, cancer cells may have a 
partially weakened DNA repair system. This phenomenon has become the basis of a new 
class of anti-tumour agents, which cause ‘synthetic lethality’ by destroying alternative DNA 
repair systems in cancer cells, predisposing them to death {Kaelin, 2005}. Just at the time of 
writing this thesis, the results were reported of phase 1 clinical trial of a new drug called 
Olaparib (AZD2281), which was designed based on synthetic lethality to inhibit the 
Polyadenosine triphosphate ribose polymerase (PARP) in prostate, breast and ovarian cancer 
patients with BRCA 1 or BCRA 2 mutations (DNA repair defect) {Fong et al, 2009}. The 
PARP1 enzyme plays a key role in the repair of DNA single-strand breaks through the repair 
of base excisions. The inhibition of PARPs leads to the accumulation of DNA single-strand 
breaks, which can lead to DNA double-strand breaks at replication forks. Normally, these 
breaks are repaired by means of the error free homologous-recombination double-stranded 
DNA repair pathway, key components of which are the tumor- 
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Table 1.2 Putative Tumour-Suppressor genes 
{Coleman & Tsongalis, 2002} 
Gene Chromosomal 
Location 
Inherited Cancer Sporadic Cancer 
Rb1 13q14 Retinoblastoma Retinoblastoma, 
sarcomas,bladder,breast,oesophageal, and 
lung 
p53 17p13 Li-Fraumeni cancer 
family syndrome 
Bladder, breast, colorectal, oesophagus, 
liver, lung and ovarian carcinomas, brain 
tumours, sarcomas, lymphomas, and 
leukaemias. 
DCC 18q21 - Colorectal carcinomas 
MCC 5q21 - Colorectal carcinomas 
APC 5q21 Familial 
adenomatous 
polyposis 
Colorectal, stomach and pancreatic 
carcinomas. 
WT1 11p13 Wilms tumour Wilms tumour 
WT2 11p15 Weidemann-
Beckwith syndrome 
Renal rhabdoid tumours, embryonal 
rhabdomyosarcoma 
WT3 16q Wilms tumour - 
NF1 17q11 Neurofibromatosis 
type 1 
Colon carcinoma and Astrocytoma 
NF2 22q12 Neurofibromatosis 
type 2 
Schwannoma and Meningioma 
VHL 3p25 von Hippel-Lindau 
syndrome 
Renal cell carcinomas 
MEN1 11q23 Multiple endocrine 
neoplasia type 1 
Endocrine tumours such as pancreatic 
adenomas 
Nm23 17q21 - Melanoma, breast, colorectal, prostate, 
Meningioma, others 
MTS1 9p21 Melanoma Melanoma, brain tumours, Leukamias, 
sarcoma, bladder, breast kidney, lung and 
ovarian cancers. 
 
suppressor proteins BRCA1 and BRCA2. A germ-line mutation in one BRCA1 or BRCA2 
allele is associated with a high risk of the development of a number of cancers, including 
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breast, ovarian, and prostate cancer. It is reported that 2% of men with early onset prostate 
cancer harbour germ line mutation in BRCA2 gene {Edwards et al, 2003}. Cells carrying one 
functional copy of the BRCA gene can loose the wild type due to second hit mutation 
(Knudson theory of 2 hits) resulting in deficient homologous recombination DNA repair, 
which causes the genetic aberrations that drive carcinogenesis. This leads to the emergence of 
tumour cells that carry DNA repair defects which are not shared by normal cells of the 
patient. This tumour specific defect can be exploited using PARP inhibitors (Olaparib) to 
induce selective tumour cytotoxicity, sparing normal cells {Fong  et al, 2009}. 
 
1.1.3 Cancer Progression 
Cancer development is a multi-step process through which cells acquire increasingly 
abnormal proliferative and invasive behaviours. The main trigger for tumourigenesis is 
mutation. It is now known that neoplastic cells also acquire multiple somatic mutations, 
which result in genetic variations and/ or abnormal gene expressions that enhance their ability 
to invade (migrate to) neighbouring normal tissues. This involves a clonal expansion of 
transformed neoplastic cells in a process of natural selection {Isaac JT, 1997}. Neoplastic 
cells often have a growth advantage that allows them to proliferate, loose contact inhibition 
and increase mobility; and invade adjacent tissues. In some organs, cancer progression is 
predictive, for example, in the colon, the transition from benign to malignant occurs in 
discernible stages: benign adenoma, carcinoma in-situ, invasive carcinoma; local and distant 
metastasis. Such progression is characterized by accumulation of multiple genetic alterations 
in the affected cells. However, in many others, the progression is unpredictable, for example, 
in the prostate gland, the development of pre-malignant lesions, collectively known as 
prostatic intraepithelial neoplasia (PIN) does not, in all cases, progress predictably to 
malignant lesions {Bostwick, 1996; Isaac, 1997}. Invasiveness describes the ability of cancer 
cells to penetrate basement membrane of underlying tissue stroma. This is caused by 
increased mobility of cancer cells. This is different from metastasis, which describes the 
spread of cancer cells to near and distant organs via blood and lymph vessels and neural 
networks. Both characteristics are indicators of aggressiveness of cancer cells. Invasive 
cancer cells require supply of nutrients, which often result from formation of new blood 
vessels (angiogenesis). 
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In cancer progression, specific genetic alterations have been shown to correlate with well-
defined histopathologic stages of tumour development {Fearon & Vogelstein, 1990}. Figure 
1.1 shows the morphologic continuum from normal prostatic epithelium through increasing 
grades of prostatic intraepithelial neoplasia to early invasive carcinoma, according to the 
disease-continuum concept {Bostwick, 1996}. These morphologic changes correlate, in many 
cases, with the genetic variations shown in Figure 1.2. In many cases of prostatic biopsy, 
multi-foci of different lesions (benign and malignant) often co-exist in the same sample. This 
heterogeneous phenotype corroborates with the notion that the development of a malignant 
prostate cancer from normal prostatic epithelium requires multiple transformation events 
{Isaac, 1997; Montironi et al, 2006}. Due to the multi-step nature of prostatic carcinogenesis, 
cells that have undergone some but not all of the transformation steps are present in pockets 
within the prostates of aging men, and the clonal expansion of these partially transformed 
cells produces morphologically detectable premalignant lesions in the gland {Bostwick, 1996; 
Isaac, 1997}.Molecularly, there is a prominent clustering of changes in expression for many 
biomarkers between benign epithelium and high grade PIN, indicating that this is an 
important threshold for carcinogenesis.  
 
 
Figure 1.1 Morphologic continuums for Prostate cancer progression. This illustrates changes 
from normal prostatic epithelium through increasing grades of prostatic intraepithelial 
neoplasia to early invasive carcinoma, according to the disease-continuum concept 
{Bostwick, 1996}. 
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Figure 1.2 Genetic changes associated with prostate cancer progression. Some biomarkers 
show upregulation or gain (indicated by + sign), whereas others are downregulated or lost (-
sign). There is a prominent clustering of changes in expression for many biomarkers between 
benign epithelium and high grade PIN, indicating that this is an important threshold for 
carcinogenesis {Bostwick, 1996}. 
 
Another study {Mosquera et al, 2007} showed a correlation between gene rearrangements 
(TMPRSS2-ERG fusion on chromosome 21) and morphologic phenotypes of prostate cancer 
progression (high grade tumour). Five morphological features were associated with 
TMPRSS2–ERG fusion prostate cancer: blue-tinged mucin, cribriform growth pattern, 
macronucleoli, intraductal tumour spread, and signet-ring cell features. It is therefore believed 
that the biological effects of TMPRSS2–ERG over expression may drive pathways that favour 
these common morphological features {Mosquera et al, 2007}. In breast and colon cancers, 
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microsatellite instability from the BRCA1 gene mutations is known to drive cancer 
progression, inducing morphologically detectable lesions. 
 
1.1.4 Pathways and Patterns in Carcinogenesis 
 
One of the hallmarks of cancer development and progression is that neoplastic cells do not 
respond to normal regulatory pathways. Often regulatory networks are disrupted in tumours, 
through inactivating mutations and epigenetic suppression, by activating mutations, gene 
amplification and translocations, or as a result of alterations in micro RNA expression. The 
escape from normal regulation alters cell cycle and mitosis in neoplastic cells, causing 
abnormal patterns in cell proliferation, apoptosis, senescence and angiogenesis {Hanahan and 
Weinberg, 2000}. Implicitly, not all cells of the cancer population are ‘exempt’ from normal 
regulation, however, the ‘cancer stem cells’ are elusive from normal regulation as they 
provide the continuity in clonal expansion of neoplastic cells. Secondly, cancer cells do not 
necessarily cycle faster than normal cells; in most cases the difference is that many of the 
cancer cells are cycling at the same time compared to the normal population {McKinnell et 
al, 2006}. Figure 1.3 shows the cell cycle and the key regulators (the cyclins, cyclin-
dependent kinases (CDKs) and their inhibitors in regulating the cell cycle, {Kumar et al, 
2009}. Defects in these pathways (regulatory networks) may be genetic (directly affecting 
DNA sequence), or epigenetic (through alteration in gene transcript without change in DNA 
sequence), features of which are abundant in many human cancers. The key regulatory 
pathways and events in cell division cycles are as follows {Stein & Pardee, 2004; Wylie, 
2008}: 
 
i) Cyclins and cyclin-dependent kinases (CDKs) form the basic clockwork of the cycle 
{Hartwell & Kastan, 1994; Sherr CJ, 1996}, (Figure 1.3). The cell cycle is driven by a series 
of transient complexes each involving a cyclin protein, whose concentration varies with cell 
cycle phase, and CDKs, which are present throughout the cycle. The activity of CDKs is 
regulated by the cyclin partner, through a series of mutual phosphorylation reactions (a well 
defined example is Cyclin B and CDK1). The Cyclin B-CDK1 complex appears in G2, peaks 
in early metaphase and is destroyed in anaphase. On binding cyclin B, the ATP-binding site 
of CDK1 is blocked by phosphorylation. To initiate cell division (mitosis), the phosphate (P) 
must be removed. This is done by the phosphatase, CDC25, which is the critical trigger for 
mitosis. It opens the CDK1 active site and permits several simultaneous phosphorylation 
events responsible for nuclear envelope breakdown, chromosome condensation, spindle- 
 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
12 
 
Figure 1.3 Regulators of cell cycle. This illustrates the role of cyclins A, B and E (classes of 
cyclins), cyclin-dependent kinases (CDKs), and inhibitors, in regulating the cell cycle 
{Kumar et al, 2009}. 
 
Formation and fragmentation of the endoplasmic reticulum (ER) and Golgi appartus. A final 
substrate of CDK1 is the anaphase promoting complex, often called the cyclosome (APC/C), 
which, on activation, behaves as a ubiquitin ligase and targets cyclin B for degradation in the 
proteasome. Very similar transient complexes form between members of the cyclin and CDK 
families at other phases of the cell cycle: cyclins D1, 2 and 3 with CDK4 and CDK6 in G1, 
cyclin E with CDK2 at the G1-S transition, and cyclin A with CDK2 through S phase into G2 
{Pardee, 1989}. Other kinases are also known to involve in driving the cell cycle: the Aurora 
Kinases (A, B and C) are involved in spindle and centriole function events {Scharer CD, et al, 
2008}. 
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ii) The retinoblastoma protein Rb is an important substrate of the cyclin D/ CDK4 
complex {Stein & Pardee, 2004}:  The Rb is a nuclear protein which inhibits replication 
through sequestration of the transcription factor E2F-1 in a deep intra-molecular pocket. This 
binding (Rb/E2F-1) promotes chromatin condensation to a transcriptionally silent 
configuration. Cyclin D/CDK4 complexes hyperphosphorylate Rb, disrupting the binding to 
E2F-1. The activated E2F-1, in turn, activates transcription of a number of genes required for 
S phase entry, including the critically important oncogenes c-MYC {Kumar V et al, 2009} . 
The G1-S interface is very important in cell cycle because at that point the cell commits either 
to replication of the genome or to quiescence or differentiation or both {Sherr, 1996; Shapiro 
& Harper, 1999}. It is known as the G1 checkpoint. The Rb gene is mutated in a variety of 
cancers including inherited retinoblastoma and sporadic retinoblastoma and sarcomas. 
 
iii) APC/C regulates the exit from mitosis (Figures 1.4 and 1.5) {Stein & Pardee, 2004; 
Blow  & Tanaka, 2005}: During formation of the spindle, microtubules are polymerised from 
centres around the centrioles, radiating across the cell to anchor against the polar cell 
membrane, microtubules arriving from the opposite centriole, or the specialized region of the 
chromosomes called the kinetochore. This is a little platform, mounted on the pole-wards face 
of the centrosome (Figure 1.6), which captures the microtubules as they advance across the 
cell. The capacity of the microtubules to extend and shorten by alternating polymerisation and 
depolymerisation is called dynamic instability. Through a combination of the dynamic 
instability of microtubules and the action of molecular motors (kinesin-and dynein- like 
motors), the chromosomes gather at the cellular equator during metaphase (Figure 1.5). 
Remarkably, further progression through mitosis halts until the last kinetochore has achieved 
attachment to a microtubule (by the delay of APC/C activation). This is known as the 
Metaphase checkpoint. At that point, through molecular signals from kinetochore proteins 
(MAD2, Bub1, BubR1) that permit release of a critical cofactor (cdc20), the ubiquitin ligase 
activity of the anaphase promoting complex (APC/C) is switched on. 
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Figure 1.4 Overview of cell cycle licensing and mitosis. The MCMs and Cohesion  
proteins are very vital in marking DNA for replication and chromosomal segregation during 
mitosis {Blow & Tanaka, 2005}. G= Gap, S= synthesis, 
M=mitosis. 
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Figure 1.5 Mitosis in animal cells. During interphase (G1-S-G2 phases of cell cycle) DNA is 
doubled in preparation for cell division. During the prophase, the nuclear envelope breaks 
down and a spindle forms between the centrioles.  
https:/.../Katie+Mitosis+and+Meiosis+Lab. 
 
Cyclin B is destroyed, leading to restoration of the nuclear envelope and chromatin 
decondensation. APC/C also digests a protease inhibitor called securin, releasing its partner, a 
protease called separase, to the proteolysis of a family of proteins called cohesins (members 
of the family include Smc1, Smc3, Scc1 and Scc3) (see Figure 1.4). The cohesins are 
responsible for binding the chromatids together. Their degradation permits chromatids to 
separate and anaphase to proceed. 
 
iv) MYC is an important regulator of the cell cycle {Kumar V et al, 2009}. Myc proteins 
are transcription factors that ultimately promote synthesis of; a) the proteins required for 
DNA synthesis (examples: DNA polymerase, dihydrofolate reductase (DHFR), thymidine 
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kinase and origin of replication complex 1 (ORC1) and Minichromosome maintenance 
complex proteins (MCM 2-7), proteins of the DNA replication complex), b) proteins required 
for cell cycle progression (cyclins E and A, cdk2) and c) proteins that cause cycle arrest or 
apoptosis (p73 and p14ARF). 
 
v) DNA replicates only once per cell cycle {Stein & Pardee, 2004}. Although thousands of 
replication forks are active throughout S-phase, each DNA sequence replicates only once in 
each S-phase {Blow & Tanaka, 2005}. As G1 proceeds, replication origins recruit several 
proteins from the MCM family. These are required to license DNA for replication (Figure 
1.4), and their loading on to chromatin is facilitated by cyclin A {Tye, 1999}. They are 
displaced by the replication fork in S phase and destroyed by proteolysis, so they are not re-
instated on the newly replicated DNA. On inception of the next S-phase, however, perhaps 
because of nuclear envelope breakdown in the intervening mitosis, MCM proteins from the 
cytoplasm reappear in the nucleus, so re-licensing it for replication {Stoeber  et al, 2001}. 
 
vi) The cell cycle includes many different checkpoints {Shapiro & Harper, 1999}. Notable 
checkpoints in the cell cycle are the G1/S checkpoint, the G2/M checkpoint and the 
metaphase checkpoint. They form part of a physiological regulatory system designed to 
restrain replication, or arrest it temporarily, perhaps to permit repair of damage. Cancer cells 
usually by-pass these checkpoints as they escape regulation. Several small proteins bind to 
and inhibit the cyclin-cdk complexes to enforce these checkpoints. Some of the inhibitors 
include p21, p27 and p57, some of which are activated by cytokines, but others are 
transcribed in response to DNA damage or hypoxia through the activation of the 
nucleoprotein p53. Incompletely replicated or damaged DNA arrests cell cycle progression at 
a further checkpoint just before entry to mitosis (the G2/M checkpoint). Here the signal is 
processed through the kinases CHK1 and 2, which inhibit the phosphatase cdc25.  
 
vii) P53 causes cycle arrest at the G1/S checkpoint {Stein & Pardee, 2004}. The tumour 
suppressor protein, p53 is one of the most important regulators of the G1/S checkpoint. Its 
concentration in the nucleus is usually low, but is the result of a fine balance between 
continuous transcription, translation and nuclear import on one hand, and rapid proteolysis on 
the other. The balance is sustained through a negative feedback loop involving the protein 
MDM2- a transactivation product of p53 itself that binds to p53 and facilitates proteolysis. 
P53 stability can therefore be very rapidly altered, through modification of its binding to 
MDM2, and this can be achieved by p53 phosphorylation at the appropriate sites. DNA 
damage –particularly the formation of double-strand breaks-activates a protein kinase called 
ATM (because the inherited disorder Ataxia Telangiectasia results from its mutation) that 
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effects this phosphorylation. By this means, the concentration of p53 in the nucleus can 
increase many fold within a few minutes of DNA injury, thereby stopping G1-S phase 
progression to allow for DNA repair or apoptosis. A slower but probably longer-lasting 
dissociation of p53 and MDM2 is effected by production of the protein p14 ARF, which is 
translated from mRNA transcribed from the INK4 gene, but using an alternative reading 
frame. 
 
viii) Entry into the cell cycle is initiated by extracellular signals {Hanahan & Weinberg, 
2000}. Most cells in complex tissues are out of cycle altogether. To initiate replication, 
special signals are required, often specific for cell type and usually extracellular. These 
signalling molecules are often embedded in extracellular matrix (ECM) (having been secreted 
there by other cells) or may be on the surface of neighbouring cells. Examples of such growth 
factors are shown in Table 1.3. The receptor for many of these possess tyrosine kinase 
domains (often more than one) in their cytosolic moieties, that can thus relay complex 
multiple signals to the cell interior (Figure 1.6) through phosphorylation of tyrosine, serine or 
threonine amino acid residues of substrates {Coleman  & Tsongalis, 2002}. It is important to 
note that some of these growth factors have oncogenic potential. 
 
Table 1.3 Growth factors involved in cellular regulation {Coleman & Tsongalis, 2002} 
Bone morphogenetic proteins (BMPs) 
Epidermal growth factor (EGF) 
Erythropoietin (EPO) 
Fibroblast growth factor (FGF) 
Granulocyte-colony stimulating factor (G-CSF)  
Granulocyte-macrophage colony stimulating factor (GM- CSF) 
Growth differentiation factor-9 (GDF9) 
Hepatocyte growth factor (HGF) 
Insulin-like growth factor (IGF) 
Myostatin (GDF-8) 
Nerve growth factor (NGF) and other neurotrophins (NT-3 and BDNF) 
Platelet-derived growth factor (PDGF) 
Thrombopoietin (TPO)  
Transforming growth factor alpha (TGF-α)  
Transforming growth factor alpha (TGF-β) 
Vascular endothelial growth factor (VEGF)  
Wnt family (Wnt-1 and Wnt-3) 
Interleukins (IL-2 and IL-3) 
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ix) Ras activation is critical in pathway connecting receptor tyrosine kinases to 
reprogrammation of transcription {Stein & Pardee, 2004}. Generally, signal transducing 
proteins are widely grouped into two categories: a) non-receptor associated tyrosine kinases, 
for example c-abl (Abelson gene), cytoplasmic associated serine and threonine kinases; and 
b) receptor -associated GTP (guanidine triphosphate)-binding proteins (which include c-ras 
proteins, named after its first discovery in rat sarcoma). The mechanism of action of c-ras 
(which has three members: H-ras, K-ras and N-ras) is shown in Figure 1.7 {Coleman & 
Tsongalis, 2002}. The c-ras is active when complexed with GTP, and this interaction is 
facilitated by guanidine nucleotide-releasing or exchange factors (GEFs) in response to 
growth factor stimulation. 
 
 
Figure 1.6 A schematic representation of transmembrane tyrosine kinase showing the 
extracellular domain, transmembrane domain and cytosolic domains. 
 
The ras-GTP undergoes a conformational change that permits it to signal to the 
serine/threonine kinase, RAF and almost immediately activates its own GTPase function and 
hydrolyses the bound GTP to GDP. GTP hydrolysis is also stimulated by GTPase activating 
proteins (GAPs), such as neurofibromin. Downstream from RAF lies a cascade of 
phosphokinases (MEK and MAPK), whose ultimate substrate is the transcription factor AP-1, 
a heterodimer of two peptides, FOS and JUN. Phosphorylation enhances the activity of AP-1 
and turns on the transcription of many immediate early response genes, including the 
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transcription factor, MYC. Mutated c-ras protein (as seen in cancer) has a decreased ability to 
hydrolyze GTP, or an increased rate of exchange of bound GDP for free GTP. By either 
mechanism, the result is increased activated c-ras. 
 
 
 
Figure 1.7 c-ras mechanism of action. The c-ras is active when complexed with GTP, and this 
interaction is facilitated by guanidine nucleotide-releasing or exchange factors (GEFs) in 
response to growth factor stimulation. 
 
X) The P13 kinase pathway influences many growth-related cell functions {Kumar et al, 
2009}. P13 is a lipid kinase that is activated by signals transmitted by many transmembrane 
receptors with protein kinase cytosolic domains (see Table 1.3 and Figure 1.6). This 
activation leads to production from membrane inositol of the inositol phospholipids: Ptdlns 
(3, 4, 5) P3 (PIP3) and Ptdlns (3, 4) P2. These in turn signal to a constitutive membrane 
threonine kinase, PDK-1, and a cytosolic protein kinase called AKT. This leads to the 
formation of an AKT/PDK-1 complex that phosphorylates many highly significant substrates 
including TOR (target of the drug rapamycin), S6kinase (an activator of protein translation) 
and protein kinase C (Figure 1.8). Other substrates are inhibited, including p21 (so releasing 
cells from G1 arrest), GSK3, which targets cyclin D for proteolysis and Bad, a pro-apoptotic 
protein. The activity of the AKT signalling pathway is inhibited through removal of the 
phosphate groups from the PIP3 by the PTEN (Phosphatase and Tensin homolog, which is 
same as 3’ phosphoinositide phosphatase). The PTEN is one of the most commonly lost 
tumour suppressor genes in human cancers including prostate cancer, endometrial cancer and 
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Glioblastoma. PTEN mutations cause a variety of inherited predispositions to all sorts of 
human cancers. 
 
 
Figure 1.8 The P13K/ AKT signalling pathway. The AKT/PDK-1 complex phosphorylates 
many highly significant substrates including TOR (target of the drug rapamycin), S6kinase 
(an activator of protein translation) and protein kinase C. Other substrates are inhibited, 
including p21 (so releasing cells from G1 arrest), GSK3, which targets cyclin D for 
proteolysis and Bad, a pro-apoptotic protein. PTEN, commonly mutated in many cancers, 
inhibit the AKT pathway. http://www.cellsignal.com/pathways/akt-signaling.jsp. 
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X1) The Wnt pathway also connects external signals related to cell-to-cell contact with 
reprogrammation of transcription {Hanahan and Weinberg, 2000}. Wnt is a paracrine 
growth factor. When Wnt is bound to its receptor (called frizzled), the latter releases a 
cytoplasmic protein that inhibits the phosphokinase activity of GSK3. Under basal conditions, 
GSK3 forms a protein complex with the scaffold protein axin and the large regulatory protein 
APC (Adenomatous Polyposis Coli, the product of this tumour suppressor gene is mutated in 
most colon cancers). The complex (with APC in particular and the GSK3 kinase active) has 
the ability to entrap, phosphorylates and targets for proteasomal destruction of a substrate 
called β -catenin. The β -catenin can shuttle from the cell membrane, where it docks on the 
cytosolic domain of the cell-cell adherence protein E-cadherin (which is differentially 
expressed in prostate cancer), to the nucleus where it pairs with TCF (T cell factor) to form a 
heterodimeric transcription factor (Figure 1.9). Amongst the genes induced by β-catenin/TCF 
transcription factor is the MYC. Therefore, the Wnt stimulations lead to cell cycle activation 
provided the levels of APC do not rise at the same time. 
 
XII) The notch pathway also mediates cell to cell interaction {Kumar et al, 2009} (Figure 
1.10). Notch is a receptor for signals delivered by cell-bound ligands (Delta-like, serrated and 
jagged). When activated by ligand binding, the intracytoplasmic domain of notch is cleaved 
by a γ-secretase and becomes a nuclear –seeking transcription factor. Although the biology of 
notch is varied, it is essential for many developmental processes, notably the development of 
vascular networks. 
 
XIII) The process that regulates telomere stability is frequently abnormal in cancers 
{Bodnar AG et al, 1998}. Telomeric DNA consists of repetitive TTAGGG sequences, 
without which the chromosome ends are unprotected from nuclease damage and the 
chromosomes themselves become unstable. Under normal conditions in most cells of most 
human tissues, one TTAGGG unit is lost from each DNA end in each cell replicative cycle. 
Certain cells, including stem cells, possess an enzyme called telomerase, which catalyses the 
extension of the telomeric tandem repeats. Telomerase is a protein complex that consists of a 
rate-limiting reverse transcriptase catalytic subunit called hTERT and an RNA template. 
Tumour cell populations often show reduced telomere length relative to normal tissues, 
together with activation of telomerase. The hTERT can be used to immortalize pre-senescent 
cells. 
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Figure 1.9 The Wnt/β-catenin signalling pathway. The β -catenin can shuttle from the cell 
membrane, where it docks on the cytosolic domain of the cell-cell adherence protein E-
cadherin, to the nucleus where it pairs with TCF (T cell factor) to form a heterodimeric 
transcription factor.  http://www.cellsignal.com/pathways/wnt-hedgehog.jsp. 
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Figure 1.10 The notch signalling pathway. When activated by ligand binding, the 
intracytoplasmic domain of notch is cleaved by a γ-secretase and becomes a nuclear –seeking 
transcription factor 
 
xiv) Regulatory RNAs:  The discovery of RNA interference in 1998 by Andrew Fire and 
Craig Mello {Blow, 2009}; and the ubiquity of microRNAs in diverse biological systems 
have clearly established that novel species of RNAs regulate transcription and translation in 
hitherto unexpected ways {Stillman & Stewart, 2007}. Table 1.4 summarizes functions of 
currently known regulatory RNAs (double- and single-stranded non-coding RNAs). 
 
The central theme of regulatory RNAs is that small RNAs (20-30 nucleotides long) and 
diverse non-coding RNAs (60 to several hundred nucleotides) can use their base-pairing 
potential to regulate the activity of DNA {Stillman & Stewart, 2007; Winter et al, 2009}. 
RNAs are also involved in catalysis as demonstrated by self-splicing introns and RNA 
cleavage. The entire field of regulatory RNAs is rapidly expanding, seeking answers to many 
questions such as how non-coding RNAs (RNAs other than the triumvirate of mRNA, rRNA 
and tRNA) dominate the regulatory circuitry of the cell; how these non-coding RNAs are 
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synthesized and processed in humans. It underpins the paramount importance of the 
interactome in the expression of cancer genes.  
 
Table 1.4 Novel species of Regulatory RNAs 
Types of RNA Function 
snRNA Small nuclear RNAs 
Function in a variety of nuclear processes, including splicing of 
pre-mRNA 
snoRNA Small nucleolar RNAs 
Process and chemically modify rRNAs 
scaRNA Small cajal RNAs 
Modify snoRNAs and snRNAs  
miRNA Micro RNAs (20-30 nucleotides long) 
Regulate gene expression. Bind to 3’untranslated regions (UTR) 
of targets. About 1000 microRNAs are known. 
Block translation of selective mRNAs. Could be of diagnostic & 
therapeutic uses including understanding of cell: cell signalling. 
siRNA Small interfering RNAs 
Turn off gene expression 
Direct degradation 
Establishment of compact chromatin structure 
Other non coding RNAs 
(ncRNAs) 
Telomere synthesis 
X-chromosome inactivation 
Transport of proteins into the endoplasmic reticulum 
Anti-sense transcripts of unknown function. 
 
In summary, carcinogenesis requires multiple events. It is associated, almost invariably, with 
abnormalities that indicate there have been a much larger number of events (cellular and 
molecular). Some of these events are ‘drivers’, directly responsible for the abnormal 
behaviour of the clonally expanding cancer cells, but many are probably ‘passengers’. In 
reality, the regulatory pathways are interwoven in a complex network, which cancer cells tend 
to escape or modify. For example, aberrant K-ras and Wnt signalling have been reported to 
form synergy, accompanied by elevated androgen receptor, cyclooxygenase-2 and c-Myc 
levels in the acceleration of prostate tumourigenesis in mouse models {Pearson  et al, 2009}. 
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1.2  Pathology of the Prostate gland 
 
1.2.1  Physiologic Anatomy of the Prostate 
The prostate is the largest accessory gland of the male reproductive system, measuring 
approximately 3cm in length, 20g in weight and is the size of a walnut in a normal adult 
{Kumar  et al, 2009}. It lies underneath the urinary bladder with its base encircling the neck 
of the bladder (Figure 1.11). Embryologically, the glandular part is of epithelial origin 
(ectodermal) and comprises approximately two thirds of the prostate; while the other third is 
fibromuscular and mesenchymal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Posterior view of the prostate gland during digital rectal examination {Moore et 
al, 1992}. 
 
Although not clearly distinct anatomically, the prostate consists of five lobes in relation to the 
urethra. The anterior lobe, or isthmus, lies anterior to the urethra and it is wholly 
fibromuscular. The posterior lobe lies posterior to the urethra and inferior to the ejaculatory 
ducts; it is readily palpable by DRE. The lateral lobes on either side of the urethra form the 
major part of the prostate. The middle (median) lobe lies between the urethra and the 
ejaculatory ducts and is closely related to the neck of the bladder. However, in the adult, 
prostatic parenchyma can be divided into four biologically and anatomically distinct zones or 
regions: the peripheral, central, and transitional and periurethral zones (Figure 1.12). The 
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central zone is comparable to the middle lobe. The types of proliferative lesions are different 
in each region.  
 
 
Figure 1.12 Anatomic zones of adult prostate gland. CZ is central zone, PZ is peripheral 
zone, and TZ is transitional zone {Kumar et al, 2009}. Most prostate cancers arise from the 
peripheral zone. 
 
For example, most hyperplasias arise in the transitional and periurethral zones and are more 
likely to produce urinary obstruction earlier on than are carcinomas; whereas most 
carcinomas originate in the peripheral zone of the organ and are often palpable during digital 
rectal examination ( DRE) {Kumar  et al, 2009}. 
 
Histologically, the prostate is a compound tubuloalveolar gland, which presents small to 
fairly large glandular spaces lined by two layers of epithelial cells: a basal layer of low 
cuboidal epithelium covered by a layer of columnar mucus-secreting cells. Molecularly, four 
cellular types exist within the prostate, which are identifiable by specific markers (basal cells, 
transient amplifying cells, luminal and neuroendocrine cells) {Agrawal & Dunsmuir, 2009}. 
It is suggested that the ‘prostate stem cells’ reside in the basal cell layer and may produce 
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intermediate transient amplifying cells, which exhibit both luminal and basal cell markers 
{Litvinov  et al, 2006}. The glands all have a distinct basement membrane and are separated 
by an abundant fibromuscular stroma. 
 
The prostate is a richly innervated organ, having parasympathetic fibres from the pelvic 
splanchnic nerves and sympathetic fibres from the inferior hypogastric plexus {Powell  et al, 
2005; Moore et al, 2006}.Prostatic neuroanatomy is important due to its relationship with 
prostate cancer in the process of perineural invasion, which constitutes the primary 
mechanism of metastasis more than direct extension{Powell  et al, 2005}. Perineural invasion 
has been used as a prognostic marker, with the ability to predict progression, capsular 
extension, radiation therapy failure and PSA/biochemical recurrence {Powell et al, 2005}. 
The arterial blood supply to the prostate is by the prostatic arteries, which are mainly 
branches of the internal iliac artery including inferior vesical arteries, internal pudendal and 
middle rectal arteries. The veins that drain the prostate join to form a plexus around the sides 
and base of the prostate. This prostatic venous plexus, between the fibrous capsule of the 
prostate and the prostatic sheath, drains into the internal iliac veins. The prostatic venous 
plexus is continuous superiorly with the vesical venous plexus and posteriorly with the 
internal vertebral venous plexus {Moore et al, 2006}. The lymphatic vessels drain into the 
internal iliac and sacral lymph nodes, forming immediate access for metastasis.  
 
The growth and function of the prostate is dependent on androgens. The two predominant 
androgens are testosterone, which is synthesized by Leydig cells of the testis from 
androstenedione and 5α-dihydrotestosterone (DHT), which is formed in the prostate from 
circulating testosterone by 5α-reductase type 2 {Vihko P et al, 2006}. DHT is the most active 
androgen in the prostate {Soronen et al, 2004}. Androgens are thought necessary for the 
initiation of prostate cancer because the balance between androgen induced proliferation and 
apoptosis regulates the growth of the normal and cancerous prostate{Vihko  et al, 2005; 
Vihko  et al, 2006}. The prostate secretes the prostatic fluid, which constitutes about 20% of 
the seminal plasma and is rich in PSA (prostate specific antigen). Normal prostate is a self-
renewable tissue with low significant proliferative capacity; much similar to the mammary 
gland {Leblond, 1963}. The three main pathologic processes that affect the prostate gland are 
inflammation (prostatis), benign nodular enlargement, and tumours. 
 
1.2.2  Diseases of the Prostate 
 
a) Inflammations: Inflammation of the prostate is known as prostatitis, and has three 
categories: acute and chronic bacterial prostatitis and chronic abacterial prostatitis. 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
28 
Differentiation among the three categories is based on quantitative bacterial cultures and 
microscopic examination of fractionated urine specimens and expressed prostatic secretions 
{Kumar et al, 2009}. In acute bacterial prostatitis, there is an acute focal or diffuse 
suppurative inflammation in the prostatic substance due to bacterial infection. Common 
pathogens are strains of E.coli, enterococci and staphylococci. Symptoms include fever, chills 
and dysuria; on DRE the prostate is exquisitely tender and boggy. Chronic bacterial prostatitis 
also results from bacterial infection mainly from recurrent urinary tract infections. It may 
present with low back pain, dysuria, perineal and suprapubic discomfort. Chronic abacterial 
prostatitis is clinically indistinguishable from chronic bacterial prostatitis; however there is 
usually no history of recurrent urinary tract infection. Diagnosis is based on presence of > 10 
leukocytes per high field in prostatic secretions, but uniformly negative bacterial cultures. 
Likely pathogens include C.trachomatis, U. urealyticum and M. hominis. Proliferative 
inflammatory atrophy (PIA) co-exists in many foci of PCa biopsies and it is considered a 
precursor to prostate malignancy {Agrawal & Dunsmuir, 2009}. 
 
b) Nodular hyperplasia. This is also known as benign prostatic hypertrophy or hyperplasia. 
This is a very common disorder in men over age 50 years. Histologic evidence of nodular 
hyperplasia can be seen in approximately 20% of men 40 years of age, a figure that increases 
to 70% by age 60 and to 90% by age 70 {Kumar et al, 2009}. It is estimated that more than 
400,000 transurethral resections (for correcting nodular hyperplasia) are performed every year 
in the United States {Droller, 1997}. The disease is characterized by hyperplasia (increased 
number of cells) of prostatic stroma, predominantly smooth muscle cells and epithelial cells, 
resulting in the formation of large, fairly discrete nodules in the periurethral region of the 
prostate. It is believed to be caused by the continuous growth of the prostate gland throughout 
life {Coleman & Tsongalis, 2002}, a feature that requires minimally a supply of androgens 
{Vihko et al, 2006} and also the assistance of oestrogens {Droller, 1997}. Enlarged prostatic 
nodules compress and narrow the urethral canal causing partial or sometimes virtually 
complete obstruction of the urethra. This leads to difficulty in urination, retention of urine in 
the bladder with subsequent distention and hypertrophy of the bladder, infection of the urine 
and development of cystitis and renal infections. Patients experience increased frequency of 
need to urinate, nocturia, difficulty in starting and stopping the stream of urine, overflow 
dribbling and dysuria. Treatment includes catherization, surgical resection and antibiotics. 
Many studies have shown that nodular hyperplasia is however not a premalignant lesion, and 
therefore not a precursor to prostate tumours {Kumar et al, 2009}. 
 
c) Prostate tumours. The most common malignant tumour of the prostate is the prostate 
adenocarcinoma (prostate carcinoma or prostate cancer). Although there are many dysplasias 
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of the prostate (with various microscopic descriptions), the generally recognized precursor of 
prostate carcinoma is the prostatic intraepithelial neoplasia (PIN){Bostwick  1996; Montironi  
et al, 2006}. PIN is ‘associated with progressive abnormalities of phenotype and genotype 
which are intermediate between normal prostatic epithelium and cancer, indicating 
impairment of cell differentiation and regulatory control with advancing stages of prostatic 
carcinogenesis’ { Meikle  & Smith. 1990; Bostwick 1996}. PIN and tissue hypoxia are also 
considered as precursors to prostate tumours. A rare carcinoma of the prostate known as small 
cell carcinoma of the prostate (SCPC) has also been described {Yao et al, 2008}. It can be 
found in both the pure form and mixed with conventional prostatic carcinoma. SCPC has 
typical histologic features of small cell carcinoma seen in the lung and other extra-pulmonary 
sites. Gleason grading does not apply to SCPC. 
 
1.2.3. Aetio-Pathogenesis and Natural History of Prostate Cancer.  
 
a) Aetiology: The exact cause of prostate cancer is not yet known. Conceptually, there are 
three approaches towards unravelling the causes of PCa. The first, which is most extensively 
reviewed in the literature is the epidemiological approach based on multi-factorial causes of 
PCa {Dijkman & Debruyne, 1996; Freedland & Isaacs 2005}. It is believed that prostate 
cancer is aetiologically heterogeneous, involving interplay of multi-step disease processes. 
Available data on the disease process of PCa suggest that genetic factors appear to be 
permissive, as are hormonal factors, which are partially regulated by genetics. Environmental 
factors (diet, pollutants and life style) appear to be promotional in genetically susceptible men 
{Meikle & Smith, 1990}.  
 
The hormonal involvement in aetiology of prostate cancer is based on the fact that prostate 
epithelia possess androgen receptors, which are mutated and/ or aberrantly expressed in PCa. 
This results in abnormal androgen sensitivity to ligands, which is believed to drive prostate 
carcinogenesis. Several reports have produced strong evidence in favour of hormonal 
inducement of PCa disease process. For example, simultaneous oestrogen and testosterone 
treatment have been used to sensitize rodents to the development of prostate cancer {Prins GS 
et al, 2001}. It is also known that the increased level of oestradiol in aging men induces an 
increase in androgen receptors, rendering cells more susceptible to the action of 
dihydrotestosterone (DHT){Droller, 1997}. Androgen ablation therapy is another indication 
that hormonal inducement is paramount to the development PCa, although prostate cancer 
cells tend to develop resistance after a certain period of treatment. However, from 
embryological evidence of ‘oestrogen imprinting’ or ‘oestrogenization’, it is proposed that 
excessive oestrogen levels during prostatic development may contribute to the high incidence 
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of benign prostatic hyperplasia and prostatic carcinoma currently observed in the aging 
population {Sato et al, 1996}. The interactive effects of androgens, 17 β-oestradiol and their 
receptors are, therefore, very crucial in PCa pathogenesis. 
 
The second approach, which essentially is also part of the first approach is the molecular 
genetics approach based on genetic mutation and inheritance as opposed to environmental 
determinants. In recent years much interest has been focused on the genetics and molecular 
pathogenesis of prostate cancer using analytical techniques such as array comparative 
genomic hybridization (aCGH), fluorescent in situ hybridization (FISH), gene expression 
profiling, loss of heterozygosity (LOH) analysis; and epigenetic studies such as DNA 
methylation. Molecular genetics approach asserts that cancer susceptibility genes are 
responsible for the development of PCa rather than hormones, which are only responsible for 
the maintenance of prostatic epithelium in both normal and cancerous cells. This approach 
speculates a possible germ line inheritance susceptibility gene mapped to chromosome 1q24-
25 as causing prostate cancer irrespective of environmental exposure {Bostwick et al, 1996}. 
But this gene has not been identified. Several other gene loci have been associated with 
prostate cancer, for example, the 11q13, 8q24 and 17q12, these loci are known to harbour 
genetic variants responsible for prostate cancer risk {Zheng et al, 2009}. Several putative 
cancer-suppressor genes that are lost early in prostate carcinogenesis have also been mapped 
to chromosomes 8p, 10q, 12p, and 16q, of which E-cadherin has been found at location 16q22 
{Standford  et al, 2006}. Isaacs (1997) also reported a common loss of genetic material 
localised on chromosome 11p11.2, which is believed to suppress prostate cancer metastasis. 
But the identification of the principal susceptibility gene is yet to be reported. A study, based 
on genetic segregation analysis, suggested an autosomal dominant gene, a rare high risk allele 
to be responsible for the early onset of prostate cancer, but also agreed that chromosome 8p, 
10q and 13q are frequently mutated or deleted in PCa {Haggman  et al, 1997} .  
 
The molecular mechanisms, exact roles of suspected genes and hereditary patterns likely to 
be involved are not yet elucidated; the cancer susceptibility gene model is still speculative. 
However, the discovery in 2005 by Tomlins et al of the gene fusion: TMPRSS2 and members 
of ETS gene family (ERG, ETV1 and ETV4) in more than 50% of prostate cancer cases has 
rekindled the investigation of molecular events underlying prostate cancer development 
{FitzGerald et al, 2008}. It is found that the promoter region of TMPRSS2, which is 
androgen-regulated, is fused with members of the ETS transcription factors (proto-oncogenes 
that are highly over-expressed in PCa). The oncoproteins encoded by the gene fusion is 
believed to drive prostate tumourigenesis. But some cases of TMRPSS2 -ERG or TMPRSS2-
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ETV gene fusions were reported in benign, PIN and normal prostatic epithelia, once again a 
reminder of the heterogeneous aetiology of PCa. 
The third approach is the virology approach, based on a suggestion of possible viral aetiology 
for prostate cancer, different from the well-trod cancer epidemiology. The discovery of a 
novel species of xenotropic murine retrovirus (XMRV) in prostate tumours of patients that 
have the R462Q variant of the RNASEL gene (which is involved in prostatic antiviral 
defence) has sparked the speculation that virus (es) may be involved in PCa aetiology 
{Urisman  et al, 2006}. Mutations of the RNASEL gene were associated with 13% of all 
prostate cancers. Most of the mutated RNASEL prostate tumours had the XMRV (which is 
related to the xenotropic murine leukaemia virus), suggesting that viruses may be involved 
directly or indirectly in the mutation events and / or the development of the PCa especially in 
genetically susceptible males. After all, the involvement of viruses in human cancers has been 
known for decades; Harald zur Hausen received a Nobel Prize in 2008 for his work on the 
human papilloma virus in cervical cancer aetiology. Table 1.5 shows infectious agents that 
are implicated in human cancers {Bird, 2009}. Recently the Merkel cell polyoma virus has 
been associated with aetiology of the Merkel cell carcinoma, a rare but aggressive form of 
skin cancer, widely believed to be caused by sun exposure {Feng  et al, 2008}. The viral 
involvement in PCa is currently very speculative, not much evidence to support it. However, 
it is worth investigating, knowing that the prostate gland is a rich haven for bacterial infection 
and may equally attract viruses.  
 
Because the disease process in PCa involves a multi-step transformation of genetically altered 
prostate cells {Isaacs, 1997}, the epidemiological approach remains a preferred platform for 
most studies on aetiology of prostate cancer. From these, several risk factors that predispose 
humans to prostate cancer have been well- documented. These include family history, race; 
advancing age, environment and diet. It is important to point out that predisposition (risk 
factors) to a disease is not the same as causation. 
 
b) Factors predisposing men to Prostate cancer: 
 
i) Age: The majority of men with prostate cancer are aged 50 years and above {The Institute 
of Cancer Research UK, 2006}.This has formed the basis of a proposition by patient and 
physician groups, advocating annual mass screening of men aged 50 years  {WHO, 2004}. 
Most public health authorities refute this idea on the basis of health cost and lack of 
controlled randomised clinical trial evidence to underpin additional health benefit through 
mass screening. However, several studies have shown that advancing age is the strongest 
predisposing factor to PCa {Meikle & Smith, 1990; Jemal, 2008}. It is believed that the 
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prostate gland grows steadily throughout life, a process that makes its prone to genetic 
alterations which could lead to prostate cancer or in most cases nodular hyperplasia 
{Coleman & Tsongalis, 2002}. 
 
Table 1.5 Infections linked to human cancer.  
{Bird, 2009} 
Tumour type                                                                                        Infectious cause 
Some B-cell and T-cell lymphomas                                              Epstein-Barr virus (EBV) 
Burkitt’s lymphoma 
Nasopharyngeal cancer 
Hodgkin’s disease (30-40%) 
Gastric cancer (10%) 
Cervical, anal and perianal cancers                                          Various human papillomavirus 
(HPV) types 
Vulval, penile and vaginal cancers 
Oropharyngeal cancer (25%) 
Specific squamous cell carcinomas of the skin 
Hepatocellular carcinoma                                                      Hepatitis B (HBV) and C (HCV) 
viruses 
Adult T-cell leukaemia                                              Human T-lymphotropic  virus  
(HTLV-1) 
Seminoma (?)                                                                          Endogenous human retroviruses 
Kaposi’s sarcoma                                                                    Human herpes virus- 8 (HHV-8) 
Gastric cancer and gastric lymphoma                                    Helicobacter pylori 
Bladder and rectal cancer                                            Schistosoma haematobium and possibly   
other schistosoma species 
Chlolangiocarcinoma                                                      Opisthorchis viverrini and O. felineus, 
Clonorchis sinensis and possibly Helicobacter bilis 
 
 
ii) Family history/Genetics: Men with a brother or father who developed PCa at a young age 
have an increased risk of developing prostate cancer. Men with a family history of breast and 
ovarian cancers, Hodgkin’s disease, leukaemia, liver cancer and melanoma are also at a 
higher risk of developing prostate cancer {Hemminki & Chen, 2005}. Monozygotic twins 
have double risks of predisposition to prostate cancer compared to dizygotic twins. At the 
moment, there is no single gene wholly responsible for predisposition of humans to prostate 
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cancer although involvements of possibly recessive or X- linked mechanisms have been 
suggested {Hemminki & Chen , 2005}. Other suggestions include mutation carriers of BRCA 
1&2 genes, which encode proteins involved in double-stranded DNA repair and maintenance 
of chromosomal integrity. But inactivation of same genes has been reported in higher risk of 
pancreatic cancer; endometrial cancer is also related to BRCA 1 mutation and melanoma to 
BRCA 2 mutation. This plausibly explains some of the associations among cancers rather 
than causation. Another example is the occurrence of low penetrance genes such as RNASEL, 
MRS1 and the Toll-like receptor cluster in prostate cancer. These genes are also involved in 
inflammation and immunity {Sun et al, 2006}; which may explain the association of prostate 
cancer with non-Hodgkin’s lymphoma and Hodgkin’s disease. Several other chromosomal 
loci and genetic variants (mainly single nucleotide polymorphisms (SNPs)) have been 
associated with prostate cancer risk, including 11q13, 8q24 and 17q12; SNPs such as 
rs10896449, rs12418451, rs198977 and rs2664155 have been reported to show strong 
association with prostate cancer risk {Nam  et al, 2006; Zheng SL et al, 2009}. The human 
genome diversity project (HapMap project) is aimed at unravelling genetic variants of 
humans in different geographical regions of the world, an effort that will help, among other 
things, map SNPs and haplotypes associated with disease risk 
http://www.hapmap.org/abouthapmap.html. There are about 10 million known SNPs in the 
human genome. Tags for SNPs (haplotypes) may help identify more genes and regulatory 
RNAs associated with prostate cancer development. Another genetic variant implicated in 
prostate cancer is microsatellite instability in the androgen receptor gene where a 
trinucleotide (CAG) polymorphic repeat length varies with prostate cancer risk. It was 
reported that patients with shorter CAG repeat length (usually below 22) tend to respond 
poorly to hormone treatment in metastatic PCa {Shimbo et al, 2005}. 
 
iii) Race: PCa is more common in men of African descent than other ethnic/racial 
backgrounds. It is rare in Asians; although lack of adequate diagnostic strategy has been 
blamed for the reported low incidence rate in Asian population {Zhang et al, 2009}. Certain 
genetic factors associated with PCa have been reported to show ethnic/racial differences. For 
example, it has been reported that there was a significantly higher oestrogen receptor α 
expression in stroma of non-neoplastic prostate tissues from Hispanic and Asian men than 
those of Caucasian and African-American men, who are at higher risk for prostate cancer 
{Haqq et al, 2005}. Ethnic/racial biologic differences were reported on plasma levels of 
androgens {Ross R et al, 1986}, sensitivity of androgen receptors (due to reduced number of 
CAG or GGC repeats in exon 1) and altered insulin- like growth factor binding protein 3 
(IGFBP-3) expressions in plasma {Haqq  et al, 2005}. Freeman et al 1997 reported racial 
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difference in histological grade of prostate cancer, with American blacks having a 
significantly higher burden of high histologic grade than whites. However, a review 
suggested that ethnic/ racial differences in prostate cancer arose from multi-factorial causes 
spanning genetics, economics and sociology {Freedland SJ & Isaacs WB, 2005}. Data from 
the HapMap project is beginning to reveal the genetic variations associated with ethnic 
groups and disease risk; for example the risk allele (G allele in AG or GG genotypes) of the 
SNP rs10896449 localised on 11q13 is associated with aggressive prostate cancer and has the 
highest frequency in African ancestry (58-76%), followed by Caucasians (52-53%), Mexicans 
(32%), Asians in America (9-27%) and least frequency in Asians at their native home (3-8%). 
This information from the HapMap project is consistent with previous epidemiological 
observations {Dijkman & Debruyne, 1996}. 
 
iv) Environment: Factors such as industrial pollution, occupational hazards and radiation 
exposures are environmental determinants, which have been implicated in the aetiology of 
prostate cancer. A very significant mortality rate from PCa was reported in rubber and tyre 
workers {Dijkman & Debruyne, 1996}. Farming and pesticide exposure were also weakly 
associated with PCa. Exposure (or dietary intake) of trace elements such as zinc and cadmium 
plus radiation exposure directly correlate with the mortality from prostate cancer {Meikle & 
Smith, 1990}. The fact that incidence of PCa tend to rise among those enjoying a low-
incidence rate when they migrate to a high incidence locale is consistent with a role of 
environmental influences {Kumar et al, 2009}. 
 
v) Dietary Factors: Based on epidemiological research and migrant studies, it is presumed 
that the development of prostate cancer is associated with some dietary components {Hebert 
et al, 1998}. Diets that contain high levels of animal saturated fat, low fibre content, reduced 
vitamins A and D levels are variously reported to increase risk of prostate cancer {Hebert  et 
al, 1998 ; Dijkman  & Debruyne , 1996}. It is generally thought that high fibre (for example 
grains, cereals and nuts) and low fat (fish) intakes are more likely to protect men from PCa. A 
recent dietary advice report recommends foods rich in vitamins, polyphenols, phytoestrogens, 
lignans, stilbens and carotenoids (lycophene) as being very protective; such foods can be 
sourced from vegetables, soy beans, cherries, strawberries, onions, nuts and grains, tomatoes 
and carrots {Thomas  et al, 2006}. There are, however, some conflicting reports on the 
protective roles of Vitamins A and D.  The trace elements: zinc, Cadmium and Selenium are 
also controversial in their roles in prostate tumourigenesis {Meikle & Smith, 1990}. 
However, there are several ongoing clinical trials on food and trace elements in prostate 
cancer management: i) Vitamin E supplement in PCa prevention, registration ID 
NCT00895115; ii) Cholecalciferol treatment on active surveillance patients, registration ID 
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NCT00887432 and iii) prostate and diet study: ISRCTN95931417 (http://www.controlled-
trials.com/; http://apps.who.int/trialsearch .  Dietary studies in prostate cancer prevention and 
management especially for high risk males and localized low grade prostate cancer patients 
on ‘watchful waiting’ has become important following reports of beneficial effects 
comparable to primary therapy{Thomas R et al, 2006; Bill-Axelson et al, A 2005}. 
 
vi) Other Factors: Many other factors have been loosely associated with prostate cancer 
development. These include life-style (stress management and exercise), religion, and 
economic status; body size, physical activity and sexual activity. Data on these factors are 
conflicting and some are unconvincing in most cases. However, there are now more 
randomized controlled trials to evaluate most of these factors in relation to prostate cancer 
http://www.controlled-trials.com/. 
 
c) Pathogenesis of Prostate Cancer. The molecular details of prostatic carcinogenesis have 
not been fully delineated, but it is clear that the development of a malignant prostate cancer 
cell from a normal prostatic glandular cell requires multiple transformation events {Isaacs, 
1997}. The disease process is likely to have started from clonal expansion of genetically 
altered prostate epithelial cells. One hypothesis claims that the primary genetically altered 
cells reside in the basal layer of the prostate as ‘ Prostate stem cells’, serving as a progenitor 
for terminally differentiated cancer cells {Agrawal  & Dunsmuir, 2009}. This results in 
dysplastic and/or hyperplastic lesions in the prostatic epithelium that are, at the beginning, 
androgen dependent like the normal epithelia. The early stage genetic and morphological 
changes are very similar to those of PIN and BPH. There are many reported similarities 
between early prostate cancer and BPH: i) the parallel increase in prevalence with age; ii) 
both require androgens for growth and development, and iii) both respond to anti-androgen 
treatment regimens {Dijkman  & Debruyne, 1996}, although advanced PCa tend to be 
hormone refractory in later stages.  
 
Part of the multi-step transformation concept also implies that some of the cells may remain 
partially transformed and unable to progress to the next stage, accounting for the 
heterogeneity in the disease processs {Isaac, 1997}. The hyperplastic lesions are believed to 
slowly progress to prostatic intraepithelial neoplasia (PIN), which has low and high grade 
forms. PIN is characterized by progressive basal layer disruption (invasive), abnormalities in 
markers of secretory differentiation, increasing nuclear and nucleolar alterations; increasing 
cell proliferation, variation in DNA content (ploidy) and increasing genetic instability 
{Bostwick 1996; Haggman  et al, 1997}. PIN is precancerous and is generally regarded as the 
precursor to localised prostate carcinoma {Agrawal S & Dunsmuir, 2009}. Within 5 to 10 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
36 
years, some PINs progress to histologically detectable cancers, but others don’t {Droller, 
1997}. The ability of the neoplastic cells to invade the basement membrane of the gland is the 
key element in the disease progression. As the cancer cells expand, it is believed that newer 
cells are produced from the basal layer (cancer stem cells) {Quinn et al, 2005}. The tumour 
cells are mostly contained within the prostatic capsule; however the ability of the neoplastic 
cells to invade the prostatic capsule, spreading to the prostatic sheath and adjacent structures 
such as seminal vesicles, ejaculatory duct and the urethra is a mark of its aggressiveness.  
 
The mechanisms of its spread include perineural invasion and lympho-haematogeous spread. 
In most cases the disease spread to the vertebrae as well as visceral organs such as liver and 
brain {Kumar et al, 2009}.The disease process is fairly correlated with Gleason scoring 
(morphological features of the prostate); poorly differentiated PCa tend to be more aggressive 
and lethal. However, the disease process is not well characterized molecularly. Although 
several molecular markers are prognostic of PCa in a multivariate model {Agrawal & 
Dunsmuir, 2009}, their use as single independent prognostic markers are limited. Molecular 
grading of prostate cancer could be invaluable for both prognosis and choice of patient-
tailored therapy because the disease is seemingly uniquely different in each patient.  
 
d) Natural History of Prostate Cancer:The natural history (clinical course) of PCa has a 
spectrum of duration and severity (WHO, 2004). In most cases, it has an insidious onset as a 
slow-growing, localised tumour (tumour confined within prostatic capsule, also known as 
histological tumour) strongly associated with advancing age. Like other malignant neoplasms, 
PCa is assumed to arise from a sequence of genetic (DNA damaging) events and is believed 
to present initially as a small focus {Gendler, 2001}. Autopsy studies showed that prostate 
glands in older men (glands considered to be clinically normal) contained foci of invasive 
cancer (histological cancer); the frequency of which rises from 10% in men in their fifties to 
70% in men in their seventies and eighties (Droller, 1997). Figure 1.13 shows natural history 
of prostate cancer {Cross et al, 2008}. It is believed that more than 75% of PIN cases 
progress to histological detectable prostate cancers, which are either androgen dependent or 
independent. Some of the histological PCa progress to symptomatic forms (clinical PCa), 
while others asymptomatic. Histological PCa shows little geographical and ethnic variations 
{Meikle W & Smith JA, 1990} unlike clinical PCa. 
 
There is no substantiated evidence to account for the disparity in capacity of some 
histological tumours to progress (and become symptomatic) or remain indolent 
(asymptomatic). Some progress further to metastatic PCa, which are more aggressive. 
Interestingly, some metastatic PCa are frequently asymptomatic. Epidemiological studies 
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have failed to explain this unpredictable natural history of prostate cancer. Moreover, it is not 
known if all histological prostate cancers (organ confined) have the capacity to progress to 
lethal forms and if they do, what are the stimuli to activate progression {Droller, 1997}. On 
the other hand, there are few biomarkers that can predict this capacity to progress. 
Morphologic examination of prostatic tissues often show mixed foci of inflammation, PIN, 
BPH or prostate carcinoma; sometimes very different pictures from both lobes. The 
aggressive forms of PCa tend to be hormone refractory, as they fail to respond to androgen 
ablation therapy in later stages. The molecular changes that characterize prostate cancer 
progression are beginning to emerge, for example the gene fusions (TMPRSS2-ETS), AR 
mutations and microsatellite polymorphism, p53 and Bcl-2 alterations, fatty acid synthase 
metabolic alterations and GSTP1 methylation {Benedettini et al, 2008}.  
 
 
Figure 1.13 Natural course of Prostate cancer progression. Most prostate cancers arise from 
prostatic intraepithelial neoplasm (the precursor) and develop to organ-confined cancer. 
{Cross et al, 2008} 
 
However, the correlation between the molecular markers and the currently used Gleason 
grading and pathology staging of prostate cancer is poor. Histological grading and staging 
still remains the most independent predictor of disease outcome and response to therapy. But 
intermediate grades (Gleason 5 and 6) behave unpredictably; requiring additional markers to 
define that group. One important fact about the natural history of PCa is that if offers a unique 
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opportunity for early detection by screening because of slow onset of disease process and 
long asymptomatic period. 
 
1.2.4 Steroid hormones and receptors in prostate Cancer. 
 
a) Steroid Hormones: Steroid hormones (SHs) are lipophilic molecules synthesized from 
cholesterol, and produced in the adrenal cortex (glucocorticoids, mineralocorticoids, and 
adrenal androgens), the testes (testicular androgens, oestrogen), and the ovary and placenta 
(oestrogens and progestagens or progestins). SHs are transported to their target cells through 
blood, where they are bound to carrier proteins, and because of their lipophilic nature they 
diffuse into cells {Soronen et al, 2004}. Within the cytoplasm of target cells, SHs bind to 
steroid hormone receptors (SHRs), which mediate the action of the hormones. The functions, 
characteristics and references ranges of some steroid hormones in humans are shown in Table 
1.6. The growth and function of the prostate is controlled by androgenic SHs. The two 
predominant androgens are testosterone that is formed mainly in the testis from 
androstenedione(A-dione) and 5α-dihydrotestosterone (DHT), which is formed in the prostate 
from testosterone by 5α-reductases type 2 and is the most active androgen in the prostate 
{Scholzen  & Gerdes, 2000} 
 
The metabolism of steroid hormones in human prostate is shown in Figure 1.14. In normal 
conditions, a steady state exists between synthesis and inactivation of active androgens 
{Vihko et al, 2006}. A change in the balance (increased synthesis, decreased inactivation) 
can lead to androgen influence and increased cell proliferation. The majority of prostate 
tumours arise from the secretory, androgen-dependent epithelial cells, which forms the basis 
of hormonal therapy (ablation of androgens in the circulation and prostate tissue by surgical 
or chemical castration to treat PCa). Most prostate cancers are initially responsive to 
androgen withdrawal but become later refractory to the therapy and begin to grow androgen-
independently {Soronen et al, 2004}. It is important to note that PCa that originate from 
neuroendocrine cells, the small cell carcinoma of the prostate do not respond to hormone 
therapy at all {Yao JL et al, 2008} 
 
b) Steroid hormone receptors (SHR): SHRs are hormone- activated transcription factors. 
They belong to a sub-group of nuclear receptor super-family, which currently has 48 
members in humans{Faus  & Haendler, 2006}. The SHR sub-group is composed of the 
androgen receptor (AR), two oestrogen receptors (ERα and ERβ), the progesterone receptor 
(PR); the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). A variety of 
isoforms of SHRs have been identified; and these may be expressed in distinct cell types and 
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developmental stages, suggesting that they play specific physiological roles{Picard , 2006}. 
For example, the expression of oestrogen receptor α molecularly divides human breast 
cancers into ERα positive and ERα negative cancers; the ERα positives are mainly luminal 
breast cancers, which also express progesterone receptor and they appear to have the best 
outcome of therapy{Marchio & Reis-Filho, 2008}. The ERα negative breast cancers 
encompass the sub-groups of HER2 positive cancers, normal breast-like and basal-like 
cancers. This molecular classification based on ERα status and subsequent genetic signatures 
define choice of treatment and inform prognosis 
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Table 1.6 Functional characteristics and reference ranges of some steroid hormones in 
humans. {Zubay, 1996} 
Steroid hormone Characteristics Functions Reference 
ranges (in 
males) 
Testosterone 
 
C19 steroid with unsaturated 
bond between C-4 and C-5, a 
ketone group in C-3 and a 
hydroxyl group in the β position 
at C-17. Mr is 288.4. It is both a 
hormone and a prohormone. 
It promotes male sexual 
development; promotes and 
maintains male sex 
characteristics. It also 
influences erythropoiesis by 
stimulating renal production 
of erythropoietin. It 
influences neural 
development and activity. 
In males, 
prepubertal 
(late) level in 
serum is 0.1-
0.2 ng/ml; in 
adult the level 
is 3.0-10.0 
ng/ml. 
Dihydrotestosterone 
 
It is a metabolite of testosterone; 
derived in target cells, e.g. 
prostate gland, by the action of 
5α-reductase type 2 enzymes. It 
has a ketone group at C-3 but no 
unsaturated bond between C-4 
and C-5. Mr is 290.44. 
Most potent form of 
testosterone, binds to AR 
with higher affinity than 
testosterone. 
Varies 
depending on 
target cell 
reduction of 
circulating 
testosterone. 
17 β oestradiol (E2) 
 
C18 steroid hormone with a 
phenolic A ring. It has two 
hydroxyl groups, one at C-3 and 
the other at C-17. Mr is 272.4. It 
is the most potent natural 
oestrogen, produced mainly by 
the ovary, placenta, and in 
smaller amounts by the adrenal 
cortex and the male testes. 
Chimeric forms of it exist. 
It is responsible for sexual 
development in the female; 
promotes and maintains 
female sex characteristics. 
In males 
oestradiol level 
is < 60 pg/ml. 
There is 
increased level 
at old age. 
Hydrocortisone 
(cortisol) 
 
C21 steroid, also known as 
glucocorticoid (generic name). It 
has two ketone groups, one at C-
3 and the other at C-20, an 
unsaturated bond between C-4 
and C-5 and hydroxyl groups at 
C-17 and C-21. Mr is 362.47. 
It promotes gluconeogenesis; 
suppresses inflammatory 
reactions  
Concentration 
in peripheral 
plasma varies 
with day time: 
 At 8 a.m, level 
is 16µg/100ml 
while at 4 p.m. 
the level 
4µg/100ml. 
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Steroid receptors are mainly found, in the absence of hormone (ligand), in the cytoplasm 
complexed to chaperone proteins such as heat shock protein 90 (Hsp90). SHRs appear to rely 
on the Hsp90 machine for folding, regulation of the allosteric switch and recycling{Picard, 
2006}, Figure 1.14 
 
 
Figure 1.14 Steroid metabolism in human prostate tissue.1, 2, 4, 5,7,10 and 11 are different 
17 HSD types; E1, oestrone, E2, oestradiol; A-dione, androstenedione; T, testosterone; 
DHEA, dihydroepiandrosterone; 5α A –diol, 5α-androstenediol; 5αA-dione, 5α-
androstanedione, 5α-R1, 5α-reductase 1, 5α-R2, 5α-reductase 2; DHT, dihydrotestosterone; 
3βA-diol, 5α-androstane-3β 17β-diol; 3αA-diol,5α-androstane-3α,17β-diol;3β-hydroxysteroid 
dehydrogenase type 1. Androgens and oestrogens are eliminated as sulphate or glucuronide 
derivatives. 
{Soronen et al, 2004}. 
 
Following ligand binding, SHRs undergo conformational changes and relocate to the nucleus 
where they activate or repress target genes as homodimers {Faus H & Haendler B, 
2006}.SHRs are structurally organized in four main domains: an N-terminal region bearing 
important transactivation functions, a DNA-binding domain (DBD) composed of two zinc 
fingers, a hinge region harbouring the nuclear localisation signal and a ligand-binding domain 
(LBD) with additional transactivation functions {Vihko  et al, 2006}. 
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Figure 1.15. Folding and signal transduction overlap steroid receptors. Steroid receptors are 
assisted by the Hsp90 molecular chaperone machine, which acts both as a facilitator and 
repressor. The hormonal ligand triggers the completion of folding and maturation and pushes 
the equilibrium towards signal transduction {Picard, 2006}. 
 
Binding of agonistic or antagonistic ligands leads to different conformational changes of 
SHRs making them capable of exerting positive or negative influences on the expression of 
target genes by different mechanisms: (i) after separation of chaperones, the hormone-SHR 
complexes can bind to chromatin organized DNA sequences in the vicinity of target genes, 
termed hormone response elements (HREs). The HRE-recruited hormone-receptor-complexes 
are then able to initiate chromatin remodelling and to relay activating or repressing signals to 
the target genes transcription machinery; (ii) through protein-protein interactions with other 
sequence-specific transcription factors; by this mechanism SHRs can also regulate the activity 
of many genes that are switched on, for instance, during stress or an inflammatory response; 
(iii) the SH response can also be integrated in the intracellular signalling network via cross-
talk of SHRs with signal transduction pathways that transmit extracellular signals via 
membrane receptors and activation of protein kinase cascades to nuclear transcription factors 
that activate various target genes. By all these different mechanisms SHRs modulate 
numerous and specific responses in a large variety of cells, whereby their particular effect 
depends on the physiological, cellular and genetic context {Faus & Haendler, 2006}. 
 
The recent discovery of oestrogen receptor beta (ERβ) and its possible role as an anti-
proliferative agent has renewed interest in the role of steroid hormone receptors in prostate 
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cancer {Walton  et al, 2009}. It has been reported that ERα, ERβ, PR and AR expressions 
were increased in male breast cancers compared to female breast cancers where ERβ 
expression was dramatically reduced {Murphy et al, 2006}. There are conflicting reports on 
ERβ gene expression in prostate cancer; majority of protein studies document a down-
regulation of ERβ in PCA. However, a recent study using qRT-PCR analysis of SHRs gene 
expression in laser microdissected PCa specimens (11 samples) revealed an up-regulation of 
ERβ gene expression compared to benign controls {Walton et al, 2009}.The same study 
reported, arguably, no significant differences in AR, ERα or PSA gene expression between 
cancer groups and benign controls. In contrast, PR gene expression was significantly down-
regulated in the cancer group. Understanding the distribution and expression patterns of SHRs 
in prostate cancer may offer a wide range of applications for both therapeutic and diagnostic 
interventions. In a very remarkable study reported in 1963, Leblond showed that the prostate 
gland and the breast share similar proliferative capacity; an observation that underpins the 
importance of SHRs in carcinomas of both organs. 
 
c) Transformation to Androgen Insensitivity: The cause of androgen resistance in PCa 
treatment remains largely unknown. There are four different theories in the AR involvement 
in hormone insensitive (hormone refractory) status of prostate cancer cells. First, that prostate 
cancer cells loose the ability to express AR {Droller, 1997}. This hypothesis is the least 
favourable explanation of androgen insensitivity because it is now known that AR is more 
expressed in malignant than benign prostate cells {Rong Hu et al 2009}. Second, that prostate 
cancer cells express mutated AR, with ligand binding domain (LBD) unable to bind ligands 
(androgens and anti-androgens). The mutated AR lack regulatory activity, and have abnormal 
spatial conformation, which inadvertently allows it to bind other enhancers, for example, 
gastrin releasing peptide even in the presence of androgens {Yang et al 2009}. The AR is 
known to have numerous mutations, which makes this hypothesis worth further investigation. 
Third, that clones of androgen –resistant cells develop from mutated stem cells (cancer stem 
cells) ab initio and expand as androgen-sensitive clones die due to treatment. That is 
treatment selects mutant clones. Fourth, that clones of androgen-resistant cells evolve (by 
sporadic mutations, deletions, etc) and survive during androgen therapy {Droller, 1997}. 
Such adaptive responses will also include the expression of alternatively spliced AR variants 
that lack LBD, for example, the AR-V1 and AR-V7 described by {Rong et al 2009}; 
evolution of somatic mutations that confer resistance against anti-androgens {Hara et al 
2005} and possible gene amplification (copy number variations). The AR is discussed further 
in chapter two. Another secondary explanation to androgen insensitivity in prostate cancer 
progression is the evidence from transformation studies on refractory phase of PCa in 
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LNCAP cell line. The study reported substantial changes in androgen and oestrogen 
metabolism in the cells during transformation suggesting oestrogen influence as the cause 
{Soronen et al, 2004}. This was supported by cDNA microarray screening results which 
showed over-expression of several genes up-regulated by oestrogen in the LNCaP cells. But 
this does little to explain how oestrogen influence can induce androgen insensitivity because 
oestrogens are known to stimulate AR synthesis {Droller, 1997}.  
 
1.2  Diagnosis of Prostate Cancer 
 
Current clinical diagnosis of prostate cancer involves six different tests: i) prostate specific 
antigen (PSA) test, ii) prostatic alkaline phosphatase (PAP) test, iii) Digital rectal 
examination, iv) Transrectal ultrasonography (TRUS), v) Prostate cancer antigen 3 (PCA-3) 
test vi) Histopathological examination of prostate biopsy. None of these tests can be 
substituted for the other; each provides additional information necessary for clinical decision. 
However the first five tests are primarily screening tests, histology is the definitive test for 
diagnosis. Of the first four screening tests, a randomized controlled trial carried in Rotterdam 
between 1994 and 1996, reported PSA as the strongest predictor for prostate cancer in favour 
of DRE and TRUS {Rietbergen  et al, 1997}. 
 
1.3.1  PSA testing 
 
PSA is the most important and most widely used tumour marker for prostate cancer; useful 
for diagnosis, staging and monitoring of progression {Darson, 1997; Darson et al, 1999; 
Becker et al, 2000}. The PSA is a glycoprotein produced predominantly by the columnar 
epithelial cells of the prostate. It functions to liquefy the seminal coagulum, facilitating 
motility of sperm cells and fertilization. The molecular forms and physicochemical properties 
of PSA are discussed in Section 2.3. The PSA was identified and reported by several 
independent groups in the 1970s, and by the 1980s it became translated into clinical use 
{McCormack, 1995}. It is measured in serum or plasma using enzyme linked immunosorbent 
assay (ELISA), an immunometric sandwich assay in which specific anti-PSA antibodies are 
used to detect and quantify the marker photometrically. ELISA can detect as low as 0.1ng/ml 
of PSA in serum. Normal prostate epithelial cells produce more PSA glycoprotein than the 
malignant prostate tissue, and PSA mRNA is also expressed at higher levels in benign tissue 
than in malignant prostatic tissue {Panek et al, 1997}. It is believed that the PSA leaks into 
the blood stream as a result of deformations in the architecture of the prostate gland during 
trauma and or disease {McCormack, 1995}. 
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Large amounts of PSA (0.5mg/ml) are present in the seminal fluid (SF); while the 
serum/plasma level depends on the patient’s age and prostatic volume. For men aged 50 
years, the serum level is usually below 4.0ng/ml. It can increase up to 6.5ng/ml in men aged 
70-79 years {Moul, 2000}. PSA is also detectable in urine but the urinary levels have no 
clinical significance {Panek et al, 1997}. There is a substantial overlap in serum PSA levels 
in men with BPH, PIN, acute prostatis; prostatic ischaemia, and men with PCa {Panek et al, 
1997}.  
 
There is a controversy on exact cut-off level for accepting normal PSA, but the European 
association of Urology (EAC) guidelines on prostate cancer recommends < 2.5-3.0ng/ml 
especially for younger men (< 50 years of age) {Heidenreich  et al, 2008}. The reason for the 
controversy is that the sensitivity and specificity of PSA testing vary inversely at any chosen 
cut-off level (Table 1.7) {Djavan, 2004; Vickers et al, 2007}. In many countries 4.0ng/ml cut-
off point is commonly used, giving sensitivity and specificity of ~ 20% and 94% respectively 
{Thompson et al, 2005}. The implication of this is that the PSA as a biomarker has a weak 
correlation with prostate malignancy.  To improve the diagnostic utility of PSA testing, some 
other modifications of the test (ratiometric tests) have been evaluated: free to total PSA ratio, 
PSA velocity, PSA density, PSA doubling time and PSA and hK2 product. These 
modifications are discussed in Section 2.3. As a result of weak correlation with malignancy, 
elevated PSA is not on itself conclusive, further tests such DRE, PAP test, TRUS, PCA-3 are 
conducted before eventually carrying out a prostate biopsy. 
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Table 1.7 Sensitivity and Specificity for PCa by Cut points of PSA {Djavan, 2004}. 
                                                                                                 Any Cancer (n=1225) vs.  
                                                                                                 No Cancer (n=1362) 
PSA, ng/ml Sensitivity Specificity 
1.1 83.4 18.9 
1.6 67.0 58.7 
2.1 52.6 72.5 
2.6 40.5 81.1 
3.1 32.2 86.7 
4.1 20.5 93.8 
6.1 4.6 98.5 
8.1 1.7 99.4 
10.1 0.9 99.7 
 
Despite the pitfalls (weak correlation and inconclusive outcome), PSA testing is widely used 
in mass screening exercises for early prostate cancer detection. The test is cost-effective, 
technically straight-forward and requires only a photometer to conduct the assay. Recent 
results of the European Randomized study of Screening for Prostate Cancer showed that mass 
screening using PSA test and DRE, followed by prostate biopsy for men with PSA > 3.0ng/ml 
yielded a 20% reduction in mortality from PCa {Andriole et al, 2009}. Other reports have 
also shown that PSA testing has increased the rate of prostate cancer detection, although with 
also an increase in the number of negative prostate biopsies {Welch et al, 2007}. The 
American Cancer Society recommends a yearly PSA testing for men aged 50 years, 
continuing until the man’s life expectancy is less than 10 year; other studies suggest an initial 
PSA test at age 44-50 as the stronger predictor of long-term PCa risk {Vickers, 2007}. 
 
1.3.2  Digital Rectal Examination 
 
DRE is usually carried out by a urologist or ultrasonography technician. Any nodularity, 
induration or asymmetry is usually considered abnormal and may necessitate further testing 
(PSA and needle biopsy). However, DRE method has low specificity for PCa, since BPH 
causes most of the prostate enlargements. DRE supplements PSA testing. 
 
TRUS is also performed by a urologist or an ultrasonography technician. Early studies 
suggested that prostate malignancies tend to be hyperechoic, but with improvements in high-
frequency transducers and real- time imaging, it became evident that not all PCa exhibited 
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this characteristic and many were indeed hypoechoic {Tobocman et al, 1997}.  It is now 
known that ultrasound reflections may fail to accurately reflect the histopathology of the 
prostate. TRUS also helps to determine prostate volume, the denominator in calculating PSA 
density. 
 
1.3.3  Prostate cancer antigen 3 (PCA3) testing 
 
First described by Bussemakers and colleagues in 1999, PCA3 formerly known as differential 
display 3 (DD3) is localised at chromosome 9q21 and encodes a prostate-specific mRNA that 
is highly overexpressed in PCa tissue compared with benign prostatic tissue {Marks  et al, 
2007}. The PCA3 does not encode a protein product. Its possible use as a urinary marker for 
PCa was suggested by de Kok et al in 2002. The clinic assay for PCA3, a real time PCR, was 
developed in the Nijmegen laboratory, the Netherlands; and results of controlled clinical trials 
in Canada and Austria confirmed the potential of the assay for PCa diagnosis {de Kok et al, 
2002}. Following the acquisition of patent right from Nijmegen by DiagnoCure Company 
and later by Gen-Probe USA, a new quantitative molecular test based on target capture, 
transcription mediated amplification and hybridization protection for PCA3 received CE 
mark in 2008 and it is now used in many clinical laboratories in Europe {Torres  & Marks, 
2006} . 
 
Biologically, the median upregulation of PCA3 from normal to tumour tissue was reported as 
34- fold, increasing to 66-fold in tumour tissues containing more than 10% cancer cells 
{Hessels et al, 2003}. Although biologic function of the PCA3 is unknown, its upregulation 
in cancer tissues provided a basis for detecting the presence of the gene in tissues containing 
only a small number of cancer cells, against a background of low expression by many normal 
or BPH prostate cells, in tissue biopsies and bodily fluid {de Kok  et al, 2002}. Thus, the 
importance of denoting PCA3 as a ratio with PSA mRNA (a surrogate for background 
prostate epithelial cell nuclear material) was established {Torres & Marks, 2006}. Equally 
important, a practical application was confirmed: the PCA3 ratio determined in voided urine, 
especially after light prostatic massage, or ‘attentive’ DRE was shown to be a sensitive and 
specific test for PCa{Hessels et al, 2003}. The validity of the assay depends very largely on 
informative specimen, that is, specimen with sufficient prostatic nuclear material measured by 
PSA mRNA. The result of the assay is expressed as a score (PCA 3 score) = (PCA3 mRNA/ 
PSA mRNA) x 1000. 
 
The diagnostic reliability of the PCA3 score has been evaluated in several studies. Marks et al 
2007 reported a sensitivity of 58% and specificity of 72% at the commonly accepted cut off 
score of 35 (Table 1.8). The PCA3 score of 35 means 35 mRNA copies of PCA3 per one 
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copy of PSA mRNA. Their report also showed an inter-run variation (precision) of about 
20%. Fradet et al (2004) reported a sensitivity of 50% and specificity of 76% at the PCA3 cut 
off score of 35, with an area under the receiver operating characteristics (ROC) curve (AUC) 
of 0.68 compared to AUC of 0.54 for PSA test. The PCA-3 test was clinically superior to 
PSA test {Marks LS et al, 2007}. 
 
Table 1.8 Sensitivity and Specificity of the PCA3 assay {Marks et al, 2007}. 
PCA3 Score cut 
off 
Sensitivity Specificity Odds ratio 
10 87 28 2.5 
35 58 72 3.6 
50 47 81 3.7 
 
A particularly important role of the PCA3 test appears to be in men with persistently elevated 
serum PSA levels (> 2.50ng/ml), but a negative initial biopsy {Torres & Marks, 2006} . In 
such men, who constitute a large problematic group, the odds ratio for the PCA3 test to 
predict cancer upon re-biopsy is 3.6, compared to only 1.2 for serum PSA testing {Marks  et 
al, 2007}. At the cut off point of 35, the PCA3 could only predict a 30% positive biopsy, 
increasing to 50% at PCA3 score of 100 {Marks et al, 2007}. 
 
Currently there is no clear-cut evidence that PCA3 score correlates with Gleason score; 
molecular grading would be invaluable in predicting the clinical outcome of intermediate 
Gleason score tumours (scores 6-7). Secondly, there is also the inverse relationship between 
sensitivity and specificity of the PCA3 score, much similar to that of PSA. At lower cut off 
points the sensitivity increases as the specificity drops (Table 1.8) compared to Table 1.7 for 
PSA. However, the factors that skew PSA results such as trauma, 5α- reductase inhibitors 
(finasteride and dutasteride), prostatic volume, age, inflammation and DRE do not affect 
PCA3 score {Torres & Marks, 2006}. The test uses 20-30ml of first catch urine after prostatic 
message. There are possibilities that the PCA3 test could be improved by addition of other 
tests such as the TMPRSS2: ETS gene-fusion and KLK2. Another important factor is that the 
regulation of the PCA3 gene is not clearly defined. The nucleotide sequence for the PCA3 
RNA has several SNPs, more than 100 SNPs (using the UCSC Genome browser). More 
studies are still required to define the biologic role of this RNA. 
 
 
 
 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
49 
1.3.4  Histopathological Examination 
 
The histologic examination of prostate biopsy is regarded as the gold standard for definitive 
diagnosis of prostate cancer. By the EAC guideline, in routine clinical practice, elevated PSA 
levels, a free to total PSA of < 20% and a PSA velocity of > 0.75ng/ml/yr are valid 
parameters associated with high risk PCa, which facilitate the indication to perform a prostate 
biopsy. The number of biopsies required for the optimal detection of PCa is controversial. 
Ultrasound-guided transrectal, laterally directed 18G core biopsy has become the standard 
way to biopsy material for histopathological examination {Heidenreich et al, 2008}. The 
patients are given anaesthetics (locally via periprostatic injections or orally as effective 
analgesia) and antibiotics (usually Ciprofloxacin). The EAC guideline recommends a 
minimum of 10 systematic (5 from each side), laterally directed cores or the use of Vienna 
normograms. Many studies have shown that higher intensity biopsies (increased number of 
needle cores) improve cancer yield (proportion of men whose prostate biopsies are found to 
contain cancer){Durkan et al, 2002}; some urologists advocate ‘saturation biopsy’ (32 to 38 
needle cores) claiming that micro cancers can still be found in many negative biopsies 
{Fleshner & Klotz, 2002}.Transition zone biopsies are not recommended in the first set of 
biopsies due to low detection rates {Heidenreich  et al, 2008}. Currently the detection rate of 
PCa by biopsy is 30% {Welch et al, 2007}. The EAC guideline recommends one set of repeat 
biopsies for cases with persistent indication (abnormal DRE, elevated PSA or histological 
findings suggestive of malignancy at the first biopsy). 
 
Several factors influence the detection of PCa in contemporary prostate needle biopsies 
(Table 1.9) {Bostwick & Meiers, 2006}. It is interesting to see that the low detection rate by 
prostate biopsy is contingent on several subjective factors; for example, false negative results 
from pathologists contributed between 0.6 to 1.0%. One of the anticipations of Bostwick and 
his colleague (2006) is that molecular diagnostics of needle biopsies will help improve the 
detection rate of PCa by biopsy. Often patients who have negative repeat biopsies face the 
difficult choice of a third biopsy; molecular testing may play a key role in reducing the 
number of negative prostate biopsies and associated risk (infection, bleeding and trauma). 
 
The histopathological examination provides reports on macroscopic and microscopic changes 
on the prostate tissues. Key information includes the degree of architectural changes in the 
glandular pattern of the prostate (histopathological grading) and the extent of cancer spread to 
microenvironment and adjacent structures (pathological staging). 
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Table 1.9 Factors that influence the detection rate of cancer in y prostate needle biopsies 
{Bostwick & Meiers, 2006}. 
Uncontrolled factors 
Patient risk factors 
Patient population (e.g., screening population vs. urologic practice) 
Patient symptoms 
Serum PSA 
Clinical stage 
Patient age 
Patient race 
Prior biopsy findings (e.g., PIN, ASAP) 
Prostate-related factors 
Prostate volume 
TRUS and other imaging findings 
 
Controlled factors 
Urologist-controlled factors 
Number of needle cores obtained 
Method of biopsy (e.g., random, ultrasound guided, etc.) 
Location of biopsy (e.g., laterally-directed biopsies vs. midline, etc.) 
Amount of tissue obtained (e.g., biopsy ‘‘gun’’ employed; operator skill) 
Pathologist-controlled factors 
Histotechnologist’s skill in processing and cutting prostate biopsies 
Number of needle cores embedded per cassette 
Number of tissue cuts obtained per specimen 
Pathologist’s skill in prostate biopsy interpretation 
 
a) Gleason Score: This is the most commonly used pathological grading for prostate cancer. 
Named after Dr Gleason who first described this grading system, the Gleason grading 
stratifies prostate cancers into five grades on the basis of glandular patterns (architectural 
patterns of prostatic glands) and degree of differentiation (the resemblance of tumour gland to 
normal gland) as seen under low magnification {Kumar et al, 2009}. Figure 1.16 shows Dr 
Gleason’s own simplified drawing of the five Gleason grades of prostate cancer. 
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Figure 1.16 Dr Gleason’s simplified drawing of the five Gleason grades. Grade 1 appears on 
the far left and grade 5 on the far right. Source: 
http://www.phoenix5.org/Infolink/GleasonGrading.html#Grades 
 
Grade 1 represents the most well differentiated tumours, in which the neoplastic glands are 
uniform and round in appearance and are packed into well-circumscribed nodules {Kumar  et 
al, 2009}. They closely resemble normal prostate, seldom occur in the general population and 
have a better prognostic outcome. Grades 2 are similar to grade 1 but the tissues are loosely 
aggregated and some glands wander (invade) into the surrounding stroma (muscle). Grade 3 
is also well differentiated (have glandular patterns) but more invasive (cancer cells wander 
into stroma). The cells are darker and the glands have more variable shapes. It is the most 
common grade by far {Kumar et al, 2009}. Grade 4 involves a huge disruption and loss of 
normal gland unit Figure 1.17. 
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Figure 1.17 Grade 4 prostate carcinoma. There is a complete loss of glandular units. 
http://www.phoenix5.org/Infolink/GleasonGrading.html#Grades 
 
The appearance of grade 4 varies in many cases due to the degree of loss of glandular pattern. 
By contrast Grade 5 tumours show no glandular differentiation, and the tumour cells infiltrate 
the stroma in the form of cords, sheets and nests {Kumar et al, 2009}. They are poorly 
differentiated. 
 
Because most tumours contain more than one pattern, it is usual to assign a primary grade to 
the dominant pattern and a secondary grade to the subdominant pattern. The two numerical 
grades are then added to obtain a combined Gleason score or sum. For example, a Gleason 
score of 5 (2+3) means that the primary grade is 2 and the secondary pattern is 3. The lowest 
Gleason score is 2 and the highest is 10. In clinical practice, Gleason score of 5 and below 
(low grade) are rarely reported. The middle grade- Gleason scores 6 and 7 are the most 
abundant while the high grade consists of 8-10 (least or poorly differentiated) and are very 
aggressive. Grading (Gleason score) is of particular importance in prostatic cancer because 
there is in general fairly good correlation between the prognosis (disease outcome) and the 
degree of differentiation {Kumar V et al, 2009}.  However the clinical behaviour (degree of 
aggressiveness) of intermediate Gleason scores (5 -7) is very unpredictable and may require 
additional prognostic factors for better assessment {Isaac, 1997}. The majority of PCa (76%) 
fall into the intermediate Gleason score category {Isaac, 1997}. 
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b) Staging of PCa: There are two different stagings of PCa: pathological (done by the 
pathologist) and clinical staging (done by the Urologists).  Staging describes the anatomical 
extent of disease spread. The current system of staging is based on assessment of three 
components: T- the extent of the primary tumour, N- the absence or presence and extent of 
regional lymph node metastasis and M- the absence or presence of distant metastasis. This is 
known as the TNM system. Older systems of staging such as the ABCD (Jewett-Whitmore) 
system are still used by some Clinicians. Table 1.10 summarizes the staging of prostate 
adenocarcinomas using the TNM classification system {Wittekind et al, 2005}. Staging of 
prostate cancer is also important in the selection of the appropriate form of therapy and in 
establishing a prognosis {Kumar et al, 2009}. 
 
The EAC guideline for the primary treatment of prostate cancer is based largely on staging of 
PCa.  The combination of Gleason score and PCa staging is the strongest prognostic and 
predictive factors in the management of prostate cancer. The Partin coefficient tables (named 
after Dr Partin AW one of the authors) can be used to combine data on the PSA value, the 
Gleason score, and the clinical stage of a specific patient in order to predict the pathological 
grade of PCa tumour {Partin  et al, 1997}. The table helps to assess the risk of a patient 
having organ-confined disease (curable by surgery), capsular penetration, spread to seminal 
vesicles or lymph nodes. Although the Partin coefficient table has not been validated through 
controlled clinical trials, the authors showed that the normograms correctly predicted 
pathological stages in 72.4% of all the cases. 
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Table 1.10 The TNM classifications for Prostate adenocarcinoma 
{Wittekind et al, 2005} 
Stage                   
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1a  Tumour in ≤5% of tissue (found incidentally) 
T1b >5% of tissue 
T1c Needle biopsy (due to elevated PSA ) 
T2 Confined within prostate 
T2a ≤ half of one lobe 
T2b >half of one lobe 
T2c Both lobes 
T3 Through prostatic capsule 
T3a Extracapsular 
T3b Seminal vesicle (s) 
T4 Fixed or invades adjacent structures: bladder neck, external sphincter, rectum, 
levator muscles, pelvic wall 
N Regional lymph nodes 
M1a Non-regional lymph nodes 
M1b Bone (s) 
M1C Other site (s) 
 
1.3.5  Supplemental and Future tests 
 
Serum levels of prostatic acid phosphatase (PAP) had been used as a tumour marker of 
prostate cancer. The acid phosphatases are a group of enzymes capable of hydrolyzing esters 
of orthophosphoric acid in an acid medium {Igawa et al, 1995}. They are widely distributed 
in human tissues, with some isoenzymes that are tissue-specific. The human prostate is 
particularly rich in the PAP, a 100 kDa glycoprotein that exists in two forms: secretory and 
cellular forms, which are physico-chemically different. Although the serum PAP level is 
negligible in healthy individuals, its level is elevated in prostate cancer patients and correlates 
with the stage of prostate cancer {Veeramani et al, 2005}.  The cellular form of PAP has been 
a useful marker for the detection of metastatic prostate cancer, due to its cell-specific 
expression {Veeramani et al, 2005}. Splice variants of the cellular PAP which are membrane- 
bound have been reported to have ecto-5'-nucleotidase activity (does not hydrolyze 5'-
nucleoside monophosphates) and has been implicated in the formation of chronic pain in 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
55 
patients with bone metastases of PCa {Zimmermann, 2009}. Generally, serum PAP (secreted 
form) level has low sensitivity and specificity for diagnosis and monitoring of PCa; it is 
unable to detect early tumour stage but markedly increases in patients with bone mestastases 
of PCa. Recent studies have shown that the cellular PAP plays a role in prostate 
carcinogenesis, which has a potential application for prostate cancer therapy. It is reported 
that cellular PAP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer 
cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor 
receptor-2) at the phosphotyrosine (p-Tyr) residues {Veeramani S et al, 2005}. 
Dephosphorylation of HER-2 at its p-Tyr residues results in the down-regulation of its 
specific activity, which leads to decreases in growth and tumorigenicity of those cancer cells. 
Conversely, decreased cellular PAP expression correlates with hyperphosphorylation of 
HER-2 at tyrosine residues and activation of downstream extracellular signal-regulated kinase 
(ERK)/mitogen activated protein kinase (MAPK) signaling, which results in prostate cancer 
progression as well as androgen independent growth of prostate cancer cells {Veeramani  et 
al, 2005}. The expression of the cellular PAP decreases with progression of prostate cancer. 
However, these studies are in vitro; more clinical studies are required to confirm the activity 
of cellular PAP.  
 
New tests for prostate cancer diagnosis, staging and monitoring are emerging. Recently, the 
result of metabolic profiling of 262- prostate related bio-specimens analyzed by liquid and 
gas chromatography-mass spectrometry techniques showed that sarcosine, an N-methyl 
derivative of the amino acid glycine was a potential marker for PCa {Sreekumar  et al, 2009}. 
Sarcosine was identified as a differential metabolite that was highly increased during prostate 
cancer progression to metastasis and can be detected non-invasively in urine. It is known that 
AR and TMPRSS2: ERG gene fusion products co-coordinately regulate components of the 
sarcosine pathway {Tomlins et al, 2007; Sreekumar et al, 2009}. Although further clinical 
studies are required to establish the sarcosine urine test, it has a potential for development of 
biosensors that can be used for testing it at point of care. 
 
Another metabolic tumour marker of PCa recently reported is the fatty acid synthase (FASN). 
The FASN is a 270 kDA cytosolic complex enzyme that functions as a homodimer, catalyzes 
the synthesis of palmitate by the condensation of malonyl-CoA and acetyl CoA {Benedettini 
et al, 2008}. FASN seems to play a crucial role in PCa by conferring growth and survival 
advantages to cancer cells, maintaining membrane biogenesis and membranous signalling 
proteins regulation, providing protein palmitoylation, which is a post-translational 
modification critical in cancer progression {Benedettini  et al, 2008}. The over expression of 
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FASN in the prostate occurs during the earliest stages of neoplastic transformation (PIN 
lesions) and in nearly all invasive prostate carcinomas {Kuhajda, 2000}. FASN is a key 
player in lipid metabolism and tumour altered lipogenesis might represent a potential marker 
in tumour diagnosis (because it emerges early in carcinogenesis) and a target in treatment of 
advanced carcinomas {Benedettini  et al, 2008}. 
 
In addition to metabolic profiling, future tests for prostate cancer will also consist of 
molecular and genetic tests. A wide range of molecular markers have been reported, this is 
discussed in details in section 1.4.3. Genetic tests such as SNPs, DNA methylation and copy 
number variations are likely to be translated into clinical setting. This is discussed in section 
2.8. 
 
1.4  Molecular and Metabolic alterations in Prostate Cancer 
 
1.4.1  Metastasis of Prostate Cancer 
 
Metastasis (spread of cancer cells) is highly selective and consists of a series of sequential, 
interrelated steps that include growth, vascularisation, invasion, survival in the circulation, 
adhesion, extravasation, and proliferation at distant site {Isaacs, 1997}. In these seven steps, 
acquisition of metastatic ability by prostate cancer cells manifest not only by increased 
protein expression but also by decreased expression of metastasis- suppressor proteins 
through inactivation of their genes by either mutation, allelic loss, or epigenetic inactivation 
{Isaacs, 1997}. Any of these steps are potentially targets to serve as biomarkers of metastasis. 
For example, lack of metastatic ability in some prostate cancers is attributed to inadequate 
angiogenesis during prostatic carcinogenesis. Folkman et al (1989) demonstrated that the 
induction of angiogenesis is a critical step involving the conversion of hyperplastic lesions 
with low tumourigenic ability into cancerous lesions that can produce continuously growing 
tumours. Therefore, quantitation of angiogenesis was considered as a highly effective method 
for predicting aggressiveness of PCa. An example of such quantitation is the use of 
immunocytochemical staining with anti-factor -8- related antigen antibodies to identify 
endothelial cells, which represent vascularization {Weidner  et al, 1993}. For PCa, the subject 
of tumour aggressiveness and metastasis is particularly important because not all histological 
PCa progress to aggressive forms that are life threatening. The ability to predict which 
tumours have the capacity to manifest aggressive behaviour requiring therapy becomes a 
critical issue as greater emphasis is currently placed on screening for earlier detection of PCa.  
 
Several studies have examined various proteins, especially those involved in the seven steps 
of metastasis, as prognostic factors (disease-modifiers) for predicting outcome in prostate 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
57 
cancer patients. In Table 1.11 Isaacs, 1997 reviewed several proteins including tumour 
suppressor proteins as possible prognostic factors. Freeman et al (1999) and Alison et al 
(2002) also reported possible prognostic utility of replicative proteins, the minichromosome 
maintenance proteins (MCMs). Vihko et al 2005 reported 17β Hydroxysteroid dehydrogenase 
(17HSD), a steroid hormone enzyme, as a possible marker of malignant transformation in 
prostate tumours. Quinn ID et al 2005 reviewed extensively the molecular markers of prostate 
cancer outcome; these include molecules involved in diverse processes such as cell 
proliferation, death and apoptosis; signal transduction, androgen receptor (AR) signalling, 
cellular adhesion and angiogenesis. Biomarkers identified to have potential prognostic value 
include p53, Bcl-2, p16INK4A, p27Kip1, c-Myc, AR, E-cadherin and vascular endothelial growth 
factor.  Although a multivariate analysis on the expression of these proteins appears critical, 
at least to accurately predict the aggressive nature of individual prostate cancer {Isaacs, 
1997}, it is possible that most of these proteins are differentially elaborated as a result of 
metastatic tumour biology and not drivers of metastases. The expression of most of these 
proteins may be suitably descriptive of metastasis rather than predictive. This may limit the 
ability of most of them to predict aggressiveness and therapy response. The TMPRSS2 gene 
fusion with members of the ETS family has also been identified as a predictor of PCa 
metastasis, with its occurrence correlating to worse outcome and high histological grades 
{Cross et al, 2008}.  
 
When PCa spreads, it invades extra-prostatic tissues such as the seminal vesicles, ejaculatory 
ducts, the urethra and urinary bladder; it also seeds to the pelvic lymph nodes and in most 
cases will lead to bone metastases. It can also spread to visceral organs such as the liver and 
the brain. There is the need to establish molecular markers that can predict metastasis in 
locally confined PCa. Metastatic PCa is currently incurable. 
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Table 1.11. Possible Prognostic Factors for Identifying Aggressive Prostatic Cancers.  
{Isaacs, 1997} 
Parameters  in metastatic prostate cancers that are associated with  
increased expression include: decreased expression: 
bFGF KAI-1 
IL- 8 CD44 (standard form)  
mdr-128 E-cadherin  
72-kd type IV collagenase  Normal p53 (wild type) 
92-kd type IV collagenase  Angiostatin  
Mutant p53  β4 integrin subunit  
Angiogenesis (factor-8-related antigen)  γ-2 laminin 5 subunit  
 
1.4.2  Metabolic alterations in Prostate Cancer 
 
The metabolic changes during development and progression of PCa have been investigated in 
recent years. The prostate cancer cells, like normal prostate cells, also require androgens for 
their growth and functions. Several in vitro studies have reported alterations in androgen and 
oestrogen metabolism during neoplastic transformation of prostatic cells {Vihko et al, 2005; 
Soronen et al, 2004}. For example, Vihko P et al (2005) reported a remarkable decrease in 
oxidative 17 β-hydroxysteroid dehydrogenase (17 HSD) type 2 activity during cellular 
transformation in the prostate. Testosterone and DHT are mainly inactivated in the prostate 
by 17 HSD type 2 to A-dione and 5α A-dione. Decreased inactivation of androgens in the 
prostatic epithelium could shift the balance toward an increase in the proliferative pressure of 
cells and lead to unregulated prostatic growth. This observation is further supported by the 
fact that the chromosome locus for the gene that encodes 17 HSD, which is 16q24.1-16q24.2, 
is often deleted in prostate cancer specimens. The report by Soronen et al 2004 showed that 
during neoplastic transformation of prostatic cells, oestrogen influence is increased in the 
cells, and several of the genes up-regulated by oestrogens are over- expressed. 
 
Altered metabolism may not be the cause of prostate malignancies, although tumour cells 
may depend on altered metabolic pathways. Benedettini et al, 2008 reported that the lipogenic 
enzyme fatty acid synthase (FASN) seemed to play a crucial part in PCa by conferring growth 
and survival advantages to cancer cells. The FASN is a key metabolic enzyme that is 
responsible for the terminal catalytic step in de novo synthesis of fatty acids, which represents 
a common characteristic in human malignancies. Abnormal lipogenesis is a potential marker 
in tumour diagnosis and treatment. Cancer cells rely on anaerobic pathways to convert 
glucose to ATP, even in abundant oxygen, a phenomenon known as Warburg effect 
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{Benedettini et al, 2008}. Warburg in 1956 claimed that the first phase of cancer genesis is 
the irreversible injury to the respiratory chain. The anaerobic pathway is less efficient for 
energy supply than aerobic respiration which most of the normal cells use. In similar act, 
tumour cells produce fatty acids by de novo synthesis despite high levels of ambient fatty 
acids {Kuhajda, 2000}. Therefore over-expression of FASN in the prostate occurs during the 
earliest stages of neoplastic transformation (PIN lesions) and in nearly all invasive prostate 
carcinomas. 
 
Recent studies have also shown that amino acid metabolism, nitrogen breakdown and 
methylation are enriched during prostate cancer progression {Sreekumar et al, 2009}. There 
is a significant increase in methyltransferase activity during PCa progression. For example, 
the enzyme, histone methyltransferase (EZH2) is significantly increased in metastatic PCa 
{Varambally et al, 2008}. Through metabolic profiling, also in the context of molecular 
alterations, sarcosine was identified as a key metabolite increased most robustly in metastatic 
prostate cancer and detectable in the urine of men with organ-confined disease {Sreekumar et 
al, 2009}. The transcriptional regulators of prostate cancer progression: AR and the ETS gene 
fusions seem to regulate directly sarcosine levels by means of transcriptional control of its 
regulatory enzymes (Glycine N-methyltransferase GNMT, sarcosine dehydrogenase SARDH 
and dimethylglycine dehydrogenase DMGDH). Therefore, ‘components of the sarcosine 
pathway may have a potential as biomarkers of prostate cancer progression and serve as new 
avenues for therapeutic intervention’ {Sreekumar et al, 2009}. Other metabolites associated 
with PCa were also identified in the study: uracil, glycerol-3-phosphate, leucine, proline and 
kynurenine. 
 
The metabolism of the trace mineral selenium has also been associated with prostate cancer 
risk {Facompre & El-Bayoumy, 2009}. The report showed that the levels of selenium in 
blood and  
prostate tissue is inversely correlated with prostate cancer isk and proposed for its use for 
chemoprevention.  
 
1.4.3  Tumour markers of Prostate Cancer  
 
Tumour markers (TMs) are generally biochemical indicators (biomarkers) of the presence and 
or progression of a tumour. They include cell surface antigens, nucleic acids, cytoplasmic and 
nuclear proteins, enzymes and hormones {Eissa & Shoman, 1995; Kumar et al, 2009). 
Tumour markers (biomarkers) can be categorized into the following: 
 
a) Diagnostic markers (for detecting tumours for example PSA, PCA3). 
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b) Predictive markers (treatment modifiers because they help to match drugs with appropriate 
patients’ populations or predict response to therapy; for example HER2, KRAS mutation). 
c) Prognostic markers (correlate with disease outcome: invasiveness and metastasis, and can 
predict patients’ survival; for example TMPRSS2: ETS gene fusion, TP53 mutation, 
pathological stage, PSA relapse). 
d) Pharmacodynamic or therapeutic biomarkers (confirm biological activity; for example Bcr-
abl1, EGFR, PARP; and they can be direct targets for drug actions). 
e) Surrogate biomarkers (intended to substitute for clinical end points; for example Bcr-abl1)  
f) Risk factor (cancer susceptibility genes that portend risk; for example genetic variants such 
as SNPs, copy number variations; they predict risk but may not be causative).  
 
A single biomarker can belong to two or more categories mentioned above. Several molecular 
markers (biomarkers resulting from differential gene expression and genetic variations) of 
PCa have flooded cancer literature in recent years. Table 1.12 {Agrawal & Dunsmuir, 2009} 
summarizes the most documented molecular markers associated with PCa development and 
progression.  
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Table 1.12 Summary of molecular markers in prostate cancer 
{Agrawal & Dunsmuir, 2009} 
Marker Action Selected literature Potential use 
AKT and 
PTEN 
Prostate-specific phosphatase and tension homologue 
(PTEN) loss of function induces AKT (protein kinase) 
inhibiting apoptosis and may cause tubule regeneration with 
PIN. 
PTEN null mice develop high –grade PCa and metastasis. 
Genetic PTEN alteration seen in 10% primary PCa, > 30% 
metastases, PTEN loss induces p53 senescence. Possible 
use as gene therapy vector. See {Agrawal S & Dunsmuir 
WD, 2009} 
Prognostic and therapeutic 
AMACR Alpha methlyacyl coenzyme A racemase protein voided 
in urine. Involved in fatty acid β-oxidation. Androgen-
independent 
function as promoter of PCa 
100% sensitive, 58% specific. Small study. 
Histopathological 
biomarker 
Diagnostic 
AR 
Androgen receptor, nuclear transcription factor mediates 
Steroid hormones and stromal cell growth. AR 
Activation in luminal cells suppresses growth. 
Stimulates early PCa growth, gene amplification in 
30% AI tumours. AR mutations rare in untreated 
PCa. Vorinostat (histone deacetylase inhibitor) 
may reduce AR expression acting synergistically with 
Bicaltamide (AR antagonist) to inhibit PCa. 
Prognostic and therapeutic 
Bcl-2 
B-cell CLL/lymphoma 2, antiapoptotic protein found in 
basal cells and stem cells. Loss of expression linked to 
PIN, progression and androgen independence. 
Antisense oligonucleotides (Oblimersen) against Bcl-2 
delay progression, improves chemo-sensitivity. Docetaxel 
Combination trial underway (NCT00085228). 
Prognostic and therapeutic 
BRCA2 
Breast cancer type 2 susceptibility protein, tumour 
suppressor gene predisposes to Pca, chromosome 13q. 
< 5% Familial/young-onset cases diagnosed < 55 years 
old . 
 
Prevention 
CgA Chorionic gonadotropin alpha, neuroendocrine prehormone 
peptide. Unclear mechanism of action. 
 
Limited use and reproducibility. Correlation with time 
to androgen independence and adverse outcome . 
 
Prognostic 
Cyclin D1 Role in cell cycle from G1- to S-phase. Upregulation may be associated with androgen 
independence 
and poor prognosis. 
Prognostic 
E-
Cadherin 
Cell adhesion molecule. Down regulation/loss associated 
with invasion and metastasis. 
Close univarate T and M stage and survival significance Prognostic 
EGFR (Erb 
B1) 
Her-2/Neu 
(Erb 2) 
Activation associated with proliferation, malignant 
transformation, relapse, progression and androgen 
Independence [4]. Epidermal growth factor receptor 
(EGFR), human epidermal growth factor receptor 2 (Her2). 
Higher levels in PCa than BPH. Monoclonal 
antibodies directed against specific binding domains, 
anti-EGFR, e.g. cetuximab, anti-HER2, e.g. trastuzumab 
[16]. Lack of significant role in PCa. 
Prognostic and therapeutic 
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Table 1.12 Summary of molecular markers in prostate cancer (Continued)  
Agrawal & Dunsmuir, 2009} 
Marker Action Selected literature Potential use 
EN-2 Mouse engrailed-2 gene. Homoeobox-containing 
transcription factor/candidate oncogene, overexpressed 
in aggressive HRPC/PCa. May be positively modulated 
by PAX2. 
En-2 down regulation by siRNA decreases PAX2 and 
decreases PCa cell proliferation. PAX2 has been 
postulated as essential for PCa cell survival. 
Diagnostic 
and 
prognostic 
EPCA 1 and 
2 
 
Early prostate cell antigen, nuclear matrix protein. 
Associated with proliferative inflammatory atrophy 
(PIA), PIN and PCa. Generally not-detected in noncancer cases. 
No link to Gleeson score. Reported positive in BPH patients who 
subsequently developed PCa. EPCA 1 and 2, 92% sensitive, 94% 
specific. EPCA2 distinguishes localized vs. extracapsular disease (P 
< 0.0001). Awaiting larger trials. 
Diagnostic 
and prognostic 
 
ESR 
 
Oestrogen receptor located in stroma. Role unclear. 
 
Close univarate M stage and survival significance Prognostic 
 
EZH2 
 
Enhancer of Zeste homolog, histone methyl transferase 
Upregulation. 
 
Linked to high-grade PCa development Prognostic 
 
GSTP-1 
 
Glutathione-S-transferase P1 protects DNA from free 
radicals (caretaker gene). Loss of gene expression due 
to hypermethylation associated with PCa  
GSTP-1 hypermethylation: > 90% PCa, > 70% PIN, 
rare in benign disease. Urinary marker, may need 
prostatic massage. Small study. Diagnostic performance 
improved as a part of multiple gene panel 
Diagnostic 
 
IL-6 
 
Interleukin-6: cytokine immunomodulator. Linked to 
AR cells and suppression of androgen-dependent cells 
 
Elevated levels related to advanced disease but not 
prognostic. Possible role as combination markers 
Prognostic 
 
KLK3/PSA 
 
Encodes PSA, a kallikrein-related peptidase (serine 
protease subgroup) on chromosome 
Combination rV-PSA and fowl pox primed rF-PSA vaccines trialled. 
Phase II studies: median time to PSA progression increased (9.2–
18.2 months) (study 
ECOG7897). Phase III PARADIGM trial underway 
Prognostic and 
therapeutic 
 
KLK2/hK2 
 
Encodes hK2, a kalikrein-related peptidase (serine protease 
subgroup) on chromosome 19. Serum levels 
1% of PSA and undetectable in healthy males 
hK2 with free and total PSA significantly improved diagnostic 
sensitivity/specificity. Predicts prostate biopsy outcome (P < 0.001). 
Role in predicting recurrence/progression  
Diagnostic 
and prognostic 
 
MIB-1 
 
Mindbomb homolog 1, monoclonal antibody and cell 
proliferation marker by Ki-67 antigen recognition 
Close univarate T, M stage and survival significance Prognostic 
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Table 1.12 is by no means exhaustive; many other molecular markers such as CD44, MCM 
proteins, FASN, Aurora kinases A, B and C {Scharer CD et al, 2008; Freeman A et al 1999}; 
p16 INK4A, c-Myc, VEGF, VEGF receptors, EGFR family {Quinn et al, 2005} and those 
mentioned in Table 1.11 {Isaac, 1997} etc have been reported in PCa. Some of these markers 
have not been tested in larger clinical studies. 
 
1.5  Clinical Management of Prostate Cancer 
 
1.5.1  Primary Treatment modalities 
 
There are several options for primary treatment of prostate cancer. The EAC guideline for the 
primary treatment of PCa contains further details {Heidenreich et al, 2008}. The factors to be 
considered in choosing treatment options include: stage of PCa, patient’s age, life expectancy 
and choice, Gleason score and cost of treatment. The treatment options include: 
 
a. Watchful Waiting: This is also known as deferred treatment. It is a treatment strategy 
that includes an active standpoint to postpone treatment until it is required. In some 
cases there are proposals to encourage patients to participate in dietary and life style 
treatments. This is somewhat different from active surveillance which requires re-
biospy of patients after 18 months period {Heidenreich et al, 2008}. This treatment 
option is suitable for low grade PCa (well differentiated) PCa in patients who have 
longer life expectancy and low risk of disease progression. Some studies have shown 
that watchful waiting has a similar outcome in PCa of men aged < 65yr and with 
Gleason score < 7 compared to surgical treatment in 12 years follow-up period 
{Albertsen , 2009}. 
 
b. Surgery: This involves radical prostatectomy (RP) for clinical PCa that is still organ-
confined and localised. Nerve-sparing RP is the approach of choice for all men with 
normal erectile function and organ. 
 
c. Radiotherapy: This uses high energy rays (external beam) to destroy prostate cancer 
cells. At least 72 Gy is recommended for management of low risk PCa; dose 
escalation up to 81Gy may be used in intermediate and high risk PCa. 
d. Brachytherapy: This treatment involves implantation of radioactive ‘seeds’ (iodine-
125 or palladium-103) directly into tumour site to produce sustained-release of high 
energy for inactivation of cancer cells {Kirby & Xia, 2009}. Transperineal low-dose 
Brachytherapy is a safe and efficient technique that can be applied to patients with the 
following criteria: stage  cT1b-T2a No Mo, a Gleason score ≤ 6 , initial PSA level ≤ 
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10ng/ml, ≤ 50% of biopsy cores involved with cancer, and a prostate volume of < 
50cm3 and a good international Prostatic Symptom Score (IPSS) {Ash et al, 2000}. 
e. Cryosurgical ablation:  This involves the use of TRUS-guided transperineal freezing 
of the prostate using gas-based cryo-technology (cryo-probes), first applied in 1964 by 
Gonder et al {Langenhuijsen JF, 2008}. Patients ideally suitable for cryosurgical 
ablation of the prostate are those with organ-confined PCa, prostate size of ≤ 40ml, 
PSA serum level < 20ng/ml, and a biopsy Gleason score < 7  { Heidenreich  et al, 
2008}.  
f. High- intensity focused ultrasound (HIFU):  The HIFU treatment uses intersecting, 
precision focused ultrasound waves to raise the temperature of the prostate tissue to 
80-90oC in two to three seconds, effectively destroying the targeted cancerous tissues 
{Clement, 2004}. This does not involve incision (minimally invasive). It was 
approved by the National institute for clinical excellence (NICE) UK in 2005 for 
treatment of organ-confined PCa for research purposes only, and has achieved good 
biochemical outcomes, safety and efficacy in short-term evaluations{Ahmed  et al, 
2009} 
 
In general all primary treatment modalities have various shades of side-effects including 
urinary incontinence, impotence, urethral sloughing, urinary tract infection and rectourethral 
fistulas. 
 
1.5.2  Adjuvant and Salvage Treatments: 
Hormone therapy (HT) is the main adjuvant or neo-adjuvant treatment in PCa management. 
The luteinizing hormone-releasing hormone (LHRH) agonists have become the standard of 
care in hormonal therapy because they avoid the physical and psychological discomfort 
associated with orchiectomy and the lack of potential cardiotoxicity associated with DES 
{Heidenreich et al, 2008}.Androgen ablation is also achieved by administration of steroidal 
or non-steroidal anti-androgens (for example Bicalutamide 150mg per day). Combined 
androgen blockade is a common practice compared to monotherapy. Intermittent androgen 
blockade has also been shown to preserve quality of life and reduce treatment cost compared 
to continuous ADT {Heidenreich et al, 2008}. Indications for HT include both symptomatic 
and asymptomatic M1, N+ and locally advanced Mo stages. However, the most appropriate 
time to introduce HT in patients with advanced PCa is still controversial due to lack of 
controlled randomized studies {Moul et al, 2004}. Radiotherapy and Brachytherapy can also 
be used as adjuvant therapies. 
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Follow-up treatment with curative intent (Salvage therapy ST) varies in PCa management: 
 
a. In asymptomatic patients, a disease-specific history, PSA and DRE are the tests for 
routine follow up. The EAC guideline recommends these tests be performed at 3, 6 
and 12 mo after treatment, then every 6 mo until 3 yr, and then annually. 
 
b. Biochemical recurrence (BR): This broadly described as increase in serum PSA level 
after primary treatment. This could result from treatment failure (relapse) and or 
residual disease local or distant.  The exact definition of BR varies depending on the 
primary treatment modality {Roberts & Han, 2009}. Secondly, the clinical 
significance of BR sometimes referred to as ‘PSA only recurrence’ to survival is 
controversial in the literature. A common consensus for BR definition after radical 
prostatectomy (RP) treatment is a serum PSA level equal or greater than 0.4 ng/mL 
{Roberts & Han, 2009}.  However, the EAC guideline recommends a serum PSA 
level of equal or greater than 0.2ng/ml after RP as a BR. 
 
For radiotherapy (RT) as a primary treatment, the definition of BR remains hugely 
controversial. In 1997, the American Society for Therapeutic Radiology and Oncology 
(ASTRO) convened and defined BR as 3 consecutive rises in the PSA with the date of failure 
calculated as the midpoint between the last non-rising PSA and the first of the series defining 
failure.  In 2005 the Radiation Therapy Oncology Group (RTOG) in concert with ASTRO 
had a consensus definition of BR as a serum PSA rise of 2ng/ml above the nadir with the date 
of failure determined ‘at call’. This is also known as the Phoenix criteria, because the meeting 
was held in Phoenix Arizona {Roberts & Han, 2009}. The ASTRO criteria were then 
reserved for RT delivered in the absence of hormonal therapy (HT). The EAC guideline 
defines BR after radiation therapy as ‘a rising PSA level 2.0ng/ml above the nadir value, 
rather than a specific threshold value, is the most reliable sign of persistent or recurrent 
disease’ {Heidenreich et al, 2008}. Several studies have evaluated these definitions {Thames 
et al, 2003}. However, the importance of BR is as a predictor of metastatic progression (MP) 
and prostate cancer –specific mortality (PCSM). It is reported that BR precedes MP and 
PCSM by a median of 8 years and 13 years, respectively following RP {Roberts & Han, 
2009}. Therefore BR and other prognostic factors such as PSA kinetics (PSA doubling time 
and PSA velocity), Gleason score, pathologic stage and time interval between primary 
treatment and BR, are the key determinants of Salvage therapy options and survival outcomes 
{Roberts & Han, 2009, Heidenreich et al, 2008}. 
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c. Salvage therapy options: Timely initiation of salvage therapy may help to prevent 
further clinical progression and PCSM. Treatment options include radiation therapy, 
cryosurgical ablation, hormonal therapy, cytotoxic therapy and palliative 
management. Factors such as local or distant recurrence/ metastasis, hormone 
refractory status and side effects have to be considered. In patients with metastatic 
hormone refractory prostate cancer (HRPC), Docetaxel at 75mg/m2 every 3wk results 
in a significant survival benefit and represents the reference treatment {Heidenreich et 
al, 2008}. In patients with symptomatic bone osseous metastasis due HRPC, 
Docetaxel with prednisone is the treatment option of choice. Newer treatment options 
such monoclonal antibody therapies may improve survival outcomes in HRPC cases. 
Zoledronate may be offered to patients with skeletal metastasis to prevent osseous 
complications.  
 
d. Hormone-refractory prostate cancer (HRPC): The EAC criteria for defining HRPC 
include: i) serum castration levels of testosterone, ii) three consecutive rises of PSA 2 
wk apart resulting in two 50% increases over nadir, iii) Anti-androgen withdrawal for 
at least 4 wk, v) PSA progression despite secondary hormonal manipulations and vi) 
Progression of osseous or soft tissue lesions. Common complications due to skeletal 
metastases include bone pain, vertebral collapse or deformity pathological fractures 
and spinal cord compression. 
 
1.5.3  Advanced Therapy for PCa Management: 
 
The term advanced therapy (AT) refers to the triad of gene therapy (GT), cellular therapy 
(CT) – stem and somatic cells and tissue engineered bio-products {Schneider, 2009}. AT is 
still at the infantile stage (not yet clinically used) but remarkable progress has been made. 
 
a) Gene therapy: Several strategies for cancer gene therapy have been reported (Table 
1.13).   As at  July, 2007 there were over 1340 gene therapy trials (including 
completed, ongoing or approved trials) world wide {Edelstein  et al, 2007}. As at 
March 2009, there were 993 gene therapy protocols for cancer treatment 
http://www.wiley.co.uk/genmed/clinical/; although prostate cancer featured rarely. 
However, antisense oligonucleotides (AS) have been used to block Bcl-2 expression, 
inducing apoptosis in androgen-resistant prostate cancer cell lines. Blc-2 is anti-
apoptotic, and its over-expression is associated with PCa aggressiveness. Mu et al, 
2005 also reported that LNCaP and PC-3 prostate cell lines treated with AS were 
more sensitive to radiation therapy and showed increased p53 and p21 expressions.  
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Key challenges to cancer gene therapy include limitations in efficiency and targeting 
of gene-transfer vectors, incomplete understanding of control of gene transcription, 
long- term consequences of constitutive expression of a transferred gene , 
inflammatory responses and viral-vector tumourigenesis {Edelstein  et al, 2007}. 
 
Table 1.13 Strategies for cancer gene therapy. {Sikora & Pandha, 1997}. 
Gene marking in BMT and to detect minimal residual disease. 
 Genetic immuno-modulation 
 Cancer vaccines 
 Polynucleotide immunization 
Vectoring of bio-therapeutic genes to tumours 
 Increasing normal tissue tolerance 
Selective drug activation 
Somatic correction  of genetic defect 
 Antisense to mutant oncongene. 
 Expression of tumour suppressor gene 
 RNA interference 
b) Cellular therapy for PCa has been attempted in fewer preclinical studies, for example 
cellular vaccines expressing GM-CSF {McNeel, 2007}. 
 
c) Tissue engineered bio-products:  Preliminary results of Prostvac-VF, a vector based 
vaccine (recombinant vaccinia vector) targeting PSA in prostate cancer have shown 
negligible toxicity, and phase II trials have suggested a survival benefit after treatment 
of indolent prostate cancer cases and also possible combination with other treatment 
modalities {Madan, et al, 2009}.  Tumour –associated antigens (TAA) have become 
targets for vector-engineered bio-products designed for cancer therapy, for example 
prostate stem-cell antigen, prostate-specific membrane antigen, MUC1, epidermal 
growth factor receptor, platelet-derived growth factor and its receptor, urokinase 
plasminogen activator and its receptor, and extracellular matrix metalloproteinase 
inducer are TAAs currently targeted for PCa treatment { Li Young et al, 2009}. 
Clinical trials with immune active agents (immunotherapy) reported in the past years 
have demonstrated efficacy in the treatment of PCa. These agents include immune 
modulators such as GM-CSF and anti-cytotoxic T-lymphocyte-associated antigen 4 
monoclonal antibodies, antibody therapies targeting PSMA, and vaccines such as 
those targeting PAP, PSA, and cellular vaccines expressing GM-CSF { McNeel, 
2007}. 
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The main regulatory challenge to AT development is the need to demonstrate that an 
advanced therapy is high quality, safe and efficacious, using methods that are applicable for 
each specific product {Schneider, 2009}. There are also challenges of clinical trial design 
models since most ATs are for disease conditions with fewer alternative therapies (they will 
lack effective comparators). 
 
1.6  Trends in Prostate Cancer Research 
 
1.6.1  Overview of Progress in PCa Research 
 
There has been a remarkable advancement in prostate cancer research, especially in the PSA 
era (post 1980s). PSA measurement contributed tremendously to the increase in research 
activities in PCa. The key milestones include: 
 
a) The establishment of several prostate cell lines and xenografts (this is discussed in 
Section 1.6.2). This enabled a wide range of in vitro and ex vivo mechanistic studies 
 
b) Advancement in molecular genomics: Molecular tools such as array CGH 
interphase FISH, LOH analysis, PCR, DNA microarrays, bioinformatics and SNP 
arrays contributed immensely to prostate cancer research. For example the discovery 
of the TMPRSS: ETS gene fusion, a hallmark molecular event in PCa and 
premalignant lesions (PIN) by Tomlins et al in 2005 was largely due to insights from 
bioinformatics and the application of interphase FISH, Karyotyping and PCR {Cross  
et al, 2008}. The discovery of the PCA3 non-coding RNA by Bussemakers and 
colleagues in 1999 was another remarkable feat in PCa research, this time due to the 
application of Northern blotting and Phage Display techniques and RQ- PCR. The 
field of regulatory RNAs is burgeoning and may facilitate understanding of prostate 
tumourigenesis. 
 
c) The Human Genome project and the HapMap project: These were large scale 
events that drove all aspects of Genomics and genetics of all diseases. Launched in 
1990, the human genome project (HGP) was ‘completed’ in 2003 with > 95% of the 
human genome sequenced {Russell, 2007}. It created the physical map of the 24 
human chromosomes (22 autosomes, X and Y), identified the entire set of genes and 
mapped them all to their chromosomes; determined the nucleotide sequence of the 
estimated 3 billion base pairs and analyzed genetic variations among humans 
http://www.ornl.gov/hgmis/project/timeline.html (assessed on July 2008). Started in 
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2002, the HapMap project was an international effort to ‘identify and catalogue 
genetic similarities and differences in human beings’ 
http://www.hapmap.org/thehapmap.html.en (assessed on June, 2009). It has been able 
to identify about 10 million SNPs in humans, which provides an invaluable platform 
for clinical evaluation of genetic variations in cancer risk. Currently, there is no 
clinical genetic test for predicting prostate cancer risk but many candidate SNPs are 
evaluated. 
d) Advancement in clinical management: The introduction of robotic surgery to 
improve nerve-sparing in radical prostatectomy, advent of high intensity focussed 
ultrasound therapy and cyro-ablation gas-technology based on helium and argon gases 
have all improved the treatment of PCa and placed more demand on molecular 
characterization of the disease {Kirby & Xia , 2009}. Although more options are now 
available for treatment, the occurrence of HRPC remains the biggest challenge. More 
controlled trials are now conducted to evaluate various aspects of the disease 
management. There is optimistic prospect for tumour vaccine, gene therapy and 
targeted-therapy for PCa in the near future. 
e) Mass screening programmes: Although still hugely debated in terms of cost-
effectiveness, annual mass screenings of men in many countries have increased the 
public awareness for prostate cancer and improve early detection rate. Institutional 
funding for prostate cancer research has increased in the recent past {Kirby & Xia, 
2009}. However, the reports of the long-awaited ERSPC (European Randomized 
Study of Screening for Prostate Cancer) and the PLCO (Prostate, Lung, Colorectal, 
and Ovarian (PLCO)) clinical trials have not helped matters. The ERSPC trial showed 
a 20% reduction in prostate cancer specific mortality (PCSM) as a result of early 
detection by mass screening. However, the PLCO trial showed no significant 
reduction in PCSM as a result of early detection by mass screening (Andriole et al, 
2009). 
f) Novel technologies: Biomarker discovery and validation using multiplex array 
systems such as surface-enhanced laser desorption/ionization (SELDI) technology and 
MALDI-TOF mass spectrometry and LC/MRM-MS are widening the frontiers of 
proteomic analysis for cancer research in general {Dutton G, 2009}. For example 
there is the development of Prostaplex, a new multiplexed real time immuno PCR 
(MRI-PCR) for 10 prostate cancer biomarkers (low abundance proteins associated 
with PCa development and progression {Bradford, 2006; Wright SC, 2008}; the 
Prostaplex TM project is sponsored by the NIH (www.novoseek.com ). Such 
technologies will improve diagnostic reliability, reduce cases of negative biopsies and 
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ensure better monitoring of treatment. RQ-PCR can also used for gene expression and 
gene variation in the clinical laboratories. Samples such as urine, prostate biopsy and 
blood are evaluated in some of these technologies. 
An emerging area of diagnostics for PCa is biosensing using techniques such as 
electrochemical, optical and mass –sensitive detection techniques to develop point-of-care 
testing devices {Tothill, 2009} . Such techniques could detect proteins and nucleic acids in 
treated samples. There is also possibility of multiplex assay formats. However, factors such as 
analytical reliability, reproducibility, cost, throughput and pre-analytical variables such 
sample treatment have to be considered. 
 
Another area of interest in PCa diagnostics is analysis of volatiles in urine samples. The 
organic volatile constituents of biological fluids contain clinically useful diagnostic 
information for the recognition of metabolic disorders in man {Zlatkis et al, 1981}. For 
example, an investigation on lung cancer blood using SPME and GC-MS techniques, showed  
a much higher concentration of two aldehydes: hexanal and heptanal in lung cancer blood 
compared to control blood {Deng  et al, 2004}. By comparison of these volatiles in breath 
and in blood, it was demonstrated that hexanal and heptanal in breath were originated from 
blood and screening of lung cancer by breath analysis might be feasible. The two aldehydes 
are regarded as biomarkers of lung cancer. By using SIFT-MS technique, Spanel et al 1999, 
reported a significant elevation of formaldehyde in the headspace of urine from bladder and 
prostate cancer patients of unknown clinical history. The compound acrolein (2-propenal) 
was measured in breast cancer cells in vitro using chemical ionization mass spectrometric 
technique; acrolein was considered a maker for sensitivity of breast cells to doxorubicin drug 
{Kato et al, 2002}. 
 
1.6.2  Prostate cell lines for Research 
 
There are over 200 prostate cell lines and sublines for PCa research {Sobel & Sadar 2005}. 
These are derived from different sources including murine tumours, prostate adenocarcinoma; 
bone, liver, lymph node, vertebral and brain metastases; insertion of transgenes, viral 
immortalization and xenografts. Most of these prostate cell lines have been characterized 
based on the expression of PSA, AR, cytokeratins and other molecular makers of PCa and the 
prostatic lineage of a given line. There is a freely accessible on-line database of prostate cell 
lines for research: http://www.CaPCellLines.com.  Prostate cell lines mimic various aspects 
of human PCa and have proved useful in advancing prostate cancer research. However, it has 
been reported that most widely used prostate cell lines share common origins {van Bokhoven 
et al, 2001}. They share a high number of structural chromosomal abnormalities and nearly 
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identical DNA profiles. For example, ALVA-31, ALVA-41, PC-3, PC-3MM2, and PPC-1 all 
have a deletion of a C in codon 138 of the p53 gene and show almost identical DNA profiles. 
A study using Cytogenetics, mutational analysis and DNA profiling has shown that some of 
these cell lines could also be derivatives of one another or possibly contaminated by other cell 
lines {van Bokhoven et al, 2001}. This prompts necessity for proof of cellular origin of 
prostate cell lines used in research and for re-evaluation of results from cell line models.  
 
1.7  Aims and Objectives of this project:  
 
1.7.1  Aims of the Project: The overall aim of this research was to examine the link 
between development and progression of prostate cancer and production of 
diagnostic/prognostic molecular markers by manipulation of prostate cell lines in cultures 
supplemented with steroid hormones. The results from in vitro experiments were eventually 
compared with those of prostate tissues obtained from paraffin embedded sections, exfoliated 
urine cells and blood samples, all from prostate disease patients. There were five main 
research questions to address the overall aim of the project: 
 
a) How does the gene expression of steroid hormone receptors (SHRs) change in 
prostate cell lines in vitro in response to hormone treatment? 
b) How does the gene expression of putative molecular markers of prostate cancer 
progression change in prostate cell lines in vitro in response to hormonal modulation? 
c) Can genetic variants of KLK2 gene predict prostate cancer risk (presence of prostate 
cancer at biopsy)? 
d) Does gene expression of selected molecular markers correlate with clinico-
pathological variables in prostate cancer patients? 
e) Can organic volatiles in urine samples of prostate disease patients indicate prostate 
cancer? 
 
1.7.2. Objectives of this project: To achieve the overall aim, specific objectives were 
designed as follows: 
 
i. To evaluate gene expression of steroid hormone receptors(ER-α, ER-β and AR) in 
prostate cell lines stimulated with steroid hormones compared to untreated controls. 
Real time PCR (RQ-PCR), Immunocytochemistry (ICC) and western blotting (W/B) 
techniques were used.  
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ii. To determine diagnostic/prognostic value of SHRs expression using archived prostate 
sections and exfoliated urine cells of prostate cancer patients. RQ-PCR, IHC and W/B 
were also used 
iii. To measure the gene expression of prostate specific kallikreins (hK2 and hK3) in 
prostate cell lines modulated with steroid hormones, and in clinical samples. ELISA, 
RQ-PCR, IHC and ICC techniques were used. 
iv. To examine gene expression of molecular markers associated with apoptosis (p53 and 
Bcl-2) and cell proliferation (MCM2 and MCM5, Aurora kinases A, B and C) in 
hormonally treated prostate cell lines and in clinical samples using RQ-PCR, IHC and 
ICC. 
v. To evaluate gene expression of putative prognostic molecular markers: TMPRSS2 
gene fusions, and FASN correlation with clinical stage and histological grades. The 
RQ-PCR was used. 
vi. To measure the gene expression of molecular markers associated with prostate cancer 
metastasis (CD44 and E-Cadherin) in treated cell lines and clinical samples using 
Immunoflourescence and RQ-PCR. 
vii. To assess the frequency of genetic variants (SNPs) of KLK2 gene in predicting 
presence of prostate cancer at biopsy in both prospective patients and archived tissue 
materials. DNA direct sequencing, allelic discrimination assay and Pyrosequencing 
techniques were used 
viii) To explore the expression of volatiles in urine samples of prostate disease patients   
         using thermal desorption GC-MS technique. 
 ix) Extensive literature review of molecular markers associated with prostate cancer 
development and progression was performed. 
 
1.7.3 Study Hypotheses 
Key hypotheses in the study are as follows: 
a. Differential gene expressions of SHRs are associated with prostate cancer outcome. 
Disease outcome is measured by known clinical variables such as clinical stage and 
histological grade. The null hypothesis is that there is no significant difference in gene 
expression of SHRs in various clinical stages and histological grades of prostate 
cancer at a P value of 0.05. 
b. Frequency of SNPs in KLK2 gene predicts presence of prostate cancer at biopsy. The 
null hypothesis is that the occurrence of any SNPs is not significantly associated with 
presence of PCa at biopsy. 
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c. Molecular markers associated with cell proliferation (MCM2, MCM5 and aurora 
kinases A, B and C) are significantly over-expressed in high histological grades of 
prostate cancer, predicting worse outcome. Disease outcome is measured by known 
clinical variables such as histological grade and clinical stage. The null hypothesis is 
that there is no significant difference in the gene expression of the molecular markers 
in various histological grades and clinical stages at P value of 0.05. 
d. Molecular markers associated with prostate cancer metastasis (CD44 and E-Cadherin) 
are significantly over-expressed in high histological grades compared to low 
histological grades. The null hypothesis is that there is no significant difference in the 
gene expression of these markers in various histological grades. 
e. Gene expressions of TMPRSS2 fusion and FASN significantly correlate with prostate 
cancer progression (measured by increase in histological grade).   
f. Gene expressions of TP53 and Bcl-2 are differentially expressed in prostate diseases. 
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Chapter 2:  Molecular Markers of Prostate Cancer 
 
2.1  Molecular markers of Signal Transduction in Prostate Cancer 
 
2.1.1  Androgen receptor 
 
Androgen receptor is the key regulator of prostatic tissue functions. Located on the long arm 
of X chromosome (Xq12), the 180kb gene has 8 exons (for the longest variant), 4314 bp 
mRNA and 2,762bp open reading frame (OFR) (Figure 2.1) and codes for a 99 kDa protein of 
920 amino acid residues (longest isoform), which is found in both cytoplasm and nucleus of 
expressing cells {D'Antonio, 2008}. In the physical map of the human genome, the AR is 
localized on position 66680599 and ends at 66860844 bp from pter (based on HG 18, March 
2006). In the RefSeq database (the NCBI database) two main transcripts are curated: i) 
NM000044.2 is for longest transcript variant of 4314bp, 8 exons encoding 920 amino acid 
residues (isoform 1) and ii) NM001011645.2  is a shorter transcript variant of also 8 exons 
but 1765bp transcript length encoding 338 amino acid residues (isoform 2). This variant is 
also known as the AR45 variant. The difference between both variants is in the length of the 
5’ UTR region and the coding region (CDS) particularly the transactivation domain. For the 
longest variant, the 5’ UTR is 1.1 kb and the 3’ UTR is 6.8 kb. Several novel transcript 
variants of AR have been reported. The Ensembl genome browser describes an AR variant 
(AR-202) of 2 exons, 204bp length encoding 68 amino acid residues http://www.ensembl.org/ 
; the variant has a shorter N-terminal transactivation domain (NTTD) and DNA binding 
domain (DBD) without both the hinge region (HR) and the ligand binding domain (LDB). 
The longest transcript variant encodes a protein with all the four domains: NTTD, DBD, HR 
and LDB (Figure 2.1). Most of the novel variants differ by the absence of the DBD and/ or 
the length of the NTTD. For example Hu et al, (2009) reported 7 novel transcript variants of 
AR.  
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Figure 2.1 Structure of Androgen Receptor gene. The AR protein has four domains: N-
terminal transactivation domain NTTD, DNA binding domain DBD, Hinge region HR and 
Ligand binding domain LBD. Many novel variants of AR lack the LBD. {Litvinov et al, 
2003}. 
 
associated with HRPC (hormone refractory status) Figure 2.2.They all lack the LBD due to 
splicing at the cryptic exon (CE) points within intronic sequences, resulting in the loss of 
exons 4-8 which encode the LBD. Ligands (androgen or anti-androgens) bind to the LBD, 
with the ligand-bound receptor moving to the nucleus to cause transcriptional regulation of 
androgen- responsive genes: KLK2, KLK3, TMPRSS2 etc. Hu and his colleagues (2009) 
showed that AR-V1 and AR-V7 were particularly associated with biochemical recurrence 
(BR) and HRPC status. The protein products of these novel AR species are truncated.  
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Figure 2.2 Gene structure of novel variants of AR. CE stands for cryptic exons, that is, exons 
within intronic sequences. Exons 4-8 that encode the LBD are spliced off due to splicing at 
CE points 
 
Functionally, the AR is a nuclear transcriptional factor (mechanism of action was discussed in 
Section 1.2.4). As a result of its structure, certain ligands can activate it, especially in the 
absence of androgen or the LBD via the NTTD. For example, the neuropeptide, gastrin-
releasing peptide (GRP) which is also implicated in HRPC, is reported to aberrantly stimulate 
AR via the NTTD {Yang et al, 2009}. Another important structural feature of AR is the poly-
amino acid repeats (microsatellite polymorphism) in the NTTD (encoded by exon 1 and 
constitutes 60% of the protein); three different repeats are documented: i) the poly glutamine 
(CAG: Glu-Q), which is usually an average of 22 repeats (range 8 to 32); shorter (<18) length 
associated with increased AR transactivation and prostate cancer risk {D'Antonio, 2008},  
and also associated with worse outcome of PCa {Shimbo et al, 2005} . CAG repeats in spinal 
and bulbar muscular atrophy patients range from 38 to 62 {D'Antonio, 2008}; ii) poly Proline 
(Pro-P) has an average of 8 (not yet associated with any disease outcome); and iii) Poly 
Glycine (GGC: Glycine-G), which has an average of 23 (range 10 to 31). The AR is also 
known to have several single nucleotide polymorphisms (SNPs) and mutations; there are over 
605 reported mutations/SNPs of AR http://androgendb.mcgill.ca/map.gif. Inherited loss of 
function mutations of AR result in non-lethal loss of AR expression, a hallmark of androgen 
insensitivity syndrome (AIS), which leads to phenotypically female characteristics (Y 
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chromosome, functional testes but no male accessory organs) {D'Antonio, 2008}. The overall 
somatic mutation of AR in early PCa is estimated at < 10%. 
 
AR plays several key roles as a transcription factor of targets such as KLK2, KLK3, 
TMPRSS2, PSCA, p27,VEGF and PSMA genes; involve in cell cycle regulation, intracellular 
signal transduction and cell – to- cell signalling.  
 
AR expression is regulated by the stromal-epithelial signalling through paracrine actions of 
growth factors {Quinn, 2005}. The two prostatic cell types (stromal and epithelial) express 
AR but the epithelial cells express more AR than the stromal. Aberrant stromal-epithelial 
signalling (resulting in over-expressed AR in the epithelia and reduced AR in stroma) has 
been reported in many PCa {Hensall et al, 2001}. Over-expression of AR in the epithelia 
therefore leads to abnormal epithelial cell proliferation. However, the basal cells of the 
prostatic epithelium (believed to harbour ‘prostate stem cells’) do not express AR {Agrawal 
& Dunsmuir, 2009}. Another study also reported that AR activation in the luminal cells of the 
epithelium even suppressed prostatic growth {Dunsmuir, et al, 2000}. It is also known that 
androgens can stimulate epithelial cells to produce growth factors which act in both intracrine 
and autocrine fashions to increase AR expression. Although AR mediates the actions of 
androgens and anti-androgens, it is not clear as to what role does it play in the initiation of 
prostate malignancy. The general consensus is that increased AR expression in the epithelial 
cells leads to increased (abnormal) epithelial cell proliferation, a key feature of prostate 
malignancy. 
 
In addition, the over-expression of AR could result in part ‘from lack of response to 
homeostatic degradation mechanisms in cells with a mutated or amplified AR gene, while 
adjacent stromal cells have normal AR which is down-regulated’ {Quinn et al, 2005}. This 
proposition brings another complexity to AR signalling. Early studies on AR mutations were 
very conflicting {Wallen, et al 1999}. Most studies reported AR mutations in both normal 
and malignant prostatic tissues, and therefore concluded that it was not important for the 
initiation of malignancy. The discrepancy in most of the studies was that different exons were 
interrogated for mutations in different studies. In some cases the studies were concerned with 
AR mutations that occur during HRPC rather than at the beginning of PCa. Some other 
studies evaluated the correlation between AR mutation and AR over-expression. It is now 
known that the overall AR mutation in early PCa is less than 10% {D'Antonio, 2008}, and 
therefore cannot account for the initiation of malignancy in most of the cases. The second 
variable is the AR gene amplification (more than 3-5 copies of AR in a cell). Gene 
amplification results in gene over-expression. AR amplification is poorly documented in early 
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onset of PCa rather there are reports showing that AR is amplified in more than 30% of PCa 
recurrent after androgen ablation {Visakorpi et al, 1995}. The overall picture is that AR 
signalling in early PCa is poorly understood. However, its prognostic significance in PCa 
progression is better understood and well documented. For example the phrase ‘AR over-
expression is a feature of progression, recurrence, lymph node metastases and / or androgen 
resistance in human prostate cancer’ {Quinn et al, 2005} is a typical line of investigation in 
PCa literature, much more than early (onset) events. It is possible that in some PCa cases, AR 
may be amplified, over-expressed through epigenetic regulation and /or contain mutations 
that allow stimulation by a range of hormones and anti-androgens. The same mechanisms 
may also be applicable to AR signalling in PCa progression toward locally advanced or 
metastatic disease.  
 
Another epigenetic event is the hypermethylation of AR in about 40% of PCa cases 
{Reibenwein et al, 2007}; generally there is global DNA hypomethylation and locus-specific 
hypermethylation in PCa. One of the consistently hypermethylated gene in PCa is the GSTP1 
(in 75-95%) of PCa cases {Schulza & Hoffmannb, 2009}. The hypermethylated GSTP1 is a 
serum marker of PCa, also detectable in premalignant lesions such as high grade PIN but non-
detectable in healthy subjects {Reibenwein et al, 2007}. But in the case of AR, 
hypermethylation was also found in the serum of healthy controls. Further more, 
hypermethylation of AR promoter region is believed to down-regulate AR expression in PCa 
progression {Reibenwein et al, 2007} , an observation that contradicts the recent finding of 
AR over-expression in advanced PCa {Hu et al, 2009}. It is also known that 
hypermethylation is associated with ageing process {Schulza & Hoffmannb, 2009}.There 
might be other events causing AR hypermethylation rather than prostate cancer development 
and progression. However epigenetic alterations may play crucial roles in many adaptative 
changes that accompany PCa progression; and therefore would become highly useful for 
diagnostics and therapy of prostate cancer. 
 
Another important aspect of PCa progression is the involvement of AR in the development of 
hormone refractory status in prostate cancer. HRPC can occur in both locally advanced and 
metastatic PCa and it is very lethal. The overall theme is that the abnormality of AR 
signalling: over-expression, mutation, gene amplification, hypermethylation and/ or novel 
variants predict the occurrence of HRPC  Hu  et al, 2009; Schulza & Hoffmannb, 2009}. And 
that therapy (especially hormone therapy) could also select clones of AR expressed in HRPC 
status.  Several mechanisms may be involved simultaneously; however, AR abnormality is 
certainly a consistent feature of PCa progression. The expression of steroid hormone 
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receptors (SHR) in general is prognostic in a number of endocrine tumours; for example in 
breast cancers where oestrogen receptor (ESR) positive cases predict better outcome and loss 
of ESR expression predicts a more aggressive disease and resistance to hormone therapy such 
as tamoxifen {Marchio & Reis-Filho, 2008). Some studies have demonstrated that ESR 
positive breast cancers were also significantly AR positive and that most progesterone 
receptor (PR) negative breast cancers were also AR negative {Isola,  1993}. And the prostate 
and breast tissues are in many aspects very similar {Leblond, 1963}. 
 
2.1.2  Oestrogen receptors (ESR) 
 
There are two types of ESR: ESR alpha (ESRα, officially known as ESR1) and ESR beta 
(ESRβ, officially known as ESR2). They are located on different chromosomes, differentially 
expressed in many prostatic cell types and are believed to perform different roles {Murphy et 
al, 2006}. 
 
The ESR1 is localised on chromosome 6q24-q27 and has several transcript variants due to 
alternative splicing (http://www.ncbi.nlm.nih.gov/). The transcript variants differ in their 5 
UTRs and use different promoters. The Ensemble Genome browser (http://www.ensembl.org) 
describes 14 transcript variants of ESR1, having 2 to 10 exons, 731 to 6,466 bp transcript 
length encoding 115 to 595 amino acid residues. Some of the transcript variants encode the 
same protein. The longest variant encodes a 66 kDa protein (ESR66), some variants encode a 
truncated form (lacking N-terminal transactivation domain) and has a molecular mass of 46 
kDa (ESR46).  TheSwiss-Prot http://www.uniprot.org/ ) has a detailed analysis of the protein 
domains and amino acid modifications of the ESR1. The ESR1 (ESRα) gene was first cloned 
in 1986 {Zhao et al, 2008}. The ESR1 has a wide tissue distribution and are involved in 
pathological processes including breast cancer, endometrial cancer, and osteoporosis 
{Marchio & Reis-Filho, 2008}. 
 
The ESR2 is localised on chromosome 14q23.2, contains 8 exons and an opening reading 
frame of 1,593 bp (Figure 2.3) {Zhao et al, 2008}. The ESR2 was first isolated in rat in 1996, 
and also confirmed in humans in the same year {Kuiper et al, 1996}. It has two main curated 
isoforms: ESR beta1 (ESRβ1) and ESR beta 2 (ESRβ2) by alternative splicing. The ESRβ1 
protein is 59.2 kDa and contains 530 amino acid residues while the ESRβ2 is 55.5kDa and 
contains 495 amino acid residues {Zhao et al, 2008;  http://www.uniprot.org/ } . The ESRβ1 
sequence is the canonical sequence. The ESRβ2 protein has a unique C-terminus, where the 
amino acids corresponding to exon 8 are replaced with 26 unique amino acids. Six more 
isoforms of ESRβ have also been described at protein level {http://www.uniprot.org/}. The 
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Ensemble genome browser described 6 transcript variants (mRNA) of ESRβ, with 6 to 9 
exons, encoding 323 to 530aa residues. The ESRβ is expressed in many tissues: the ovary, the 
prostate, testis, bone marrow etc, and it is localised in the nucleus. 
 
Both forms of oestrogen receptors (ESR) share a high degree of homology in their DNA-
binding domains, a conservation of key amino acids within their ligand-binding domains and 
can form heterodimers with each other {Scobie et al, 2002}. Cellular signalling of oestrogens 
is mediated through the two receptors (alpha and beta types). Both receptors are nuclear 
transcription factors. They are essential for sexual development and reproductive functions, 
but also play a key role in other tissues such as bone {Dahlman-Wright et al, 2006}. Both are 
known to exhibit gene amplification (copy number variation) {Marchio & Reis-Filho, 2008}. 
However, there exact functions and distribution in distinct cell types vary; especially the 
function of ESRβ and its expression pattern are controversial. They are also known to 
regulate different sets of genes {Bardin et al, 2004}. They exhibit different affinities for some 
natural compounds {Zhao et al, 2008}. 
 
 
Figure 2.3 Genomic organization of human ER beta gene, protein and functional domains.  
Gene: exons are indicated with boxes and introns with lines. The numbers above each box 
indicate the size of the exons (bp); the numbers below each line designate the size of the 
respective introns (bp). Sectional lines between gene and protein point to protein domain 
junctions. Protein: numbers indicate the total size of the protein in amino acids. The shaded 
bar shows the divergent C-terminal regions between the isoforms. Amino acids 214 to530 (D-
F) represent the steroid binding domain, C is the DNA binding domain, and AB is the 
transactivation domain. {Zhao et al, 2008}. 
 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
80 
Binding of ligands (oestrogens and anti-oestrogens) activates ESR, by a mechanism that is 
similar to that of AR. However, oestrogen-modulated gene transcription is exerted via 
different mechanisms: the genomic and non-genomic pathways {Nilsson et al, 2001}. The 
representative model for ESR-mediated regulation of gene expression involves the direct 
binding of dimeric ESR to DNA sequences known as oestrogen response elements (EREs). 
The binding results in recruitment of a variety of coregulators to alter chromatin structure and 
facilitate recruitment of the RNA polymerase II transcriptional machinery. The transcriptional 
activity of ESRs can be altered by several post-translational modifications such as 
phosphorylation, acetylation, sumoylation, ubuquitination and methylation {Zhao, et al, 
2008}. 
 
In the prostate, the ESRs are expressed in both stromal and epithelial cells. The fibroblasts 
and the basal epithelial cells are known to express more ESR than other cell types; and it is 
believed that oestrogen enhances prostatic growth by direct effect on fibroblast and basal 
epithelial cells, and indirectly, as mediated by growth factor production {Droller, 1997}. 
Once again the stromal-epithelial signalling pattern involving paracrine mechanism of 
stimulation is hypothesized. However, the controversy as to which oestrogen receptor does 
what function, dates back to embryological development. Prins GS and colleagues in 2001 
demonstrated in mice that ESRα was the dominant ESR form mediating the development of 
oestrogenization of the prostate gland, a process that defined morphology and adult behaviour 
of the prostate gland in mice. They concluded that if the ESRβ were involved, it would be a 
minor role and would require the presence of the alpha type. However, in humans, the ESR 
alpha is the most extensively studied. It is the type involved in breast cancer. Luminal breast 
cancer tumours express ESR alpha which predict better prognosis {Marchio & Reis-Filho, 
2008}. In female breast cancers the ESR beta is often reduced. Murphy et al (2006) reported a 
concomitant high expression of ESR alpha and ESR beta in male breast cancers; with the 
report also showing increased expression of AR and PGR. 
 
Immunolocalisation studies have consistently identified the majority of ESR alpha staining in 
the prostatic stroma rather than epithelial cells {Bonkhoff et al, 1999}, which conforms to the 
paracrine mechanism of stromal-epithelial regulation. These studies imply that the ESR alpha 
is proliferative (activate genes that result in epithelial cell replication and proliferation). 
Several IHC studies have shown reduced ESR beta expression in prostate cancer {Horvath, et 
al, 2001; Zhu et al, 2004}. In other studies ESR beta expression was increased in metastatic 
PCa {Fixemer et al, 2003}. These conflicting reports implied that the function of ESR beta is 
either proliferative or anti-proliferative. Walton et al (2009) used laser microdissection to 
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isolate ‘pure’ population of benign and malignant prostate epithelium and measured ESR beta 
expression using RQ-PCR. The report showed that ESR beta was significantly over-expressed 
in malignant group compared to benign controls. They concluded that ESR beta could be 
proliferative; however further studies with increased sample size are required to confirm this 
finding (because Walton’s study examined only 17 specimens). It is known that oestrogens 
increase the levels of AR and stimulate prostatic basal epithelial cells to produce growth 
factors {Droller, 1997}. The emerging picture is that the stromal cells express more of ESR 
alpha while the epithelial cells express more of the ESR beta. In the healthy prostate, the 
predominant mechanism for regulating prostatic growth is the stromal-epithelial paracrine 
stimulation, but in the cancerous cells the epithelial cells are apparently independently 
regulated and may rely on their ESR beta for signal transduction (proliferation). This 
hypothesis is supported by the study of Walton et al (2009) which showed that there was no 
significant difference in AR and ESR alpha in both cancer and benign groups (because both 
receptors are involved the normal cellular proliferation). The implication of this hypothesis is 
that the ESR beta signalling could be the alternative driver of abnormal proliferation of 
prostate cancer cells; and it exerts proliferative pressure leading to abnormal AR production 
in advanced stage of the disease. Therefore ESR beta could be a therapeutic target in 
advanced PCa especially in the androgen insensitive stage. ESR beta over-expression could 
also predict poorer disease outcome. Torlakovic et al (2002) reported that ESR beta over-
expression was positively associated with Gleason Score. More studies are required to 
confirm that ESR beta over-expression is consistently observed in high histological grade 
PCa and also associated with pathological stage.  
 
2.2  Molecular markers of prostate cell proliferation 
 
2.2.1  The Minichromosome maintenance proteins (MCMs) 
 
DNA synthesis in eukaryotes is a complex, multi-step process that requires the participation 
of a number of proteins. The process involves the binding of Origin of Replication Complex 
(ORC) to replication origins, the recruitment of Cdc6 and MCM2-7 to form the pre-
replicative complex (pre-RC) and the activation of pre-RC by Cdc7 and Cdc28 protein 
kinases to initiate DNA synthesis {Tye, 1999}. The MCMs were first revealed to be involved 
in DNA replication as the result of a genetic screen for mutants defective in minichromosome 
maintenance in Yeast cells {Lei & Tye, 2001}. Localised on different chromosomes, the 
MCM complex consists of 6 members (subunits) known as MCM2-7, a family of highly 
conserved proteins that are responsible for DNA licensing to initiate DNA synthesis in all  
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eukaryotes {Tye, 1999}. However, there are other proteins also known as MCMs, for 
example, MCM1 and MCM10, these do not bear sequence homology with MCM2-7 and they 
are not directly involved with DNA licensing and formation of the pre-RC. 
 
The MCM2 gene is localised on chromosome 3q21.3, and has 16 exons, a transcript length of 
3,432 bp encoding a 102 kDa protein of 904 amino acid residues {Ensemble Genome 
Browser, 2009}. There is no known transcript variant of MCM2 (previously known as 
BM28). 
 
The MCM3 is localised on chromosome 6p12.1, and is currently known to have 4 transcript 
variants of 9, 17, 17 and 18 exons respectively; transcript length of 1030 bp to 3262 bp 
encoding a protein of 37 kDa {UCSC and Ensembl Genome browsers, 2009}. The MCM3 
interacts with MCM5 and CDC46 in the formation of pre-RC during replication licensing. It 
is also known to be acetylated by MCM3AP, a chromatin-associated acetyltransferase {Tye, 
1999}. The acetylation of MCM3 inhibits DNA licensing, disrupts initiation of DNA 
replication and halts cell cycle progression {Lei & Tye, 2001}. 
 
The MCM4 is localised on chromosome 8q11.21, and has 3 curated transcript variants of 16, 
17 and 18 exons, transcript lengths of 3.5, 3.4 and 3.3 kb encoding a protein of 93 and 97 kDa 
respectively {Ensemble Genome Browser, 2009}. The MCM4 was previously known as 
CDC21 and CDC54. Like MCM2, MCM 6 and MCM7, the MCM4 has a DNA helicase 
activity. Its binding to CDC2 protein kinase reduces the helicase activity and prevents it from 
binding to chromatin and MCM complex. 
 
The MCM5 is localised on chromosome 22q12.3, and has 11 transcript variants (10 are 
known protein coding and one has no known protein); two of the protein coding have a 
nonsense_ mediated decay (the protein products are not stable) (Ensemble Genome browser 
& Swiss-Prot, 2009). The transcript variants have 2 to 17 exons, transcript lengths of 450 to 
2545 bp, encoding protein isoforms of 7 kDa to 82 kDa (57 to 734 amino acid residues). The 
MCM5 was previously known as CDC46 {Tye, 1999; Lei & Tye, 2001}.  
The MCM6 (also known as Mis5) is localised on chromosome 2q21.3, and has 2 transcript 
variants: 3 and 17 exons, 320 and 3,743 bp transcript lengths, encoding 10 and 93 kDa 
proteins of 83 and 821 amino acid residues respectively {Ensemble Genome browser, 2009}. 
The MCM7 formerly known as CDC47 is localised on chromosome 7q22.1, and has 6 
transcript variants, 2 to 15 exons, transcript lengths of 240 to 2,821 bp encoding protein 
isoforms of 7 to 81 kDa (64 to 719 amino acids). Cyclin D1-dependent kinase, CDK4, is 
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found to associate with MCM7, and may regulate the binding of this protein with the 
retinoblastoma protein (RB1). 
 
Members of the MCM2-7 are all nuclear proteins that function together as a stable hexameric 
complexes involved in DNA licensing (MCMs bind to G1 phase chromatins to from 
replication fork) and  cell proliferation. The biochemical, physiological, evolutionary 
conservation and structural models of the MCM2-7 proteins are extensively reviewed by Tye, 
1999. Towards the beginning of the 21st Century, many studies reported the MCMs as pre-
cancer biomarkers in different types of human cancers {Freeman et al, 1999; Stober et al, 
1999; Alison et al, 2002). Most of those studies reported the MCMs as markers of 
proliferation potential and showed that their aberrant over-expression was associated with 
malignancy. In particular, the MCM5 protein was strongly associated with urothelial cancers; 
an immunoassay for its detection in urine samples was reported by Stoeber et al, (1999). 
MCM2 and MCM5 over-expressions (immunohistochemically detected) were also reported in 
muscle invasive urothelial cancers; in which they correlated significantly with both Ki-67 
proliferation- and p53 labelling-indices, and were associated with high-grade cases 
{Korkolopoulou et al, 2005}. The MCMs are down-regulated in cells undergoing 
differentiation-G2 and S phases or quiescence-G0 phase, and therefore are specific markers of 
proliferating cells {Freeman et al, 1999}. 
 
As the MCMs became established as markers of proliferation potential, many studies 
evaluated their prognostic utility. Meng et al (2001) reported that ‘prostate cancer patients 
with high MCM2 expression exhibited shorter disease-free survival’, following radical 
prostatectomy for localised PCa. However, the MCM2 expression was not associated with 
any traditional clinical or pathological factors and therefore was considered as an independent 
predictor of survival in patients with localised PCa. Another study also showed that 
deregulation of MCM proteins was characteristic of dysplasia, which also indicated early 
events in the development of malignancy {Alison et al, 2002}. However, it is important to 
point out that both normal and dysplastic cells express MCMs, but there is over-expression in 
dysplasia (intermediate stage in the progression from normal tissue to neoplasia). And the 
over-expression may not be particularly tissue specific. Therefore, dysplasia in the prostate 
would result in MCMs over-expression in as much as it would in urothelial bladder cells. But 
the diagnostic value of some specific MCMs, for example, MCM5 in urothelial cancers 
(detected by urinary assays) would still require large-scale studies to prove discrimination 
against other urological cancers including PCa. There are also variants of MCMs that are not 
protein coding, and may have differential expression in malignancy. 
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2.2.2  The Aurora Kinases (A, B and C) 
 
Cell cycle checkpoints have evolved to ensure the inheritance of undamaged DNA, and that 
each daughter cell receives the correct complement of chromosomes during mitosis {Scharer 
et al, 2008}. The Aurora family (with three members: A, B and C) of highly conserved 
serine/threonine kinases regulates cell entry into mitosis, centrosome maturation and the 
mitotic spindle checkpoint {Marumoto & Saya, 2005}. 
 
The Aurora kinase A (AURKA) is localised on chromosome 20q13.2, and has 14 curated 
transcript variants, exons ranging from 5 to 10, transcript lengths of 584 to 2,238 bp; 
encoding protein isoforms of  9 kDa to 46 kDa (79 to 403 amino acid residues) {UCSC and 
Ensemble Genome browsers, 2009}. Pseudogenes of AURKA have also been located on 
chromosomes 1 and 10. AURKA is involved in centrosome separation, microtubule 
formation and stabilization at the spindle during mitosis {Glover et al, 1995}. Over-
expression of AURKA is reported to confer resistance to the taxane paclitaxel (a mitotic 
inhibitor, which interferes with normal breakdown of microtubules during mitosis) {Scharer 
et al, 2008}; it is therefore suggested as a predictive marker for taxane resistant, ovarian 
cancer patients who are likely to benefit from a potential drug VE-465, still undergoing pre-
clinical studies. It is generally believed that AURKA may play a role in tumour development 
and progression because of its critical role in mitotic entry as well as mitotic spindle 
checkpoint {Seki et al, 2008}. Two proteins known to bind and initiate activation of AURKA 
are TPX2 and Ajuba {Scharer et al, 2008}. Qu et al (2008) reported that DNAzyme (DNA 
molecules with enzymatic cleavage activity) could be used to target AURKA mRNA in 
prostate cancer cells as a potential therapeutic agent. 
 
The Aurora kinase B (AURKB) is localised on chromosome 17p13.1 and has one transcript 
variant: 9 exons, transcript length of 1,245 bp encoding a 39 kDa protein of 344 amino acid 
residues {Ensemble Genome browser, 2009}. AURKB is a chromosomal passenger protein 
that begins mitosis localised to the centromeres but at the onset of anaphase relocates to the 
spindle equator {Keen & Taylor, 2004}. AURKB localizes to microtubules near 
kinetochores, specifically to the specialized microtubules called K-fibres; and it is known to 
regulate processes such as kinetochore and microtubule interactions, segregation of sister 
chromatids and cytokinesis {Scharer et al, 2008}. Immunohistochemical studies on prostate 
tissues and cell lines have demonstrated increased nuclear expression of AURKB in high 
Gleason score PCa compared to intermediate and low grades, as well as in all cancers 
compared to benign and normal  glands {Chieffi et al, 2006}. 
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The Aurora kinase C (AURKC) is localised on chromosome 19q13.43, and has 3 transcript 
variants of 7 exons each, variable transcript lengths (1,108 to 1,249bp) encoding protein 
isoforms of variable molecular masses (32 to 36 kDa; 275 to 309 amino acid residues 
respectively). The AURKC is expressed specifically in the male testis and has meiotic 
functions {Scharer et al, 2008}. 
Aberrant expression of the Aurora kinases can induce abnormal mitosis, centrosome 
dysfunction and chromosomal instability, which may lead to aneuploidy and neoplastic 
transformation {Lee et al, 2006}. Increased expression of AURKA and AURKB are reported 
in PIN and PCa compared to normal cells {Chieffi et al, 2006}. It is very likely that 
therapeutic agents that target the aurora kinases will be developed in near future to augment 
mitotic inhibitors like the taxanes (docetaxel and paclitaxel). 
 
2.3  Prostate tissue specific molecular markers: 
 
2.3.1  Prostate specific antigen (KLK3 gene) 
 
The KLK3 gene (PSA gene) is a member of the human tissue kallikrein family of genes (with 
known 15 members), belonging to the S1A subfamily of the serine proteases {Obiezu & 
Diamandis, 2005}. The tissue kallikreins are tandemly co-localised on chromosome 19q13.4, 
occupying a genomic space of 300 kb without any intervening non-kallikrein gene 
{Grimwood et al, 2004}. They share many common characteristics, including exon/intron 
organization (coding sequence spanning 5 exons), conservation in coding exons and intronic 
phases, presence of 5’UTRs and 3’UTRs; conserved amino acid residues and the location of 
three catalytic residues His, Asp and Ser {Yousef et al,  1999; Obiezu & Diamandis, 2005}. 
They are expressed in several different organs, and their transcripts code for single chain 
serine protease pre-proenzymes of 248-293 amino acids {Obiezu & Diamandis, 2005}. 
 
The KLK3, which encodes PSA (hK3, which is the official protein symbol) was first isolated 
from the seminal fluid (SF) in the 1970s by several independent groups {McCormack et al, 
1995}. It was then thought to be produced exclusively in males by the columnar epithelial 
cells of the prostate, although it is now known that some other tissues like the breast and 
seminiferous tubules also produce minute quantities of PSA {Partin & Marks, 2001}. 
Currently, there are 11 known transcript variants of KLK3 (due to alternative splicing) 
{Kurlender et al, 2005}, ranging from 2 to 6 exons, with the longest variant (6 exons) 
encoding a 24 kDa protein of 220 amino acid residues {Ensemble Genome browser, 2009}.  
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The molecular mass of PSA varies depending on the method of detection and also the degree 
of glycosylation (N-linked oligosaccharide attached to Asp-46, which constitute about 8% of 
PSA) {McCormack et al, 1995}. By mass spectrometry the actual molecular mass of PSA 
was 28.5kDa {Belanger et al, 1995}; and by gel electrophoresis the apparent molecular mass 
of PSA ranges from 30 to 36 kDa, which could result from aberrant behaviour of 
glycoproteins in gel systems {McCormack et al, 1995}. 
 
The primary biologic role of PSA is to cleave the major gel-forming proteins semenogelin I, 
II and fibronectin in SF into small peptides, resulting in increased sperm motility {Lilja et al, 
1993}. The diagnostic value of PSA has been discussed in Section 1.3.1 of this thesis. In that 
section, it was pointed out that the PSA has a weak correlation to prostate malignancy, and 
therefore many ratiometric (modifications) tests were introduced to improve sensitivity and 
specificity.  Some of these ratiometric tests are based on the molecular forms of PSA (Table 
2.1).  The PSA is capable of forming covalently linked complexes with certain serine protease 
inhibitors found in serum and these complexes are not dissociated by pre-analytical 
treatments{McCormack et al, 1995}. PSA is detectable in serum, urine and seminal fluid 
using immunometric assays such as ELISA. 
 
The ratiometric PSA tests include: 
a. Percent free PSA: this is the ratio of free- to- total PSA expressed in percent. In 
routine clinical practice, a free PSA ratio of < 20% in men with elevated total PSA 
levels (> 3.0ng/ml) is associated with a higher risk of PCa and facilitates the 
indication to perform a prostate biopsy {Heidenreich et al, 2008}. A cut off point of 
18% (free PSA ratio) was reported to increase sensitivity and specificity of PSA 
testing to 71 and 95% respectively {McCormack et al, 1995}. 
b.  PSA velocity:  this is the rate of change of PSA over time (expressed in ng/ml/year). 
A PSA velocity > 0.75 ng/ml/yr is an indicator for prostate biopsy {Heidenreich et al, 
2008}. The PSA velocity is reported to improve sensitivity and specificity of PSA 
testing to > 80% {Djavan, 2004}. 
 
c. PSA density (PSAD): this is the quotient of total serum PSA by prostate volume. A 
value of > 0.13 is considered abnormal {McCormack et al, 1995}.  
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d.  A product of percent free PSA and hK2: the combination (hK2 x tPSA/fPSA) was 
reported to increase specificity to 90% and sensitivity to 55% {Becker C, 2000}.  
Mean values of the product in benign and cancer patients were reported 0.3 and 0.67 
ng/ml respectively.  
 
Table 2.1 Molecular forms and Complexes of PSA.      
{McCormack et al, 1994; Obiezu & Diamandis 2005} 
Formal Name  Common Name Description 
Free PSA f-PSA Non-complexed PSA; may be proteolytically active or 
inactive in seminal fluid, only inactive in serum.  
Clipped free 
PSA 
Clipped 
positions: 
85-86,145-146 
and 182-183.  
Inactive forms of f-PSA; held together by internal 
disulphide bonds, co-migrates with active PSA as 30 
kDa in non-reducing SDS PAGE but form smaller size 
fragments in reducing SDS PAGE. 
Precursor forms PreproPSA and 
ProPSA 
PreproPSA is the proform with a signal peptide of 24 
additional residues. ~ 261 aa residues on the whole. 
The proform is the inactive zymogen, ~244 aa residues.  
Mature PSA PSA This is the extracellular PSA, enzymatically active and 
usually complexed. 
PSA Complexes PSA-ACT PSA covalently bound to α1-antichymotrypsin 
inhibitor in plasma. It is the major immunodetectable 
form in serum. 
 PSA-MG PSA covalently linked and encapsulated by α2-
macroglobulin; not immunodetectable, also known as 
occult PSA. 
 PSA-PCI PSA covalently bound to protein-C inhibitor; minor 
component in SF, not detectable in serum. 
 PSA-AT PSA covalently bound to α1-antitrypsin; trace 
components in serum. 
 PSA-IT PSA covantly bound to inter-alpha trypsin inhibitor; 
trace components in serum. 
Total PSA t-PSA All immunodetectable forms in serum, primarily f-PSA 
and PSA-ACT. 
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e. PSA doubling time (PSA DT): This is another measure of PSA kinetics, useful in 
follow-up to treatment. This is the time (usually expressed in months) it takes to reach 
twice the nadir value of PSA. For example PSA level after radical prostatectomy is 
expected to be zero because the prostate is removed. However, PSA relapse 
(biochemical occurrence) occurs in some patients, and a PSA DT of less than 10 
months is a predictor of metastatic progression {Roberts & Han, 2009}.                         
 
PSA mRNA is also detectable in blood and urine samples, but no clinical significance has 
been associated with its levels {Corey et al, 1997; Rittenhouse et al, 1997}. 
 
2.3.2  The human glandular kallikrein 2 (KLK2) 
 
The KLK2, another member of the tissue kallikrein family of genes, encodes the hK2, which 
has about 80% homology with PSA. Both are up-regulated in response to androgens and 
progestins; however the KLK2 is very prostate tissue –specific {Obiezu & Diamandis, 2005}. 
Unlike the PSA, the hK2 is expressed at higher levels in prostate adenocarcinoma than in 
normal prostate epithelium {Becker, 2000}. There are 7 known transcript variants of KLK2 
{Kurlender et al, 2005}, the longest variant encoding a 28.6 kDa mature protein of 237 amino 
acid residues {McCormack et al, 1995}. Unlike the PSA, the hK2 has trypsin-like protease 
activity, and it functions to cleave proPSA into active forms {Obiezu & Diamandis, 2005}. 
 
There are now commercially anti-hK2 antibodies that do not cross-react with PSA, 
facilitating the development of immunometric assays for hK2 {Piironen et al, 1996}. By 
comparison, in the human prostate tissue, the expression of hK2 mRNA is about 10% to 50% 
of PSA mRNA {McCormack et al, 1995}. Median value of serum hK2 (measured by a 
research immunometric assay) in a population study was reported as 56 pg/ml compared to 
3.1ng/ml for PSA {Partin et al, 1999}   Like the PSA, hK2 mRNA is detectable in blood, 
seminal fluid and urine {Corey et al, 1997}; and no clinical significance has been associated 
with its urinary level {Panek et al, 1997}. The study by Becker et al, 2001 demonstrated that 
measurement of hK2 improves diagnostic value of PSA testing. The consensus opinion in 
most reports is that hK2 supplements PSA testing not a replacement {Partin & Marks, 2001; 
Obiezu & Diamandis, 2005}.  
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2.3.3  The TMPRSS2 gene fusions 
 
The transmembrane protease, serine 2 (TMPRSS2) is a serine protease localised on 21q22.3, 
and currently has 6 known transcript variants (due to alternative splicing) encoding a 53.8kDa 
protein {Entrez gene browser}. The protein product has five domains:  a type II 
transmembrane, a receptor class A, a scavenger receptor cysteine-rich and protease domains. 
The gene is up-regulated by androgens, and also involved in many physiological and 
pathological processes including prostate cancers (84% of all cases have over-expression) 
{Cross et al, 2008} 
 
Tomlins et al in 2005 reported the recurrent gene fusion involving 5’ UTR of TMPRSS2 and 
the ETS (E26 transformation-specific) family genes in prostate cancers. It was a landmark 
discovery in molecular pathology of prostate cancer; the gene fusion occurred in about 50% 
of localised prostate cancers {Cross et al, 2008}. Members of the ETS family of genes 
(transcription factors) involved in the gene fusion consist of ERG (localised on 21q22, ETV1 
(7p21) and ETV4 (17q21). The protein products of ETS genes are transcription factors that 
activate or repress the expression of genes that are involved in cellular proliferation, 
differentiation, development, transformation and apoptosis {Cross et al, 2008}. The 
TMPRSS2: ETS gene fusions usually occur by deletion sometimes by chromosomal 
rearrangement {Tomlins et al, 2007}. The fusion leads to the juxtaposition of the androgen-
responsive promoter region of TMPRSS2 and the proto-oncogenic region of ETS genes; and 
androgens are believed to drive the over-expression of ETS gene resulting in neoplastic 
transformation {Tomlins et al, 2007}. Clarke et al (2007) reported 14 transcript variants of 
the TMPRSS: ETS fusion genes: two encoding a normal full-length ERG protein, six 
encoding N-terminal truncated ERG proteins and one encoding a TMPRSS2: ERG chimeric 
protein. The TMPRSS2: ERG is the most common variant (occur mainly by deletion 
mechanism), followed by the TMPRSS2:ETV1 and TMPRSS2: ETV4 {Mehra et al, 2007}. 
The gene fusions are detectable by both FISH (using break-apart and fusion probes) and PCR 
techniques (multiplex RT-PCR and RQ-PCR). 
 
Several studies have reported on PCa progression and clinical significance of the TMPRSS2: 
ETS gene fusion. The gene fusion occurs in high grade PIN, localised and metastatic PCa; not 
detectable in BPH {Cross et al, 2008}. The percentage of the fusions in high grade PIN is 
roughly half that of localised PCa {Hermans et al, 2006}. The report by Hermans et al, 2006  
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also showed that the effect of the gene fusion is bypassed in the late stage androgen-
insensitive PCa, which corroborates with the fact that androgen regulation fails in the HRPC 
stage. Clark et al (2007) also reported that fusion transcript variants exhibit distinct patterns 
in the foci of PCa, suggesting that the fusions may arise independently in different regions of 
the same prostate. 
 
The TMPRSS: ETS fusion is associated with high Gleason score (high histological grade) 
{Mehra et al, 2007; Tu et al, 2007}. The gene fusion is also associated with five 
morphological features in PCa: blue-tinged mucin, cribriform growth pattern, macronucleoli, 
intraductal tumour spread and signet-ring cell features {Mosquera et al, 2007}. Prostate 
cancers with TMPRSS2 fusions have a worse prognosis than those without {Cross et al, 
2008}; Nam et al (2007) reported that the gene fusion is associated with tumour recurrence 
after radical prostatectomy for localised PCa. Currently TMPRSS2: ETS gene fusions have 
not been identified in other cancers {Yoo et al, 2007}. Using RQ-PCR the TMPRSS2: ERG 
transcripts have been detected in urine samples of men with known PCa following prostatic 
massage {Laxman et al, 2006}; therefore it could used be as a diagnostic test. However, 
Tomlins et al (2007) have shown that the ETV1 gene can fuse with other partners in the 
5’UTR region, and that these fusions are also common in PCa (Figure 2.4). These findings 
add to the complexity underlying the molecular mechanism of chimeric oncogenic fusion 
products.  
 
Studies have also shown that certain SNPs in the TMPRSS2 gene are associated with 
mechanism of gene fusion (deletion or translocation) and copy number; in particular the T 
allele of the SNP rs12329760 was identified with translocation fusions and multiple copies of 
gene fusion {FitzGerald et al, 2008}. Liu et al (2007) also reported that particular sequences 
(called the Alu family consensus sequences) were associated with the likelihood of TMPRSS:  
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Figure 2.4 Prostate specific elements fused to ETV1. The 5’ partners are androgen-
responsive and they drive ETV1 over-expression. The numbers in the boxes represent exons. 
The numbers above the boxes indicate the last base of each exon. Untranslated regions are in 
lighter shades (pink and light green). {Tomlins et al, 2007} 
 
ETS fusion and type of fusion transcripts that will occur. More studies are required to verify 
these sequences in both healthy and PCa men. 
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2.4  Molecular markers of apoptosis 
 
2.4.1  The p53 gene 
 
The tumour suppressor protein (TP53, commonly known as p53) regulates the transcription of 
genes involved in G1-phase growth arrest of cells in response to DNA damage {Agrawal et 
al, 1998}. The arrest enables repair or apoptosis of unrepaired cells, preventing passage of 
damaged DNA to daughter cells. Localised on chromosome 17q13.1, the p53 gene has 
currently 9 transcript variants with the longest variant (of 11 exons, a transcript length of 
2,586) encoding a 43.6 kDa protein of 393 amino acid residues. It is also known to play roles 
in the mitotic spindle checkpoint, centrosome homeostasis and G2-M phase transition of cell-
division cycle {Quinn et al, 2005}. Primarily, the p53 gene regulates apoptosis, a role in 
which it has been described as the ‘the molecular policeman’ {Stein & Pardee, 2004}. 
 
TP53 has been associated with several human cancers. High penetrance mutations of TP53 
are associated with hereditary breast cancers, which manifest at young age (Li-Fraumeni 
syndrome) {Marchio & Reis-Filho, 2008}. Sporadic mutations of p53 are uncommon in early 
PCa, but are independently prognostic in late-stage PCa {Agrawal & Dunsmuir, 2009}. 
Exons 5-8 are the predominant mutation sites in TP53 {Oden-Gangloff et al, 2009}, and have 
been associated with nuclear p53 accumulation in tumour cells {Bartek et al, 1990}. Isaacs 
(1997) reported that tumours positively staining for p53 harbour mutations and those p53 
mutations appear to be more common with increasing tumour stage. Although the value of 
p53 nuclear accumulation (detected by IHC) as a prognostic marker in PCa is controversial, 
there is a consensus opinion that p53 mutation analysis and p53 gene expression in 
combination may more accurately define prognostically the importance of p53 dysfunction in 
PCa {Quinn et al, 2005}. Malins et al (2003) reported that concomitant homozygous PTEN-
p53 inactivation led to PCa lethality in mice. Expression of p53 has been shown to predict 
overall survival in ‘watchful waiting’ patients; predict distant metastases in radiotherapy 
treated patients and also predict PSA recurrence in radical prostatectomy patients {Quinn et 
al, 2005}. It has also been implicated in hormone resistance during PCa progression. 
Recently, p53 mutation was reported as a marker of sensitivity to cetuximab (monoclonal 
anti-EGFR therapy) in KRAS wild-type patients of colo-rectal cancer {Oden-Gangloff et al, 
2009}. TP53 expression is regulated by the Mdm-2 gene. 
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2.4.2  The Bcl-2 gene 
 
The Bcl-2 (B-cell CLL/lymphoma 2) gene is another major apoptotic regulator. Localised on 
chromosome 18q21, the Bcl-2 is the prototype of a class of oncogenes that inhibit apoptosis 
(programmed cell death) {Haldar et al, 1989}. Other members of the Bcl-2 class include Bcl-
xL and Mcl-1, both are inhibitors of apoptosis; but other members such as Bcl- xS, Bad, Bak, 
Bax and Bid are inducers of apoptosis. The Bcl-2 protein is expressed in the basal cells and 
stem cells of the prostate. Biochemically, apoptosis is the end point of a cascade of molecular 
events that are initiated by several stimuli and leads ultimately to the activation of proteolytic 
enzymes responsible for cell death {Kumar et al, 2009}. Through poorly understood 
mechanisms, the bcl-2 family of proteins, which are located in outer mitochondrial 
membrane, endoplasmic reticulum and nuclear membrane, regulate the activation of these 
proteolytic enzymes (caspases); a process that involves interplay of factors such as p53, c-
myc etc. 
 
Bcl-2 expression increases with histological grade and clinical stage in PCa {Quinn et al, 
2005}. Over-expressions of Bcl-2 confer androgen resistance, particularly in advanced stage 
PCa {McConkey et al, 1996}. Bcl-2 expression on biopsy, in advanced PCa is an independent 
predictor of response to radiotherapy. Anti-sense oligonucleotides targeted on Bcl-2 are 
known to increase sensitization of tumour cells to radiotherapy {Mu et al, 2005}. Reports on 
prognostic value of Bcl-2 on radical prostatectomy and PSA recurrence are conflicting 
{Agrawal & Dunsmuir, 2009}. 
 
2.5  Molecular markers of metastasis 
 
2.5.1  The CD44 gene 
 
The CD44 also known as the Indian blood group is located on human chromosome 11p13, 
currently has 17 curated transcript variants (of variable number of exons: 4 to 18 due to 
alternative splicing), the longest variant encodes a 80.7 kDa protein of 734 amino acid 
residues {Entrez and Ensemble Genome browsers, 2009}. The protein is an integral 
transmembrane glycoprotein that participates in specific cell-cell interactions and cell-
extracellular matrix interactions (cell adhesion and cell migration) {Isaacs, 1997}. It is a 
receptor for hyaluronic acid (HA), and can also interact with other ligands, such as  
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osteopontin, collagens, and matrix metalloproteinases (MMPs). It participates in a wide 
variety of cellular functions including lymphocyte activation, recirculation and homing, 
haematopoiesis, and tumour metastasis {Madjd et al, 2009}. CD44 is normally expressed in 
the plasma membrane of prostatic epithelial cells (the cells of origin of PCa) {Isaacs, 1997}. 
 
CD44 is believed to play a major role in tumorigenicity and metastasis in different types of 
tumour cells. Individual transcript variants and isoforms of CD44 differ in their ability to 
enhance or decrease tumorigenicity or metastatic potential {Isaacs, 1997}. Down-regulation 
of standard CD44 form at both mRNA and protein level correlates with metastasis (predicts 
aggressiveness of PCa) {Gao et al, 1997}.CD44 is a metastatic suppressor for PCa {Isaacs, 
1997}. Conversely, over-expression of mutant CD44 could be associated with tumour 
invasiness {Isaacs, 1997}; however mutations of CD44 are never evaluated in routine IHC 
studies of CD44 expression. For example, Huh et al (2009) reported an immunohistochemical 
study in which ‘standard’ CD44 over-expression was associated with tumour stage and 
overall survival in colo-rectal carcinoma. In another study, Madjd et al (2009) showed that 
CD44 positive breast cancer stem cells over-expressed Bcl-2, implying that such cells could 
be chemo-resistant. It is very vital that mutant forms of CD44 are differentiated from other 
wild type transcript variants in mapping the prognostic value of CD44 expression. Recently, 
Desai et al (2009) reported increased expression of standard CD44 (sCD44) and transcript 
variants 4 to 10 (vCD44) in prostate cells that over-express osteopontin, and also concluded 
that the surface expression of CD44 and activation of MMP9 on the cell surface are 
interdependent. In addition to transcript variations and mutations, the degree of glycosylation 
of CD44 affects its ability to recognise ligands such the HA {Katoh et al, 1995}. 
 
2.5.2  The E-Cadherin1 gene 
 
The E-Cadherin type 1 gene, officially designated CDH1, previously known as CD324 is a 
classical cadherin from the cadherin super family {Du et al, 2009}. Located on chromosome 
16q22, CDH1 encodes a 97.4 kDa calcium-dependent glycoprotein of 882 amino acid 
residues, comprised of five extracellular cadherin repeats, a transmembrane region and a 
highly conserved cytoplasmic tail {Du et al, 2009}. The protein is involved in the regulation 
of cell-cell adhesion and cell morphology through formation of complexes with other 
molecules particularly the catenins {Quinn et al, 2005}; the β-catenin signalling was 
illustrated in Figure 1.9 in Chapter one of this thesis. 
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Gene expression and mutation status of CDH1 have been associated with human cancers. 
Mutations in this gene are associated with gastric, breast, colorectal, thyroid, and ovarian 
cancers. Loss of function (by deletion or mutational inactivation) is thought to contribute to 
progression in cancer by increasing proliferation, invasion, and/or metastasis {Du et al, 
2009}. Early studies showed that benign prostate cells exhibit strong, uniform 
immunostaining for CDH1 at cell-to-cell borders, while prostate tumour cells showed reduced 
or absent E-Cadherin staining {Isaacs, 1997}. Aberrant CDH1 immunostaining correlated 
with high grade tumours (Gleason score), and was ‘a powerful predictor of poor outcome, 
both in terms of disease progression and overall survival’ {Isaacs, 1997}. Down-regulation of 
E-cadherin expression in localised PCa is associated with increased expression of other 
cadherin family members, particularly N-Cadherin {Quinn et al, 2005}. It is suggested that 
while CDH1 promotes epithelial cell-epithelial cell adhesion, N-cadherin promotes epithelial 
cell-stromal cell adhesion {Bussemakers et al, 2000}. Over-expression of CDH1 has also 
been reported in breast cancer metastasis, a paradox believed to be caused by ‘epigenetic 
mechanism during invasion and diapedesis into vessel walls, only to be reactivated at the site 
of established metastases’ {Bukholm et al, 2000}. It is possible that mutant forms of E-
cadherin type 1 could be over-expressed in PCa metastasis. It is reported that transcript 
variants of CDH1 can arise from mutation at consensus splice sites {Du et al, 2009}. Many 
studies support the fact that reduced or aberrant E-cadherin expression is associated with PCa 
(especially clinically localised PCa) and its prognosis. 
 
2.6  Sampling for Molecular Pathology of Pca 
 
Molecular techniques offer highly sensitive, dynamic range detection and quantification 
assays. For example, the RQ-PCR could detect a cancer cell in a background of nearly one 
million normal cells {Kaeda et al, 2003}. Therefore, patients’ samples that contain low level 
of prostatic cells could be analyzed using such techniques. There are three main types of 
samples for molecular testing for PCa: urine (with or without prostatic massage), blood and 
prostate biopsy samples.  
 
a. Urine and Prostatic Massage:  There are few prostatic cells in urine samples of 
healthy males {Panek et al, 1997}. In low grade, localised PCa there are also low 
infiltration of malignant cells in urine; however in metastatic PCa, more prostatic cells 
are found in urine {Agrawal & Dunsmuir, 2009}. Prostatic massage helps to increase 
the number of exfoliated cells in urine sediments.  
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b. Blood samples: PSA mRNA and KLK2 mRNA have been detected in blood of men 
with localised PCa {Corey et al, 1997}. However, in metastatic PCa, > 5 cells per 
7.5ml of blood are common {Agrawal & Dunsmuir, 2009}, which could easily be 
detected by RQ-PCR. 
 
c. Prostate biopsy: Prostate tissues, either from radical prostatectomy, resection or 
transrectal ultrasound (TRUS) guided biopsies are an invaluable source of diagnostic 
specimens. Frozen tissues, fixed and paraffin embedded tissues have all have been 
used in molecular testing. Gillio-Tos et al (2007) reported successful extraction of 
DNA from 25 years’ old paraffin embedded tissue samples. Although fixation using 
anatomical fixatives cause tissue samples to defragment and in some cases degrade, 
short sequences (≤150bp) of nucleic acids could easily be obtained from more than 
99% of archived embedded tissue samples {Antonov et al, 2005; Gillio-Tos et al, 
2007}. And real time PCR applications for gene quantification and genotyping are 
optimally designed to amplify such short amplicons, enabling accurate and 
reproducible detection as well as quantification of assay targets. In addition, histology 
of prostate tissues can assist to pin-point foci of highest tumour load, facilitating 
analysis of ‘pure cell types’ involved in a particular aberration. 
 
2.7  Genetic testing for prostate cancer risk 
 
In addition to gene expression and epigenetic studies in PCa, genetic variations such as copy 
number variations (CNVs) and single nucleotide polymorphisms (SNPs) are strongly linked 
to prostate carcinogenesis. Defined as being larger than 1kb in size, CNVs involve gain or 
losses of genomic DNA that are either microscopic or submicroscopic and are, therefore, not 
necessarily visible by standard cytogenetic G-banding Karyotyping {Shlien & Malkin, 2009}. 
There are about 21, 000 CNVs in the human genome, some associated with inherited and 
acquired diseases {Shlien & Malkin, 2009}. For example, the BRCA2 gene associated with 
<5% of Familial/young-onset PCa (diagnosed in <55 years of age) is known to have germ line 
CNV {Agrawal & Dunsmuir, 2009}. Sporadic gene amplifications of AR and ESRs are 
associated with PCa progression {D'Antonio, 2008; Zhao et al, 2008}. 
 
Through the International HapMap project about 10 million SNPs have been discovered in 
the human genome. SNPs (hereditary single base differences in humans) are the single largest  
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source of human genomic variation {Gibbs, 2005}. Mining data from genome wide 
association (GWA) studies have enabled the association of SNPs with clinical outcomes in 
patients. This has been facilitated by the advent of high-resolution, high through-put SNP 
arrays. For prostate cancer in particular, several SNPs have been associated with the 
presence/risk of prostate cancer at biopsy and PCa aggressiveness. Table 2.2 is a summary of 
selected literature on SNPs associated with PCa. Some of the SNPs have not been mapped to 
identifiable genes {Zheng et al, 2009}; others are contained in genes without known biologic 
(functional) influence on PCa development or progession. SNP studies are particularly 
important because of the potential to identify men with high risk of PCa as targets for annual 
screening. Secondly, SNPs can also predict disease outcome and therefore inform treatment 
approach at the onset of therapy. It is possible that individual SNPs or groups of clinically 
associated SNPs (haplotypes) can be tested in the near future using biosensor technologies at 
point-of-care. Information from such tests can inform likelihood of adverse reactions to 
drugs. 
 
Table 2.2 SNPs associated with PCa risk/outcome 
SNP ID Gene/Locus Clinical outcome Reference 
  rs10896449 11q13 PCa 
risk/aggressiveness  
Thomas, 2008; Zheng et al, 2009 
  rs12418451 11q13 PCa risk Zheng et al, 2009 
  rs1447295 8q24 PCa risk Pomerantz et al, 2009 
  rs13254738 8q24 PCa risk Pomerantz et al, 2009 
  rs10486567 7p15 PCa risk Wiklund et al, 2009 
  rs10993994 10q11 PCa risk Wiklund et al, 2009 
  rs4962416 10q26 PCa risk Wiklund et al, 2009 
  rs4430796 17q12 PCa risk Wiklund et al, 2009 
  rs2735839 19q13 PCa risk Wiklund et al, 2009 
  rs5945619 Xp11 PCa risk Wiklund et al, 2009 
  rs1859962 17q24.3 PCa risk Salinas et al, 2009 
  rs6983561 8q24 PCa risk Salinas et al, 2009 
  rs6983267 8q24 PCa risk Salinas et al, 2009 
  rs198977 KLK2 PCa risk Nam et al, 2006 
  rs2664155 KLK2 PCa risk Nam et al, 2006 
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Some of the SNPs show a demographic distribution pattern similar to that of incidence of PCa 
(from the HapMap project database in which 8 countries of the world participated in the SNP 
sequencing project). SNPs associated with diagnostic markers can be used to determine a 
genetically-specific cut off level, for example the case of PSA as reported by Wiklund et al, 
(2009). Currently, there are no clinical genetic tests for PCa risk; however efforts in SNPs 
studies could translate into useful clinical assays in near future. 
 
2.8  Validation of Molecular markers 
 
As new molecular markers emerge, often through new technologies, there is the challenge to 
validate these markers and the technologies before translating them to clinical use. For the 
molecular markers their diagnostic value has to be established in clinical cases. For the 
technologies their analytical reliability, applications and clinical utility should also be 
validated prior to clinical use. This is very important especially in targeted therapy, where a 
molecular marker is the target of therapy, for example the epidermal growth factor receptor 
(EGFR). The drugs erlotinib and gefitinib specifically target EGFR tyrosine kinase in variety 
of cancers. The copy number, expression level and mutation status of EGFR are therefore 
indicators of response to therapy {Dutton, 2009}. Another example is the Bcr-ABL1 gene 
fusion in chronic myeloid leukaemia and some cases of acute lymphoblastic leukaemia where 
the gene fusion product is a non-receptor associated tyrosine kinase that requires ATP for 
autophosphorylation and downstream effects {Foroni et al, 2009}. The drug imatinib 
specifically targets the gene fusion, inhibiting its ATP binding. These molecular markers 
confirm the pharmacodynamic activity of the drugs. The same case applies to molecular 
markers that predict sensitivity or resistance of cancer cells to therapy, for example the KRAS 
and TP53 mutation in advanced colorectal cancer treatment using Cetuximab (anti-EGFR 
monoclonal antibody).  Chemoresitant patients who have advanced colorectal cancer with 
KRAS mutation do not respond to Cetuximab and therefore has no survival benefit for taking 
the treatment {Lievre  & Laurent-Puig, 2009}. In another report, Oden-Gangloff et al, 2009 
showed that TP53 mutation is a marker of sensitivity, particularly in patients without KRAS 
mutations who are on Cetuximab-based chemotherapy. 
 
The process of validating molecular markers for clinical use will also consider assay formats: 
real time versus end-point, multiplex versus singleplex, high throughput or flexible 
throughput etc. Molecular markers often occur in complicated forms: transcript variants and  
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copy number variations. For example the TMPRSS2: ETS gene fusion in prostate cancer is 
known to have 14 transcript variants encoding different lengths of the chimeric proteins 
{Cross et al, 2008}. In such cases a multiplex assay is required to first identify transcript 
variant present in a sample before quantification. False negative results occur in cases where 
transcript variants are unknown due to rare gene fusion types unidentified prior to 
quantification. In many cases other assay types are required to establish the molecular 
abnormality, for example the use of Karyotyping and interphase FISH to identify gene 
rearrangements prior to molecular assays. In each assay type, the analytical sensitivity, 
specificity, quantifiable range (limit of detection) and reproducibility should be thoroughly 
evaluated during validation. The phenomenon of ‘yet another prognostic factor’ occurs in 
cancer literature where an unvalidated molecular marker is highly appraised, creating a hype 
of its potential clinical value prior to clinical assessment. Biomarker validation is the key 
towards translation of novel molecular markers and novel technologies to clinical use. 
 
The field of clinical molecular diagnostics is rapidly expanding. In this context, molecular 
diagnostics refers to laboratory testing based on DNA or RNA analysis; even though proteins 
are the end products of RNA translation, proteomic analysis is not considered as molecular 
diagnostics. In 2001, Collins & McKusick estimated that 5% of all laboratory testing is based 
on molecular diagnostics. This proportion has increased tremendously over the years as many 
diseases now require molecular diagnostics for diagnosis, classification, choice of treatment 
options and monitoring. The PCA3 test is a molecular diagnostic test now approved for PCa 
diagnosis. Many molecular tests are likely to surface in the clinics in the near future. What 
makes a good molecular test are key parameters such sensitivity and specificity (diagnostic 
and analytical reliability), predictive value, cost, practical applicability (reproducible, user-
friendly, interpretation, methodology) and clinical relevance. For example, sequencing the 
entire genome of a prostate cancer patient for about £2000 may yield a huge amount of 
information so difficult to make a meaning out of it, difficult to reproduce in other 
laboratories and requires huge electronic space to store the information; clinical relevance 
could also be difficult to discern. On the other hand, mutation analysis of exons 5 to 8 of p53 
could offer reproducible and comprehensible information, which can predict disease outcome 
in PCa patients. 
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Chapter 3:  In vitro studies on Prostate cell lines 
 
3.1  Introduction 
 
In this chapter, three prostate cell lines: PNT1A, PC-3 and MDAPCA 2b were treated with 
four different steroid hormones: testosterone (T), dihydrotestosterone (DHT), 17 β- oestradiol 
(E) and hydrocortisone (H). The aim was to evaluate the influence of varying levels of steroid 
hormones on the gene expressions of putative molecular markers of prostate cancer 
development and progression. The transcript levels of androgen and oestrogen receptors were 
measured by real time polymerase chain reaction (RQ-PCR). Other prostate tumour markers 
including CD44, TMPRSS2: ERG and ETV1 fusion genes, p53, KLK2, KLK3, CDH1, 
FASN, Bcl-2, MCM2 and MCM5 were also evaluated. Three candidate endogenous control 
genes were also assessed for normalization of the RQ-PCR results. 
 
3.2  Materials and Methods 
 
Details of all equipment used, preparation of reagents and buffers; and list of suppliers and 
their contacts are contained in appendix A. Details of experimental protocols are documented 
in appendix B. All raw data and additional result presentations are contained in appendix C. 
 
3.2.1  Cell lines and General Growth Requirements 
 
Three prostate cell lines were used in this study: MDAPCa 2b was purchased from the 
American type culture collection (ATCC, US), PNT1A and PC-3 from the European 
collection of cell cultures (ECACC, UK). All the cell lines were epithelial in origin 
 
The MDA PCa 2b cell line was established from a bone metastasis of a 63-year old black 
male with androgen-independent adenocarcinoma of the prostate {Navone et al, 1997}. The 
cell line was reported to expresses PSA and AR {Navone et al, 1997}. It is believed to mimic 
androgen sensitive progressive PCa. Passage number 33 was used at the beginning of cell 
expansion.  
 
The PC-3 cell line was established from a bone metastasis of prostate adenocarcinoma grade 
4 in a 62-year old male Caucasian {Kaighn et al, 1979}. It was reported as androgen- 
insensitive, and did not produce PSA {van Bokhoven et al, 2001; van Bokhoven et al, 2003}. 
It represents a hormone refractory metastatic PCa. Passage number 37 was used at the onset 
of cell expansion. 
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The PNT1A cell line was established by transfection of normal epithelial cells derived from a 
35 year old male Caucasian post mortem with a plasmid containing SV40 genome with a 
defective replication origin. It was reported to express AR and PSA {ECACC, 2006}. It 
represents a ‘normal’ prostate epithelium. Passage number 56 was used for cell expansion.  
 
The PC-3 and MDAPCa-2b cells were expanded in phenol-containing DMEM: F12 
(Invitrogen, UK),  supplemented with 2mM glutamine (Invitrogen UK), 10% (v/v) foetal calf 
serum(FCS) (Invitrogen, UK), 1% (v/v) Penicillin-Streptomycin mixture (5,000 units 
penicillin and 5mg streptomycin/mL) (Sigma, UK) and 0.1%(v/v) Amphotericin B 
250 µg/mL (Sigma, UK). For stimulation experiments, the cells were grown in phenol-free 
DMEM: F12 supplemented with same additives except for FCS, which was replaced with 
dextran-charcoal treated foetal calf serum (DCC-FCS) (Perbio, UK). The PNTIA cells were 
grown in RPMI 1640 media (Invitrogen, UK) supplemented with same additives. DCC-FCS 
has a reduced level of steroids and proteins compared to normal FCS {Herbert et al, 1965; 
Luo et al, 2003}.  
 
The protocols for routine cell cultures including thawing of frozen cells, feeding and splitting 
of cells are contained in appendix B (B.1-B.3)        
 
The steroid hormones used for stimulation experiments were: Testosterone (T), 5α-
Androstan-17β-3-one (dihydrotestosterone) (DHT), Hydrocortisone (H) and17β-Estradiol (E), 
all purchased from Sigma, UK. Dilutions were made as contained in appendix B.6.              
 
3.2.2  Serum Supplementation experiments 
 
After cell expansion, each cell line (2 x 105 cells per T75 flask) was weaned into culture 
media containing different sera (bovine growth serum (BGS) (Perbio UK), DCC-FCS or 
normal FCS) (Perbio, UK) at varying percentages:  10.0, 7.5, 5.0, 2.0 and 1.0 % (v/v). The 
aim of the experiment was to compare viable cell yield in different sera, to ensure that the 
DCC-FCS could support cell growth. The cultures were daily examined microscopically, and 
culture media were changed on day 3 post- incubation. The cells were harvested for viable 
cell count after 5 days of incubation at 37oC with 5% CO2 supply. Trypan blue staining and a 
manual haemocytometer were used for the cell count (appendix B.4). The experiments were 
performed in triplicate. 
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3.2.3  Determination of exponential growth phase of cell lines 
 
The growth curves of cell lines were evaluated by two different methods: by Trypan blue cell 
count (appendix B.4) and by colorimetric Sulforhodamine B (SRB) assay as described by 
{Vichai & Kirtikara, 2006} contained in appendix B.5. For the Trypan blue method, 4 x 104 
cells were seeded into micro-well plates (12-multi well tissue culture plates)-27 plates were 
seeded, and incubated at 37oC with 5% of CO2 supply. Three wells were harvested 
(trypsinized and counted-as in appendix B.4) at each time on days 1, 2, 3, 5, 7, 9, 11 and 13 
post incubation. In another set of similar experiments, 27 plates were seeded but 24 hours 
later, only three wells were harvested, the remaining 24 wells were treated with 10-6M 
concentration of steroid: dihydrotestosterone DHT, testosterone T, 17 β-oestradiol E, 
hydrocortisone H and ethanol (as a control because the steroids were dissolved in ethanol as 
contained in appendix B.6). The cells were later harvested, 3 wells at a time on days 1, 2, 3, 5, 
7,9,11 and 13 post treatment (the harvest on the day of treatment was called day zero).  
 
The aim of the experiment was to determine the log phase of the cell lines (period of 
exponential growth) and also the confluent phase (the plateau where there was no net increase 
in cell number). 
 
In the colorimetric Sulforhodamine B assay (appendix B.5), 96- well plates were used. 103 
cells were seeded per well. The experiment was done in 6 replicates (each column for a day). 
The SRB assay measured cellular protein content of viable cells stained with Sulforhodamine 
B, and results were read at 570nm in micro-plate reader (Dynex, UK). The SRB assay was 
amenable to high through-put, and subsequently used for cytotoxicity studies.    
 
3.2.4  Change in population doubling/ doubling time 
 
Two parameters that measure cell growth kinetics: doubling time and change in population 
doubling were determined for the prostate cell lines. The doubling time (DT) was defined as 
the time (in hours) required getting twice the number of viable cells seeded. Change in 
population doubling (∆PD) was calculated from the formula: 
∆PD = log (A/ (B*C))/ log 2 
Where, A is number of harvested viable cells, 
B is number of plated cells, 
C is attachment efficiency, which was calculated as number of viable cells harvested after 15 
hours of incubation divided by number of cells seeded (plated) {Korkolopoulou et al, 2005}. 
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About 2.0 x 105 cells (for each cell line) were seeded into a 6- multi-well tissue culture plates 
(triplicate was also set up) containing 3 ml of appropriate phenol-free media in a final 
concentration of 10-4 M of a hormone (DHT, or H, E, or T). Two control wells were set up: 
one with no hormone but culture media only added and another with 0.5ml of absolute 
ethanol added to 2.5ml of culture media .The plates were harvested after 5 days of incubation 
at 37oC, 5% (v/v) CO2 supply.  
 
3.2.5  Growth inhibition tests 
 
Growth inhibition assays (cell viability assays or cytotoxic tests or cell death assays) are 
increasingly used in laboratory determination of the effect of anticancer drugs on fresh 
tumour cells {Bosanquet, 2007}. Table 3.1 shows a summary of cytotoxic assays.     
 
The SRB assay was used to determine inhibition concentration of steroids on cell lines. The 
protocol for SRB assay is contained in appendix B.5. Briefly, serial dilutions (1/10) of 
steroids (range: 102 µM to 10-3 µM) were prepared as described in appendix B.6.  The 
steroids were diluted in culture media (phenol-free containing DCC-FCS at 10% (v/v)). 
About 105 cells were seeded to wells in a 96-micro well tissue culture plate. After 3 days of 
incubation at 37oC, 5% C02 supply, the cells were tested by the SRB assay. 
 
Table 3.1 Methodologies for cell death (viability) assays {Bosanquet, 2007} 
Abbreviation Name Technology Measured by 
 Trypan blue Cell membrane 
integrity 
Dye exclusion 
DiSC Differential staining 
cytotoxicity 
Cell membrane 
integrity 
Dye exclusion, 
morphology 
TRAC Tumour response to 
antineoplastic compounds 
Cell membrane 
integrity 
morphology 
MTT 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium 
bromide 
Metabolic death Dye reduction 
ATP Adenosine triphosphate  Metabolic death ATP levels 
FMC Flourometric microculture 
cytotoxicity 
Metabolic death Metabolism of fluorescein 
diacetate 
SRB Sulforhodamine B assay Cellular protein 
content 
Protein stain update 
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3.2.6 Immunometric Assays 
 
These are assays which rely on the use of antibodies specific to antigens in cells, cellular 
extracts and/ or fluids to determine the expression of proteins. In this study, they included 
immunocytochemistry (ICC), immunofluorescence (IF), enzyme linked immunosorbent assay 
(ELISA) and western blotting. 
 
a) Immunocytochemistry and Immunoflourescence 
Immunocytochemistry (ICC) is a technique for detecting cellular antigens by using specific 
primary antibodies that bind to them. Visualization is accomplished using labelling methods 
(detection systems). Broadly, detection systems can be enzymatic or non-enzymatic, requiring 
secondary antibodies that bind the primary antibodies to labels conjugated with linkers. The 
detection system used in this work is based on the biotin-avidin linker. Biotinylated 
horseradish peroxidase enzyme forms a complex with avidin reagent (AB complex), the 
complex combines with biotinylated polyclonal rabbit anti-mouse immunoglobulins 
(secondary antibody) forming efficient link to capture cellular antigen-primary antibody 
complex. The addition of a substrate chromogen (3, 3’ diaminobenzidine DAB plus hydrogen 
peroxide or 3-amino-9-ethylcarbazole AEC), which is converted by the enzyme label into an 
insoluble coloured precipitate at the site of antigen localization, is used to visualize the 
detection.  
 
However, in Immunofluorescence (IF) the primary antibody is conjugated with fluorescent 
dyes, for example, FITC; or the linker molecule for secondary antibody (streptavidin) is 
conjugated with a fluorescent dye, for example, AlexaFluor 555 (AF555), which was used in 
this study. IF was visualized using a confocal microscope. 
 
Cells for ICC and IF were prepared by two methods: slide flasks and cytospin (protocols for 
cell preparation by both methods are contained in appendix B.7. While the methods for ICC 
and IF are contained in appendix B.8, the details of antibodies and dilutions are contained in 
appendix A.3; and reagents and buffers in appendix A.2 for both ICC and IF. 
 
b) ELISA for PSA in culture supernatants   
About 106 cells cultured as described in Section 3.2.1 and treated in 6-well tissue culture 
plates with IC50, IC10 and half IC10 values of steroids. Culture supernatants were harvested at 
24, 48 and 72 hours intervals, and concentrated using protocol described appendix B.9.  Total 
PSA in culture supernatants was measured using Microwell total PSA ELISA assay  
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(Diagnostic Automation Inc, USA) according to the manufacturer’s instructions (appendix 
B.10). The aim of the experiment was to assess the effect of the steroids on PSA secretion. 
For each concentration of steroid there were triplicate samples at any of the time intervals. 
 
c) Western Blotting (W/B) 
Western blotting (immunoblotting) was used to further confirm the expression of some of the 
cellular antigens identified by the ICC staining. The protocol for W/B is contained in 
appendix B.11, using some of the antibodies described in appendix A.3. W/B involves 3 
steps:  sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), blotting 
(transfer of proteins to membranes) and detection (incubation with primary and secondary 
antibodies, and chemiluminescent detection using ECL plus (GE Healthcare, UK). Details of 
the principle of W/B, and the protocol used in this study were described in {William et al, 
2003}. 
 
The cell cultures (106 cells) were harvested using radioimmuno-precipitation assay (RIPA) 
buffer (appendix A.2) and concentrated using the Eppendorf 5301 concentrator (appendix 
B.11). 
 
3.2.7 Gene expression studies 
 
a) Hormonal stimulation 
Cell lines (106 cells) were stimulated in 12-well tissue culture micro well plates using IC10 
and 1C50 values of steroids using the protocol described in appendix B.12. Cells were 
harvested at 12-, 24-, 48- and 72- hrs for RNA extraction. No treatment (culture media only) 
and DMSO-treated controls were included. The aim of the stimulation was to create sample 
heterogeneity and assess the effect of stimulation on gene expression of some selected 
molecular markers. 
 
b) RNA extraction 
The cells were trypsinized as described in appendix B.3, washed in sterile PBS and cell 
pellets lysed in 1.0ml of guanidine isothiocyanate (GITC) buffer; 350µl of which was used 
for RNA extraction using the RNeasy mini kit (Qiagen, UK) according to the manufacturer’s 
instruction as described in appendix B.13. The remaining of the GITC lysate samples was 
stored at -20oC. RNA was eluted in 60µl from the extraction columns; and 50µl was used for 
cDNA synthesis. RNA quality and concentration was checked using the BioRad automated 
electrophoresis system (BioRad, UK) and Eppendorf photometer (Eppendorf, Germany) 
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c) cDNA synthesis 
The amount of RNA used for cDNA synthesis ranged from 0.7µg to 3µg.  Equal volume of 
RNA elute was used in cDNA synthesis using the protocol in appendix B.14. The cDNA 
synthesis was done immediately after RNA extraction. The same batch of cDNA mix 
described in appendix B.14 was used through out the study. 
 
d) Polymerase chain reaction (PCR) chemistries 
 
There are various primer and probe design types (PCR chemistries) for RQ-PCR. They 
include SYBR green, TaqMan chemistry, Molecular beacons, BHQ plus probes, Scorpion 
primers, Amplifluor primers and Plexor primers. The choice of PCR chemistry depends 
largely on cost and the sequence detection platform for quantification. In this study, the 
SYBR green and TaqMan chemistry were used. 
 
The SYBR green chemistry is based on the binding of SYBR green I dye on double-stranded 
(ds) DNA, the dye fluoresces upon binding to the ds PCR product. Emitted fluorescence is 
proportional to the amount of amplified product detected in every cycle. 
 
The TaqMan chemistry consists of the conventional TaqMan and the minor groove binding 
(MGB) TaqMan probes. The conventional TaqMan probes are traditional linear, dual-labeled 
FRET (fluorescence resonance energy transfer) probes incorporating a fluorescent quencher 
and fluorophore reporter covalently linked to the 3' or 5' ends of an oligo typically 20 to 30 
bases long. Fluorescence is released during the 5' exonuclease activity of Taq polymerase, 
which cleaves the fluorescent dye upon a probe's hybridization to its complementary 
sequence. Intact probe does not release reporter signal. In the TaqMan MGB probes, a non-
fluorescent quencher replaces the traditional fluorescent quencher and there is stabilization of 
the 5-6 bp on the 3’ end; the probe is therefore shorter and more specific for a given melting 
temperature. 
 
The list of primers and probes for all the molecular markers measured in this study including 
the amplicon size and suppliers are contained in appendix A.5 
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e) ‘Real time’ quantitative polymerase chain reaction (RQ-PCR) 
 
RQ-PCR offers a highly sensitive tool for accurate, reliable and reproducible quantification of 
gene expression {Beillard et al, 2003; Garbert et al, 2003}. It is now widely used in clinical 
molecular laboratories for diagnosis and monitoring of disease; and can detect a cancer cell in 
a background of 1 million normal cells {Kaeda et al, 2003}. Two methods of quantification 
are used: absolute quantification (requires plasmid or oligo calibrators for standard curve) and 
relative quantification (cDNA from cell lines were serially diluted in tRNA in TE buffer- as 
in appendix B.15). 
 
The Applied biosystems 7900HT sequence detection system was used in all the RQ-PCR 
according to the manufacturer’s instructions. All reactions including standards were set up in 
96-well format using a standard mode thermal profile as described in appendix B.15. 
For all the RQ-PCR assays, there were six technical parameters for accepting validity of 
results. The number of PCR cycles at which the relative fluorescent signal intensity of a 
sample or calibrator crosses a threshold line is known as the Ct value (Cycle of Threshold) 
and this value is inversely proportional to starting quantity of target transcript. 
 
i. Slope of the standard curve, which determines the PCR efficiency (E) and is related 
by the formula E= 10(-1/slope)-1.Theoretically, a slope of -3.30 corresponds to 100% 
PCR efficiency. The slope range adopted was -3.30 to -3.60 which corresponded to 
PCR efficiency of 100 to 90%. 
 
ii. The correlation coefficient (R2 value) which is a measure of the relationship between 
Ct value and log of starting quantity for a given standard curve. The R2 value of > 0.98 
was acceptable, although all obtained values were > 0.99. 
 
iii. The Y-intercept of the standard curve, which measures the Ct value that corresponds 
to a copy of target molecule. The Y intercept was ≤ 40. 
 
iv. The difference in Ct value of duplicate measures (∆Ct). Each sample was measured in 
duplicate and the ∆Ct was < 1.0. 
 
v. The relative fluorescence unit plateau value (RFU value) is the maximal normalized 
fluorescent signal at the PCR plateau. The value was consistently ≤ 1. 
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vi. Three negative controls: GITC treated as sample, water for elution treated as sample 
and no template control (NTC) which is a re-elution of RNA without the reverse 
transcriptase. These negative controls appeared undetermined (no reporter signal) for 
valid RQ-PCR. 
 
For the RQ-PCR of each of the CGs and target transcripts to be acceptable, the six parameters 
must be fulfilled. The threshold value was set at 0.05, and baseline was auto set. 
 
3.2.8  Statistical analysis 
This was performed on results using GraphPad Prism software version 4.02 
(www.graphpad.com). For all data sets, the D’Agositino and Pearson Omnibus normality 
test was performed to determine the distribution. For data sets involving more than two 
groups, analysis of variance (ANOVA) was performed using Kruskal-Wallis tests (for non-
parametric, non-Gaussian distribution) and Dunn’s multiple comparison tests. Where two 
data sets were compared, Mann-Whitney test was performed for unpaired, non-Gaussian 
distribution. A probability value of < 0.05 was considered statistically significant. Most 
graphical presentations were in logarithmic scale (power of 10). Where box plots are used, 
the box represents the upper and lower quartiles and the middle bar inside the box represents 
the median value. Where aligned dot plots are used, the bar across the plots represents the 
median value. 
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3.3  Results 
 
3.3.1  Serum supplementation and Calculation of endogenous testosterone level 
Figure 3.1 shows a representative result of the serum supplementation experiment. Results of 
replicates did not differ significantly from mean values. 
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Figure 3.1 Viable PC-3 yields in different sera. There was no significant difference in viable 
cell yield when all the three serum types were compared using Kruskal-Wallis test (P value= 
0.18). Similar results were obtained for PNT1A and MDAPCA 2b cells. Data points 
represented mean ± standard deviation of triplicate. 
 
All the three serum types supported cell growth for the five days period. Although mean 
viable cell yields at 10% serum supplementation, for PC-3 cells were 25.4 x 105, 25.5 x 105 
and 15.2 x105 for FCS, BGS and DCC-FCS respectively, there was no significant difference 
when all sera were compared for the entire serial dilution (1 to 10%). There were no 
detectable morphological changes observed in the daily microscopic examinations 
 
Based on the data provided in the certificate of analysis of each serum from the manufacturer, 
the corresponding testosterone levels in the sera were calculated as shown in shown in Figure 
3.2. At the 10% serum supplementation of culture media, the concentration of testosterone 
(by calculation) was 0.84, 3.03 and 0.30 ng/dl for FCS, BGS and DCC-FCS respectively. 
111 
Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
0
0.5
1
1.5
2
2.5
3
3.5
0 2 4 6 8 10 12
% Sera supplementation
Ca
lc
u
la
te
d 
te
s
to
s
te
ro
n
e
 
le
v
e
l(n
g/
dl
)
FCS 
 BGS
 DCC-FCS
 
Figure 3.2 Calculated testosterone levels in different sera types. Calculation was based on 
certificate of analysis provided from the manufacturer for each particular serum type. 
 
3.3.2  Determination of exponential growth phase 
Figure 3.3 shows a representative growth curve of PC-3 cells for control group (no 
treatment), DHT- and ethanol-treated groups as determined by Trypan Blue cell count 
method. Cells were in exponential phase in days 3 to 8. Similar patterns of growth curves 
were observed for the cell lines in different steroid treatment at the same 10-6M 
concentrations. The variations in manual cell count of triplicate (as shown by error bars) 
could be as much as 1000 cells. 
 
Figure 3.4 shows a representative growth curve for PC-3 cells as determined by SRB assay. 
The cells were in exponential (log) phase in days 1 to 3 (similar result was obtained for 
MDAPCa 2b cells). For the PNT1A cells the log phase was 2 to 4 days. 
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Figure 3.3 Growth curves of PC-3 cells in different treatments. The log phase was 4 to 8 days 
as determined by Trypan Blue cell count. Data points represent mean ± standard deviation of 
triplicate.  
 
However, the essence of the growth curve experiments was to determine the log phase where 
the cells were actively dividing. Harvest of cells for down- stream experiments was done in 
the log phase.  
 
Figure 3.5 shows a box plot comparison of the total viable yield of PC-3 cells in different 
steroid hormones over the 13 days period. The analysis of variance (ANOVA) by Kruskal-
Wallis test showed no significant difference in the total cell yield of various treatments. The 
concentration used for these stimulations were low (10-6M). 
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Figure 3.4 Growth curve of PC-3 cells determined by SRB assay. The cells were in log phase 
on days 1 to 3.  Cells were harvested at days 0.5, 1, 2, 3, 5, 7, 9 and 11. Days 7-11 showed a 
reduction from the plateau, and therefore were truncated in the graph. The log phase for 
PNT1A cells was 2 to 4 days. 
 
Figure 3.5 Box plots of total viable yield of PC-3 cells over 13 days period in different 
treatments. The horizontal line in box plots represents the median value. There was no 
significant different difference in the total cell yield of PC-3 cells under different treatments 
at same final concentration of 10-6M (P = 0.91, Kruskal-Wallis test). 
 
 
3.3.3  Change in population doubling and doubling time 
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Figure 3.6 shows the change in population doubling for various treatments of PNT1A cells. 
Oestradiol had the lowest change in population doubling, which implied inhibition of cell 
growth. Hydrocortisone showed a similar inhibitory effect, while the androgens caused 
increase in population doubling. For PC-3 and MDAPCa 2b cells, oestradiol and 
hydrocortisone produced similar results but DHT and testosterone did not differ from those of 
controls. The size of error bars reflected variations that could occur in manual cell count of 
triplicate over a period of time. 
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Figure 3.6 Change in population doubling of PNT1A cells.  Oestradiol and Hydrocortisone 
caused a reduction in population doubling (growth inhibition) while the androgens promoted 
cell growth. But the androgens did not promote cell growth in PC-3 and MDAPCA 2b cells. 
 
The Doubling time (DT) for PNT1A cells treated with oestradiol was 111.2 ± 5.87 hours 
compared to DTs of 52.60 ± 1.49, 63.8 ± 2.1, 47.2 ± 6.97 and 35.6 ± 4.1 hours for 
testosterone, dihydrotestosterone, ethanol and no treatment respectively. The DT values for 
oestradiol-treated PC-3 cells (71.98 ± 7.1 hours) and MDAPCA 2b cells (32.02 ± 6.2) were 
significantly lower than that of PNT1A cells (P<0.05). DT values are usually higher when 
frozen cells are seeded for expansion. However, cells harvested in log phase and re-seeded 
tend to have a reduced DT. 
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3.3.4  Growth inhibition 
Figure 3.7 shows the % control growth for PNT1A cells, from which the inhibition 
concentrations (IC) were deduced. The IC10 and IC50 values for the steroids were significantly 
different. 
 
Figure 3.7 Percent control growth of hormones on PNT1A cells. From this curve, the  
IC10 and IC50 values were calculated. 
 
The IC10 and IC50 values for oestradiol were 4.92 and 33.96µM respectively; 0.86 and 8.44 
µM for dihydrotestosterone (DHT); testosterone were 7.63 and 30.42 µM, and for 
hydrocortisone 4.64 and 261.9 µM respectively.  
 
3.3.5  Immunometric assays 
 
a) Immunocytochemistry and Immunofluorescence 
 
Figures 3.8, 3.9 and 3.10 show representative photomicrographs for immunostaining of 
selected cellular antigens (more slides are contained in appendix C.7).  PSA stained brown in 
the cytoplasm of all the cell lines. The intensity of PSA stain was strong and diffuse in the 
PNT1A cells but patchy in the PC-3 cells. The MDA PCA 2b cells also stained strong for 
PSA. 
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All the cell lines stained positive for AR, ESRα and ESRβ. The nuclei of PC-3 cells stained 
strongly and diffusely dark-brown for ESRβ; but weakly for AR. There was moderate 
staining for the ESRα in both MDAPCA 2b and PC-3 cells. The PNTIA stained strongly dark 
brown for AR more than PC-3 cells and MDAPCA 2b cells. All the cells stained positive for 
CD44 in the IF; the PC-3 cells stained stronger than the other two cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Immunolocalisation of PSA in prostate cell lines. A) Patchy cytoplasmic brown 
stain for PSA in PC-3 cells. B) PNT1A cells stained strong and diffuse for PSA. C) is a 
negative control slide for PSA stain. D) Moderate and diffuse cytoplasmic staining of PSA in 
MDAPCA 2b cells. Scale 1cm is 23µm (x 400 magnifications). Cells were prepared by 
cytospinning. 
      
A) PSA positive PC-3 cells.                                               B) PNT1A:  positive for PSA 
                                          . 
      
C) PNTIA: PSA negative control                                        D) MDA PCA 2b: positive for PSA 
. 
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Figure 3.9 Immunolocalisation of oestrogen and androgen receptors in prostate cell lines. A = 
is ESRβ positive PC-3 cells, nuclei stained strongly dark- brown. B =  ESRα- positive PC-3 
cells, nuclei stained dark brown. C is PC-3 negative control slide. D = AR positive PNT1A 
cells, nuclei stained strongly dark brown. All the prostate cell lines expressed the three 
receptors; PC-3 cells stained weakly for AR receptors. Scale 1cm is 23µm. x 400 
magnifications. Cells were grown on slide flasks. 
 
 
 
 
 
 
 
 
            
A)  ESR beta2 in PC-3 cells                                             B) ESRα positive PC- cells 
 
    
C) PC-3 negative control slide                                     D) AR positive PNT1A cells 
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Figure 3.10 Immunofluorescent localization of CD44 positive PC-3 cells. Alexa fluor 555 
fluorophore was used. PC-3 cells expressed more CD44 in the cell membrane than the 
PNT1A and MDAPCA 2b cells. 
 
b) PSA secretion in culture supernatants 
 
Secreted PSA was not detectable in the culture supernatants of stimulated PC-3 and 
MDAPCA 2b cells. Figure 3.11 shows the PSA ng/ml in various steroid treatments in PNT1A  
 
A = CD 44 positive PC-3 cells. 
 
 
B = PC-3 cells Negative control 
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cells. In Figure 3.11b, DHT treatment did not produce a significant increase in PSA secretion 
(P = 0.20, Kruskal –Wallis test) for the 24-, 48- and 72- hours time intervals. However, there 
was a slight increase in the PSA content of cell lysates in PNT1A cells also treated with DHT 
(Figure 3.10c) compared to controls, but this was statistically non-significant (P = 0.09). 
Higher concentrations of oestradiol and hydrocortisone caused a reduction in PSA secretion 
(Figures 3.11d and e); although these were again statistically non-significant (P = 0.06).  
Because there were only three time points of measurement (24-, 48- and 72-hrs), the 
statistical analysis for the group would not be reliably robust. 
 
In Figure 3.11f, low level of testosterone (3.82µM = 0.5 of IC10 value) caused an increased in 
PSA secretion, although statistically non-significant when compared with controls in that 
group (P= 0.18). 
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Figure 3.11 PSA levels in culture supernatants of treated PNT1A cells. A is the PSA standard 
curve; B is PSA DHT treated cells; C is PSA in cell lysate of DHT treatment; D = H- treated 
cells; E is oestradiol treated cells and F= T- treated cells. 
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c) Immunoblotting 
Figure 3.12 shows the immunoblots for protein extracts from the cell lines. PC-3 cells had very weak 
expression of PSA and also expressed AR. Both MDAPCa 2b and PNT1A expressed PSA (size 
corresponding to 40 kDa in the blots). The AR expressed in PC-3 cells and MDAPCA 2b cells were 60 
kDa, while the PNTIA expressed a 90 kDa AR protein. All the cells expressed ESRα, ESRβ1 and 
ESRβ2; the latter was over-expressed in the MDA PCA 2b cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Immunoblots of protein extracts from prostate cell lines. A is β-actin blot as a control protein (Lanes 1-5 are 
ladder, no sample, PC-3, MDAPCA 2b and PNTIA cells respectively).  B) AR blots which were about 60 kDa in MDAPCA 
2b cells (lane 1) and PC-3 cells (lane 2) but 90 kDa in PNT1A cells (lane 3). C) PSA blots, PC-3 cells did express PSA 
(weakly) and D) ESRα expressed in all the cell lines; E) 60 kDa ESRβ2 expressed in MDAPCA 2b and PC-3 cells only. 
 
  Lanes>                                                                                                                                 
       
 
                
            A) 40kDa β-actin control                          B) AR blots in prostate cell lines 
    
                  
         C) PSA blots in prostate cell lines              D) ESRα blots in prostate cell lines 
 
 
            
           E) ESRβ2 blots in prostate cell lines 
 
Size 
 
90kDa 
 
 
 
60kDa 
 
 
 
 
40kDa 
1 2 3 4 5 1 2        3     
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3.3.6 Gene expression of molecular markers 
 
Figure 3.13 shows a representative RNA chromatogram, the average 28S/18S ratio was 1.75 (range 1.61 
to 2.01).  
 
Figures 3.14 and 3.15 show representative amplification plot and standard curves. A ten fold serial 
dilution of plasmid calibrators (106 to 100) were used in generating standard curves. For each dilution 
point, the standards were measured in triplicate. From the amplification plot and standard curve, the six 
parameters of valid RQ-PCR were easily deduced. In place of plasmid calibrators, serial dilutions of 
cDNA from cell lines were used to construct a standard curve and determined PCR efficiency, especially 
in normalized relative quantification (NRQ). 
 
 
Figure 3.13 A representative RNA Electropherogram. Average 28S/18S was 1.75. Overall RNA quality 
was good for RQ-PCR. 
 
Figure 3.16 shows the absolute gene expression of candidate endogenous control genes (CG): Abelson 1 
gene (ABL1), beta-glucuronidase (GUS) and glucose 6 phosphate dehydrogenase (G6PD). The use of a 
control gene in RQ-PCR informs assay sensitivity, assesses sample quality and analytical 
reproducibility. This is achieved by parallel amplification of the target gene and one or more 
endogenous control genes (CGs). 
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Figure 3.14 Amplification plot of a duplex real time PCR for ABL1 and G6PD. 
 
Figure 3.15 Standard curves for a duplex RQ-PCR for ABL1 and G6PD. ABL1 was detected by FAM 
and G6PD by TET. PCR efficiencies were within the 90 to 100% range (slope -3.3- to -3.60). 
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There are three main criteria for selecting control genes: absence of pseudogenes, good level and 
stability of expression, and little variation due to any pre-analytical treatment (e.g. GITC lysis of cells, 
RNA extraction etc). The three chosen candidate genes satisfied all the criteria. 
In Figure 3.16 the median value of ABL1 copies (transcript number) was 1.72 x 104 (range: 3.62 x 100 to 
2.22 x 105). There was no significant difference in the ABL1 transcript copies across the three cell lines.  
 
In Figure 3.17 the median value of GUS copies was 1.44 x 104 (range: 6.15 x 100 to 1.56 x 105) in the 
cell lines; also no significant difference across the cell lines.  
In Figure 3.18 the median value of G6PD transcript number was 4.76 X 104 (range: 1.71 x 100 to 5.91 x 
105) in the cell lines; no significant difference across the cell lines.  
The mean value of ABL1 transcript number related to that of GUS by a ratio of 1.19 and to that of 
G6PD by a ratio of 0.36 across the cell lines. Conversely, the mean value of G6PD transcript number 
related to that of GUS by the ratio of 3.30 and ABL1 by a ratio 1.25. Both median and mean ABL1 
transcript numbers were in between that of GUS and G6PD.  
 
 
 
Figure 3.16 ABL1 transcript levels in the prostate cell lines. There was no significant difference in 
ABL1 transcript number across the cell lines. 
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Figure 3.17 GUS transcript levels in the prostate cell lines. There was no significant difference in GUS 
transcript number across the cell lines. 
 
 
Figure 3.18 G6PD transcript levels in the prostate cell lines. There was no significant difference in 
G6PD transcript number across the cell lines. 
However, in Figure 3.19, the candidate control genes were compared against one another and also 
against their geometric means (GM). The purpose was to find out if geometric mean of the three CGs 
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differed from their individual values because it is also a common practice for two or more CGs to be 
used in normalization of RQ-PCR. There was no significant difference between the GMs and ABL1 
transcript number in all the cell lines (P > 0.05). There were significant differences between GUS and 
G6PD in PC-3 cells (P < 0.01), between G6PD in PC-3 and GUS in MDAPCA 2b (P < 0.01), G6PD in 
PNT1A and GUS in MDAPCA 2b (P < 0.05) and vice versa. There was no significant between either 
G6PD or GUS and ABL1 across the cell lines. ABL1 transcript was stably expressed across the cell 
lines. 
 
Figure 3.19 Comparison of all control genes with geometric means in the cell lines. There were 
significant differences between GUS and G6PD in PC-3 cells (P < 0.01), between G6PD in PC-3 and 
GUS in MDAPCA 2b (P < 0.01), G6PD in PNT1A and GUS in MDAPCA 2b (P < 0.05) and vice versa. 
There was no significant between either G6PD or GUS and ABL1 across the cell lines. ABL1 transcript 
was stably expressed across the cell lines. 
 
Figure 3.20 shows the effect of steroid treatment on ABL1 transcript number. In Figure 3.20a, higher 
dose of 17β oestradiol caused a significant reduction in ABL1 transcript level. This was consistent with 
previous findings in which 17β oestradiol caused a reduction in population doubling and increased 
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doubling time of prostate cell lines. Similar variations were observed for G6PD and GUS. In figure 
3.20b there was stable ABL1 expression in DHT-treatment. 
 
 
Figure 3.20 Effect of hormonal treatment on ABL1 transcript number. A is 17β oestradiol (E) treatment, 
B is DHT treatment; ND stands for no drug (culture media only); DMSO = dimethyl sulphoxide used as 
a solvent. 
 
Figure 3.21 shows the normalized relative quantity (NRQ) of AR in all the prostate cell lines following 
treatment. The AR expression was calculated from NRQ= E Ct AR/ E Ct ABL where E is the PCR efficiency 
of each target {Pfaffl, 2001}. 
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Figure 3.21 Normalized relative expression of AR in prostate cell lines. AR is significantly over-
expressed in MDAPCA 2b and PC-3 cells compared to PNT1A cells. 
 
Transcript number of AR was significantly higher in both cancerous cell lines compared to the ‘normal’ 
PNT1A cell line (P < 0.0001). The primers used in the RQ-PCR of AR were designed to amplify exons 
2 and 3, which is preserved in both standard and novel variants of AR reported to date {Hu et al, 2009}.  
 
Figure 3.22a shows the gene of expression of ESR beta (oestrogen receptor beta) while Figure 3.22b 
shows the variation in ESR beta due to 17β oestradiol treatment. ESR beta was significantly up-
regulated in the cancerous cell lines compared to the ‘normal’ cell line (PNT1A). Both AR and ESR beta 
were significantly up-regulated in the two cancerous cell lines compared to the PNT1A cells. Unlike in 
the AR expression, the MDAPCA 2b significantly expressed more ESR beta than the PC-3 cells (P < 
0.001).  
 
17β oestradiol (E) treatment of the cells significantly increased ESR beta expression in surviving cells 
compared to control groups (P < 0.05). 
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Figure 3.22 Modulation of ESR beta expressions in prostate cells. A is NRQ of ESR and B is variation 
due to oestradiol treatment. 
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In Figure 3.23 IC10 value of oestradiol did not produce any significant increase in ESRβ expression in 
the cell lines. Figure 3.24 shows the basal level of ESRβ in all the cell lines untreated for 12-, 24-, 48- 
and 72 hours. 
 
 
Figure 3.23 Effect of IC10 oestradiol treatment on ESRβ gene expression. There was a significant 
difference in transcript number only at the 72-hr harvest. 
 
Figure 3.24 Basal level of ESRβ in untreated prostate cell lines. The MDAPCA 2b expressed a 
significantly higher levels of ESRβ for 12-, 24-, 48- and 72-hours period. 
 
Figure 5.25 shows the effect of hydrocortisone at IC10 value on ESRβ transcript level. 
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Although hydrocortisone showed inhibitory effect on the population doubling in the previous section, it 
didn’t reduce the transcript level of ESRβ. There were significant differences only between non-treated 
PNT1A cells and non-treated MDAPCA 2b cells (P < 0.05) and non-treated MDAPCA 2b and DMSO-
treated PNT1A cells (P <0.05). ESRβ transcript number was significantly highest in MDAPCA 2b cells. 
The androgens-testosterone and dihydrotesterone also did not alter the transcript level of ESRβ in the 
cell lines. 
 
 
Figure 3.25 Effect of Hydrocortisone stimulation on transcript number of ESRβ Hydrocortisone did not 
significantly lower ESRβ transcript levels in MDAPCA 2b cells. ND stands for no drug treatment. H 
stands for Hydrocortisone. DMSO stands for dimethyl sulphoxide, which was used as a solvent. 
 
 
 
Figure 3.26 shows that ESRβ transcript number also increased in testosterone treated PNT1A cells but 
not higher than the increase in the cancerous cell lines. 
 
Figure 3.27 shows the gene expression of ESR alpha in the prostate cell lines. There was no significant 
difference in ESRα expression between MDAPCA 2b and PNT1A (P > 0.05); but PC-3 cells 
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significantly over-expressed ESRα (P < 0.001). ESRα was also up-regulated by the administration of 
17β oestradiol (E).  
 
Figure 3.26 Effect of IC50 value of testosterone on ESRβ transcript number. PNT1A cells treated with 
testosterone expressed more ESRβ transcripts but not more than the cancerous cell lines. 
 
Figure 3.28 shows normalized absolute quantification of KLK2 gene. A plasmid standard with KLK2 
insert was prepared using the protocol described in appendix B.16. Absolute quantity of KLK2 was 
divided by that of ABL1, and the ratio expressed as a percentage. 
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Figure 3.27 Normalized relative gene expression of ESR alpha in prostate cells. ESR alpha was 
significantly over-expressed in PC-3 cells compared to MDA PCA 2b and PNT1A cells. 
 
 
Figure 3.28 KLK2 expressions in prostate cell lines. PNT1A has a significantly higher expression of 
KLK2 transcripts compared to the cancerous cell lines (P < 0.05). 
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Figure 3.29 shows the expression of CD44 in the prostate cell lines. The cancerous cell lines 
significantly over-expressed CD44 compared to PNT1A cells.  
 
 
Figure 3.29 CD44 expressions in prostate cell lines. Cancerous cells over-expressed CD44 (P < 0.05). 
 
 
Figure 3.30 shows the expressions of MCM2 and MCM5 replication licensing factors. There was no 
significant difference in the MCMs expressions in all the cell lines. 
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Figure 3.30 Transcript levels of MCM2 and MCM5 in prostate cells. A is the transcript number of 
MCM2 and B is the transcript level of MCM5 across the prostate cell lines. There was no significant 
difference in the expression of the MCMs (P > 0.05). 
 
Figure 3.31a shows the E-Cadherin type 1 (CDH1) is significantly over-expressed in cancerous cell lines 
compared to the ‘normal’ cell line (PNT1A) (P < 0.001. In Figure 3.31b, TP53 transcript level was 
significantly higher in PNT1A cells compared to the cancerous cell lines (P < 0.001).  
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Figure 3.31 Gene expressions of CDH1 and TP53 in prostate cell lines. A shows CDH1 is significantly 
over-expressed in cancerous cells; B shows higher expression of TP53 in PNT1A cells. 
 
Figure 3.32 shows KLK3 expression in prostate cell lines. There was no significant difference in KLK3 
transcript number among the cell lines (P = 0.24). 
 
Figure 3.33a shows Bcl-2 transcript levels in prostate cell lines. PC-3 has a significant over-expression 
of Bcl-2 compared to PNT1A cells (P= 0.001). Bcl-2 was also significantly higher in MDAPCA 2b 
compared to PNT1A cells (P < 0.05). 
 
Figure 3.33b shows FASN transcript levels in prostate cell lines. FASN transcript number was 
significantly higher in MDAPCA 2b compared to PNT1A (P < 0.05) but not with PC-3 cells.  
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Figure 3.32 Transcript levels of KLK3 in prostate cell lines. There was no significant difference in 
KLK3 transcript levels in the cell lines. 
 
 
The TMPRSS2 fusion genes (TMPRSS2: ERG and TMPRSS2:ETV1) were not detected in any of the 
three cell lines.  
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Figure 3.33 Gene expressions of Bcl-2 and FASN in prostate cell lines. A: Bcl-2 was significantly over-
expressed in PC-3 cells; B: fatty acid synthase (FASN) was significantly over-expressed in MDAPCa 
2b.  
 
3.4  Discussion 
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3.4.1  Growth characteristics of cell lines under standard culture conditions 
Although DCC-FCS supplemented culture media had reduced levels of steroid hormones and proteins, it 
could support the growth of the prostate cell lines without a significant reduction in viable cell yield. 
The reduced hormone level, for example testosterone in the DCC-FCS serum, would enable, without 
masking effect, the observation of stimulatory/inhibitory effects on the growth of prostate cell lines due 
to steroid treatment. 
 
Two different methods gave comparable results on the growth phases of the prostate cell lines. The 
exponential growth phase was shorter in the SRB assay, which used the 96-well format compared to the 
12-well tissue culture plate. The difference between the two methods could be a result of the effect of 
limiting surface area on cell growth (contact inhibition). In the SRB assay, 72 hours was optimal in the 
exponential (log) phase of the three cell lines. Therefore, cells were harvested after 72 hours for the 
cytotoxicity assays using the 96-well format. But for cell expansion to get sufficient number of cells for 
downstream applications, 5 days period was optimal for cells grown in the 12-well tissue culture plates 
and or T75 flasks. Low concentrations of the steroid hormones (10-6M) did not alter significantly the 
growth curve characteristics of the cell lines. This provided the platform to observe the effects of higher 
doses’ stimulation on the growth of the cells. The concentrations of steroids used in the growth curve 
experiments were intentionally kept very low to avoid growth inhibition. Yousef & Diamandis (1999) 
had shown that 10-6M concentration of the steroids would not significantly inhibit growth of the cell 
lines, which was also confirmed in this study. The viable cell yield remained relatively the same in all 
the treatments for the 13 days period. 
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3.4.2 Growth inhibition of prostate cells 
The ∆PD takes into account the epithelial nature of the cells as it measures their ability to form 
monolayer in tissue culture plates {Korkolopoulou et al, 2005}. The observed inhibitory effect of 
oestradiol has also been reported in other studies {Qiao et al, 2007; Arnold et al, 2007}. The doubling 
time for oestradiol-treated cells were the longest, confirming the inhibitory effect of oestradiol on 
prostatic growth In addition, the result also showed that hydrocortisone could significantly inhibit 
growth of prostate cell lines in vitro. Analogues of hydrocortisone are normally used in palliative care of 
patients with metastatic PCa {Droller, 1997; Heidenreich et al, 2008}. They inhibit synthesis of 
prostaglandins which mediate inflammation, thereby providing pain-relief. Cyclo-oxygenase-2 (COX-
2), an enzyme involved in the synthesis of prostanoids including prostaglandins, is over-expressed in 
around 75% cases of PCa {Thomas et al, 2006}. Therefore the activity of hydrocortisone might be 
directed against COX-2 and similar mediators of inflammation. 
 
Although androgens promoted growth of prostate cells, higher concentrations (more than physiological 
nM range) appeared to inhibit in vitro cell growth. According to Quinn et al (2005), dysfunction in the 
homeostatic breakdown mechanisms of steroids could affect their ligand activity. However, the 
mechanism of the observed in vitro androgen ‘toxicity’ (at higher micro molar concentrations) to 
prostate cells is unclear and has not been reported in the literature. But 17β oestradiol and 
hydrocortisone are known to inhibit prostatic cell growth in vitro {Droller, 1997; Thomas et al, 2006; 
Qiao et al; Arnold et al, 2007}. In the report by Qiao et al (2007), only 10 nM of DHT was used to 
induce cell growth while 10 µM of 17β oestradiol was used to inhibit prostatic cell growth in LAPC-4 
prostate cells. In addition, the inhibitory range of 17β oestradiol observed in this study (4.92 to 33.96 
µM) for inhibiting growth of 10 to 50% of prostate cell population in vitro could be useful in designing 
stimulation experiments with oestrogens. Direct inhibition of AR by oestrogens has also been 
demonstrated in prostate cells {Hedlund et al, 2003}. Therefore, in vitro studies to evaluate proliferative 
roles of AR and isoforms of ESR receptors in prostate cell lines would require oestrogen stimulation. 
These results would guide choice of concentrations for the four hormones studied. 
 
 
 
 
 
3.4.3 Selection of housekeeping gene for normalization of real time PCR experiments 
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The overall quality of RNA obtained from the RNeasy mini spin columns was good for RQ-PCR. 
DNAse digestion was not used, but it could improve RNA quality {Burmeister and Reinhardt, 2008}. 
Although few studies have been conducted looking at the normalization of prostatic tumour markers, 
there are no validated control genes applicable for clinical use. In 2006 Schmidt et al, reported a 
quantitative multi- gene expression profiling of nine prostate tumour markers using 4 control genes 
(GAPDH, HPRT, PBGD and TBP) to normalize gene expression of target amplicons.The GAPDH gene 
is known to have 60 pseudogenes (www.pseudogenes.org/), which can result in the amplification of 
non-functional genomic DNA. The PBGD has alternative transcriptional start sites {Beillard et al, 
2003}, which can produce undetectable transcript variants. The HPRT and TBP are also reported to have 
pseudogenes, and the TBP shows very low expression level which is tissue dependent {Garbert et al, 
2003}. Nonetheless, in that study the TBP gene was chosen for normalization because it showed no 
differential expression between paired tumour and tumour- free samples. In another study, Antonov et al 
(2005) reported the RQ-PCR of degraded RNA of house keeping genes (endogenous control genes) in 
formalin fixed, paraffin embedded (FFPE) breast tissues. Although the report showed that gene 
transcript quantification could be done on RNA extracted from FFPE materials, the choice of controls 
genes like 18S rRNA which is known to have a very high expression in normal tissues {Beillard et al, 
2003} and GAPDH also known to have several pseudogenes were inappropriate. It is still very common 
to see many gene expression studies that are normalized using beta-actin gene even though it is known 
to have 8 pseudogenes. Therefore, the choice of an endogenous control gene for normalizing transcript 
quantification of prostatic tumour markers is still a crucial issue and a consensus has yet to be found.  
The results from the RQ-PCR in this study showed that ABL1 gene was the most stably expressed 
among the three candidate control genes. It has no known pseudogene, and it had also been evaluated in 
multi-centre studies for haematological malignancies {Garbert et al, 2003}. The ABL1 gene is not tissue 
specific; however, its expression was stable across different cell types. The stability in expression and 
absence of pseudogenes are the most important criteria for choosing an endogenous control gene for 
RQ-PCR normalization and sample quality check.  
 
The reduction in ABL1 transcript number as a result of 17β oestradiol treatment of cells was a direct 
reflection of the reduction in number of viable cells. A good control gene varies according to cell 
number in samples. Although G6PD transcript number was also stable, it varied significantly with that 
of GUS, another commonly used house keeping gene. Good level and stability of expression was 
observed in the ABL1 transcript number. Therefore, ABL1 was used in the normalization of the 
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molecular markers. The notion of using two or more control genes for normalization, by taking their 
geometric mean, does not necessarily improve assay sensitivity. A single stably expressed control gene 
offers the advantage of multiplexing it with target transcripts for simultaneous quantification, which 
could reduce inter-run variation and assay cost while making analysis simpler without any change in 
sensitivity of the assay. 
 
3.4.4  Influence of steroid hormones on expression of steroid receptors 
The immunolocalisation of steroid receptors (AR, ESR alpha and beta) in the prostate cells and other 
endocrine tissues have been variously reported {Isola, 1992; Pelletier & El-Alfy, 2000; Murphy et al, 
2006}. Isola, (1992) reported that most breast tumours that expressed ESR alpha also expressed AR. 
Walton et al (2009) also reported the immunopositivity of ESR beta in prostate tissue. The results from 
this study showed that AR, ESRα and ESRβ were expressed in the three prostate cell lines Contrary to 
the report by van Bokhoven et al (2003), the PC-3 cells stained positively for AR and PSA .The possible 
explanation to this observation could be a contamination with other cell lines over the previous years of 
passaging {van Bokhoven et al 2001}. Or sublines that express PSA and AR could have emerged over 
the years of passaging as a result of selective growth pressure. 
Although PC-3 cell expressed AR and PSA in the immunocytochemistry and western blots, it did not 
produce detectable PSA in culture supernatants. The MDAPCA 2b cells also failed to secrete detectable 
PSA in the culture supernatants It had been reported that prostate cell lines which expressed AR could 
still be androgen insensitive due to lack of AR promoter function and inactivating mutations {Chlenski 
et al, 2001}.  
 
The AR and ESRβ were significantly over-expressed in the cancerous prostate cell lines compared to the 
PNT1A; the ESRα was only significantly higher in the PC-3 cells. Their expressions were confirmed at 
both mRNA and protein levels. Although 17β oestradiol inhibited prostate cell growth, it up-regulated 
the expression of ESRβ in both time- and dose- dependent manner. This up-regulation suggested a 
proliferative role for ESRβ in PCa progression. The MDAPCA 2b cells mimic a progressive prostate 
cancer. It expressed the highest transcript levels of ESR β, which was increased only by 17β oestradiol 
stimulation. The treatment by hydrocortisone did not lower the expression of ESRβ; neither did the 
stimulation by androgens. In aging men, the level of oestradiol is increased. A possible hypothesis from 
these in vitro findings could be that oestrogen receptors, predominantly the ESRβ mediate the later stage 
proliferation of prostate cancer cells. This is consistent with the fact that the administration of DHT and 
testosterone did not alter the levels of AR in the MDAPCA 2b and PC-3 cells. The PNT1A cells 
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responded better to the androgens than the cancerous cells. However, the administration of oestradiol 
also increased the transcript levels of AR in the cancerous cell lines Arnold et al (2007) reported the 
induction of PSA production by the activity of oestradiol on both oestrogen receptors and AR receptors, 
and concluded that both receptors mediated the activity of the metabolite dihydroepiandrosterone (a 
precursor to both androgens and oestrogens). ESR stimulation in general is also known to induce 
production of AR {Droller, 1997}. It is also possible through the transactivation domain in all the 
receptors to activate them by common ligands {Hu et al, 2009}. Therefore, selective targeting of ESRβ 
in prostate cancer cells could offer therapeutic advantage in reducing cell proliferation. 
 
The ESRα was only highly expressed in the PC-3 cells which mimic metastatic prostate cancer. Prins et 
al (2001) had shown that ESRα was the key mediator of oestrogenic activity in developing prostate 
gland of mice. The results from this study suggest a reversal of role for the ESRα. It appeared to play a 
minor role in proliferation in the later stage progression of cancer; its transcript level and protein 
expression was lower than those of ESRβ. 
 
In summary, the steroid hormones caused a differential expression of the receptors especially the ESRβ 
receptor. In view of the overall aim of this study which is the examination of the link between 
development and progression of prostate cancer and production of diagnostic/prognostic molecular 
markers, this finding warrants a further investigation into the in vivo expression of these receptors in 
benign, non-involved and prostate cancer cases. The further objective was to find out if the up-
regulation of ESRβ gene expression (observed in the cell lines) was associated with prostate malignancy 
and its phenotype. 
 
3.4.5 Influence of steroid hormones on expression of PSA and KLK2. 
Only the PNT1A cells secreted PSA in the culture supernatants; and low levels of testosterone induced 
the highest production of secreted PSA. Higher levels of DHT did not produce higher secretions of PSA, 
an observation that was congruent with the inhibitory effect of higher doses of androgens observed 
previously. Even the cell lysate of PNT1A cells treated with higher dose of DHT did not produce higher 
amount of cellular PSA compared to lower doses of testosterone. Similar result was observed at the 
transcript level. PSA mRNA level did not differ significantly in the three prostate cell lines. The 
immunoblots also showed that all the three cell lines expressed high PSA. However, there was a 
reduction in PSA secretion due to oestradiol and hydrocortisone treatment compared to testosterone 
treatment. This was contrary to the report by Arnold et al (2007) but in agreement with Qiao et al (2007) 
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who also reported a reduction in PSA level of culture supernatant as a result of 17β oestradiol treatment. 
PSA at both transcript and protein levels were inconsistent in correlation with malignancy (prostate 
cancer cell lines). 
 
The KLK2 was significantly over-expressed in PNT1A cells compared to the cancerous cell lines. 
Down-regulation of KLK2 transcripts in prostate cancer cells had been reported by Magklara et al, 
(2001). This was contrary to the popular observations that KLK2 are up-regulated in PCa. On the other 
hand, the PNT1A cells in this study responded to androgen stimulation; and KLK2 is androgen-
regulated {Diamandis & Obiezu, 2005}. However, the cancerous cell lines were less responsive to 
androgen stimulation as observed in lack of PSA secretion in culture supernatants compared to the 
PNT1A cells. The up-regulation of KLK2 and KLK3 in PNT1A cells is consistent with androgen 
regulation of human tissue kallikreins {Yousef & Diamandis, 2003}. Normal cells hardly harbour AR 
mutations, and therefore respond to androgen stimulations unlike prostate cancer cells where AR 
mutation inactivates its response to ligands. Further in vivo studies would still be required to assess the 
diagnostic/ prognostic value of KLK2 transcript levels in prostate malignancy since it was up-regulated 
in vitro in the prostate cell lines.  
 
3.4.6  Influence of steroid hormones on expression of CD44 and E-Cadherin type 1 
Several studies have reported over-expression of standard CD44 in prostate, colorectal and breast 
cancers {Jung et al, 2009, Madjd et al, 2009}. Early studies had suggested that only mutant forms of 
CD44 are over-expressed in prostate cancer {Isaacs, 1997}. In this study, the CD44 over-expression in 
the prostate cancer cell lines compared to the ‘normal’ cell line indicated an association with prostate 
malignancy. However, mutation analysis of CD44 was not part of this study; and it would be required to 
find out if CD44 over-expression was associated with mutations. The primers for CD44 RQ-PCR were 
designed to amplify all major transcript variants. It is known that transcript variants of CD44 might be 
differentially expressed in various tissue types. In this study, the overall CD44 transcript level was 
consistently significantly higher in the cancerous cell lines. A similar pattern of expression was observed 
for E-cadherin type 1 (CDH1); its transcript level was also consistently higher in the cancerous cell lines 
compared to the ‘normal’ cell line. Quinn et al (2005) reported over-expression of CDH1 in metastatic 
PCa. Isaacs (1997) suggested that over-expressed CDH1 in PCa could be mutated. Standard CDH1 is 
known to be down-regulated in PCa {Bussemakers et al, 2000}. Further in vivo studies would be 
required to confirm the over-expression of CD44 and CDH1 transcript levels in prostate malignancy and 
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its association with mutations. Their up-regulation in steroid stimulated prostate cancer cell lines 
indicated an association with malignancy. 
 
3.4.7 Influence of steroid hormones on expression of MCM2 and MCM5. 
MCMs are essential for cell replication. All proliferating cells express high levels of MCMs. All the cell 
lines involved in this study were actively proliferating, and therefore there was no difference in both 
MCM2 and MCM5 transcript levels. 
MCM expression is not tissue specific, and therefore has been associated with many human cancers. For 
example, urothelial cancers significantly over-express MCM5 [Stober et al, 1999}. Prostate cancer cells 
have also been shown to over-express the MCMs {Freeman et al, 1999}. But this in vitro study has 
shown a very limited value of MCM transcript level in the diagnosis of prostate malignancy. Further in 
vivo study would be required to assess possible association of MCM transcript level with prognosis. 
 
3.4.8  Influence of steroid hormones on expressions of TP53 and Bcl-2. 
TP53 was significantly over-expressed in the ‘normal’ cell line compared to the cancerous cell lines. 
This suggested that the apoptotic role of TP53 was significantly functional in ‘normal cells’ compared to 
cancerous cells. TP53 mechanism is usually dysfunctional in PCa. It is known that TP53 nuclear 
accumulation in human cancers harbour inactivating mutations especially in exons 5-8 {Oden-Gangloff 
et al, 2009}. 
However, the anti-apoptotic agent, Bcl-2 was significantly over-expressed in the cancerous cell lines. It 
was reported that the over-expression of Bcl-2 confer androgen resistance, particularly in advanced stage 
PCa {McConkey et al, 1996} and that Bcl-2 expression increased with PCa progression {Quinn et al, 
2005}. 
 
3.4.9 Influence of steroid hormones on expression of FASN and TMPRSS2 fusion genes. 
FASN aberrant expression is believed to occur early in PCa development {Benedettini et al, 2008}. 
FASN transcript level was only significantly over-expressed in the MDAPCA 2b cells; there was no 
significant difference in the PC-3 cells which represents later stage malignancy. There was also no 
significant increase in FASN gene expression in the PNT1A ‘normal’ cell lines. This supported the 
hypothesis that FASN aberrant expression is an early stage event in prostate cancer development. 
The TMPRSS2 gene fusions (TMPRSS2: ERG and TMPRSS2:ETV1) were not detectable in the three 
prostate cell lines. This could be due to complex re-arrangement of the ETS genes with several other 5’ 
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partners, some times difficult to detect in prostate cell lines {Tomlins et al, 2007}. Such re-arrangements 
are detectable by interphase FISH, which was not included in this study.  
 
3.5  Conclusions 
 
• Prostate cell lines provide an in vitro model for manipulation of expressions of molecular 
markers using steroids. The summary of findings in this chapter includes: 
• DCC-FCS (a steroid and protein depleted form of FCS) supported growth of prostate cell lines 
without a statistically significant reduction in viable cell yield. This would enable the observation 
of steroid stimulation effects on growth of cells and gene expression of molecular markers 
without ‘masking effect’. 
• 17β oestradiol and hydrocortisone reduced cell growth by increasing doubling time and reducing 
change in population doubling. The IC10 to IC50 range of 17β oestradiol observed in this study 
(4.92 to 33.96 µM) could be very useful in designing in vitro stimulation experiments with 
oestrogens. The observation also supported growth inhibition of prostate cancer cells by both 
agents, which could be exploited therapeutically. 
• The gene expressions of AR, ESRα and ESRβ and PSA were confirmed at both protein and 
mRNA (transcript) levels in the PNT1A, MDAPCA 2b and PC-3 cells. They showed differential 
expression which should be investigated further in vivo model. 
• The MDAPCA 2b and PC-3 cells failed to produce detectable levels of secreted PSA in culture 
supernatants. The PNT1A proved a better model for inducing PSA secretion in vitro. 
• The PC-3 cells were not responsive to androgen stimulation in vitro. 
• The KLK3 transcript level in the prostate cell lines was inconsistent with the protein expression 
and had limited association with prostate cancer cells. 
• The KLK2 was up-regulated in PNT1A cells in response to steroid stimulation but down-
regulated in cancerous cell lines. The transcript levels of both kallikreins showed little promise 
for diagnostic utility. The down regulation of KLK2 mRNA in prostate cancerous cells was 
inexplicable. It requires further investigation especially with regards to the role of regulatory 
RNAs (micro RNAs in particular) in prostate cancer. 
• ESRβ gene expression was up-regulated by 17β oestradiol in both dose and time dependent 
manner. 
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• The expression of ESRβ transcripts in the prostate cell lines supported a proliferative role for late 
stage prostate cancer cell proliferation. Therefore selective targeting of the ESRβ could offer a 
therapeutic advantage in controlling late stage prostate cancer proliferation. 
• The ESRα could play a minor role in late stage prostate cancer cells proliferation. 
• The CD44 and CDH1 were significantly over-expressed in prostate cancer cells and could be 
associated with progression of prostate malignancy. 
• The transcript levels of MCM2 and 5 showed a limited value for application to prostate cancer 
diagnosis. 
• TP53 gene was over-expressed in normal cells but down-regulated in prostate cancer cells, while 
the Bcl-2 was over-expressed in the cancerous cell lines. 
• The FASN transcript level supported an over-expression in early stage prostate cancer 
development 
• The TMPRSS2 fusion genes were not detectable in the three prostate cell lines. 
 
The findings from the in vitro studies provided answers to the overall research questions. The gene 
expression of some of the steroid hormone receptors were significantly altered by the hormonal 
stimulation, in particular the ESRβ .The gene expressions of some of the selected molecular markers 
were also significantly altered due to hormonal stimulation. Because the interplay of steroid hormones 
and gene expression are vital in the pathogenesis of prostate cancer, further in vivo studies were 
designed in subsequent chapters 4 and 5 to evaluate these markers in prostate diseases. The cell line 
model is still far from representing in vivo situations in human tissues. 
 
Table 3.2 Summary of  change in normalized transcript ratio of biomarkers in prostate cell lines. 
Increased in prostate cancer cell 
lines compared to normal cell 
line 
Decreased in prostate cancer cell 
lines compared to normal cell 
line 
No significant change between 
prostate cancer cell lines and 
normal cell line 
• ESRβ 
• CD44 
• CDH1 
• Bcl-2 
• FASN 
• KLK2 
• TP53 
• KLK3 
• MCM2 
• MCM5 
• ESRα 
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Chapter 4:  Genetic variants of KLK2 gene in Prostate Cancer. 
 
4.1  Introduction: Several single nucleotide polymorphisms (SNPs) have been associated with 
prostate cancer risk as previously discussed in Section 2.7 of this thesis. In this chapter, the frequency 
and association with prostate cancer risk of alleles of KLK2 gene was investigated. The KLK2 gene 
encodes the human glandular kallikrein.protein (hK2) which was discussed in Section 2.3.2. The aim of 
this chapter was to find out if SNPs in the KLK2 gene (alleles) could predict the presence of prostate 
cancer at biopsy, and if they had any association with the disease phenotype. SNPs in the entire KLK2 
gene were investigated using three different techniques: Direct DNA re-sequencing, Allelic 
discrimination assay (TaqMan genotyping) and Pyrosequencing.  
 
4.2  Materials and Methods 
 
4.2.1  Ethical Approval: Thirty healthy male participants (with no history of prostate disease or 
current urinary symptoms) were recruited at Cranfield University, and favourable ethical approval was 
obtained from the Cranfield Health Ethics Research Committee. Sixty consecutive patients who attended 
the TRUS-prostate biopsy sections for prostate cores at the Primrose cancer unit, Bedford hospital, were 
recruited, and favourable ethical approval was obtained from the Bedfordshire Research Ethics 
Committee. All the participants gave their informed consent before sample collection. One hundred and 
thirty eight archived FFPE prostate tissue blocks were obtained from both Cheltenham and 
Gloucestershire hospitals, and favourable ethical approval was given by the Gloucestershire Research 
Ethics Committee. All the documents for ethics application and the approval letters are contained in 
appendix D. 
 
4.2.2 Experimental design 
 
The study on clinical samples were designed to sample urine, blood and formalin fixed, paraffin 
embedded (FFPE) samples from patients and controls with the exception of healthy controls from 
Cranfield University who were sampled for urine and blood only. Power analysis for sample size was 
calculated using the NCSS/PASS software {McGraw, USA}. Gene expressions were measured in both 
urine and FFPE samples. In two of the centres (Bedford hospital, n = 60; Cranfield University, n = 30), 
the sampling was prospective; and another centre (Gloucester and Cheltenham, n = 138 of FFPEs only) 
the sampling was retrospective.  The clinical samples were evaluated for gene expressions of selected 
molecular markers; and genetic variations of KLK2 gene. Clinical data including patient’s age, patitent’s 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
150 
ethnicity, PSA at referral, Gleason Score, Clinical stage and Prostatic volume were extracted from 
clinical notes. FFPE tissue samples were prepared from prostate cores; sections for molecular analysis 
were cut adjacent to those which had been used for histopathology diagnosis and grading. 
 
4.2.3 Sample collection and Processing 
 
a) Blood Sample: 5ml of venous blood was collected into K3 EDTA tubes from each of the participants 
(healthy males (control group, n=30) and patients (n= 60) using standard venepuncture techniques. 
Plasma was harvested after centrifugation at 1800g for 5 minutes, and stored at -20oC until required for 
use. The cell sediments were lysed and white cells harvested using the protocol in appendix B.17. White 
cell pellets were lysed in 350µl of GITC for genomic DNA extraction. Samples from healthy controls 
were not processed for genomic DNA extraction. 
 
b) Urine sample: The participants voided 20ml of early morning urine. Within 6 hours of sample 
collection, the urine samples were centrifuged at 1800g for 10 minutes, decanted and cell sediments 
washed in 15ml of sterile PBS (Invitrogen, UK). Cell pellets were lysed in 350µl of GITC buffer for 
RNA extraction. The cell lysates were homogenized manually using 2ml syringes and blunt end needles. 
The decanted urine was stored at -80 oC for thermal desorption gas chromatography mass spectrometry 
(GC-MS) analysis. 
 
c) Archived FFPE tissue sections: Tissue blocks (from 2006 to 2008 from Gloucester and Cheltenham, 
n = 138; and 2008 from Bedford n = 60) were chosen based on pathology reports (all Bedford patients 
were included because their urine and blood samples were collected). For Gloucester and Cheltenham, 
selected samples were 30 cases of nodular hyperplasia (BPH); 5 cases of Gleason score ≤ 5 (very low 
grade prostate carcinomas); 30 cases of Gleason score 6; 30 cases of Gleason score 7; 30 cases of 
Gleason score 8-10 (high grade) and 12 cases of non-involved prostate tissues (cases of chronic 
inflammation, no dysplasia, no carcinoma). Only tissue blocks with highest lesions of its category were 
sampled for microtomy. Two pieces of 25µM thick sections were cut using decontaminated microtome 
blades, and were aseptically picked into 2ml eppendorf tubes. The tubes were briefly centrifuged, 
deparaffinised in two washes of 1ml xylene for 10 minutes each; the xylene decanted and the tissue 
rehydrated by two washes in 1ml of 100% ethanol before allowing the pellets to dry for 5 minutes on a 
dry heat block kept at 37oC.  The tissue pellets were digested overnight in 540µl of ATL tissue lysis 
buffer and 60 µl of proteinase K (Qiagen, UK). The digest was centrifuged for 5 minutes and the 
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supernatant (containing nucleic acids) were collected. A 350µl of the supernatant was used for RNA 
extraction and 200 µl used for genomic DNA extraction. 
 
4.2.4  Nucleic acids extraction and cDNA synthesis. 
 
RNA was extracted from urine cell lysates and FFPE tissue lysates using RNeasy spin columns (Qiagen, 
UK) using the protocol described in appendix B.13;  cDNA synthesis was done immediately by random 
hexamer priming using the protocol described in appendix B.14. Genomic DNA was extracted from 
white cell lysates and FFPE tissue lysates using QiaAmp DNA mini kits (Qiagen, UK) using the 
Qiacube automated DNA extraction system (Qiagen, UK) according to the manufacturer’s instruction. 
DNA was eluted in 100µl. Genomic and complementary DNA was stored at -20oC until required for 
analysis. Quality of gDNA from FFPE materials were checked by both bioanalysis using the BioRad 
automated electrophoresis system and by PCR amplification of 150bp G6DP. 
 
4.2.5  DNA sequencing 
The Big dye terminator direct sequencing technique was used to determine the nucleotide sequences of 
KLK2. The Big dye terminator sequencing is based on cycle sequencing in which successive rounds of 
denaturation, annealing, and extension in a thermal cycler results in linear amplification of extension 
products (Figure 4.1). The dideoxyribonucleotides (ddNTPs): A, C, T, and G are labelled with 
fluorescent dyes (four colours are generated). The fluorescent labelled DNA products (fragments) are 
then injected into a capillary for electrophoresis and subsequent detection. The ABI 3130 genetic 
analyzer platform (Figure 4.2) was used. 
 
The KLK2 gene was divided into four PCR product sizes, amplified with primer sets shown in Table 
4.1. First, a standard PCR reaction was carried out as described in appendix B.18; the quality of 
amplification was checked by 2% agarose gel electrophoresis and Syber safe staining (appendix B.19). 
Second, a big dye terminator reaction was set up in 96-micro well PCR plate (Applied biosystems, UK) 
using the protocol described in appendix B.18. Third, the PCR products were purified using the big dye 
x terminator purification kit (Applied biosystems, UK) as described in appendix B.18 according to the 
manufacturer’s instructions. Fourth, the purified PCR products were loaded into the genetic analyzer, 
and run according to manufacturer’s instructions. Fifth, after the run, the data were inspected, analyzed 
and transferred into a DNA sequence editing software (DNA star) which aligned sequences from all 
samples and identified nucleotide differences. Canonical sequences of KLK2 gene were copied from the 
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UCSS genome browser, which also highlighted known SNPs.Only gDNA from blood samples of 
Bedford patients (n = 60) were sequenced. 
 
 
 
Figure 4.1 An illustration of big dye terminator sequencing reaction. Fluorescent dyes are used in 
labeling ddNTPs which give specific colours in the electropherograms. {Applied biosytems, 2009}. 
 
Figure 4.2 The ABI genetic analyzer 3130. This is a four capillary electrophoresis sequencing platform. 
It uses the 96-well micro PCR plates. 
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Table 4.1 Sequencing design for the KLK2 gene {Nam et al, 2006} 
 
 
4.2.6  Allelic Discrimination Assay 
 
The use of direct DNA sequencing for interrogation of genetic variants is limited by its cost and labour-
intensiveness. Although a definitive method, the direct sequencing is also not suitable for genomic DNA 
from FFPE tissue materials due to defragmentation of such gDNA by fixation. However, most FFPE 
tissue materials could yield 100% on less than 200 bp gDNA, which would still be insufficient for most 
common sequencing techniques. A new technique for genotyping based on TaqMan chemistry real time 
PCR application was used to genotype gDNA from the FFPE tissue materials (n = 138). 
 
This method of allelic discrimination (AS) is based on the use of two different dual-labelled TaqMan 
MGB probes (commonly FAM and VIC) to detect the alleles of a gene which differ in a nucleotide 
sequence. The primer sets would be the same but the probes would differ, targeting specific sequences 
of the alleles. A single nucleotide difference alters the melting temperature of the PCR products, 
resulting in fluorescent intensity that is indicative of a particular allele or its combination (See Figures 
4.3 and 4.4 for illustration). This is a cheap, flexibly high throughput and reproducible technique for 
clinical genotyping. It uses the same platform for RQ-PCR (gene quantification), in this case the 
Applied biosystems 7900HT sequence detection system was used  
 
The 60 samples ( from Bedford patients) that were already investigated by direct DNA sequencing were 
also tested by the TaqMan genotyping assay for validation of the new assays prior to using the assays on 
DNA from FFPE tissue materials. Pre-designed TaqMan genotyping assay kits for SNPs rs198977 and 
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rs198972 were purchased from Applied biosystems, UK. The protocol for setting up the genotyping 
assay is described in appendix B.20. 
 
 
Figure 4.3: A schematic illustration of TaqMan allelic discrimination assay. FAM and VIC labelled 
probes are used to target alleles. {Applied biosystems, UK}. 
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Figure 4.4 Signal detection in AS TaqMan genotyping assay. At user-interface, the cluster plot shows 
the alleles and control samples in quadrant pattern. 
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4.2.7  Pyrosequencing 
 
Some allelic variants could be more than two forms, for example the SNP rs6072 located in exon 2 of 
KLK2 gene has A> C>G. Such variations are not suitably detectable by the TaqMan Genotyping assay. 
The technique of Pyrosequencing, first described in 1996 by Ronaghi et al, is a non-electrophoretic, 
real-time bioluminometric method for DNA sequencing, especially short segments (<150bp) {Csako, 
2006}. It measures the formation of pyrophosphate, the by-product of DNA polymerization. The 
principle of pyrosequencing is illustrated in Figure 4.5. The instrument used for the pyrosequencing was 
the PyroMark-24 (Figure 4.6) (Qiagen, UK) according to manufacturer’s instructions. 
 
The rs6072 (A>C>G) and rs1064676 was further investi 
gated in both Bedford patients and FFPE cases from Gloucester and Cheltenham. The primer sets for 
pyrosequencing are included in the list of primers and probes in appendix A.5. The protocol for setting 
up the assay is contained in appendix B.21. 
 
 
Figure 4.5 A schematic illustration of Pyrosequencing technique.{Biotage, 2008}. 
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Figure 4.6 The pyrosequencing instruments and kits. {Biotage, UK}. 
 
4.3  Results 
 
4.3.1  Quality of genomic DNA 
 
Figure 4.7 shows an agarose gel stain of  gDNA from FFPE tissue materials. The quality of gDNA was 
good and concentration (average A260/A280 was 1.85) provided sufficient template for analysis. 
 
Figure 4.7 Sybr safe stain of 150bp G6PD in gDNA of FFPE samples. 
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Figure 4.8 shows a Sybr safe stain of PCR products prior to big dye terminator reaction. Single intensely 
stained bands of appropriate sizes for each exon was suitable for big dye terminator reaction (prevents 
sequencing of non-specific products). 
 
Figure 4.8 Sybr safe stains of KLK2 PCR products. L to R, the first five lanes were 578bp products 
(exon 1 of five samples), the next five were 410bp products (exons 2 of same five samples), and the next 
five on the right were 664bp products (exon 3+4 of same five samples). The letter R is on the 100bp 
DNA ladder lane.  
 
4.3.2  Direct DNA sequencing  
 
Figure 4.9 shows a representative SNP (C/T genotype) in an electropherogram while Figure 4.10 shows 
a homozygous wildtype. A heterozygous genotype will have two nearly equal chromatograms, one 
overlaid on the other with a letter of ambiguity (for example Y for C or T  nucleotides; S for C or G 
nucleotides, M for A or C, W for A or T etc). A homozygous genotype will have a single chromatogram 
at that same position (Figure 4.10). 
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Figure 4.9 A representative DNA electropherogram. This was the chromatogram for participant number 
1106 in this study, showing a heterozygous C/T genotype (depicted as Y in position 216 of the 
electropherogram-highlighted in red by the machine) in exon 5 for SNP rs11549921. On the top left 
hand corner shows the run ID of this participant including date and well number of the sample. 
 
Figure 4.11 shows a representative view of Edit Sequence in DNA star software, which aligns all 
sequences and highlight SNPs (for example the letter S highlighted in red stands for C or G). 
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Figure 4.10 A representative DNA electropherogram for homozygous genotype. There was no letter of 
ambiguity shown in nucleotide sequence. On the top left hand corner is the participants study number 
1107, well number and date of sequencing. 
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Figure 4.11 A representative view of Edit Sequence of DNA star software. It aligns all sequences and 
highlights the SNPs (in this case S for C/G genotype). 
 
A total of 18 already curated SNPs were identified using the four primer sets covering exons 1 to 5 of 
KLK2 gene. Table 4.2 shows the frequency of all identified SNPs. Their SNP IDs were identified 
through co-aligning canonical sequences from UCSS genome browser with the sequencing from the 
patients’ samples. The SNPs consisted of intronic, coding exons and untranslated region of the gene. 11 
(61%) of the identified SNPs (highlighted in yellow) had 100% frequency of the reference allele; and 
therefore were not investigated further. The other 7 SNPs had a heterozygosity of 0.07 to 0.40 in the 
sample population (n = 60). Four of them were intronic SNPs; three were coding sequence (CDS) SNPs. 
Alleles of two of the 7 SNPs (rs2664155 and rs198977) had been previously reported as having strong 
association with prostate cancer risk {Nam et al, 2006}.  
 
 
 
 
Table 4.2 Frequency distribution of identified SNPs in KLK2 gene  
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SNP ID 
Molecular 
type Genotypes and their frequency (n = 60) 
Reference 
allele 
rs62113073 intronic C/G (17%) C/C (83%) G/G (0%) C 
rs2664155 intronic A/G (37%) G/G (60%) A/A (3%) G 
rs2664156 intronic C/T (13%) C/C (77%) T/T (10%) T 
rs34652810 5'UTR 
Del/G 
(0%) 
Del/del 
(100%) G/G (0%) del 
rs2070854 intronic A/G (0%) A/A (100%) G/G (0%) A 
            
rs198970 intronic A/T (0%) A/A (100%) T/T (0%) A 
rs6072 CDS-misense 
A/C/G 
(0%) G/G (100%) 
A/C/G 
(0%) G 
rs61750342 exon C/T (0%) C/C (100%) T/T (0%) C 
rs10422897 CDS-misense C/T (7%) C/C (93%) T/T (0%) C 
            
rs198972 CDS C/T (40%) C/C (53%) T/T (7%) C 
rs1064676 CDS C/T (0%) C/C (100%) T/T (0%) C 
rs6070 intronic A/T (40%) T/T (60%) A/A (0%) T 
rs6071 intronic A/G (0%) A/A (100%) G/G (0%) A 
            
rs1064703 CDS C/T (0%) T/T (100%) C/C (0%) T 
rs198977 CDS C/T (37%) C/C (56%) T/T (7%) C 
rs60268688 CDS A/C (0%) A/A (100%) C/C (0%) A 
rs1059712 CDS A/G (0%) G/G (100%) A/A (0%) G 
rs11549921 3'UTR C/T (0%) T/T(100%) C/C (0%) T 
 
Three of the CDS located SNPs: rs10422897, rs198972 and rs198977 were in codons for amino acids: 
Arginine (R), Leucine (L) and Arginine (R) or Tryptophan (W) respectively. The association of the 
CDS- located SNPs with prostate cancer in the sample population (n= 60) is shown in Figure 4.12. 
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Figure 4.12 Association of cds-located SNPs with Prostate diseases. A is SNP rs10422897, B is 
rs198972 and C is 198977. All cases of T/T alleles of rs198977 had prostate cancer. 
Four intronic SNPs: rs62113073, rs2664155, rs2664156 and rs6070 showed differential frequency 
distribution (Figures 4.13 and 4.14). 
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Figure 4.13 shows the frequency distribution of two intronic SNPs in KLK2 gene: rs62113073 and 
rs2664155. SNP rs62113073 showed no significant association with any particular prostate disease. 
However, the A/A genotype of SNP rs2664155 was only observed in benign hyperplasia cases. The A/A 
and A/G variants were also observed in both benign and prostate cancer cases with any significant 
differences. 
 
Figure 4.13 Frequency distribution of intronic SNPs in KLK2 gene. A is rs62113073 and B is SNP rs2664155. The A/A 
allele of rs2664155 occurred only in benign cases. 
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In Figure 4.14, SNPs rs2664156 and rs6070 showed no significant association with any disease status (P 
values 0.49 and 0.78, Chi-Square, respectively). The rs6070 had not been described in previous studies. 
The A/A allele was not observed in the sample population (though it was a small size).  
 
Figure 4.13 Frequency distribution of intronic SNPs in KLK2 gene. A is rs62113073 and B is SNP 
rs2664155. The A/A allele of rs2664155 occurred only in benign cases. 
 
Figure 4.14 Intronic SNPs on KLK2 gene. A is rs2664156 (P value = 0.49, Chi-square) and B is rs6070 
(P value = 0.78, Chi-square). No significant association with any disease status. 
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4.3.3  TaqMan SNP genotyping 
 
The results of the previous 60 samples tested by TaqMan SNP genotyping were the same with those of 
direct sequencing, no discrepancy was observed. Figure 4.15 shows the results for rs198972 and 
rs198977 on retrospective archived FFPE tissue materials (n=138) determined by TaqMan SNP 
genotyping technique. 
 
The samples, at 50 to 100ng per reaction yielded good quality signals. For the rs198972 there was no 
significant association with any prostate diseases. Sample (disease) groups had a proportional frequency 
of each genotype type. For the rs198977, the T/T genotype was found only in some PCa cases. Although 
the proportion was 5.2% (compared to the 33% in the Bedford patients, probably due to small sample 
size), all cases of T/T variant (rs198977) had PCa. Average heterozygosity for the C/T of rs198977 was 
0.38 (it was comparable to previous results as well as the data from the HapMap project). The frequency 
of the reference allele (the C variant) was 0.96 (comparable to the previous results on 60 patients. Figure 
4.16 shows the global distribution of the rs198977 allelic variants for  various countries participating in 
the HapMap project. 
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Figure 4.15 KLK2 SNPs in FFPE  materials. T/T alleles of rs198977 were only found in PCa cases 
(5.2%) of the sample population. 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
168 
 
 
Figure 4.16 Global frequency distribution of the rs198977 allelic variants. 
{HapMap International Consortium, 2009}. 
 
4.3.4 Pryrosequencing 
 
The results of rs6072 and rs1064676 obtained from pyrosequencing did not differ from those of  direct 
DNA sequencing; therefore the method was validated for use in the FFPE cases. Figure 4.17 shows the 
rs6072 results in FFPE cases (n= 138), it had 100% of the reference allele G in the study population. 
Currently, the frequency distribution of rs6072 SNP from a British population is not documented in the 
HapMap project. 
 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
169 
 
Figure 4.17 Frequency distribution of two SNPs determined by the pyrosequencing assay. A is the 
rs6072 which had 100% of the reference allele (G) in the study population; B is the rs1064676 which 
had 1.45% of the derived allele (T) in the study population. 
 
The C/T variant of rs1064676 occurred only in BPH cases (~7% of the BPH); the frequency of the 
heterozygosity was 1.45% in the study population. Again there is no data on British population in the 
HapMap data base for comparison. 
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4.4  Discussion 
 
4.4.1  CDS-located SNPs 
From the simple frequency distribution tables, SNPs rs10422897 and rs198972 were not significantly 
associated to any particular prostate disease. However, the T/T homozygous allele of rs198977 was only 
found in prostate cancer cases. Although the sample size was small, the result was in agreement with the 
report of Nam et al, 2006. Unlike previous studies including Nam et al, 2006, BPH and PIN cases were 
included in this study, and the T/T alleles were only found in prostate cancer cases The first 60 cases in 
this study were prospective; and were also histologically established (at Bedford hospital). By 
implication (from this particular result), a proportion of prostate cancer patients will always have the T/T 
alleles of rs198977; or all males who have the T/T allele are very likely to suffer prostate cancer (larger 
validations studies are still required). The second implication is that genetic screening for T/T alleles in 
adult male populations could help select men with higher risk of developing prostate cancer and enroll 
them for annual screening (early detection). The stratum could be widened by considering males with T 
alleles (T/T and C/T) which accounted for 66% of all PCa in this study. However, the other 34% of men 
without the T/T alleles or men with only C/C genotypes could still be at risk of PCa.  
 
Functionally, the C> T alleles of rs198977 are described as ‘coding synonymous’ {UCSS Genome 
browser} which means there is no change in peptide for allele with respect to reference assembly 
(whichever allele the patient has the amino acid at that position will still be Leucine). The average 
heterozygosity of the rs198977 from the HapMap project is 0.479 ± 0.101. From this study, the 
heterozygosity was 0.40; however the participants in this study are purely a British Caucasian 
population. After extensive literature search, there was no existing data for the British population on the 
frequency of the reference allele of this SNP (the C allele); from this study it was found to be 0.93, that 
of the French was 0.69 and Italians 0.62 {HapMap Project}. 
 
Another important observation was that of the overall 7 cases of T/T genotype (rs198977), two of them 
had Gleason score 8 to 10; four cases had Gleason score 6 and one case had Gleason score 7. Although 
this was a small sample size, it did appear that the T/T genotype was associated with high grade prostate 
tumours (larger studies are required to confirm this trend). 
 
The TaqMan SNP genotyping provides a fast and reliable method for genotyping FFPE tissue materials; 
the cost is estimated at less than a £1.30 per test done in duplicates. From the optimization data, it 
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required about 50 to 100ng of genomic DNA for optimal data collection. Also known (positive controls 
for all the allele variants) obtained by direct sequencing is very important for validation and quality 
control of the assay. The significance of the T/T allelic variant of rs198977 requires further large scale 
prospective studies in both blood and FFPE materials of patients. 
The pyrosequencing technique, like the TaqMan genotyping, is cheap and flexibly high throughput; and 
both could be clinically used to genotype FFPE tissue materials without the labour- and capital-intensive 
direct DNA sequencing technique.  
 
It is also conceivable that biosensor-based genotyping techniques could be available in the near future 
for genotyping at point of care. From results in this study, it was clearly demonstrated that FFPE 
materials could be successfully genotyped for clinically relevant SNPs. 
 
4.4.2 Intronic SNPs in KLK2 gene 
 
The biologic effects of intronic SNPs are very unclear especially variations that are not localised in the 
first two or last two bases of intron. The frequency distribution of the intronic SNP rs62113073 has no 
significant association with PCa risk (similar pattern of distribution was also found in non-involved 
cases). For the SNP rs2664155 located on intron 1 (near the promoter region) of the KLK2 gene, Nam et 
al, 2006 reported that the G allelic variants (G/G and A/G) were significantly associated with prostate 
cancer. As mentioned before, most previous SNP association studies did not include BPH as a separate 
case group, which is the most prevalent prostate disease. Contrary to previous reports, the G allelic 
variants (G/G and A/G) of rs2664155, were associated with almost equal chance to  BPH and prostate 
cancer (Odds ratio (OR) = 0.58; 95% CI = 0.026 to 13.02); a participant who had G allelic variants was 
half a chance to suffer BPH or prostate cancer. On the other hand, the A/A genotypes of rs2664155 were 
exclusively found in BPH cases (larger studies are required to verify this). Previous studies also did not 
find any association between A/A genotype of rs2664155 and prostate cancer, Nam et al reported an odd 
ratio of 1.27 and P value of 0.22. 
 
One of the reasons for the interest on KLK2 SNPs is that the protein product of this gene (hK2) is 
differentially expressed in prostate diseases (with an increased expression in PCa). Several reports 
documented the elevated serum levels of hK2 in PCa {Lintula et al, 2005}. Early genotyping studies 
indicated that SNPs rs2664155 and rs198977 were associated with both elevated serum hK2 and PCa 
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risk {Nam et al, 2006}.Genetic variants in the form of SNPs could help stratify patients into genetic risk 
groups and improve early detection programmes 
 
4.4.4  Clinico-pathological features of sample population 
Some clinical data of the sample population were collected and / or measured including age, serum PSA, 
prostatic volume, Gleason score and clinical stage of tumours. 
 
a)Age and PSA distribution 
 
Figure 4.18 shows the age and total PSA distribution of the n = 138 cases from Gloucester and 
Cheltenham. The mean ages for the BPH, Gleason scores (GS) 4-5, 6, 7, 8-10 and non-involved (NI) 
cases were 74, 66, 65, 64, 72 and 74 years respectively.  Significant differences in age (P < 0.05, 
Kruskal-Wallis test) were observed between BPH and GS 6 cases; BPH and GS 7 cases; NI and GS 7 
cases. 
 
For total PSA ng/ml, the mean values for NI, BPH, GS4-5, GS6, GS7 and GS 8-10 were 4.88, 5.28, 
8.95, 8.56, 8.00 and 14.64 ng/ml respectively. Significant differences (P < 0.05) were observed in total 
PSA levels between BPH and GS6; BPH and GS7; BPH and GS8-10; between NI and GS6; NI and GS 
7; and NI and GS8-10. But there was no significant difference in total PSA between NI and BPH. The 
trend showed that total  serum PSA could significantly discriminate between benign and cancer cases; 
and between non-involved cases (e.g. chronic inflammation etc) and cancer cases; but could not 
discriminate between BPH and non-involved cases. However, total PSA was not associated with 
histological grades (PSA had weak correlation with tumour grade). 
All the cases had PSA value > 4.0ng/ml (commonly used cut-off point). 
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Figure 4.18 Age and PSA distribution in FFPE cases. NI stands for non-involved cases, GS for Gleason 
score, BPH for benign nodular hyperplasia. 
 
For the Bedford patients (n= 60), there was no significant difference in age for PIN, BPH, NI and PCa 
cases (mean was 67 years, range 56 to 79 years). There was a significant difference in total PSA levels 
between NI and PCa cases (P < 0.05); the mean values for NI and PCa cases were 5.13 and 21.52 ng/ml 
respectively. In this cohort, PSA could only discriminate between NI and PCa cases. There were no 
significant differences in PSA density; mean values for BPH, NI, PIN and PCa cases were 0.22, 0.12, 
0.10 and 0.54 respectively. A PSA density of > 0.13 would be considered abnormal. Overall, only 20% 
of the Bedford patients had prostate cancer; the rest were BPH cases (63%), NI cases (13%) and PIN 
cases (4%). 
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For the Cranfield health volunteers, the mean age was 51years (range 42 to 65 years); and the mean total 
PSA ng/ml was 0.70 (range was 0.50 to 1.91). Both age and the serum PSA levels were significantly 
lower in the Cranfield health volunteers compared to patient groups in Bedford, Cheltenham and 
Gloucester groups. Ageing is a strong predisposing factor for PCa. 
 
b) Gleason Score and Clinical stage 
 
For the Gloucester and Cheltenham cases, the design was that of  a case- control study; the number of 
GS 6 , GS7 and GS 8-10 were 30 each (21.7% of the study population each); BPH cases were also 
21.7%; NI cases were only 12 (9%) ( cases available between 2006 and 2008); GS 4-5 cases were 0.2% 
(available within the study period).  Of the 96 prostate cancer cases, 60 cases (62.5%) were T2 stage and 
36 cases (37.5%) were T3 stage. 80% of the Gleason score 8-10 were T3 stage tumours. 
 
For Bedford patients, 87.5% of the prostate cancer cases were intermediate grades (Gleason score 6-7), 
and all the intermediate grades were T2 stage. Only 6.25% of the PCa cases were GS 9; the remaining 
6.25% were GS3. 
 
4.5  Conclusions 
 
In summary, two SNPs appeared very promising for detecting risk groups in prostate disease screening: 
the T/T variant of rs198977 for detecting prostate cancer risk, and the A/A genotype of rs2664155 for 
detecting BPH; and both could be genotyped in the same plate using the cheap and fast TaqMan 
genotyping assay. 
 
The T/T allele was also significantly associated with high tumour grade. This could be very useful to 
clinical management of patients; indolent prostate cancer cases with the risk alleles of KLK2 would be 
considered for radical primary treatment on time before further spread of disease.  However, further 
large scale studies would be required to examine the correlation between tumour stage and risk alleles of 
KLK2 gene and to rule out possible effects of genetic diversity on such results. 
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Chapter 5: Gene expression profiling of prostate cancer patients 
 
5.1  Introduction 
 
This chapter describes the measurement of a panel of molecular markers at the mRNA (transcript) level 
using RQ-PCR technique. The markers included KLK2, KLK3, MCM2, MCM5, TP53, Bcl-2, CD44, 
CDH1, AURKA, AURKB, and AURKC; ESRα, ESRβ, AR, FASN, TMPRSS2: ERG, and 
TMPRSS2:ETV1. Three endogenous genes: ABL1, GUS and G6PD were also measured for 
normalization of the target gene expression. The aim was to find out the expression profile of these 
markers in FFPE tissue materials and urine samples of prostate cancer, non-involved and benign nodular 
hyperplasia patients. In chapter three of this thesis, the expression of some of these markers in cultured 
cell lines in response to hormonal modulation was reported. In this chapter, the level of expression of 
these markers in benign (BPH), non-involved (N-I) and prostate cancer cases were compared. Where it 
was significant, the expressions of these molecular markers were also compared with tumour grades. For 
urine samples, the aim was to find out if the molecular markers were detectable in exfoliated urine cells 
without prostatic massage (non-invasive sampling); and if there was a differential expression in 
detectable cases. 
 
5.2  Materials and Methods 
 
5.2.1 RNA extraction, cDNA synthesis and RQ-PCR: The methods for sample collection, RNA 
extraction and subsequent cDNA synthesis have been previously described in Section 4.1.2. The method 
of two-steps RQ-PCR used in gene expression profiling has also been described in Section 3.3.4. The 
list of primers and probes used in the RQ-PCR are contained in appendix A.5. The sample size (n) was 
138 for FFPE prostate tissue cases (BPH= 30 cases, PCa = 96 cases and 12 non-involved cases); for 
urine samples, n = 83 (control group = 30, patients who attended TRUS-prostate biopsy sections = 53). 
The ethical approval processes have been previously described in Section 4.1. In the RQ-PCR, some 
markers were measured by absolute quantification using plasmid calibrators; and the results normalized 
and expressed as a ratio. Cases with higher ratios expressed more mRNA of the target gene than those 
with lower ratios. In other cases, normalized relative quantification (NRQ) was done without plasmid 
calibrators. The NRQ measures fold increase of a molecular target in a sample compared to another 
sample of a different group. Higher NRQ means lower expression of the target. 
 
5.2.2  Immunohistochemical staining (IHC): IHC of PSA, AR, ESRα and ESRβ were performed on 
30 cases from the Bedford samples (BPH cases = 12, PCa cases =12 and non-involved cases = 6). 
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Sodium citrate buffer in water bath was used for antigen retrieval in the tissue sections (appendix B.22). 
The method for IHC has been previously described in Section 3.2.6, and the protocol for IHC is also 
contained in appendix B.8. The aim of the IHC was to confirm the expression of these markers at protein 
level. There was no semi-quantitation of the degree/intensity of staining. 
 
5.2.3 Statistical analysis: This was performed on results using GraphPad Prism software version 4.02 
(www.graphpad.com). For all data sets, the D’Agositino and Pearson Omnibus normality test was 
performed to determine the distribution. For data sets involving more than two groups, analysis of 
variance (ANOVA) was performed using Kruskal-Wallis tests (for non-parametric, non-Gaussian 
distribution) and Dunn’s multiple comparison tests. Where two data sets were compared, Mann-Whitney 
test was performed for non-Gaussian distribution. A probability value of < 0.05 was considered 
statistically significant. Most graphical presentations were in logarithmic scale (power of 10). Where 
box plots are used, the box represents the upper and lower quartiles and the middle bar inside the box 
represents the median value. Where aligned dot plots are used, the bar across the plots represents the 
median value. 
 
5.3  Results  
 
5.3.1  The endogenous control genes (CGs): The three candidate control genes reported in Section 
3.3.4 for prostate cell line studies were also evaluated in the FFPE tissue materials and urine samples. 
Figures 5.1, 5.2 and 5.3 show the transcript levels of ABL1, GUS and G6PD in the FFPE materials. For 
ABL1 and G6PD, there was no significant difference in the expression levels in BPH, non-involved (N-
I) and PCa cases (P> 0.05, Kruskal-Wallis test). But for GUS, there was a significant difference between 
N-I and PCa cases (P< 0.05). When the geometric means of all three CGs were compared to each of the 
CGs for all the cases (BPH, N-I and PCa), there was no significant difference observed (P = 0.41). The 
median value of ABL1 gene was related to those of G6PD and GUS by ratios of 1.03 and 0.82 
respectively. Conversely, the median value of G6PD was related to those of ABL1 and GUS by 1.25 and 
3.30 respectively. 
 
Figure 5.4 shows the transcript levels of the candidate control genes in both patient group (Px) and 
control group (Cr) in exfoliated urine cells. There was no significant difference in ABL1 transcript 
number between the patient group and control group (P = 0.13, Mann-Whitney test); similar result was 
also obtained for G6PD (P = 0.08). But there was a significant difference in the GUS transcript number 
between patients and control group (P = 0.0019), which was similar to the result in FFPE tissue 
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materials. There was no significant difference between the geometric mean of ABL1 and G6PD 
compared to either ABL1 or G6PD (P = 0.34, Kruskal-Wallis test).  
 
Figure 5.1 ABL1 transcript levels in FFPE tissue materials. There was no significant difference in the 
expression of ABL1 gene in benign (BPH), non-involved (N-I) and prostate cancer (PCa) cases (P > 
0.05). 
The median ABL1 transcript number in the urine samples was 1.40 logs compared to 1.99 logs in the 
FFPE tissue materials.  
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Figure 5.2 GUS transcript levels in FFPE tissue materials. There was a significant difference between N-
I and PCa cases (P < 0.05). 
 
Figure 5.3 G6PD transcript levels in FFPE tissue materials. There was no significant difference among 
the group. 
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Figure 5.4 Transcript levels of endogenous control genes in exfoliated urine cells. GUS had a significant 
difference between patient group (Px), n = 53 and control group (Cr), n=. 30. 
 
The effect of sample age on CGs, particularly for the FFPE tissue materials, was assessed.  Figure 5.5 
shows the variations in ABL1 transcript level in different ages of samples. There was a significant 
difference between 2006 and 2008 samples (P< 0.001); as well as 2007 and 2008(P < 0.001), but no 
difference between 2006 and 2007 samples. Similar results were also obtained for G6PD and GUS. 
There was more than a log reduction in ABL1 level for greater than one year old samples. RQ-PCR 
sensitivity is reduced in aged samples. Of the 2008 samples, the most recently processed FFPE materials 
had ABL1 level in the range of 3 to 4 log (similar also in G6PD); and that range informs a better assay 
sensitivity. 
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Figure 5.5 Effect of sample age on ABL1 transcript number. There was more than a log reduction in 
ABL1 in more than a year old samples. Most recently processed samples in 2008 group had ABL1 in the 
range of 3 to 4 log, which is better for assay sensitivity. 
 
5.3.2  KLK2 transcript levels in FFPE prostate tissue materials and urine samples:  The 
normalized relative quantity (NRQ) of KLK2 transcript number in FFPE tissue materials is shown in 
Figure 5.6. There were significant differences in NRQs of BPH and PCa cases (P < 0.001) and N-I and 
PCa cases (P < 0.001).  The NRQ of KLK2 was significantly increased in prostate cancer cases 
compared to benign and non-involved cases; however there was no significant difference between 
benign and non-involved cases. That means that KLK2 transcripts are more expressed in benign cases 
than prostate cancer cases. However, the NRQ of KLK2 was not significantly different in various 
histological grades of PCa (Gleason Score -GS) (P = 0.16); low (GS 4-5), intermediate (GS 6-7) and 
high (GS 8-10) grades of PCa had similar expression level. 
 
Figure 5.7 shows the NRQ of KLK2 in exfoliated urine cells. There was a significant difference between 
BPH and control (Cr) cases (P = 0.0047); between PCa and Cr cases (P = 0.0115). However, there was 
no significant difference between PCa and BPH cases (P = 0.816); non-involved and PCa cases  
(P = 0.587). The sample sizes for PCa, N-I and PIN cases were very small (these patients were sampled 
prospectively prior to histology examination). 
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Figure 5.6 Normalized relative expression of KLK2 in FFPE tissue materials. The NRQ of KLK2 was 
significantly higher in PCa cases (reduced expression of KLK2 transcript in prostate cancer cases). The 
horizontal lines (bars) represent median values (the distribution was Non-Gaussian). 
 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
183 
 
 
Figure 5.7 Box plots of KLK2 transcript levels in exfoliated urine cells. No significant difference 
between N-I and PCa cases. Cr stands for control group. 
 
5.3.3  KLK3 gene expression in FFPE tissue materials and urine samples: Figure 5.8 shows the 
normalized relative quantity of KLK3 transcripts in FFPE tissue sections. KLK3 expression was 
significantly higher in prostate cancer cases than benign cases (P = 0.01). KLK3 expression was also 
significantly lower in non-involved cases compared to PCa cases (P <0.05). But there was no significant 
difference in KLK3 expression between BPH and N-I cases (P > 0.05). 
 
Figure 5.9 shows the KLK3 transcript level in benign, non-involved and PCa cases of urine samples. 
There was no significant difference in the KLK3 normalized relative quantity (NRQ) in all the cases (P 
= 0.104) 
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Figure 5.8 Box plots of NRQ of KLK3 transcripts in FFPE materials. KLK3 was significantly more 
expressed in prostate cancer cases than benign cases (P = 0.0003). 
 
Figure 5.9 Normalized relative expression of KLK3 in urine cells. No significant difference among the 
group. Cr stands for control group. 
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5. 3.4  MCM2 and MCM5 gene expressions in FFPE tissue materials and urine samples: 
 
Figure 5.10 shows the MCM2 transcript levels in healthy control group, benign, prostate and non-
involved cases. There was a significant difference in MCM2 expression between the control group and 
BPH cases (P < 0.01). But there was no difference between the BPH and prostate cancer cases; no 
difference also between non-involved and prostate cancer cases. 
 
 
Figure 5.10 MCM2 transcript levels in exfoliated urine cells. There was a significant difference between 
only BPH cases and healthy control group. 
 
Figure 5.11 shows the MCM2 transcript levels in FFPE tissue materials. There was a significant 
difference between BPH and PCa cases (P < 0.01); but no significant between non-involved (N-I) and 
PCa cases (P > 0.05). MCM2 was more expressed in the prostate cancer cases than in benign cases. 
When compared with Gleason Scores (GS), there were significant differences between GS 6 and GS7 (P 
< 0.05); GS6 and GS 8-10 (P < 0.01) (Figure 5.12). 
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Figure 5.11 MCM2 transcript levels in FFPE tissue materials. There was a significant difference 
between benign (BPH) and prostate cancer (PCa) cases. 
 
 
Figure 5.12 MCM2 expressions in various tumour grades. There were higher transcript levels in GS 6 
than any other tumour grade. 
 
Figure 5.13 shows MCM5 transcript levels in urine cells. There was no significant difference among the 
group (P = 0.056).  
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Figure 5.14 shows the MCM5 expression in FFPE tissue materials. There was also no significant 
difference in transcript level among the group (P = 0.17). 
 
Figure 5. 13 MCM5 transcript levels in urine cells. There was no significant difference among the 
group. 
 
 
Figure 5.14 MCM5 transcript levels in FFPE materials. There was no significant difference among the 
group. 
 
 
 
 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
188 
5.3.5  TP53 expression in FFPE tissue materials and urine cells: 
Figure 5.15 shows TP53 expression in FFPE tissue materials. TP53 was significantly under-expressed in 
non-involved cases (P = 0.02). There was no significant difference between the benign and prostate 
cancer cases (P > 0.05). 
 
 
Figure 5.15 TP53 transcript levels in FFPE tissue materials. TP53 was significantly over-expressed in 
non-involved cases. 
 
TP53 was also significantly over-expressed in GS 8-10 compared to GS 6 and GS 7 (P < 0.01). 
 
Figure 5.16 shows the TP53 expression in exfoliated urine cells. There was a significant difference in 
TP53 transcript level between healthy group and benign cases (P < 0.05); also between healthy group 
and prostate cancer cases (P< 0.05). But there was no difference between benign and prostate cancer 
cases (P > 0.05) similar to what was observed in the FFPE tissue materials. 
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Figure 5.16 TP53 transcript levels in urine cells. There were significant differences between healthy 
group and benign cases; healthy group and prostate cancer cases. 
 
5. 3. 6  TMPRSS2 fusion genes in FFPE and exfoliated urine cells: 
The TMPRSS2: ERG gene fusion was not detected in the urine cells of healthy control group (n= 30). 
Only 3 cases were detected in the urine cells of patient group; and all the cases were prostate cancer 
patients (representing 25% of all cancer cases for the urine cell analysis). The mean Ct values for the 3 
cases were 18.35, 17.53 and 16.65 respectively. Figure 5.17 shows the normalized relative quantity of 
TMPRSS2: ERG fusion gene in FFPE tissue materials. There were 2 cases of TMPRSS2: ERG gene 
fusion in BPH group, 13 cases in the prostate cancer group and 2 cases in the non-involved group. About 
12.3% of the sample population was positive for TMRPSS2: ERG gene fusion; and 13.5% of the entire 
prostate cancer cases (n = 96) were positive for TMPRSS2: ERG. However, there was no significant 
difference in the NRQ of TMPRSS2: ERG positive cases (between BPH and PCa cases, N-I and PCa 
cases, BPH and N-I cases; P = 0.17). Of the prostate cancer cases, 3 were GS8-10, 4 cases were GS7, 
another 4 were GS6 and 2 cases were GS4-5. 
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Figure 5.17 TMPRSS2: ERG transcript levels in FFPE tissue materials. There was no significant 
difference in the normalized relative quantity between the cases in BPH and prostate cancer cases. The 
gene fusion also occurred in two non-involved cases. 
 
The TMPRSS2: ETV1 fusion type was not detectable in the urine cells of both healthy and patient 
groups. However, 2 cases of TMPRSS2: ETV1 fusion were detected in the FFPE tissue materials: one 
case was Gleason score 6 and the other was Gleason score 7.  
In summary, a total of 15 cases of TMPRSS2 fusion genes were detected in the 96 prostate cancer cases 
(representing 15.6% of the cancer cases). The predominant fusion type was the TMPRSS2: ERG (87% 
of the positive cases). 
 
5.3.7  Gene expressions of Aurora kinases (A, B, C) in FFPE tissue materials 
 
Figure 5.18 shows the transcript levels of Aurora kinase A in FFPE tissue materials. There was a 
significant difference in the transcript number of AURKA between BPH and PCa cases (P < 0.05); 
AURKA expression was increased in PCa cases. Figure 5.19 shows significant differences between 
BPH and N-I cases (P< 0.05), PCa and N-1 (P < 0.01) in the transcript levels of AURKB; there was also 
increased expression of AURKB in prostate cancer cases (similar to AURKA expression).  
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Figure 5.18 The gene expression of Aurora kinase A in prostate tissue sections. There was a significant 
increased expression of AURKA in prostate cancer tissues.  
 
 
Figure 5.19 The gene expression of Aurora kinase B in prostate tissue sections. There was also a 
significant increased expression of AURKB in prostate cancer tissues. 
 
Figure 5.20 shows a significant increase in the transcript level of AURKC in both benign and prostate 
cancer cases compared to non-involved cases (P < 0.05). There was no significant difference between 
BPH and PCa cases. Unlike the AURKA and AURKB, the AURKC transcript level was not 
significantly increased in prostate cancer compared to benign cases; but the levels in both benign and 
prostate cancer cases were higher than in non-involved cases. 
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Figure 5.20 The gene expression of AURKC in prostate tissue sections. There was a significant 
reduction in AURKC transcript level. 
 
5.3.8  Gene expressions of CD44 and CDH 1 in prostate tissue sections 
 
In Figure 5.21a, the transcript levels of CD44 were significantly increased in prostate cancer cases 
compared to benign and non-involved cases (P < 0.01). And the CD44 transcript level in prostate cancer 
cases was also associated with tumour grade (Figure 5.21b). Higher tumour grades (Gleason score 8-10) 
expressed less CD44 compared to intermediate grades (Gleason scores 6 and 7). The lower grade 
(Gleason score 4-5) expressed more CD44 than higher grades. 
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Figure 5.21 Gene expression of CD44 in prostate tissues. (A) CD44 mRNA level was significantly 
increased in prostate cancer cases compared to benign and non-involved cases.  However, in (B) CD44 
transcript level was associated with tumour grade. 
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Figure 5.22 shows no significant difference in the normalized relative quantity of CDH1 transcript level 
among benign, non-involved and prostate cancer cases (P = 0.77). 
 
Figure 5.22 Gene expression of CDH1 in prostate tissues. There was no significant difference in 
transcript level. 
 
5.3.9  Gene expression of FASN in urine cells and prostate tissues 
 
Figure 5.23 shows no significant difference (P = 0.71) in the normalized absolute quantity of fatty acid 
synthase in exfoliated urine cells of benign, prostate cancer, non-involved and healthy controls. 
 
Figure 5.23 Absolute ratio of FASN transcript number in urine cells.  
 
Figure 5.24 shows also no significant difference in the transcript levels of FASN prostate tissues of 
benign, non-involved and cancer cases (P= 0.17). Similar to the results from urine cells, the FASN 
transcript number was not differential among the prostate tissues. 
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Figure 5.24 Transcript levels of FASN in prostate tissues. There was no significant difference. 
 
5.3.10  Gene expression of Bcl-2 in FFPE prostate tissues 
 
Figure 5.25 shows no significant difference in Bcl-2 transcript levels in FFPE prostate tissue of benign, 
non-involved and prostate cancer cases (P = 0.20). There was low level of Bcl-2 transcripts across the 
samples (most Ct values were around 37). 
 
 
Figure 5.25 Transcript levels of Bcl-2 in FFPE tissues. 
 
5.3.11 Gene expressions of steroid hormone receptors in prostate cancer 
 
Figure 5.26 shows the transcript levels of ESRβ in prostate tissues. In Figure 5.26A, ESRβ was 
significantly over-expressed in prostate cancer cases compared to benign cases (P < 0.001). There was 
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also a significant increase in expression of ESRβ in non-involved cases compared to benign tissue (P < 
0.05); non-involved cases include cases of chronic inflammation and dysplasia ‘suspicious of 
malignancy’ that were not histologically confirmed as malignancies. In Figure 5.26B, the ESRβ 
expression was significantly associated with Gleason score (P < 0.0001); there was over-expression in 
higher tumour grades compared to lower and intermediate tumour grades. However, within a tumour 
grade (Gleason score 8-10), the ESRβ expression was not significantly associated with pathological 
stage (P = 0.65, Mann-Whitney test). 
 
Figure 5.27 shows no significant differential expression of ESRα in prostate cancer cases compared to 
benign and non-involved cases (P = 0.33).  
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Figure 5.26 Gene expressions of ESRβ in prostate tissues. A is aligned dot plot showing a significant 
over-expression of ESRβ in prostate cancer cases. B a bar plot showing that ESRβ over-expression was 
associated with tumour grade. 
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Figure 5.27 Transcript levels of ESRα in prostate tissues. There was no significant difference among the 
sample groups. 
 
Figure 5.28 shows a significant over-expression of androgen receptors (AR) in prostate cancer cases 
compared to benign cases (P < 0.01). However, the increase was not associated with tumour grade and 
pathological stage. 
 
Figure 5.28 Transcript levels of AR in prostate tissues. There was a significant over-expression of AR in 
prostate cancer and non-involved cases. 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
199 
5.3.12 Immunohistochemistry (IHC) 
 
Figures 5.29 to 5.31 are a panel of representative photomicrographs of PSA. AR, ESRβ and ESRα 
staining in benign, non-involved and PCa cases; benign hyperplasia cases stained more strongly for PSA 
than PCa cases. 
 
 
 
Figure 5.29 Representative photomicrographs of immunostained tumour markers. A is PSA positive 
PCa, B is ESRβ positive, C is a negative control slide; D is AR positive and E is  ESRα positive slide. 
The SHRs stained dark-brown mainly in the nuclei while the PSA stained brown in the cytoplasm. 
Scale: 1cm = 23 µM (x 400 magnification). 
A    B  
C  D    
                                          
                                        E 
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Figure 5.30 Representative photomicrographs of immunostained tumour markers in benign cases. A is 
PSA positive PCa, B is ESRβ positive, C is a negative control slide; D is AR positive and E is  ESRα 
positive slide. The SHRs stained dark-brown mainly in the nuclei while the PSA stained brown in the 
cytoplasm. Scale: 1cm = 23 µM (in x 400 magnification). 
 
 
 
 
 
A    B  
 
C     D  
 
 E  
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Figure 5. 31 PSA immunostaining of non-involved prostate cases. X400 magnifications. Scale: 1cm = 
23µm. PSA stained brown in the cytoplasm of epithelial cells (Moderate and patchy intensity was 
observed in non-involved cases). 
 
 
 
 
 
 
 
 
 
 
A = Non- involved prostate case: PSA positive 
 
 
B= Non-involved prostate case- PSA negative control. 
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5. 4  Discussion 
 
5.4.1  Endogenous control genes: The choice of a single stably expressed control gene is very crucial 
to normalization of target transcripts of molecular markers.  From the results, GUS was not stably 
expressed in both the FFPE tissue materials and exfoliated urine cells; and therefore not suitable for use 
in normalization of target genes.  ABL1 and G6PD transcript levels emerged stable in all the samples 
groups; however the median ratios of ABL1 to GUS and G6PD remained steady compared to that of 
G6PD. In addition, both G6PD and ABL1 showed no difference when compared to the geometric mean 
of both. Therefore, ABL1 was used to normalize gene expression of all the target transcripts. Some 
multi-centre studies had also shown that ABL1 transcript levels were stably expressed in other cell 
types, especially in haematological malignancies {Beillard et al, 2003; Garbert et al, 2003}. The ABL1 
gene has no known pseuodogenes unlike many other CGs that had been used in prostate cancer gene 
expression studies {Schmidt et al, 2006}. 
 
Both FFPE tissue materials and exfoliated urines offer the opportunity to profile prostate cancer patients 
molecularly. But the urine samples have an advantage of non-invasive collection. Most recently 
processed FFPE tissue materials yielded higher levels of CGs; aged samples would reduce RQ-PCR 
sensitivity due to degradation of RNA of target transcripts. 
 
5.4.2  KLK2 gene expressions in FFPE tissue materials and urine cells: 
In the FFPE tissue materials, the KLK2 transcript levels were differentially expressed (decreased in 
prostate cancer); this was similar to what had been reported in several studies {Kurlender et al, 2005; 
Diamandis & Obiezu, 2005}. But in the urine cells, the KLK2 transcript level was not differentially 
expressed; there was no significant difference between N-I and PCa cases contrary to the finding in 
FFPE materials. Similar finding was also reported by Panek et al, 1997 and Magklara et al (2000) who 
reported a decrease in the KLK2 transcripts in malignant compared to non-malignant tissues. However, 
several studies at protein level had shown that KLK2 protein product (hK2) was differentially expressed 
in prostate cancer (increased in prostate cancer) {Darson et al, 1999; Becker et al, 2000}. In addition, 
the results from this study show that KLK2 transcript level does not correlate with tumour grade. 
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5.4.3  KLK3 gene expressions in FFPE tissue materials and urine cells: 
The findings in this study showed that KLK3 transcript level in prostate FFPE tissue sections would not 
be clinically useful for detecting or staging prostate cancer. The transcript level of KLK3 was higher in 
prostate cancer cases compared to benign cases. This was not comparable to the IHC results where 
benign cases stained intensely and diffusely for PSA compared with moderate staining in PCa cases. 
Previous studies had also reported that KLK3 transcript level in blood and urine samples were not 
diagnostically useful for detection and staging of prostate cancer {Corey et al, 1997; Becker et al, 2000}. 
However, some molecular tests, for example, the PCA-3 test rather use PSA transcript level as an 
endogenous, prostate specific, control gene for normalization of PCA-3 transcript level in urine samples. 
Although the PSA level did not vary in the urine samples, the reliability and robustness of PSA as a 
control gene compared to other endogenous control genes remained unclear. The PCA-3 molecular test 
was reported to have a moderate sensitivity and specificity; and relied on the ‘tissue- specificity’ of 
PSA. But there is also the problem of extra-prostatic PSA, contributing to the entire PSA pool. 
 
5.4.4  MCM2 and MCM5 gene expression in FFPE tissue materials and urine cells: 
The MCM2 and MCM5 are part of the MCM family of proteins involved in DNA licensing for cell 
replication. The transcript levels (expressed as absolute ratios) of MCM2 in FFPE tissue materials 
showed a significant difference between the benign and prostate cancer cases; MCM2 transcripts were 
over- expressed in PCa cases. Many other studies had reported increased MCM2 expression in human 
cancers {Freeman et al, 1999; Stober et al, 1999; Alison et al, 2002. However, the non-involved cases 
consisting of acute and chronic inflammation also showed over-expression of MCM2. Therefore, the 
MCM2 transcript level in FFPE tissue materials has a limited application for diagnosis. However, 
MCM2 transcript level showed an association with tumour grade; there was higher expression in 
Gleason score 6 grades than any other grade. Meng et al (2001) reported that prostate cancer patients 
with high MCM2 expression had shorter disease-free survival, following radical prostatectomy for 
localised PCa. Therefore, MCM2 could have a prognostic value in patients undergoing prostatectomy. 
The MCM2 transcript levels in exfoliated urine cells were also of limited diagnostic value. It could not 
differentiate between cancer and benign cases. The MCM5 transcript levels in both urine and FFPE 
tissue materials showed no diagnostic value in prostate cancer. However, some studies had shown that 
MCM5 expression was strongly associated with urothelial cancers {Stoeber et al, 1999}. 
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5.4.5  TP53 gene expression in FFPE tissue materials and urine cells: 
In both urine cells and FFPE tissue materials, there was no significant difference in TP53 transcript 
levels between benign and prostate cancer cases. However, TP53 in prostate cancer cases (n=96) was 
over-expressed in higher tumour grades (GS 8-10). The prognostic value of TP53 gene expression has 
been controversial. Some studies reported increased nuclear accumulation of TP53 as a prognostic 
marker in PCa {Quinn et al, 2005}. Isaacs (1997) reported that increased positive staining for TP53 was 
associated with TP53 mutations and higher tumour grades. 
 
5.4.6  TMPRSS2 fusion genes in FFPE and exfoliated urine cells: 
 
The TMPRSS2 gene fusion was detectable in both urine and FFPE tissue materials. The predominant 
fusion type was the TMPRSS2: ERG.  Contrary to the report by Mehra et al (2007), there was no 
significant association of the TMPRSS2 fusion genes with tumour grade (Gleason score) observed in 
this cohort. Only two common variant types of the fusion gene were tested for in this study; there are 14 
known transcript variants of the gene fusion (Section 2.3.3). Secondly, the TMPRSS2: ERG gene fusion 
was also detected in benign and non-involved cases, contrary to the report by Cross et al (2008). 
However, Tomlins et al (2007) reported the fusion of ETV1 gene with other 5’ partners in place of 
TMPRSS2 in many negative cases of TMPRSS2:ETV1 gene fusion. Studies on the TMPRSS2/ETV 
gene fusion would require interphase FISH technique and multiplex PCR approach to identify complex 
gene rearrangements and resulting fusion types. 
 
5.4.7  Gene expressions of Aurora kinases (A, B, C) in FFPE tissue materials 
The transcript levels of the Aurora kinases A an B were consistently increased in prostate cancer cases 
compared to non-involved and benign cases. Aberrant expression of Aurora kinases were associated 
with abnormal mitosis, the increased transcript levels of AURKA and B observed in this study was 
agreement with the report of increased expression by Chieffi et al (2006). It is possible that Aurora 
kinases could have increased transcript level and dysfunction in prostate cancer; a condition that could 
be exploited chemotherapeutically. Nevertheless, more studies would still be required to confirm the 
expression patterns of Aurora kinases in prostate cancer. Most recently processed FFPE tissue sections 
should be used to enhance the sensitivity of RQ-PCR. However, previous studies on Aurora kinases 
were immunohistochemical; mutant forms of aurora kinases could also contribute to increased abnormal 
expression of the Aurora kinases. 
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5.4.8  Gene expressions of CD44 and CDH 1 in prostate tissue sections 
CD44 is a cell adhesion molecule. It was over-expressed in prostate cancer tissues compared to benign 
cases. Some studies have associated over-expression of CD44 in prostate cancer with mutation {Isaacs, 
1997}; other studies have reported increased expression (detected by IHC) of the standard form of CD44 
in human cancers {Hu et al, 2009}. The finding from this study showed that CD44 transcript level was 
over-expressed in prostate cancer cases. However, the mutation status of these transcripts was not 
investigated.  Secondly, the primers used in the RQ-PCR were designed to amplify the common variants 
of CD44; it is possible that other novel variants of CD44 could occur in prostate cancer cases. Further 
studies, designed to investigate mutation status and frequency of transcript variants, would be required 
to elucidate the role of increased CD44 transcripts observed in this study. The transcript level was also 
associated with tumour grade. Higher Gleason score had lower CD44 transcript number. Although 
CD44 transcript level was significantly higher in prostate cancer cases, there was decreased transcript 
level with increasing tumour grade. Prostate lesions are often heterogeneous; foci of malignancy could 
co-exist with benign lesions. And without microdissection of particular cell types and lesions, the 
explanation of gene expression studies in prostate could be difficult. 
 
The transcript levels of CDH1 did not significantly differ among benign, non-involved and prostate 
cancer cases. Some previous studies had reported reduced CDH1 immunostaining in prostate cancer, 
with benign cases showing a much uniform cell to cell border staining immunohistochemically. The 
finding from this study showed that the transcript level did not differ in all the cases. Factors such as 
post-translational modifications could alter protein products of genes in tissues. It is also becoming 
apparent that regulatory RNAs could alter the expression of gene transcripts in different tissues. At 
transcript level, CDH1 did not show any diagnostic value in prostate cancer cases evaluated in this 
study. 
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5.4.9  Gene expression of FASN in urine cells and prostate tissues 
 
Fatty acid synthase (FASN) is a key enzyme in lipid metabolism. Its abnormal expression had been 
reported as an early event in prostate cancer development. Although it was detectable in urine cells; it 
showed no differential expression at transcript levels among the study groups. Similar results were 
obtained also for the FASN transcript ratios in FFPE tissue materials; there was no differential 
expression. 
 
5.4.10  Gene expression of Bcl-2 in FFPE prostate tissues 
The transcript levels of Bcl-2 were detectably low; and showed no significant variation among the 
groups. Using most recently processed FFPE tissue materials could improve the detection of Bcl-2. 
Previous immunohistochemical studies had shown that Bcl-2 expression increased with tumour grade. 
However, the transcript levels, from this study, were not differential between benign and prostate cancer 
cases. 
 
5.4.11  Gene expressions of steroid hormone receptors in prostate cancer 
 
The results from this study showed that ESRβ was over-expressed in prostate cancer tissues compared to 
benign tissues; and the over-expression was also significantly associated with tumour grade and not 
pathological/clinical stage. The role of ESRβ in prostate cancer progression has been controversial. 
Early studies reported a decreased expression of ESRβ (mainly by immunostaining) and thought it was 
anti-proliferative. However, some recent studies have shown that ESRβ was over-expressed in prostate 
cancer {Walton et al, 2009}. The results from this study show that ESRβ is over-expressed in prostate 
cancer, and probably for the first time, indicate that the over-expression is also associated with tumour 
grade. This implies a proliferative role for ESRβ. The results from prostate tissue were also similar to 
the in vitro results where ESRβ was over-expressed in MDA PCA 2b at protein and mRNA levels, a 
form of progressive prostate cancer cell line. These findings plus previous reports in this direction would 
require further studies on specifically targeting ESRβ in high grade tumours with selective oestrogen 
antagonists for therapeutic purposes. 
 
 
Although no association with pathological /clinical stage was observed, there was lack of clarity in 
clinical notes on pathological versus clinical stage. The over-expression of ESRβ in prostate cancer 
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cases refutes the null hypothesis, which stated that there was no differential expression of ESRβ in 
prostate tissues. 
 
On the other hand, ESRα was not differentially expressed among the sample groups. This reinforced the 
observation that ESRβ could be the key mediator of oestrogenic activity during prostate cancer 
progression. It does appear that there is a reversal of oestrogen receptor role in prostate cancer 
progression compared to the embryological development of the prostate, where Prins et al (2001) 
demonstrated in mice that ESRα was the key mediator of oestrogenic activity.  
Androgen receptors AR, like the ESRβ were also significantly over-expressed in prostate cancer cases 
compared to benign cases. Increase synthesis of oestrogen receptors are known to induce concomitant 
production of androgen receptors {Droller, 1997}. Several immunohistochemical studies have shown 
that steroid hormones are often expressed in a similar pattern in most endocrine tissues {Quinn et al, 
2005; Murphy et al, 2006}.  
 
Results of immunohistochemical staining in this study also confirmed the expression of these steroid 
hormone receptors (SHR). However, the interesting observation is that ESRβ is the most predominant 
form of oestrogen receptors in prostate cancers and was associated with high tumour grade. In breast 
cancers, for example, the ESRα is the predominant form of oestrogen receptor that molecularly 
characterises the behaviour of the disease. It would be useful to investigate the prognostic and 
therapeutic value of ESRβ in prostate cancer. 
 
5.5  Conclusions 
 
The key findings in this chapter include: 
• ABL1 transcript level is the most stably expressed endogenous control gene in both FFPE tissue 
materials and exfoliated urine cells. Therefore it was used to normalize gene expression of target 
transcripts. Each target transcript is expressed per copy of ABL1 in the tissue sample. 
• Most recently processed FFPE tissue materials yielded better results; aged samples reduced RQ-
PCR sensitivity. Aged samples (samples older than 1 year) had lower transcript number of 
ABL1, which implied degradation and loss of mRNAs including those of target transcripts. 
• KLK2 transcript levels in FFPE tissue materials were decreased in prostate cancer cases and 
showed no correlation with tumour grade. 
• KLK2 transcript levels in urine cells were not differential in both healthy and prostate disease 
cases. 
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• KLK3 transcript levels in urine were not clinically useful in detection or staging of prostate 
cancer. At mRNA level, KLK3 was more expressed in prostate cancer tissues compared to 
benign and non-involved cases; however at the protein level there was higher expression of PSA 
in benign tissues than prostate cancer and non-involved samples. 
• The transcript levels of both KLK2 and KLK3 were not consistently reliable for diagnosis using 
urine samples. 
• MCM2 transcript levels in exfoliated urine cells have a limited diagnostic value; it could not 
differentiate between cancer and benign cases. However, the MCM2 transcript number in FFPE 
tissue materials could have prognostic value; over-expression was associated with Gleason Score 
6. 
• MCM5 transcript level has no diagnostic value in prostate cancer. 
• TP53 gene over-expression was associated with higher tumour grade. 
• TMPRSS2: ERG was the most predominant variant of the gene fusion with ETS genes in 
prostate cancer. 
• The TMPRSS2 gene fusions were also detectable in benign and non-involved prostate cases. 
• Only 15.6% of the prostate cancer cases expressed the TMPRSS2 gene fusion in the sample 
population. 
• However, some novel variants of the ETS gene fusions could have been undetectable by the two 
assays used in this study. 
• Aurora kinases A and B were consistently significantly increased at transcript level in prostate 
cancer cases compared to benign and non-involved cases, but Aurora kinase C did not differ in 
both benign and prostate cancer cases. 
• CD44 was over-expressed in prostate cancer tissues and also associated with tumour grade. 
• Transcript levels of CDH1 did not show any differential expression among benign, prostate 
cancer and non-involved cases. 
• Fatty acid synthase transcript numbers in urine cells and FFPE prostate tissue materials were not 
differentially expressed in benign, prostate cancer and healthy controls. 
• Bcl-2 transcript levels in prostate tissues were not differentially expressed between benign and 
prostate cancer cases. 
• ESRβ was remarkably over-expressed in prostate cancer cases, and was also associated with 
tumour grade. 
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• ESRα did not show any differential expression in prostate diseases. 
• AR was also over-expressed in prostate cancer cases, but was not associated with tumour grade. 
Overall, of the 16 molecular markers investigated, 7 of them showed significant association with 
prostate cancer progression: TP53, TMPRSS2 fusion genes, AURK A, AURKB, CD44, ESRβ and 
AR. Future studies would be required to establish the prognostic value of these seven molecular 
markers in prostate cancer. Most recently processed FFPE tissue materials, no longer than one year 
old should be used in designing RQ-PCR studies for markers. Also ABL1 gene emerged as the most 
stable candidate control gene for normalization of RQ-PCR. 
 
 
   
     Table  5.1 Summary of  change in normalized transcript ratio of biomarkers       
      
Increased transcript ratio in 
Prostate cancer compared to 
benign cases 
 
Decreased transcript ratio in 
prostate cancer compared to 
benign cases 
No significant change between 
prostate cancer and benign 
cases 
• MCM2 
• TP53 
• TMPRSS2:ERG 
• Aurora A 
• Aurora B 
• CD44 
• ESRβ 
• AR 
 
• KLK2 • KLK3 
• MCM5 
• Aurora Kinase C 
• FASN 
• ESRα 
• CDH1 
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Chapter 6:  Exploratory GC-MS study on urine volatiles in prostate disease 
 
6.1  Introduction 
 
Organic volatile constituents of biological fluids could contain clinically useful diagnostic information 
for the recognition of metabolic disorders in man {Zlatkis et al, 1981}. A short review on the application 
of volatile gas analysis to cancer screening was described in Section 1.6.1f. In this study, urine samples 
of randomly selected ten patients from the Bedford Hospital cohort were analyzed by the method of 
thermal desorption gas chromatography mass spectrometry (GC-MS). The aim was to explore the 
presence and quantity of organic volatiles in the urine samples for possible identification of metabolic 
markers for prostate cancer. 
 
6.2  Materials and Methods 
 
The ethical approval and all documentations used in recruiting patients are contained in appendix D. The 
random selection of patients was based on the total PSA level at the time of referral to TRUS-prostate 
biopsy clinic. Three of the selected patients had PSA < 5.0 ng/ml; four patients had PSA between 
6.0ng/ml to 13.0ng/ml and another three patients had PSA > 13ng/ml. The PSA class interval was 
arbitrary; and on the presumption that the three groups of patients would have non-involved, benign and 
malignant cases.  
 
Decanted urine samples were stored at -80oC until required for analysis. During preparation for analysis, 
the urine samples were thawed overnight at 4oC; and 5ml was dispensed into sterile plastic bag for each 
sample, and air-tightly sealed with plastic clips. The sealed bags were heated in an enclosed thermal 
chamber at 40oC for 5 minutes, enabling the headspace of each bag to be aspirated into a thermo-
desorption (TD) tube. The TD tubes were then loaded into the carousel of an automatic thermal 
desorption system (ATD400) (Perkins Elmer, USA); and analyzed using Auto system XL Gas 
chromatograph linked to Turbomass mass spectrometer (Perkins Elmer, USA). A blank and two 
standards (calibrators with known separation time and peaks) TDs were also included. Set up details 
include auto injection at injection volume of 1ml at the rate of 1.56250 parts per second; run time was 30 
minutes, and initial oven temperature was 50oC for 20 minutes. 
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6.3  Results  
 
Results of histological analysis from the Bedford hospital cellular pathology department later confirmed 
that eight of the selected patients had BPH, one had prostate cancer and one was non-involved case. 
 
The GC-MS analysis through an in-built chemical search library identified, at > 85% homology, a total 
of 873 different organic volatiles in the urine samples. The chromatograms of the samples are shown in 
Figures 6.1, 6.2, and 6.3. A visual inspection of the chromatograms showed a high level of 
isothiocyanate in one BPH patient (Figure 6.2, sample ID: Nna011). 
 
Principal component analysis (PCA) was carried out on the GC-MS data. Figure 6.4 and 6.5 show the 
three-dimensional PCA score plots.   
 
Figure 6.6 shows the 2-D plot of the PCA score of the analytes. From these plots, eight analytes were 
found to be differentially expressed in the prostate cancer patient compared to the eight benign patients 
and non-involved case. These were Ethanethiol, Dimethyl sulfide, Propyn-1-ol acetate, Nitro-2-
propanone, pentane, Hydrazine, Methanamine and Nitrous oxide. The quantity ranged from 0.01% to 
5%. Of these eight, Methanamine is a urinary antiseptic and could have been taken by the patient in 
preparation for the TRUS- biopsy or as a result of urinary tract infection. The other 7 analytes are used 
in various complex mixtures in the laboratory but could also result from cancer metabolism. 
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Figure 6.1 Chromatograms of volatiles from headspace urine analysis of high PSA patients. 873 different volatiles were identified but 
no differential trend in presence and quantity of the volatiles. 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
214
 
Figure 6.2 Chromatograms of volatiles from headspace urine analysis of medium PSA patients. 873 different volatiles were identified; 
isothiocyanate a drug metabolite (retention time 17.83) was found in large quantity in one of the BPH patients (sample Nna011), but 
no overall differential trend in presence and quantity of the volatiles. 
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Figure 6.3 Chromatograms of volatiles from headspace urine analysis of low PSA patients. 873 different volatiles were identified but 
no differential trend in presence and quantity of the volatiles. 
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Figure 6.4 Three dimensional PCA score plot of the patients based on GC-MS data. The blue tagged numbers represent the patients 
ID. Patient 96 (the only prostate cancer patient) was significantly different from the rest on PC1 (29.6%). 
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Figure 6.5 Three dimensional PCA score plot of both patients and analytes based on GC-MS data.  
The red tagged numbers represent the ID of the analytes identified by GC-MS. 
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Figure 6.6 Two-D PCA plot of analytes and patients based on GC-MS data..
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6.4  Discussion and Conclusion. 
 
There was no remarkable change in the visual chromatogram pattern of the samples. Only one 
BPH patient had a high level of isothiocyanate, with 98% homology in the chemical search 
library. The retention time for the isothiocyanate was 17.83 minutes. Isothiocyanate is an 
anti-carcinogenic metabolite of several sulforaphane containing drugs or vegetables (for 
example broccoli) {Zhang et al, 1994}.  
 
The principal component analysis (PCA) showed that eight analytes were differentially 
expressed in the prostate cancer patient compared to benign and non-involved cases. Further 
analysis would still be required to examine these individual volatiles. The first emphasis is to 
rule out that these analytes were not contaminants of any source. The second priority would 
be to rule out that they were not metabolites of drugs which the patients had taken prior to 
TRUS-prostate biopsy. However, some could be analytes that truly resulted from prostate 
cancer metabolism. In particular, pentane is known to be produced in oxidative stress. In 
comparison to lung cancer where two aldehydes: hexanal and heptanal are volatile markers 
and are also commonly used in the laboratory.  
 
In summary, analysis of urine volatiles is a non-invasive technique, and may provide 
additional method for prostate cancer screening. Future studies are recommended to screen 
further seven of the analytes identified in this study. Care should be taken to recruit naive 
patients who are not on any sort of chemotherapy. 
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Chapter 7: Discussion, Conclusion and Future Work 
 
7.1 Discussion 
 
Over one hundred different molecular markers are associated with prostate cancer 
development and/ or progression. As new molecular markers emerge through new 
technologies, there is the need to validate both the biomarkers and the technologies through 
which they are discovered. In many cases most of these biomarkers fail to progress to clinical 
use. This is very typical of prostate cancer where little molecular grading/classification does 
exist. Despite the similarities of the prostate to the breast, molecular grading has become a 
standard practice in breast pathology and its clinical management but not the case with the 
prostate. The most commonly used tumour marker in prostate cancer, the prostate specific 
antigen PSA, has a weak correlation with the malignancy. The recently approved PCA-3 
molecular test has also a modest diagnostic value. The definitive method of prostate cancer 
diagnosis which is histological examination has at best 30% detection rate at first biopsy for 
patients with elevated serum PSA and/ or abnormal digital rectal examination. All these 
necessitate the need for more molecular characterization of prostate diseases. 
 
Through extensive literature review, sixteen different molecular markers were selected and 
evaluated in prostate cancer, benign and non-involved cases. The markers included KLK2, 
KLK3, MCM2, MCM5, TP53, Bcl-2, CD44, CDH1, AURKA, AURKB, and AURKC; 
ESRα, ESRβ, AR, FASN, TMPRSS2: ERG, and TMPRSS2:ETV1. The primary aim was to 
use molecular techniques to determine the gene expression of these markers in prostate cancer 
cases and to assess their association, if any, with tumour grade and pathological stage. 
 
An in vitro model was designed using three prostate cell lines: PC-3, PNT1A and MDA PCA 
2b to evaluate the expression of these molecular markers in response to steroid hormone 
treatment. The prostate gland depends on steroid hormones, mainly the androgens, for its 
growth and functions. Analysis of the transcript levels (mRNA) showed differential 
expression for most of the markers. 
All the prostate cell lines expressed AR, ESRβ, ESRα and PSA at both mRNA and protein 
level. There had been previous reports that PC-3 cells do not express AR and PSA {van 
Bokhoven et al, 2003}. However, the results from this study showed that the PC-3 cells 
expressed AR and PSA. Alimirah et al (2006) also reported the expression of AR in PC-3 
cells. However, on stimulation with androgens, the PC-3 did not secrete PSA that is 
detectable in culture supernatants by ELISA. But western blot of cell lysates showed cellular 
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PSA; immunocytochemistry also confirmed PSA expression. The transcripts of PSA in PC-3, 
detected by RQ-PCR did not show up-regulation by androgens. The western blot showed that 
both PC-3 and MDAPCA 2b expressed a 60 kDa AR while the PNT1A expressed a 90 kDa 
AR. Although the PC-3 expressed AR, it was still androgen-insensitive. There are several 
reasons for the expression of AR in PC-3 cells. It could result from contamination with other 
prostate cell lines over years of passaging. It could also result from evolution of sublines of 
the PC-3 cells that become AR positive in response to growth conditions. But the awareness 
that the PC-3 cells, regarded as one of the ‘classical prostate cell lines’ expressed these 
receptors would guide design of in vitro experiments in future. In addition, the MDAPCA 2b 
cells over-expressed ESRβ more than the PC-3 and the PNT1A cells; and it was up-regulated 
by the administration of 17 β oestradiol. The AR in PNT1A cells responded to androgen 
stimulation and produced secreted PSA detectable in culture supernatants. 
 
Of the sixteen molecular makers, the TMPRSS2 fusion genes (TMPRSS2: ERG and 
TMPRSS2:ETV1) were the only markers undetected in the three prostate cell lines. The 
MCMs (MCM2 and MCM5) did not show any differential expression in response to steroid 
treatment in the prostate cell lines. The evaluation of three candidate endogenous control 
genes showed that the ABL1 gene was the most stably expressed house-keeping gene and 
could be reliably used to normalize RQ-PCR of prostate tumour markers. The expression of 
the ABL1 was stable in all the sample categories when benign cases were compared against 
prostate cancer and non-involved cases in both exfoliated urine cells and prostate tissues 
(FFPE materials). 
 
Further analysis of the transcripts of the sixteen molecular markers in tissue materials showed 
that only seven of them were strongly associated with prostate cancer progression. These 
were TP53, TMPRSS2 fusion genes, AURK A, AURKB, CD44, ESRβ and AR. The TP53 
over-expression was associated with tumour grade. The TMPRSS2 fusion genes (TMPRSS2: 
ERG and TMPRSS2:ETV1) were expressed in 15.6% of the prostate cancer cases. It is 
possible that other variants of the TMPRSS2 fusion genes could still be detectable from the 
sample population in this study. Interphase FISH method and multiplex RT-PCR could be 
used to investigate more of the TMPRSS2 fusion genes. However, the fusion gene was also 
detectable in two benign cases. The TMPRSS2: ERG was also detectable in exfoliated urine 
cells. 
 
The Aurora kinases A and B were consistently significantly over-expressed in the prostate 
cancer cases compared to the benign cases. Because of the roles the play in cell mitosis, these 
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two kinases could be targets for therapeutics. However, the over-expression of AURK A and 
AURKB were not associated with tumour grade and pathological stage. 
 
CD44 was over-expressed in the prostate cancer cases and was also associated with tumour 
grade. It is believed that CD44 over-expression in prostate cancer could result from mutant 
forms although the over-expression of standard CD44 has been reported in breast and colon 
cancer cases {Desai et al, 2009; Madjd et al, 2009}. It is also possible that transcript variants 
of CD44 could contribute to the over-expression in prostate cancer. The role of the CD44 
protein is also affected by its degree of glycosylation. 
 
The ESRβ was also over-expressed in prostate cancer cases. Because the ESRα did not show 
any differential expression in the study group, this finding strongly favoured a proliferative 
role for ESRβ. Remarkably, the androgen receptor AR was also up-regulated in those prostate 
cancer cases compared to the benign cases. It is strongly very likely that the ESRβ is the key 
mediator of oestrogenic activity in prostate cancer progression. Walton et al (2009) also 
reported over-expression of ESRβ in prostate cancer cases (although in 17 samples); but 96 
prostate cancer cases were involved in this study. The over-expression of ESRβ, probably for 
the first time, was also associated with high tumour grade. Therefore selective targeting of 
ESRβ could provide a therapeutic means of slowing prostate cancer progression. Early studies 
on ESRβ had reported anti-proliferative role and therefore thought that it could be protective. 
But the finding from this study suggest otherwise. At both  mRNA and protein levels, the 
ESRβ was over-expressed in prostate cancer and was significantly associated with high 
tumour grade and increased AR expression. In vitro studies also showed similar results; the 
ESRβ was also up-regulated by the administration of 17β oestradiol, a hormone whose level 
increases in ageing men. 
 
The seven molecular markers would require further confirm studies using most recently 
processed FFPE tissue materials. Aged samples showed reduced RQ-PCR sensitivity; the 
levels of the control genes were reduced by more than a log in one year older samples. 
 
The two kallikreins: KLK2 and KLK3 were not consistent in both urine and tissue samples; 
their transcript levels were not significantly associated with prostate cancer cases. The KLK2 
transcript was reduced in prostate cancer cases in tissue samples while the KLK3 was 
significantly over-expressed. Both transcripts were not differentially expressed in urine cells. 
The PSA immunolocalisation on prostate tissues was stronger and more diffuse in benign 
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cases than prostate cancer cases. All these point to the fact that the two kallikreins have weak 
correlation with prostate malignancy especially at transcript levels. 
 
Further genetic analysis on the KLK2 gene showed that two variants for SNPs rs2664155 and 
rs198977 had strong association with prostate diseases. The T/T genotype of rs198977 
predicted presence of prostate cancer at biopsy and was also associated with high tumour 
grade. However, the A/A genotype of rs2664155 was found only in BPH cases. The 
association of both SNPs to prostate cancer had also been reported by Nam et al (2009); but 
contrary to previous reports, this study showed, for the first time, that the A/A genotype of 
rs2664155 was associated with benign nodular hyperplasia. 
 
Combination of gene expression and genetic tests could assist in the risk stratification of 
patients for both screening and treatment options. The natural course of prostate cancer is 
hugely unpredictable. In some cases the disease could be undetectable, or treatment might be 
not necessary. And in many other cases treatment could be vital but may not necessarily 
prolong life of patients.  Therefore molecular characterization of patients using gene 
expression and genetic studies could help identify high risk groups who might need annual 
screening for early detection, or determine those who might benefit from early radical 
treatment in comparison to those who possibly would not require the treatment. In addition, 
there are various treatment options, molecular grading could help in defining response to 
therapy and inform better choice of therapy. From this study seven already known molecular 
markers with a strong association to the disease were identified. The strength of gene 
expression techniques lies on ultra sensitivity, accuracy and reproducibility. They also 
provide multiplex formats for measuring several targets in one assay, which is highly cost-
effective and flexibly high throughput. Therefore these seven markers could improve the 
molecular grading of prostate cancer. 
 
An exploratory GC-MS study on ten patients suggested seven analytes that could be 
investigated further: Ethanethiol, Dimethyl sulfide, Propyn-1-ol acetate, Nitro-2-propanone, 
pentane, Hydrazine and Nitrous oxide. These analytes could be contaminants or metabolites 
of drugs or foods; however, they appeared differential on principal component analysis of 
urine samples of eight benign patients, a non-involved case and one prostate cancer case. 
Although in trace amounts, they were more expressed in the prostate cancer case compared to 
the benign and non-involved cases. 
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7.2 Conclusion 
 
Seven molecular markers were strongly associated with prostate cancer progression: TP53, 
TMPRSS2 fusion genes, AURK A, AURKB, CD44, ESRβ and AR. They could help to 
molecularly characterize prostate cancer.  The ESRβ in particular was found proliferative in 
prostate cancer cases and could be the key mediator of oestrogenic activity in prostate cancer 
progression. Therapeutic targeting of the aurora kinases-A and B involved in cell mitosis and 
the ESRβ could help slow down prostate cancer progression.  
 
RQ-PCR technique provides a cost- effective, high through put multiplex format for 
quantifying these markers in prostate tissue sections and in exfoliated urine cells. Most 
recently processed tissue sections should be used to confirm these findings. Two genetic 
variants of the KLK2 gene were also predictive of prostate diseases: the T/T allele of 
rs198977 was found only in prostate cancer cases and was associated with high tumour grade. 
The A/A allele of rs2664155 was associated with benign nodular hyperplasia. A combination 
of gene expression and genetic variation, using the RQ-PCR application, could help improve 
diagnostic histopathology of prostate diseases. An emerging area of interest is the non-
invasive analysis of urine samples using GC-MS technique to identify organic volatiles from 
prostate cancer cells’ metabolism.  Seven organic volatiles: Ethanethiol, Dimethyl sulfide, 
Propyn-1-ol acetate, Nitro-2-propanone, pentane, Hydrazine and Nitrous oxide were 
differentially expressed in a prostate cancer sample. Further studies would be required to rule 
out possible contamination or products of drug metabolism. 
 
7.3 Future Work 
• Further analysis is required on the GC-MS of urine samples. 
• Further studies are required to verify mutation status of CD44 and TP53 expressed in 
prostate cancer. 
• Further studies are also required to confirm the proliferative role of ESRβ 
• Validation of a multiplex RQ-PCR assay in which TP53, CD44, AURKA, AURKB 
and ABL1 are measured in one reaction. This pentaplex assay could identify 
aggressive prostate cancer from indolent cases. Another pentaplex assay could 
measure AR, ESRβ, and TMPRSS2: ERG and TMPRSS2:ETV1 and ABL1. 
Therefore, establishing a baseline value in tissue sections would be necessary for 
clinical translation of these assays. The ABL1 would be used to normalize the results. 
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These two sets of pentaplex assays are capable of molecularly characterizing all 
prostate cancer cases. 
• Large scale genotyping of archived FFPE tissue cases for rs2664155 and rs198977 
using TaqMan SNP genotyping assays to confirm their association with prostate 
diseases. 
     The  most promising single assay panel for molecular profiling of prostate cancer patients 
would consists of TMPRSS2:ERG, Aurora kinases A and B (AurkA & AurkB), Oestrogen 
receptor beta (ESRβ), Androgen receptor (AR) and CD44. Further study would be required to 
decide between choosing AurKA or AurkB in order to include a control gene (ABL1) for 
normalization. Analytical optimization and validation of a pentaplex real time PCR for these 
four markers using exfoliated urine cells would be clinically useful in diagnosis and 
prognostication of prostate cancer patients. Analytical optimization will involve mainly 
primer and probe concentration to achieve consistent and uniform amplification plots for all 
targets. Validation may also require preparing a single plasmid standard with inserts of all the 
five target markers for clinical laboratory assays. 
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Appendix A: Equipment, Preparation of Reagents and Buffers 
 
A.1 Equipment: Jencon’s variable pipettes and tips: 2-20µl (lot no. E066044), 20-200µl (lot no. 
ER46745) and 200-1000 µl (Lot no. EN 3358); Sartorius analytical balance model MC22; Heraeus 
biological safety hood model H59 (level II containment); Tissue bank model RS 3000; Sanyo C02 
incubator model MCO-17A1C, Olympus phase contrast microscope model TMS; Carl Zeiss Axioskop 
microscope and axiocam (camera); Beckman micro-centrifuge lite model 2A; Multispeed refrigerated 
centrifuge PK131R; Jouan refrigerated centrifuge model B41; WPA light wave UV/Visible 
spectrophotometer model S2000; 1.0cm light path cuvettes, pH meter model 410A; Grant water bath JB1 
5PC; Heat stirrer model HB502; CFX96 Real time PCR system (BioRad, UK); ABI 7900HT Sequence 
detection system (Applied biosystems, UK); ABI Genetic analyzer 3130 (Applied biosystems, UK); 
Eppendorf concentrator 5301 (Eppendorf, Germany); BioRad power pack and Mini-protean III 
Electrophoresis system (BioRad, UK), Q-Mark 24 Pyrosequencing system (Qiagen, UK); MJ PTC 2000 
thermal cycler (BioRad,UK), Accuri flow cytometry system (Accuri, UK);  Gene Genius bio-imaging 
system (Syngene, UK); Carl Zeiss LSM 510 Meta Confocal microscope, and general laboratory 
glassware and plastics. The pipettes were calibrated according to manufacturer’s standard procedures. 
 
A.2 Reagents & Buffers: 
i) Ammonia water: 1.4ml of concentrated ammonium hydroxide (Sigma UK) was added to 250ml of 
distilled water and mixed by swirling. 
ii) DAB substrate chromogen buffer: 0.1g of 3, 3’ diaminobenzidine (DAB) (Sigma, UK) was 
dissolved in 10ml of distilled water, and 250µl of 10M HCl added and mixed for 10 minutes 
(solution turned brown). Aliquots were stored at -20oC until required for use. 100µl of 30% H202 
(Sigma, UK) was added to 10ml distilled water, mixed, aliquoted and also stored at -20oC. For a 
working solution, 250µl of the DAB solution was added to 5ml of PBS (pH 7.2, Invitrogen, UK), 
mixed and 250µl of the H202 dilution was added to the mixture (tube covered with foil. The mixture 
was used within less than 6 hours of preparation. 
iii) Trypsin/ EDTA solution (TES) (Sigma UK): Commercially prepared 20 x solutions were diluted 
to 1x strength using PBS. 
iv) TBS (pH 7.6): 6.06g of TRIS base and 8.7g of Nacl were dissolved in 400ml of distilled water; 
the pH adjusted to 7.6 using 0.1M HCL and the buffer made up to one litre with distilled water. 
v) PBS: commercially prepared tablets were used: 2 tablets dissolved in 400ml of           distilled 
water (dH20) and made up to 1.0 litre using dH20. PBS was aliquoted in bijou bottles and autoclaved 
at 1210 C for 15 min   before use. Also commercially prepared sterile PBS solution (Invitrogen, UK) 
was used in cell cultures and IHC. 
vi) RIPA buffer: It was made up of Sodium chloride 0.88g, Sodium deoxycholate 0.5g, Sodium 
dodecyl sulphate SDS 0.1g, Tergitol type NP-40 1.0g and 100ml of Tris-HCl (pH 6.8). It was 
properly mixed, filtered and stored at 4oC. For cell pellets, 200 µl of RIPA buffer was used for 
protein extraction: cells were lysed for 10 minutes, centrifuged at 100g for 5 minutes and 
supernatants collected for analysis. 
vi) Running buffer 5x: Glycine 144g, SDS 5g, Trizma 30g and 1litre of distilled water; properly 
mixed using a stirrer. 
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vii) Transfer buffer 10x: Glycine 144g, Trizma 30g and 1 litre of distilled water properly mixed 
using a stirrer. 
viii) TBS 10x: Nacl 40g, KCl 1g and Trizma 15g; mixed properly and pH 7.4 using 1M HCl. 
ix) Sample loading buffer for western blot: NUPAGE LDS sample buffer 4x (Invitrogen, UK) 
and NUPAGE sample reducing buffer 10x (Invitrogen, UK). 
x) Separating gel for SDS PAGE:  Shown in Table A.1 
Table A.1 Composition of Separating gel for SDS PAGE 
Separating Gel 7.5% 10% 12% 
Tris-HCl pH 8.8 buffer  2.5ml 2.5ml 2.5ml 
Bis-acrylamide (30%)(BioRad, UK) 2.5ml 3.3ml 4.0ml 
Distilled water 5.0ml 4.2ml 3.5ml 
10% APS(Fresh) 50µl 50µl 50µl 
TEMED 33µl 33µl 33µl 
 
xi)   Stacking gel:  
               Tris-HCl pH 6.8 Buffer ……..1.2ml 
         Bis-acryl amide………………750µl 
         Distilled H20 ……………...….3.0ml 
        10% APS…………………......30µl 
        TEMED………………………..20µl 
 
xi) Sodium Citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0): 
2.94g of Tri-sodium citrate (dehydrate) in 1000ml of distilled water, mixed 
properly and pH adjusted to 6.0 using 1M HCl and then 0.5ml of Tween 20 
added and mixed again. The solution was stored at room temperature and 
used within 3 months of preparation. 
xii) Avidin-Biotin complex (Dako, UK). 100µl of solution A (Avidin) and 100µl of 
solution B (Biotin) were added to 5ml of TBS and mixed ready for use. 
xiii) 10% rabbit serum: Normal rabbit serum (Dako, UK), 10ml of it added to 
90ml PBS. 
xiv) 0.057 %( wt/vol) SRB: 57g of SRB (Sigma, UK) in 1% (vol/vol) acetic acid. 
xv) 10% (wt/vol) TCA: 10g of TCA in 100ml of distilled water (handled with 
extreme care in fume hood). 
xvi) 10X Red cell lysis buffer (RCLB):  Ammonium chloride (NH4Cl) (Merck, 
UK) 248.7g, EDTA 0.5M (Gibco, UK), and Potassium bicarbonate (KHC03) 
were fully dissolved in 2.5 litres of distilled water (contained in Winchester 
bottle) and stored at 4-8oC.  
xvii) 1x RCLB:  1 litre of 10x RCLB was added to 9litres of distilled water, kept 
overnight at 4-8oC, and next day pH was adjusted to 7.4 with concentrated 
HCl. The 1x RCLB was stored at 4-8oC. 
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xviii) Tris acetate EDTA buffer (TAE):  50X stock was prepared by adding 605g 
of Tris base, 36.5g EDTA and 125ml glacial acetic acid, making it up to 
2.5litres using distilled water. The stock buffer was stored in a Winchester 
bottle at room temperature. To make 10 litres of 1x TAE, 1 litre of stock 
was made up to 10 litres with distilled water. 
 
A.3   Antibody dilutions for ICS, IHC and IF 
Antibody Supplier Parameters 
Mouse anti-androgen receptor 
(AR) IgG. 
Invitrogen, 
UK. 
Monoclonal; Clone AR27; IgG1 isotype; 
antibody concentration 0.1mg/ml. 1 in 50 
dilutions used (based on manufacturer’s 
recommendation). 1% (v/v) normal rabbit 
serum in PBS was used as diluent in all 
commercial antibody dilutions. 
Mouse anti-oestrogen receptor 
(ERβ1) IgG. 
Serotec, UK  Monoclonal; clone number PPG5/10; IgG2 
isotype; antibody concentration 1mg/ml. 1 in 40 
dilutions used based on manufacturer’s 
recommendation. 
Mouse anti-oestrogen receptor 
(ERβ2) IgG. 
Serotec, UK. Monoclonal; clone number ID5; IgG1 kappa 
isotype. Antibody body concentration 1mg/ml. 
1 in 40 dilutions based on manufacturer’s 
recommendation. 
Mouse anti-oestrogen receptor 
(ERα) IgG. 
Serotec, UK. Monoclonal; clone number 6f11; antibody 
concentration 1mg/ml, IgG1 isotype; 1 in 50 
dilutions used based on manufacturer’s 
recommendation. 
Mouse anti-human p53 IgG 
(aa213-217). 
Serotec, UK. Monoclonal; clone number PAb240; antibody 
concentration 0.1mg/ml. It is IgG1 isotype. 1 in 
40 dilutions used based on manufacturer’s 
recommendation. 
Mouse anti-human MCM 2 IgG. Serotec, UK. Monoclonal; clone number CRCT2.1, antibody 
concentration 1.0 mg/ml. IgG1 isotype. 1 in 50 
dilutions used based on manufacturer’s 
recommendation. 
Biotinylated polyclonal rabbit 
anti-mouse IgG (secondary 
antibody for detection system). 
Dako, UK. Polyclonal (reacts with IgG subclasses and 
mouse IgM). 1 in 200 dilutions were used based 
on supplier’s recommendation. 
Mouse anti-human CD324 
(CDH1) 
Serotec, UK Isotype IgG1, Clone 6F9; 1 in 40 dilution used. 
Mouse anti-human CD44 Serotec, UK Isotype IgG2a, Clone F10-44-2, 1 in 50 dilution 
used. 
Mouse anti-human Bcl-2 Serotec, UK Isotype IgG1, Clone 100, 1 in 50 dilution used. 
Monoclonal anti-β-actin Sigma, UK Isotype: IgG2a, Clone: AC-74, 1 in 5,000 
dilution; used as internal control for western 
blotting. 
Mouse anti-human PSA Zymed, UK Isotype IgG2a, Clone Z009, prediluted. 
Mouse anti-human  hK2 Immuquest, 
UK 
Isotype: IgG1, Clone 6B7, 1 in 50 dilution was 
used according to manufacturer’s 
recommendation. 
GAPDH (14C10) Rabbit 
monoclonal 
Cell 
Signaling,USA 
Isotype IgG1,Clone 14C10, 1 in 400 dilution 
for IHC, and 1 in 1000 dilution for  W/B. 
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A.4 List of Suppliers and their contacts 
 
 
 
 
 
 
 1 Dako UK Ltd. 
Denmark House 
Angel Drove, Ely 
Cambridgeshire, CB7 4ET 
Tel: +44 (0) 1353 669911 
Fax: +44 (0) 1353 668989 
Email: info@dako.com    
www.dako.co.uk  
 
1 Sigma-Aldrich Company Ltd. 
The Old Brickyard 
New Road, Gillingham 
Dorset, SP8 4XT 
Tel: +44 (0)  1747 833000 
2 Invitrogen Ltd 
3 Fountain Drive 
Inchinnan Business Park 
Paisley, UK.  PA4 9RF 
Tel: 0141 8146100 
Fax: 0141 8146260 
Email: euroinfo@invitrogen.com 
3 Serotec UK Ltd 
22 Bankside, station approach 
Kidlington, Oxford OX5 1JE,  
United Kingdom 
Tel: +44 (0) 1865 852700 
Fax: +44 (0) 1865 852739 
serotec@serotec.co.uk      www.serotec.com 
4 American Type Culture Collection 
10801 University Blvd 
P.O.Box 159 
Manassas, VA 20108  
USA.The: +1 (703) 365 2700.Fax: +1 703 
365 2750. 
5 Perbio Science UK Ltd 
Unit 9, Atley Way, North Nelson Industrial Estate. 
Camlington, Northumberland 
NE23 1WA 
United Kingdom. Tel: 080025 2185 
Fax: 0800 0858772.Email: uk.info@perbio.com 
6. Applied biosytems, UK 
Lingley House 
120 Birchwood Boulevard Birchwood 
WA3 7QH, Warrington 
United Kingdom 
T +44 1925 282588 
F +44 1925 282504 
www.appliedbiosystems.com 
 
8. Qiagen, UK 
QIAGEN HOUSE  
Fleming Way  
Crawley  
West Sussex  
RH10 9NQ 
Tel: 01293-422-911 
www.qiagen.com  
 
10. ImmuQuest Ltd UK 
18 Houghton Banks, 
Ingleby Barwick, Cleveland, TS17 5AL 
UK. Tel: 01642 308 831. 
www.immuquest.com  
 
7. Diagnostic Automation /Cortez Diagnostics, Inc. 
 
23961 Craftsman Road, Suite D/E/F, Calabasas, California 
91302 USA 
Website: http://www.rapidtest.com 
Phone: 818-591-3030 Fax 818-591-8383 
E-mail: Marketing5@rapidtest.com 
 
9. GE Healthcare 
GE Healthcare (UK) Ltd 
 
Amersham HP7 9NA 
GB 
http://www.gelifesciences.com  
 
 
11. BioRad Laboratories 
Bio-Rad Laboratories Ltd. 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire HP2 7DX 
Phone: 020 8328 2000 
Freephone: 0800 181134 
Fax: 020 8328 2550 
E-mail: techsupport.uk@bio-rad.com  
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A.5 List of Primers and Probes 
Gene Oligo Sequence (5' to 3') Exons Amplicon (bp) 
ESRα F/P TGAATCTGCAGGGAGAGGAGTT 6 77 
  R/P GGACAGAAATGTGTACACTCCAGAAT 7   
  Probe [TET]TGTGCCTCAAATCT[TAM]         6&7   
ESRβ F/P TGATCCTGCTCAATTCCAGTATGT 7 86 
  R/P GTTCAGCAAGTGAGCCAGCTT 8   
  Probe [6FAM]CCCTCTGGTCACAGCG[BHQ1]          7&8   
AR F/P TGGGAGCCCGGAAGCTG 3 66 
  R/P GGTGCTGGAAGCCTCTCCTT 4   
  Probe [Cy5]AAGAAACTTGGTAATCTGAAACT[BHQ2]         3&4   
KLK2 F/P TGCCCATTGCCTAAAGAAGAATAG 2 73 
  R/P CCTGTGTCTTCAGGCTCAAACA 3   
  Probe [TET]CTGGGTCGGCACAAC[TAM]         2&3   
MCM2 F/P CAGCATGCGCAAGACTTTTG 14 74 
  R/P TCAGTATGAAGAGCAACAGCTCATT 15   
  Probe [FAM]CCGCTACCTTTCATTCCGGCGTG[TAM]      14&15   
ABL1 F/P GATACGAAGGGAGGGTGTACCA 3 94 
  R/P CTCGGCCAGGGTGTTGAA 4   
  Probe [FAM]GCTTCTGATGGCAAGCTCTACGTCTCCT[TAM]        3&4   
G6PD F/P GGCGATGCCTTCCATCAG 11 64 
  R/P CCAGGTCACCCGATGCA 12   
  Probe [TET]CGGATACACACATATTC[NQF]      11& 12   
GUS B F/P GAAAATATGTGGTTGGAGAGCTCATT 2 101 
  R/P CCGAGTGAAGATCCCCTTTTTA 3   
  Probe [FAM]CCAGCACTCTCGTCGGTGACTGTTCA[TAMRA]         2&3   
KLK3   ABI predesigned assay ID: Hs01105076_m1         2&3 65 
CD44   ABI predesigned assay ID:Hs01081475_m1         5&6 82 
CDH1   ABP predesigned assay ID: Hs00170423_m1         2&3 61 
TP53   ABI predesigned assay ID: Hs99999147_m1       9&10 72 
MCM5   ABI predesigned assay ID: Hs01052142_m1      16&17 70 
Bcl-2   ABI predesigned assay ID: Hs99999018_m1        2& 3 76 
AURKA   ABI predesigned assay ID: Hs0182073_m1          6&7 117 
AURKB   ABI predesigned assay ID: Hs00177782_m1        2& 3 130 
AURKC   ABI predesigned assay ID: Hs00152930_m1       4&5 91 
PTEN   ABI predesigned assay ID:Hs02621230_s1         9&9 135 
FASN   ABI predesigned assay ID:Hs00188012_m1          8&9 144 
TMPRSS2:ERG   ABI predesigned assay ID: Hs03063375_ft          1&4 106 
TMPRSS2:ETV1   ABI predesigned assay ID:Hs03024759_ft          1&4 123 
rs1064676 SNP F/P [Biotin]AGCTTCCCACACCCGCTCTAC   228 
  R/P ATCTGGCCCAGGCGTACACT 3   
  
SNP 
primer GCTCCTGGGTGGGCA 3   
rs6072 F/P TTGGGTCTGATCCCCCTGA 2 82 
  R/P [Biotin]CTCCCAGCCTCCCACAAT 2   
  
SNP 
primer ACCCCCTCCGCAGGT 2   
F/P = forward primer, R/P = reverse primer. 
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Appendix B:  Protocols for experiments 
 
B: 0 Protocol for cell cultures {Harrison & Rae, 2004; Freshney, 2005}.  
 
B.1 Expansion of prostate cell lines: 
• A water bath was set to 37oC, culture media containing 1.0  2.0, 5.0, 7.5 and 10.0 %( v/v) 
FCS or BGS or DCC-FCS were brought to room temperature; a waste beaker containing 2% 
(w/v) virkon disinfectant was prepared and culture hood disinfected using 70% (v/v) 
isopropanol (IPA) and allowed for 15 minutes. A small container was filled with liquid 
Nitrogen for thawing cells. 
• Each vial of cell line was removed from the tissue bank, held in the small liquid nitrogen 
container with the lid of the vial covered in silver foil and then thawed in the water bath set 
at 370C. A vial of one cell line was thawed and plated at a time. Before thawing another 
different cell line, the hood was disinfected and allowed to clear for 15 minutes. All the 
details of each cell line, such as passage number and date frozen were logged in the 
laboratory notebook and tissue bank log book. Eye goggles were worn when handling liquid 
nitrogen. 
• During thawing, vials were shaken gently to ensure that all cell lumps disaggregated. 
• Vial was removed from water bath as soon as the last lump thawed, sprayed with 70% (v/v) 
IPA and placed in the hood. 
• The contents of the vial were aspirated into a 15ml centrifuge tube and drops of culture 
media added using Pasteur pipette while gently swirling the tube for about 5 minutes (5ml 
of the culture media was added drop wise). Then another 5 ml of media was added with 
gentle swirling. 
• The tube was centrifuged at 40C, 1300 rpm (100g) for 5 minutes. 
• Cell pellet was resuspended in 1ml of media and added to T25 flask and supplemented with 
a further 6ml of media. Flasks were properly labelled. 
• T25 flask was swirled gently to ensure even distribution of cells and incubated at 370C, with 
5% (v/v) CO2 supply. 
• Flasks were checked routinely under the microscope and macroscopically; and culture 
media replaced during routine feeding. 
Note: In the first thawing, cells were expanded in appropriate phenol-containing media supplemented 
with 10% (v/v) FCS, but in subsequent experiments, cells were weaned in the different sera types; and 
during hormonal stimulation appropriate phenol-free media were used. 
 
B.2 Feeding prostate cell cultures: 
Culture media were changed when they turned slightly yellow (from usual pink colour) or when cells 
were harvested for splitting, counting or further seeding for hormonal stimulation using the protocol 
below: 
• Stored culture media were warmed to 370C ready to use. 
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• A waste beaker containing disinfectant and the culture hood were prepared ready for use as 
described in the protocol for thawing cells. 
• A few flasks of a cell line were removed from the incubator at a time, sprayed with IPA and 
placed in the hood. 
• Culture media in T25 or T75 was aspirated and replaced with new media, one flask at a time. 
• Care was taken not to touch the neck of the flask and to carry the entire procedure aseptically. 
 
B.3 Splitting prostate cell cultures by trypsinization: 
Confluent cell cultures, in which cells cover more than 70-80% of the available flask surface, were split, 
counted and re-seeded for hormonal stimulation, cell expansion or frozen for storage. Hormonally- 
treated cells were also trypsinized for viability assessment and cell count. 1x of Trypsin/EDTA solution 
(10X 0.5% trypsin, 0.2% EDTA) (Sigma, UK) was used to detach the cells from the flasks using the 
protocol below: 
• Trypsin/EDTA solution (TE), sterile PBS (pH 7.2) (Invitrogen, UK) and appropriate serum 
supplemented culture media were warmed to 370C ready to use.  
• Culture media was aspirated from the flask to be split and the residual media rinsed away using 
sterile PBS. 
• 5ml of TE was added into each T75 flask and placed in incubator for 1 minute; the flask was 
taped gently and examined under the microscope for cell detachment. This was repeated until all 
cells were detached and in suspension. For the 6 multi-well hormone stimulation experiment 
(section 2.1f) only 1ml of TES was used to trypsinize cells. In all trypsinization, the cells were 
never incubated for more than 10 min to reduce cellular damage. 
• During the detachment, 5ml of culture media was added into 15 ml centrifuge tube and then the 
cell suspension was also transferred into the tube. The media helped to inactivate trypsin and 
prevent cell lysis. For the 6 multi-well hormone stimulation experiment (section 2.1f) only 1 ml 
of culture media was added into a 2 ml eppendorf tube before transferring the cell suspension. 
• The tube was centrifuged at 1300 rpm (≈ 100g), at 4oC  for 5 minutes. 
• The cell pellet was resuspended in desired volume of media for plating. In general, T25 flask 
was split 1:3 (pellet resuspended in 3ml of media) and T75 was split 1:6 (pellet resuspended in 
6ml of media). For the 6 multi-well hormone stimulation experiment (section 2.1f), the cells 
were re-suspended  in 1-3ml of PBS (depending on pellet size) and 100µl transferred to a 0.5ml 
tube for cell counting (see appendix B.3). The hormonally-treated cells were not re-seeded in 
any further experiment. Their remaining suspensions were discarded into Virkon disinfectant. 
• 1ml of cell suspension (for the cells being expanded) was added to clean sterile flask (T75 
flask), followed by 9ml of media, and then swirled gently to ensure adequate dispersion of cells. 
• The flasks were incubated at 37oC, with 5% CO2 supply. 
The protocols for thawing, feeding and splitting of prostate cell lines were used to expand the cell lines 
enough for the entire work, and many vials were stored for future use. The passage numbers for all the 
cell lines were recorded.  
 
B.4 Cell Counting using Improved Neubauer Chamber and Trypan blue reagent: 
 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
258 
Once cells were trypsinized, pellet was re-suspended in 1-4ml of PBS (depending on pellet size) and 100µl was 
transferred to a 0.5ml tube to assess viable cell yield. 100µl of Trypan blue (Sigma, UK) was added and the 
solution mixed together and left to stand for 1 min. The improved Neubauer haemocytometer was assembled as 
shown in figure B.1. The haemocytometer contained two identical grids one on the upper counting chamber and 
another on the lower counting chamber (Fig.B.1 and Fig.B.2). Each grid contained 9 squares, measuring 1mm2 
each. Four corner squares (out of the 9 squares) were designated quadrants A, B, C and D. Each quadrant had 16 
smaller squares. Cells were counted in these four quadrants except when cell number exceeded 200, in which 
case cells were counted in the central squares containing 25 smaller squares each  (Fig.B.2) in both grids or  cell 
suspension diluted further and counter on the 4 quadrants. A hand held tally counter was used in counting the 
cells (Figure B.3). 
 
Figure B.1 Assembly of a haemocytometer. A cover slip is moistened and placed on the   
Haemocytometer covering the 2 central channels. Cell suspension got into the grid lines by capillary action.   
The depth between cover slip and grid was 0.1mm. {Harrison & Rae, 2004} 
    
 
 
 Figure B.2 Grid lines on haemocytometer. The chamber contained 9 squares (1mm x 1mm each), the four 
corners squares A, B, C and D contained 16 smaller squares each. Regular counting was done on the four 
quadrants. 20µl of cell suspension (mixed with Trypan blue reagent) was dispensed underneath the cover slip 
until the whole chamber was filled without spilling over to the side troughs. 
 
 
 
Central 
Square 
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   Calculation of cell Count:  An average of cell count in the 
four quadrants was calculated and the number of cells in, for 
example, 2ml suspension was calculated as follows: 
Total number of cells = average cell count x 10,000* x 2 
(dilution factor) x 2 (suspension volume).* 1ml = 1cm3 
=1000mm3. 
   Figure B.3 Hand held tally counter.  
 
 
 
 
Cell viability, expressed in percentage, was obtained by counting dead or dying cells, which appear blue and 
viable cells, which remain clear. 
% of viable cells = total viable cells x 100 
                               Total cell number (viable cells+ dead cells) 
 
Note: Each quadrant had a volume of 0.1mm3 and that gives N number of cells per average quadrant. Therefore 
1ml of diluted cell suspension (1000mm3) would contain N x 104, that is per ml. But to account for dilution 
using Trypan blue reagent (1 in 2 dilution), the cell number per ml will be N x 104x2. For the entire cell yield in 
a suspension, the cell count per ml would be multiplied by the suspension volume.  
 
B.5 Summarized Protocol for Sulforhodamine B assay {Vichai & Kirtikara, 2006}. 
Cells in the log phase were harvested and seeded (105) per well in a 96-micro well tissue culture plate; 
appropriate volume of steroid hormone dilution (ranging from 10-4 to 102M final concentration) was also added. 
After 72-hrs of incubation at 37oC with 5% C02 supply, the cells were fixed in 10% trichloroacetic acid (TCA) at 
4oC for 1 hr. The cells were then washed four times with slow-running tap water and completely dried using a 
blow dryer. 100µl of 0.057% Sulforhodamine B (SRB) was added to each well and incubated at room 
temperature for 30min. The SRB stain was washed off four times and wells dried. 200 µl of 10mM Tris base 
solution (pH 10.5) was used to solubilise the protein- bound dye; the plate was placed on gyratory shaker for 
5min. Optical density (absorbance) was read photometrically at 510nm using the Varioskan Flash plate reader. 
% of control cell growth = Mean ODsample x 100 
                                              Mean OD negative control 
Negative control is the well without any steroid treatment. 
% growth inhibition = 100-% of control cell growth. 
IC10 and IC50 values were derived from curve- fitting using the Origins Lab software. 
For the determination of cell growth phase only using this method, steroid hormones were not used rather cell 
cultures in the micro well plate were harvested at days 1, 2, 3, 5, 7, 9, 11, and 13. The starting number of cells 
seeded was 103 per well.  
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This method was cheap, flexibly high throughput and very convenient to use (each test point was done in 6 
replicates). Prior to the testing, cell density was optimized by seeding varying cell densities (103, 104, 105 and 
106 per well) to assess OD values and linearity. 
 
B. 6 Steroid Hormone dilution 
Table B.1 Dilution of steroid hormones 
All steroids were purchased from Sigma UK. Absolute ethanol was used as a diluent. 
 
B.7 Slide flask method and Cytospin. 
i) Preparing cells for ICS and IF by slide flask 
Cells (105) were grown directly on slide flasks (Figure B.7) supplied by Fisher Scientific, UK. Cells were 
harvested after 5 days of incubation, washed in cold PBS thrice and snapped off the container according to 
manufacturer’s instructions; fixed by immersion in cold methanol for 10 min, left to dry at 4oC for 15 min and 
wrapped in foil; and stored at -20oC until required. 
 
 
 
Figure B.4: Tissue culture slide flasks. 
 
Hormone 
Purity % Molecular 
Weight 
Dissolution 
5α-Androstan-17β-
ol-3-one (DHT) 
97.5 290.40 Dissolve 0.297785g in 10 ml of absolute ethanol to get 
0.1M stock solution. 0.1ml of stock solution was added to 
9.9ml of absolute ethanol to get 10-3 M solution for further 
dilutions. 
Hydrocortisone 98 362.47  0.369867g was dissolved in 10ml of absolute ethanol to 
get 0.1 M stock solution. 0.1ml of stock solution was added 
to 9.9ml of absolute ethanol to get 10-3 M solution for 
further dilutions. 
Testosterone 98 288.40 Dissolve 0.294286g in 10ml of absolute ethanol to get 
0.1M stock solution. 0.1ml of stock solution was added to 
9.9ml of absolute ethanol to get 10-3 M solution  for further 
dilutions 
 17β-Estradiol 98 272.39 Dissolve 0.138974g in 10ml of absolute ethanol to get 
0.05M stock solution and further dilutions made to get 10-
3M solution. 
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ii)  Preparing cells for ICS and IF by cytospinning: 
     Cytospinning is a method for preparing a monolayer of cells on a glass slide by centrifugation. Cells 
can then be used for ICS and/ or IF. 
• Clean glass slides were first coated with poly-L-lysine by immersing the slides in 0.01% (v/v) 
poly-L-lysine solution (Sigma, UK) for 5 minutes and then allowed to air-dry over-night. 
Commercially coated slides (Sigma, UK) were also used. 
• Cell lines in culture plates were trypsinized (appendix B.3) 
• The cell pellets were resuspended in normal culture media (containing 10% FCS) for each cell 
line and counted using haemocytometer (appendix B.4)). 
• Appropriate dilutions were made to ensure that cell suspensions for cytospinning were in the 
order of 105 cells per ml. 
• The cyto-chamber was assembled according to manufacturer’s instructions (Boeco-28, 
Germany) by placing a coated slide in the chamber, covered with filter card and then the 
chamber well.  
• 100 µl of homogenous cell suspension (105 cells per ml) was dispensed into each chamber well 
and centrifuged at 3,000 rpm (≈800g) for 5 minutes. 
• Once completed, the chamber well and filter cards were carefully removed to avoid scratching 
the monolayer of cells. Excess solution was blotted. 
• The slides were allowed to air-dry completely before fixation in cold methanol for 10 minutes. 
The fixed slides were dried at 4oC for 30 minutes before use or wrapped in foil and stored at -
20oC until required. 
 
 
B.8   Protocols for ICS, IHC and IF. 
 
i) Protocol for ICS using in- house reagents and DAB chromogen 
• Slides were removed from the freezer (still wrapped in foil) and kept at room temperature 
for 10 minutes and then unwrapped. Cell sections were circled with diamond pencil (to 
form a well on slide for reagents). 
• Three drops of 0.03% (v/v) H2O2 in methanol were added onto the slide and incubated for 5 
min in a humid chamber at room temp. Three drops was ~ 150 µl. The slides were rinsed 3x 
in PBS with Tween 20, for 2 minutes each. 
• Three drops of 10% (v/v) normal rabbit serum in PBS with Tween 20 were added and slides 
incubated for 15 min in humid chamber. Excess serum was tapped off and slides wiped 
carefully around the edges.  
• Three drops of primary antibody were added to test slide, 3 drops of 1% (v/v) normal rabbit 
serum in PBS to control slide and all incubated in humid chamber at room temperature for 
1hr min.Slides were washed 3x in PBS with Tween 20 for 2 min each. 
• Three drops of diluted (1/200 dilution) secondary antibody (rabbit anti-mouse IgG-
conjugated with biotin) were added and slides incubated for 30 minutes in humid chamber 
at room temperature. Slides were washed 3x in PBS with Tween 20 for 3 min each. 
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• Three drops of AB complex (avid-biotin conjugated with peroxidase) (Dako, UK) were 
added and slides incubated for 30 min in humid chamber at room temperature. Slides were 
rinsed in PBS with Tween 20 twice, 3 min each. Excess buffer was tapped off and slides 
carefully wiped around the edges.
 
• Three drops of substrate chromogen (DAB) (appendix A.3) were added and slides incubated 
for 3 min in humid chamber. Slides were washed 3x in PBS with Tween 20 for 2 min each.
 
• Slides were stained in Mayer’s haematoxylin for 1 min and gently rinsed in slow-running 
tap water to avoid washing off specimens.
 
• One drop of Glycergel (Dako, UK), an aqueous mountant, was added and cover slip placed 
on top. 
Slides were examined microscopically at x10 and x40 magnifications using Carl Zeiss microscope with 
Axiom camera, and photomicrographs taken.  
 
ii) Protocol for ICS using Histostar kit (Dako, UK) 
• Two drops of reagent A (serum blocking reagent) were added to completely cover slide section 
and incubated in a humid chamber at room temperature for 10 min. Slides were drained or 
blotted but never rinsed. 
• Two drops of primary antibody was added and incubated in moist chamber for 45 min. Slides 
were rinsed three times in PBS for 2 min each time. 
• Two drops of reagent B (biotinylated second antibody) was added and incubated for 10 min. 
Slides were rinsed in PBS for 2 min, 3x. 
• Two drops of enzyme conjugate (reagent C) were added and incubated for 10 min. Slides were 
rinsed in PBS for 2 min, 3x. 
• Two drops of cold AEC single solution was added and incubated for 10 min, and slides were 
rinsed in distilled water. 
• Two drops of Mayer’s haematoxylin was added and incubated for 2 minutes and rinsed gently in 
running tap water. 
• A drop of glycergel was added and cover slip placed on top. 
• Slides were examined microscopically at x40 objective, and photomicrographs taken. 
 
iii) Protocol for IF staining 
• Two drops (100µl) of reagent A (serum blocking solution) was added enough to 
completely cover cells on each section, and incubated in a humid chamber at room 
temperature for 10 minutes. The solution was drained or blotted off (not rinsed). 
• Two drops of Primary antibody added to cover each section, and incubated for 45 
minutes in a humid chamber at room temperature. Rinsed with PBS for 2 minutes, 3 
times. 
• Two drops Alex fluor 555-conjugated secondary antibody were added to each section, 
and incubated for 15 minutes. Rinsed with PBS for 2 minutes, 3 times. 
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• Two drops of Sytox Green nuclear counterstain at 500nM in DMSO (or enough to 
completely cover cells) were added on each section and incubated for 10 minutes. 
• Gently rinsed, one drop of Dako fluorescent mounting medium was added and a cover 
slip placed on top. Slides were examined using Carl Zeiss LSM 510 Meta Confocal 
microscope according to the manufacturer’s instructions. 
B. 9 Concentration of culture supernatants: 2ml vivaspin (MW CO 20,000) (Vivascience, Germany) 
was used, according to the manufacturer’s instructions, to concentrate culture supernatants before 
performing ELISA. Briefly, samples were added into vivaspin columns and assembled according to 
manufacturer’s instructions. The columns were centrifuged at 10,000g for 10 min. The flow through 
discarded, the columns were reverse-centrifuged to obtained concentrated supernatants for PSA ELISA. 
 
B.10 ELISA protocol:  Total and free PSA (Cat No: 4222 and 4322 respectively) were measured using 
ELISA kits from Diagnostic Automation/Cortez Diagnostics, Inc USA according to the manufacturer’s 
instructions. Briefly, the test was a sandwich assay in which a rabbit anti-PSA was already coated on the 
surface of microwells in 96 well plate. Samples were added to appropriate wells followed by the addition 
of anti-PSA monoclonal antibody labelled with horseradish peroxidase as a tracer. Unbound antibody-
enzyme tracers were removed by washing. The peroxidase activity was measured (by the addition of a 
substrate chromogen (TMB)) colorimetrically (at 450nm using Varioskan Flash, Thermo Scientific, UK). 
Optical absorbance was proportional to concentration of PSA in serum/plasma. 
 
B.11 Protocol for western blotting:  The method of immunoblotting is described in details by Williams 
et al, 2003. Briefly, SDS-PAGE was done using the BioRad mini-protean electrophoresis system (Figure 
B.5) according to manufacturer’s instructions. Run time was 1 hr at 100 volts. Samples were prepared in 
the NUPAGE LDS sample loading buffer (Invitrogen, UK). Wet blotting (liquid transfer) was done using 
PVDF membranes for 1hr at 100volts. Membranes were blocked in 5% non fat dry milk in 1x TBS with 
0.1% (v/v) Tween 20, and incubated with primary antibody overnight at 4oC in gyratory shaker; washed 
in TBS with Tween 20 for 3x, 5min each. Membranes were incubated in secondary antibody (1: 2000 
dilution of HRP conjugated secondary antibody), washed 3x for 5 min each before chemiluminescent 
detection using ECL Plus system (GE healthcare, UK). 
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Figure B.5 Mini-protean electrophoresis from BioRad. 
 
 
B.12 Protocol for hormonal stimulation: 
Cells harvested in the log phase were counted and seeded into a 12-well tissue culture plate. Phenol-free 
media of appropriate type supplemented with 10% DCC-FCS were used. After 6 hours of incubation at 
37oC with 5% C02, steroid hormones were added into appropriate wells (IC10 and 1C50 values) and the 
cells incubated for 12-, 24-, 48- and 72 hrs before harvesting the cells for RNA extraction. 106 cells were 
seeded per well. For each hormone, there were two control set ups: culture media only (no treatment) and 
DMSO treated cells for all the time intervals. For each cell line, there were 48 samples (covering the four 
time intervals, the two steroid hormone concentrations, four different steroids and two treatment 
controls). 
 
B.13 RNA extraction:  
 
The RNeasy mini kit (Qiagen, UK) was used according to the manufacturer’ instructions. 350µl of GITC 
lysate of sample (cell pellet) was added to 350µl of 70% ethanol, and the mixture dispensed into the 
RNeasy spin column contained in a 2ml collection tube. The column was centrifuged at 8000g for 15 s 
and the flow through discarded. 650 µl of RW1 buffer was added to the RNeasy column and centrifuged 
at 8000g for 15 s. The flow through was also discarded. Then 500µl of RPE buffer was added to the spin 
column and centrifuged at 8000g for 15 s; the flow through discarded and the step also repeated but with 
2 min centrifugation. The flow through was again discarded, the spin column was placed on a new 2ml 
tube and centrifuged at 10,000g for 1 min. Finally the spin column was placed on a 1.5ml tube and 60 µl 
of RNase-free water added into the column and centrifuged for 1 min at 10,000g. 50µl of the elute was 
used for cDNA snythesis; 5 µl was used for RNA quality and quantity check. 
 
B.14 cDNA snythesis 
A batch of cDNA mix was first prepared as shown in Table B.2. Each tube of the cDNA mix served for 
10 samples. To each cDNA mix, kept on ice during set up, 12µl of RNasin (RNase inhibitor 40 u/µl) 
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(Promega, UK) and 24µl of M-MLV reverse transcriptase (200 u/µl) (Invitrogen, UK) were added and 
mixed by pipetting. 42 µl of the mixture was added into each RNA elute (50 µl), mixed by pipetting and 
incubated at 37oC for 2hr in dry thermal block. The tubes were then transferred to another dry thermal 
block at 65oC for 10min to inactivate the reverse transcriptase. The tubes were pulse-centrifuged, labelled 
and stored at -80oC until required. 
 
 
 
Table B.2 Preparation of cDNA mix 
Reagent Volume 
5X Buffer 5.06ml 
0.1M DTT 2.53ml 
25 mM  dNTP mix 506 µl 
Random primers (hexamer) 3µg/µl 50µl 
RNAse-free, DNAse-free water 3.354ml 
Total 11.5ml 
420µl aliquoted into 1ml sterile tubes and stored at -80oC. This would serve for 250 reactions. 5X 
buffer, DTT and dNTP (Promega, UK); hexamer and water (Invitrogen, UK). 
 
 
B. 15 RQ-PCR set up. 
 
For all RQ-PCR the 96-micro well PCR plates (Applied biosystems, UK) were used. Each set up required 
reagent a trough, a PCR plate, primer and probe mix, DNAse-free, RNase-free water, dedicated pipettes, 
microfilm, plate holder and  a biological hood. In some cases, reactions were run in duplex format (two 
targets measured simultaneously in each well), and in many as singleplex format. Where primers and 
probes were designed, optimal primer and probe concentrations were determined prior to sample testing. 
For predesigned assays (Applied Biosystems, UK) manufacturer’s recommendations were followed. Two 
platforms were used: ABI 7900HT sequence detection system was used for cell line studies; and the 
CFX96 Real PCR system was used for clinical samples. Results from both platforms were comparable. 
Total reaction volumes for the CFX96 system was 10µl while that of the ABI 7900HT was 25 µl. A 
typical reaction set up is shown in Figure B.3.  
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  Table B.3 - Reaction Mix for control genes. 
  Volume (µl) per 
25µl for ABL1  
Volume (µl) 
per 25µl for 
GUS 
Volume (µl) 
per 25µl for 
G6PD 
Forward primer 0.094 (300nM) 
  
0.75 (300nM) 0.094(300nM) 
Reverse primer 0.094  (300nM) 
  
0.75(300nM) 0.094(300nM) 
Probe 0.1     (100nM) 1.0  (100nM) 0.1 (100nM) 
Universal master mix 12.5 12.5 12.5 
Water (RNase-free, DNAse- free) 9.712 8.85 9.712 
cDNA 2.5 2.5 2.5 
 
For a predesigned assay on the CFX 96 system, a typical reaction would be Universal master mix = 5µl, primer 
and probe mix = 0.5 µl, water = 2.50 µl, cDNA= 2.0 µl. Where duplex format was used, for example, ABL1 and 
G6PD were run together with a FAM and TET dyes respectively, the TaqMan gene expression master mix was 
used in place of the Universal TaqMan master mix. Results of duplex did not differ from singleplex of each of 
the targets. Thermal profile was same for all reactions: 50oC for 2 minutes, initial denaturation at 95oC for 10 
minutes; cycle denaturation of 95oC for 15 seconds, annealing and extension at 60oC for 1 minute for 40 cycles. 
Data was acquired at all stages. Calibrators were done in triplicates, 6 points of triplicate each (18 points overall) 
were used in generating standard curves; samples were measured in duplicates. 
 
B.16 Protocol of KLK2 and TP53 plasmid cloning 
Plasmid calibrators for KLK2 and TP53 were prepared using TOPO 10 cloning kit from Invitrogen UK, purified 
with EZ Maxi kit from VH Bio Ltd UK. Briefly, for the TOPO 10 cloning kit, target transcripts were amplified 
from the prostate cell lines using standard PCR method and PCR master mix from ROVLAB, sold by VH Bio 
Ltd UK. The PCR product was electrophoresed on 2% agarose gel stained with SYBR Safe (Invitrogen UK) to 
check for the quality. 4µl of the fresh PCR product was used for cloning the target sequence into the TOPO 
vector (pCR2.1-TOPO). 6µl of the TOPO cloning reaction was dispensed into a vial of one Shot E.coli 
(chemically competent), to transform the E.coli through heat-shock for 30 s at 42 oC. 250 µl of SOC medium 
was added to the cells, and mixed by shaking at 37oC for 1 hour. 50 µl of the transformation was spread onto dry 
LB agar plates containing X-gal and 50µg/ml ampicillin and incubated overnight. About 5 white colonies where 
picked and emulsified in DNAse-, RNAse-free water and standard PCR performed to check for successful 
transformation. About 10 colonies were then emulsified in LB medium containing 50µg/ml ampicillin and 
incubated overnight at 37oC, from which plasmids were harvested using the EZ Maxi kit (VH Bio, UK). The OD 
of plasmid was checked on Eppendorf photometer, and copies of DNA calculated using the calculator in the 
website http://www.uri.edu/research/gsc/resources/cndna.html . Six serial dilutions of plasmids were made to 
give a dynamic range of 101 to 106 copies per 2µl in tRNA in TE buffer. The plasmid calibrators were used to 
generate standard curves for absolute quantification of target genes. The plasmid calibrators for ABL1 and 
G6PD endogenous genes were a kind gift from the laboratory of Prof. Letizia Foroni, Imperial College London.   
 
B.17 Red cell lysis: 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
267 
The preparation of the red cell lysis buffer (RCLB) is described in appendix A.2. Participants’ blood samples in 
K3EDTA were carefully emptied into labelled Falcon’s tubes (50ml) in a biological hood. 30ml of 1x RCLB was 
added to each tube, mixed by inversion and placed on ice for 10min. The tubes were centrifuged at 1800g for 
7min; and supernatants carefully decanted into Virkon containing waste bucket. The step was repeated with 
20ml of 1x RCLB, with the tubes vortexed to resuspend white cell pellets and placed on ice for 10min. The 
tubes were centrifuged at 1800g for 7min and supernatants carefully decanted. The cell pellets were then 
resuspended in 15ml of PBS (pH 7.2) by vortexing, and later centrifuged at 1800g for 7min. The supernatants 
were discarded and the tubes briefly drained on a clean blue towel. The white cells were then lysed in 
appropriate volumes of GITC. 
 
 
 
 
B.18 PCR of KLK2, TP53 and other targets for Sequencing 
Standard PCR was performed on all targets (cDNA or gDNA) for sequencing. All standard PCR used ROVLAB 
2 X PCR Master mixes (VH Bio, UK) which contained all reagents required for PCR except primers and DNA. 
Set up for all PCR is shown in Table B.4. 
 
 
Table B:4 Standard PCR set up  
Reagent For genomic DNA Complementary DNA 
2 x PCR Master mix 10 µl 10 
Forward primer 0.6µl (300nM) 0.6µl (300nM) 
Reverse primer 0.6µl (300nM) 0.6µl (300nM) 
Water 7.8 µl 6.8 µl 
Template 1 µl 2 µl 
Total reaction volume 20 µl 20 µl 
 
Primer concentration of 300nM was optimal for most standard PCR applications. 
The thermal profile for most applications (annealing temperature determined by Gradient PCR) is shown 
in Table B.5. 
Table B.5 Thermal profile for standard PCR. 
Step Time Temperature Cycles 
Initial 
denaturation 
2 min 94oC 1X 
Denaturation 1 min 94oC 
Annealing 30s 58 oC 
Extension 1 min 72 oC 
25 x 
Final extension 7 min 72 oC 1x 
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For annealing temperature (Ta), the gradient PCR showed that the range 55 to 60 oC was optimal for all 
the reactions. Figure B.6 shows PCR products at Ta = 58 for KLK2 of two different sizes from many 
samples. 
 
 
 
 
Figure B.6 KLK2 PCR products from a Ta of 58oC. Two different product sizes were run at same Ta, yielding 
distinct bands. 
 
To prepare for sequencing, 1 in 10 dilutions of the PCR products were made. A sequencing reaction was set up 
in a 96 well plate as follows 
DNA template             1µl 
Primer (F or R)            1µl 
Big Dye v 1.1             0.5µl 
Sequencing buffer        2µl 
Water   5.5µl 
Final volume     was 10µl 
 
The Big Dye and Sequencing buffer were purchased from Applied biosystems, UK. A larger reaction mix could 
be set up by scaling all other reagents appropriately except the DNA template. The plate was sealed with 
microfilm and pulse-centrifuged. Covered with a compression pad (to prevent evaporation), the PCR sequencing 
reaction was performed for 25 cycles using the thermal profile: 
96oC for 10s 
50 oC for 5s 
60 oC for 4 min 
The Sequencing PCR product was then purified using the Big Dye X terminator purification kit: 
To each well of PCR product, 45µl of SAM solution (Applied biosystems, UK) and 10 µl of Big Dye X 
terminator solution (Applied biosystems, UK) were added, the plate firmly sealed and mixed by vortex at 2000 
rpm for 15 min. The plate was centrifuged at 1000g for 2 min and run on the Genetic Analyzer 3130 (Applied 
Biosystems, UK) according to the manufacturer’s instructions using the protocol BDX_x36cm_POP7_SetE. 
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B.19 Agarose gel electrophoresis. 
 
All agarose gel electrophoreses were done using Tris Acetate EDTA TAE buffer (appendix A.2). 2g of agarose 
gel was dissolved in 100ml of 1x TAE, heated for 3 min in microwave with occasional mixing. 10µl of Syber 
Safe (Invitrogen, UK) was added to the 100ml of molten agarose gel. After cooling for a few minutes, the gel 
was poured onto gel plate with combs inserted and allowed to set.  BioRad horizontal electrophoresis system 
was used. 
10 µl of PCR product and 2 µl of loading dye (Promega, UK) were loaded to each well accordingly. 8 µl of 
DNA ladder (mainly 100bp ladder, Promega, UK) mixed with 2 µl of loading dye was added to the ladder lane. 
Electrophoresis was run at 100v for 45-60min. After electrophoresis, gels were viewed in Syngene Gene Genius 
bio-imaging system. 
 
B. 20 Protocol for SNP genotyping 
The protocol for SNP genotyping using ABI predesigned TaqMan genotyping assays for allelic discrimination 
was basically the same with standard RQ-PCR except for a pre-read and post read scanning. Using the protocol 
in Section B.15 of RQ-PCR the reaction for SNP genotyping was set up, and standard format of allelic 
discrimination assay on ABI 7900HT platform was chosen. The first step was to pre-read the plate for 
background fluorescence, and then a standard RQ-PCR run was done; followed by post-read scan using the same 
pre-read window.  The post read did the base calling and results were analyzed. The ABI predesigned  SNP 
assays came with CD-ROM to enable faster loading of the assay run protocol and identity into the system. 
 
 
B.21 Protocol for setting up Pyrosequencing assay 
The Pyrosequencing assay had 5 main steps. Prior to these steps, the primers were designed using the PSQ assay 
designer software (Biotage, Sweden). The pyrosequencing (PS) assay required 3 primers, one of which must be 
biotinylated. The assay design software chose the primer to be biotinylated. All the primers for PS assay were 
purchased from Sigma, UK, 
The first step was to perform a standard PCR using two of the primers, one of which was biotinylated. The 
reaction set up was in a 24-well plate as follows 
 
PCR  master mix (ROVLAB)           15µl 
F-primer (biotinylated)                      0.9 µl (300 nM) 
R-primer                                             0.9 µl (300 nM) 
Water                                                  11.2 µl 
Genomic DNA                                    2 µl 
              Final volume                         30 µl 
The standard PCR thermal profile described in B.18 was used to perform the PCR. 
The second step was to bind the PCR products (biotinylated) to Sepharose beads containing Streptavidin for 
separation. 
 
Binding buffer                                40 µl 
Water                                              28 µl 
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Sepharose beads                              2 µl 
PCR products           10 µl 
    Final volume     was                   80 µl 
The Sepharose beads were purchased from GE Healthcare, UK. All other reagents and materials were purchased 
from Qiagen, UK. The mixture was vortexed for 30min at 2000rpm. 
The third step was to anneal SNP primer (the third form of primer) to the biotin-streptavidin PCR 
product. 
 
 
Annealing buffer                                           24.25 µl 
10 µM SNP primer                                          0.75 µl 
             Final volume                                       25 µl 
 
The fourth step involved the addition of the biotinylated PCR product to the 25 µl annealing mixture. Using the 
workstation shown in Figure 4.18 and in accordance with the manufacturer’s instructions, the biotinylated DNA 
strand was washed in 70% ethanol, denatured in 0.2M NaOH and washed again in a Washing buffer, all using a 
vacuum pump. The biotinylated strand was then transferred to the annealing mixture in the Pyromark plate (24-
well plate) and kept on a heat dry block at 80oC for 2 min. Enzyme, substrate and nucleotides were mixed and 
dispensed into a cartridge according to pre-run calculations from the Pyromark 24 software (Qiagen, UK) 
 
The fifth step: the plate was run in the PyroMark-24 machine (Qiagen, UK) using a run schedule from the 
Pyromark 24 software. It took about 13 minutes to run a 24 well plate on the machine. Results were analyzed on 
the PyroMark 24 software, giving the pyrograms for samples and reference calibrators.   
    
 
B.22 Sodium Citrate buffer antigen retrieval method  
The preparation of Sodium citrate buffer was described in Section A.2. 
Tissue sections for antigen retrieval were already deparaffinised in 2 changes of xylene, 5 min each; hydrated in 
2 changes of absolute ethanol for 3 min each, 95% and 80% ethanol for 2 min each and rinsed in  distilled water. 
Slides were immersed in pre-heated water bath containing sodium citrate at boiling point of 100oC for 30min. 
The slides were then removed and allowed to cool for 20 min, and rinsed twice in 2 changes of PBS with Tween 
20 for 2 min each. Sections were then taken for IHC as described in Section B.8. 
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Appendix C: Raw Data and Additional Result Presentation 
 
 
C.1 Raw data for serum supplementation experiment 
 
% 
Serum 
level Cell line FCS    BGS   DCC-FCS   
    
Mean Cell 
count Std 
Mean Cell 
count Std 
Mean Cell 
count Std 
  PNT1A X10E5           
10   39.85 0.84 35.5 3.03 10.85 0.3 
7.5   18.15 0.63 16 2.27 5 0.23 
5   12.35 0.42 12 1.52 4.85 0.15 
2   2.65 0.19 9 0.61 1.15 0.06 
1   1 0.08 1.65 0.3 1 0.03 
 PC-3             
10   25.35 0.76 25.5 1.13 15.15 0.76 
7.5   18.5 0.12 21.15 0.53 13.35 0.17 
5   18.35 0.29 19.85 0.59 12.35 0.23 
2   17 0.32 12.65 0.36 9.65 0.06 
1   7.65 0.02 9 0.06 6.50 0.00 
  
MDAPCa 
2b             
10   30.28 0.96 30.00 0.20 22.40 0.17 
7.5   25.6 0.17 25.72 0.06 21.08 0.06 
5   24.8 0.10 13.20 0.35 18.80 0.52 
2   20.92 0.06 9.88 0.06 14.68 0.06 
1   8.66 0.03 7.87 0.02 7.98 0.04 
 
C.2 PNT1A cell yield in varying percents of different sera. 
Figure C.1 PNTIA cell yield in different sera.
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C.3 Raw data for growth curves 
 
    
PNT1A 
(X10e4) 
 Treatment Group 
   
  No drug    Ethanol   DHT   Oestradiol 
Days of 
Incubation Mean std Mean std Mean std Mean std 
Di 8.00 0.00 8.00 0.00 8.00 0.00 8.00 0.00 
D0 1.20 0.69 1.20 0.69 1.20 0.69 1.20 0.69 
D1 8.67 1.80 2.27 0.23 0.53 0.23 0.47 0.12 
D2 8.80 0.40 3.07 0.83 1.07 0.23 2.00 0.40 
D3 6.93 1.67 5.73 1.01 0.80 0.40 0.93 0.46 
D5 87.00 2.65 62.33 8.08 43.00 7.00 28.00 2.00 
D7 52.40 7.99 27.60 3.17 27.40 3.62 54.73 3.80 
D9 45.73 6.47 40.60 0.00 53.20 13.36 40.60 2.80 
D11 27.20 5.00 20.80 3.46 28.80 8.40 49.93 4.87 
D13 18.00 1.20 12.80 1.83 26.60 4.39 27.47 2.14 
    
PC-3 
(X10e4)             
  No drug   Ethanol   DHT   Oestradiol 
  Mean std Mean std Mean std Mean std 
Di 4.00 0.00 4.00 0.00 4.00 0.00 4.00 0.00 
D0 3.33 0.58 2.67 0.58 2.33 0.58 2.67 0.58 
D1 7.33 1.15 3.33 1.15 6.67 1.15 4.67 1.15 
D2 21.33 3.06 9.67 0.58 14.00 4.58 19.33 1.53 
D3 57.33 8.33 46.67 4.62 56.00 8.00 61.33 8.33 
D5 122.67 8.33 56.00 4.00 144.00 21.17 82.67 6.11 
D7 166.67 34.02 128.00 20.78 108.00 14.42 133.33 12.22 
D9 188.00 17.44 148.00 17.44 180.00 17.44 210.67 12.22 
D11 154.67 11.55 100.00 14.42 136.00 18.33 54.67 8.33 
D13 134.54 7.68 96.88 5.21 132.54 13.23 53.44 4.32 
    
MDAPCA 
2b (x10e4)             
  No drug   Ethanol   DHT   Oestradiol 
  Mean std Mean std Mean std Mean std 
Di 2.00 0.00 2.00 0.00 2.00 0.00 2.00 0.00 
D0 0.77 0.06 0.83 0.06 0.87 0.06 0.63 0.06 
D1 6.67 1.15 2.67 1.15 4.00 0.00 5.33 1.15 
D2 6.33 0.58 3.67 1.15 6.67 1.15 2.00 0.00 
D3 38.67 8.33 26.67 6.11 14.67 4.62 21.33 4.62 
D5 44.00 6.93 34.67 4.62 53.33 11.55 26.67 8.33 
D7 50.67 8.33 70.67 14.05 74.67 16.17 40.00 4.00 
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D9 81.33 8.33 101.33 24.44 66.67 16.65 58.67 14.05 
D11 58.67 11.55 98.67 12.86 56.00 6.93 64.00 14.42 
D13 54.23 6.42 96.54 10.23 55.32 5.61 54.24 10.56 
 
C.4 Raw data for change in population doubling. 
 
Change in 
Population  
Doubli
ng 
(∆PD)e
xpt                 
Drug 
PC-3  
count AE 
PC-3 
count   
MDA 
Pca 2b 
count AE 
MD
A 
count     
  
(16-
hrs)x10 
exp 4 
For 
PC-
3  
(120 hrs 
)x10 exp 
4 
PC-
3 ∆ 
PD 
 (16-
hrs)x10 
exp 4 
MDA 
Pca 2b 
(120 
hrs) 
x 10 
exp4 
MD
A 
Pca 
2b ∆ 
PD std 
Ethanol 3 0.75 14.3 2.25 1.4 0.35 20 3.84 0.08 
Dihydrotest
osterone 2.5 0.95 33 2.94 1.4 0.35 33 4.56 0.11 
Testosterone 3.8 0.95 29.3 2.38 1.4 0.35 30 4.42 0.06 
Estradiol 3.8 0.95 7.3 0.94 1 0.25 10 3.32 0.04 
Progesteron
e 2.6 0.65 20.3 2.97 1.3 0.33 30 4.53 0.12 
Aldosterone 3.6 0.9 25.3 2.81 1.3 0.33 27 4.38 0.14 
No drug 3.7 0.93 25 2.77 1.1 0.28 22 4.32 0.07 
Hydrocorti
sone 2.5 
0.6
3 4.3 
0.7
8 0.8 0.2 8 3.32 0.06 
seeding 
density 
4x10e
xp4 
                
Volume of 
drug 
25 
microli
tre                 
Molar 
conc. 
 10 
exp 4                 
Micro-well 
volume 
3.155
ml   3.217ml             
Suspension 
Volume 0.5ml   1.0ml             
          
 
C.5 Raw data for doubling time 
Cell  Yield & Doubling  
Time 
(DT) Stimulation expt. Result   
  1 2 3   
Sample Mean DT DT(hrs) DT(hrs) DT(hrs) mean DT (hrs) std 
PC-3 Negative 34.32 27.96 38.4 36.6 34.32 5.580967658 
PC-3 Alcohol 28.22 21.17 37.1 26.4 28.22333333 8.120014368 
PC-3 Oestradiol 71.98 64.55 72.8 78.6 71.98333333 7.060512257 
PC-3 Testosterone 30.68 16.84 32.8 42.4 30.68 12.91120444 
PC-3 Dihydrotestosterone 26.82 26.67 29 24.8 26.82333333 2.104194224 
       
MDA Pca 2b Negative 25.05 27.96 24.8 22.4 25.05333333 2.788643637 
MDA PCa 2b Alcohol 27.89 25.49 27.6 30.6 27.89666667 2.567884992 
MDA Pca 2b Oestradiol 32.02 26.67 30.6 38.8 32.02333333 6.188992918 
MDA Pca 2b Testosterone 23.47 26.92 23.8 19.7 23.47333333 3.621067982 
MDA Pca 2b DHT. 25.3 27.69 24.6 23.6 25.29666667 2.132142897 
1st expt. 
Cell 
count 
x10exp5 
10.3 
13.6 
19.8 
17.1 
10.8 
10.3 
11.3 
10.8 
10.7 
10.4 
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DT PNTIA DT (in hours)  std 
PNTIA-Ethanol 47.21333333 6.976427 
PNTIA-No Drug 35.60666667 4.1236068 
PNTIA-DHT 63.76333333 8.3751557 
PNTIA-Testosterone 52.63666667 1.4897091 
PNTIA-Oestradiol 111.2233333 5.8736388 
PNTIA-Progesterone 45.91333333 9.0712807 
PNTIA-Aldosterone 40.62 4.2514468 
PNTIA-Hydrocortisone 41.18 3.5125347 
 
 
C.6 Raw data for % control growth of hormones on PNTIA cells 
  
Cell density 
optimization 
assay for 
MTT Optimization assay fo    
PNTIA-72HR         
Cells/ml  Optical Density    Av.OD STD 
Blank 0.193 0.331 0.102 0.109 0.085 0.116 0.156 0.093552 
1000 0.833 0.665 0.779 0.703 0.893 1.019 0.815333 0.129895 
5000 0.309 0.382 0.252 0.596 0.372 0.626 0.422833 0.153399 
10000 0.532 0.368 0.485 0.409 0.56 0.706 0.51 0.120325 
50000 0.264 0.589 0.301 0.382 0.443 0.243 0.370333 0.130812 
100,000 0.278 0.336 0.284 0.444 0.246 0.259 0.307833 0.073486 
500,000 0.42 0.31 0.401 0.241 0.348 0.381 0.350167 0.066252 
1,000,000 0.436 0.271 0.414 0.574 0.39 0.366 0.4085 0.099229 
         
MDA-72HR         
Cells/ml  Optical Density    Av.OD STD 
Blank 0.057 0.05 0.049 0.05 0.053 0.052 0.051833 0.002927 
1000 0.567 0.563 0.098 0.316 0.508 0.405 0.4095 0.181033 
5000 0.366 0.51 0.606 0.478 0.47 0.628 0.509667 0.096436 
10000 0.45 0.602 0.572 0.516 0.674 0.604 0.569667 0.077866 
50000 0.531 0.507 0.485 0.568 0.53 0.546 0.527833 0.029075 
100,000 0.372 0.579 0.558 0.545 0.566 0.528 0.524667 0.076816 
500,000 0.288 0.414 0.514 0.481 0.601 0.629 0.487833 0.125579 
1,000,000 0.178 0.297 0.728 0.576 0.445 0.483 0.451167 0.195785 
 
  
SRB-PNTIA-
Estradiol            
Drug 
Con   OD             
µm 1 2 3 4 5 6 7 8 9 Av OD Std OD 
%CCG-
mean %gin 
% cells 
killed 
100 
0.28
5 
0.25
4 
0.23
8 
0.24
6 
0.29
8 
0.31
4 
0.25
6 
0.26
4 
0.27
5 0.27 
0.0251
45 
10.79184
616 
89.208
15 
89.204
32  
10 
0.55
9 
0.66
6 
0.59
2 
0.57
2 
0.53
9 
0.67
6 
0.56
8 
0.62
3 
0.58
2 
0.5974
44 
0.0476
97 
23.87867
484 
76.121
33 
76.111
78  
1 1.07 
1.03
1 
0.96
7 
1.05
5 
1.03
8 
1.05
3 
1.15
3 
1.03
2 
1.12
2 
1.0578
89 
0.0540
66 
42.28173
017 
57.718
27 
57.701
36  
0.1 
1.17
7 
1.15
6 
1.12
5 
0.98
6 
1.01
2 
1.12
3 
1.03
5 
0.98
8 1.12 
1.0802
22 
0.0746
72 
43.17434
941 
56.825
65 
56.808
39  
0.01 1.19 1.25 1.11 
1.04
2 
1.03
4 
1.12
4 1.21 
1.12
3 
1.28
2 
1.1516
67 
0.0871
23 
46.02984
279 
53.970
16 
53.951
75  
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0.001 
1.40
4 
1.86
7 
1.59
3 
1.51
7 1.74 
1.64
8 
1.53
9 
1.72
5 1.76 
1.6436
67 
0.1441
93 
65.69411
138 
34.305
89 
34.279
62  
0.0001 
1.43
9 
1.99
6 
1.92
8 
1.83
6 
1.70
9 
1.85
7 
2.07
2 
1.93
8 
1.36
7 
1.7935
56 
0.2444
61 
71.68487
432 
28.315
13 
28.286
46  
0.00001 
1.71
8 
1.64
8 
1.67
9 
1.87
5 
1.54
4 
1.42
8 
1.48
8 
1.48
5 
1.10
5 
1.5522
22 
0.2182
5 
62.03925
748 
37.960
74 
37.935
94  
0.00000
1 
1.33
9 1.36 
1.12
8 
1.22
8 
1.17
2 1.37 1.39 
1.31
4 
1.37
1 
1.2968
89 
0.0964
51 
51.83408
828 
48.165
91 
48.145
19  
0.00000
01 
0.68
1 
0.66
3 
0.86
6 
0.87
9 
0.71
5 
0.70
3 
0.66
8 
0.67
2 
0.87
9 
0.7473
33 
0.0969
83 
29.86943
778 
70.130
56 
70.118
62  
0 
2.18
3 
2.09
7 
2.43
3 
2.60
1 
2.69
3 
2.60
3 
2.66
3 
2.63
7 
2.60
7 
2.5018
89 
0.2185
75 
99.99555
911 
0.0044
41 
-
0.0355
4  
 
   SRB-PNTIA-DHT         
Notes 100 10 1 0.1 0.01 0.001 0.0001 
0.0000
1 
0.0000
01 1E-07 
Negat
ive 
contr
ol  
 0.09 0.133 0.289 0.301 0.314 0.324 0.324 0.347 0.324 0.315 0.328  
 0.094 0.147 0.29 0.303 0.327 0.33 0.329 0.354 0.33 0.332 0.332  
 0.1 0.149 0.293 0.308 0.329 0.331 0.337 0.354 0.342 0.337 0.337  
 0.101 0.151 0.311 0.311 0.338 0.335 0.339 0.355 0.345 0.342 0.343  
 0.108 0.16 0.313 0.319 0.341 0.343 0.342 0.355 0.346 0.344 0.344  
 0.112 0.165 0.314 0.322 0.341 0.349 0.345 0.328 0.347 0.347 0.357  
 0.116 0.176 0.319 0.332 0.343 0.35 0.347 0.327 0.35 0.359 0.364  
 0.133 0.185 0.319 0.338 0.344 0.354 0.354 0.345 0.356 0.362 0.371  
 0.141 0.185 0.325 0.338 0.346 0.364 0.365 0.346 0.36 0.363 0.407  
Average 
OD 
0.11055
6 0.161222 0.308111 
0.31911
1 
0.33588
9 
0.34222
2 
0.34244
4 
0.34566
7 
0.34444
4 
0.34455
6 
0.353
667  
OD std 
0.01720
5 0.018089 0.013743 
0.01442
6 
0.01049
3 
0.01313
2 
0.01241
1 
0.01104
5 
0.01144
7 
0.01562
9 
0.024
688  
%CCG 
mean 
31.25
979 
45.585
88 
87.1189
9 
90.22
926 
94.97
321 
96.76
397 
96.82
68 
97.73
789 
97.39
231 
97.42
372 
99.9
999
1  
%Growth 
inhibition 
68.7402
1 54.41412 12.88101 
9.77074
2 
5.0267
94 
3.2360
32 
3.1731
98 
2.2621
09 
2.6076
95 
2.5762
78 
9.43E-
05  
Drug con %CGG %GI  IC10 1C50        
100 31.26 68.74  0.85μM 8.65μM  2      
10 45.59 54.414     1      
1 87.12 12.88     0      
0.1 90.23 9.77     -1      
0.01 94.97 5.027     -2      
0.001 96.76 3.24     -3      
0.0001 96.82 3.17     -4      
0.00001 97.74 2.26     -5      
0.000001 97.39 2.61     -6      
0.0000001 97.42 2.58     -7      
C.7 Additional ICS slides 
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C.9 Raw data on PSA ELISA  
 
 
 
 
 
 
 
 
 
Standard Curve for total PSA         
Conc ng/ml OD1 OD1 Av OD Conc ng/ml Av OD      
0 0.049 0.047 0.048 0 0.048      
2 0.182 0.177 0.1795 2 0.1795      
4 0.231 0.257 0.244 4 0.244      
15 0.718 0.8 0.759 15 0.759      
50 1.696 1.872 1.784 50 1.784      
100 3.039 3.138 3.0885 100 3.0885      
           
  PNTIA Cell line ON Cellular lysate      
 DHTIC10  Av OD Control1  Av OD Control2   Av OD DHT IC50 
24hrs 0.047 0.079 0.063 0.048 0.06 0.054 0.054 0.054 0.054 
48hrs 0.048 0.046 0.047 0.053 0.046 0.0495 0.047 0.045 0.046 
72hrs 0.051 0.054 0.0525 0.05 0.039 0.0445 0.046 0.05 0.048 
  
Summary 
of DHT-
PNTIA 
stimulation     
PSA level in PNTIA treated 
with DHT (Lysate) 
  
 DHT IC10 DHT IC50 C1 C2   DHT 10(ng/ml) 
DHT 50 
(ng/ml) 
C1 
(ng/ml) C2 (ng/ml)
24hrs 0.063 0.0505 0.048 0.054  24hrs 0.692307 0.5549445 0.527472 
48hrs 0.047 0.0475 0.053 0.047  48hrs 0.516483 0.5219775 0.582417 
72hrs 0.0525 0.0525 0.05 0.046  72hrs 0.5769225 0.5769225 0.54945 
           
    PNTIA PSA secretion      
 DHTIC10  Av OD Control1  Av OD Control2   Av OD DHT IC50 
24hrs 0.047 0.04 0.0435 0.046 0.051 0.0485 0.047 0.051 0.049 
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hydroc
ortison
e               
 
Tim
e 
C1 
OD   C2 OD   
H 
IC10   
H 
0.5I
C10    
 
24
hrs 0.064 0.071 0.0675 0.065 
0.07
4 
0.06
95 
0.06
1 
0.06
2 
0.0
615 
0.0
73 
0.
06
4 
0.0
68
5  
 
48
hrs 0.079 0.062 0.0705 0.067 
0.06
5 
0.06
6 
0.06
4 
0.05
6 
0.0
6 
0.0
74 
0.
06
9 
0.0
71
5  
 
72
hrs 0.08 0.079 0.0795 0.064 
0.05
4 
0.05
9 
0.05
8 
0.06
3 
0.0
605 
0.0
65 
0.
06
4 
0.0
64
5  
    
summary of 
PSA 
secretion 
(ng/ml)           
 
Ti
me 
C1 
(ng/
ml) C2 (ng/ml) HIC10 
H0.5I
C10          
 
24
hrs 
0.741
758 0.763736 0.675824 
0.752
7465          
 
48
hrs 
0.774
725 0.725274 0.65934 
0.785
7135          
 
72
hrs 
0.873
626 0.648351 0.664835 
0.708
7905          
               
Testost
erone 
Tim
e 
C1 
OD   C2 OD   T10   
T0.
5    
 
24
hrs 0.064 0.071 0.0675 0.065 
0.07
4 
0.06
95 
0.07
328 
0.06
2 
0.0
676
4 
0.0
73 
0.
06
4 
0.0
68
5  
 
48
hrs 0.079 0.062 0.0705 0.067 
0.06
5 
0.06
6 0.08 
0.06
5 
0.0
725 
0.1
66 
0.
08
1 
0.1
23
5  
 
72
hrs 0.08 0.079 0.0795 0.064 
0.05
4 
0.05
9 
0.08
1 0.09 
0.0
855 
0.1
3 
0.
20
7 
0.1
68
5  
  
Summary of PSA secretion 
by PNTIA line treated with 
Testosterone            
 
Ti
me 
C1 
(ng/
ml) C2 (ng/ml) T10 (ng/ml) 
T0.5(
ng/ml
)          
 
24
hrs 
0.741
758 0.763736 0.743254 
0.752
7465          
 
48
hrs 
0.774
725 0.725274 0.796703 
1.357
1415          
 
72
hrs 
0.873
626 0.648351 0.93956 
1.851
6465          
   
PNTIA-free PSA 
(OD reading)            
Free 
PSA 
Tim
e C1OD C2OD E10 E0.5 H10 H0.5 T10 T0.5      
 
24
hrs 0.042 0.038 0.044 0.043 
0.04
1 
0.04
5 
0.04
6 
0.04
5      
 
48
hrs 0.042 0.039 0.043 0.044 
0.03
9 
0.04
8 
0.06
8 
0.06
4      
 
72
hrs 0.042 0.074 0.112 0.044 0.38 
0.03
8 
0.07
6 
0.07
8      
   
Free-PSA ng/ml 
for PNTIA line            
 
Tim
e C1 C2 E10 E0.5 H10 H0.5 T10 T0.5      
 
24
hrs 
0.020
916 0.018924 0.021912 
0.021
414 
0.02
041
8 
0.02
241 
0.02
290
8 
0.02
241      
 
48
hrs 
0.020
916 0.019422 0.021414 
0.021
912 
0.01
942
2 
0.02
390
4 
0.03
386
4 
0.03
187
2      
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72
hrs 
0.020
916 0.036852 0.055776 
0.021
912 
0.18
924 
0.01
892
4 
0.03
784
8 
0.03
884
4      
               
 
C.10 Raw data on Gene expression studies. 
ABL-PNTIA GUS-PNTIA G6PD-PNTIA ABL-MDAPCA GUS-MDAPCA G6PD -MDAPCA ABL-PC-3 GUS-PC-3 G6PD
2.71E+04 2.63E+05 1.63E+05 3.81E+03 3.71E+03 1.93E+04 5.80E+04 1.13E+04 
2.49E+04 2.36E+04 9.24E+04 2.95E+04 4.75E+04 9.64E+04 9.65E+02 7.09E+02 
2.20E+05 3.44E+04 6.14E+05 7.32E+04 2.61E+04 2.77E+05 1.30E+05 7.48E+03 
5.67E+04 1.87E+04 1.42E+05 1.41E+04 1.69E+04 9.86E+04 1.65E+04 6.72E+03 
2.67E+05 3.63E+05 7.15E+05 4.46E+04 7.94E+03 1.36E+05 1.82E+05 2.09E+04 
2.82E+04 6.96E+04 1.14E+05 1.79E+04 2.34E+04 9.16E+04 6.38E+04 4.57E+04 
1.85E+04 1.49E+04 7.24E+04 4.96E+04 2.53E+04 5.46E+04 5.17E+04 4.17E+03 
2.93E+04 1.42E+04 4.30E+04 1.94E+04 1.87E+04 3.30E+04 6.01E+04 1.66E+04 
1.02E+05 1.97E+04 1.66E+05 2.61E+04 4.98E+03 8.50E+04 4.68E+04 2.25E+04 
9.06E+03 1.50E+04 9.35E+03 1.08E+04 6.89E+03 4.89E+04 9.76E+03 1.80E+04 
2.61E+05 2.19E+05 5.29E+05 2.34E+04 4.18E+03 7.11E+04 4.49E+04 2.46E+04 
6.26E+02 2.00E+02 1.58E+03 5.02E+03 2.45E+03 2.33E+04 2.10E+04 1.52E+04 
7.47E+02 2.80E+02 1.29E+03 2.03E+04 2.04E+04 9.56E+03 1.94E+04 6.62E+03 
9.58E+03 4.04E+02 9.18E+03 3.12E+04 3.47E+04 3.05E+04 3.17E+04 2.56E+04 
7.38E+04 1.18E+04 1.07E+05 1.81E+04 1.25E+04 6.42E+04 5.01E+01 3.49E+01 
1.09E+02 1.19E+01 1.70E+02 8.78E+00 2.34E+01 4.35E+01 1.09E+00 9.37E-01 
8.34E+03 4.12E+02 1.12E+04 2.03E+04 1.31E+04 4.54E+04 3.17E+01 4.07E+01 
9.74E+01 1.19E+01 2.27E+02 3.50E+01 2.21E+01 7.19E+01 1.23E+04 4.28E+03 
9.58E+01 1.25E+02 1.17E+02 1.73E+03 7.15E+02 6.66E+03 1.32E+03 1.03E+03 
3.75E+04 6.83E+04 1.16E+05 5.35E+01 2.24E+01 1.75E+02 4.28E+02 3.29E+02 
6.66E+04 7.36E+04 8.60E+04 4.98E+03 3.82E+03 1.51E+04 2.23E+04 1.69E+04 
9.01E+01 6.85E+01 1.61E+02 3.43E+03 3.03E+03 1.34E+04 6.49E+03 5.34E+03 
4.11E+05 3.52E+05 9.17E+05 5.17E+03 1.96E+03 3.13E+04 9.21E+04 3.25E+04 
6.12E+04 1.46E+05 2.00E+05 2.23E+04 1.17E+04 5.03E+04 7.64E+04 3.06E+04 
1.49E+00 1.44E+00 9.56E+00 1.38E+03 7.35E+02 5.49E+03 2.44E+01 6.37E+00 
5.47E+02 3.99E+02 3.99E+03 2.26E+03 1.18E+03 5.89E+03 8.36E+01 3.41E+01 
3.41E+04 5.56E+04 5.89E+04 8.90E+03 8.62E+03 3.10E+04 1.37E+03 9.85E+02 
2.03E+00 5.82E+00 1.18E+01 2.45E+04 2.27E+04 5.60E+04 2.44E+01 8.13E+00 
1.91E+05 2.22E+05 3.15E+05 4.99E+04 2.08E+04 9.54E+04 1.48E+05 3.12E+04 
2.81E+04 7.79E+04 8.00E+04 2.80E+04 3.14E+04 2.80E+04 4.94E+04 2.35E+04 
1.00E+00 1.00E+00 1.00E+00 3.18E+01 1.65E+01 2.12E+02 6.80E+00 6.07E+00 
1.64E+01 1.12E+01 1.34E+02 4.97E+01 2.81E+01 2.22E+02 1.30E+01 1.17E+01 
9.79E+01 1.76E+02 2.57E+02 2.66E+03 3.04E+03 5.25E+03 4.34E+01 9.35E+01 
1.40E+03 1.16E+03 2.47E+03 3.68E+02 2.13E+02 1.37E+03 1.18E+01 1.52E+01 
2.14E+05 2.20E+05 3.69E+05 3.76E+04 6.70E+03 4.80E+04 3.87E+04 1.75E+04 
6.21E+03 2.38E+04 1.01E+04 6.61E+04 2.97E+04 1.51E+05 6.12E+04 2.03E+04 
7.28E+03 4.54E+04 1.61E+04 4.80E+03 1.13E+04 1.33E+04 6.87E+04 4.22E+04 
3.95E+04 1.77E+05 1.10E+05 4.72E+03 2.27E+04 2.44E+04 6.51E+04 3.22E+04 
2.31E+04 6.58E+04 7.75E+04 3.28E+04 1.96E+04 1.40E+05 6.16E+04 2.94E+04 
2.53E+04 6.35E+04 4.91E+04 7.38E+02 1.81E+03 8.04E+03 1.56E+04 1.79E+04 
1.73E+05 1.83E+05 4.88E+05 2.87E+04 3.79E+04 1.36E+05 4.70E+04 2.60E+04 
1.41E+04 7.79E+04 4.72E+04 2.22E+04 2.15E+04 6.51E+04 3.25E+04 2.68E+04 
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5.44E+00 1.22E+00 1.00E+00 5.82E+03 1.06E+04 2.91E+04 2.32E+03 1.82E+03 
2.09E+03 1.77E+03 7.42E+03 1.03E+04 1.51E+04 4.36E+04 7.56E+01 7.85E+01 
1.21E+04 2.32E+04 2.57E+04 2.53E+03 1.63E+03 1.31E+04 1.45E+04 1.31E+04 
1.00E+00 1.52E+00 2.05E+01 1.21E+04 2.16E+04 4.39E+04 3.11E+03 2.99E+03 
1.35E+05 2.44E+05 3.38E+05 7.57E+03 5.34E+03 3.47E+04 3.87E+04 3.95E+04 
4.76E+04 3.22E+05 6.97E+04 7.32E+03 2.37E+04 7.57E+04 2.45E+04 5.68E+04 
2.08E+04 2.15E+04 4.82E+04 1.06E+04 9.61E+03 3.22E+04 2.02E+04 1.22E+04 
5.56E+04 7.32E+04 1.29E+05 1.68E+04 1.27E+04 4.91E+04 3.38E+04 1.46E+04 
 
 
 
ABL-
PNTIA GUS-PNTIA 
G6PD-
PNTIA 
ABL-
MDAPCA 
GUS-
MDAPCA 
G6PD -
MDAPCA ABL-PC-3 
GUS-PC-
3 
G6PD-
PC-3 
4.432969 5.419955748 5.21143725 3.580925 3.569374 4.2857642 4.763428 4.053078 4.972811 
4.396199 4.372912003 4.96561726 4.469822 4.676694 4.9842691 2.984527 2.850646 2.500023 
5.342423 4.536558443 5.78786359 4.864511 4.416641 5.4430246 5.113943 3.873902 5.548174 
4.753583 4.271841607 5.15212689 4.149219 4.227887 4.9937043 4.217484 3.827369 5.040215 
5.426511 5.559906625 5.85420034 4.649335 3.899821 5.1348763 5.260071 4.320146 5.761695 
4.450249 4.84260924 5.05812001 4.252853 4.369216 4.9617467 4.804821 4.659916 5.159488 
4.267172 4.173186268 4.85994577 4.695482 4.403121 4.7375598 4.713491 3.620136 4.756956 
4.466868 4.152288344 4.63344704 4.287802 4.271842 4.5183182 4.778874 4.220108 4.831513 
5.0086 4.294466226 5.21915977 4.416641 3.697229 4.9291773 4.670246 4.352183 5.441913 
3.957128 4.176091259 3.97075982 4.033424 3.838219 4.689249 3.98945 4.255273 4.904573 
5.416641 5.340444115 5.72344135 4.369216 3.621176 4.8517923 4.652246 4.390935 5.217684 
2.796574 2.301029996 3.19957144 3.700704 3.389166 4.3675222 4.322219 4.181844 4.587737 
2.873321 2.447158031 3.10960969 4.307496 4.30963 3.9806693 4.287802 3.820858 4.42005 
3.981366 2.606381365 3.96287367 4.494155 4.540329 4.4843449 4.501059 4.40824 4.592579 
4.868056 4.071882007 5.03006699 4.257679 4.09691 4.8075747 1.699838 1.542825 2.26043 
2.037426 1.075546961 2.23048136 0.943495 1.369216 1.6383556 0.037426 -0.02826 0.940995 
3.921166 2.614897216 4.05078857 4.307496 4.117271 4.6568852 1.501059 1.609594 2.05448 
1.988559 1.075546961 2.35614264 1.544068 1.344392 1.8568344 4.089905 3.631444 4.092865 
1.981366 2.096910013 2.06890345 3.238046 2.854306 3.8234093 3.120574 3.012837 3.851754 
4.574031 4.834420704 5.06270838 1.728354 1.350248 2.2421196 2.631444 2.517196 3.345095 
4.823474 4.866877814 4.93431472 3.697229 3.582063 4.1795187 4.348305 4.227887 4.977683 
1.954725 1.835690571 2.20591184 3.535294 3.481443 4.1285477 3.812245 3.727541 4.593562 
5.613842 5.546542663 5.96233417 3.713491 3.292256 4.4960508 4.96426 4.511883 5.756595 
4.786751 5.164352856 5.30171204 4.348305 4.068186 4.7017736 4.883093 4.485721 5.077894 
0.173186 0.158362492 0.98055928 3.139879 2.866287 3.7398372 1.38739 0.804139 1.868197 
2.737987 2.600972896 3.6006937 3.354108 3.071882 3.7698588 1.922206 1.532754 2.382874 
4.532754 4.745074792 4.7701049 3.94939 3.935507 4.491375 3.136721 2.993436 3.504751 
0.307496 0.764922985 1.07268284 4.389166 4.356026 4.748137 1.38739 0.910091 1.800727 
5.281033 5.346352974 5.49895333 4.698101 4.318063 4.9795828 5.170262 4.494155 5.654916 
4.448706 4.891537458 4.90287306 4.447158 4.49693 4.4474683 4.693727 4.371068 5.369835 
0 0 0 1.502427 1.217484 2.3271217 0.832509 0.783189 1.891013 
1.214844 1.049218023 2.12863897 1.696356 1.448706 2.34674 1.113943 1.068186 2.104553 
1.990783 2.245512668 2.40945412 3.424882 3.482874 3.7197714 1.63749 1.970812 2.231508 
3.146128 3.064457989 3.39283302 2.565848 2.32838 3.13767 1.071882 1.181844 1.878011 
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5.330414 5.342422681 5.5665169 4.575188 3.826075 4.6815062 4.587711 4.243038 5.225566 
3.793092 4.376576957 4.00461341 4.820201 4.472756 5.1786385 4.786751 4.307496 5.555235 
3.862131 4.657055853 4.20620917 3.681241 4.053078 4.1249905 4.836957 4.625312 5.074539 
4.596597 5.247973266 5.04181051 3.673942 4.356026 4.3872995 4.813581 4.507856 4.942882 
4.363612 4.818225894 4.88941572 4.515874 4.292256 5.1456642 4.789581 4.468347 5.417788 
4.403121 4.802773725 4.69071388 2.868056 3.257679 3.9051123 4.193125 4.252853 4.860029 
5.238046 5.26245109 5.68849706 4.457882 4.578639 5.1336551 4.672098 4.414973 5.137189 
4.149219 4.891537458 4.67433833 4.346353 4.332438 4.813251 4.511883 4.428135 5.053399 
0.735599 0.086359831 0 3.764923 4.025306 4.46417 3.365488 3.260071 3.810311 
3.320146 3.247973266 3.87047123 4.012837 4.178977 4.6395273 1.878522 1.89487 2.552249 
4.082785 4.365487985 4.41004945 3.403121 3.212188 4.1168251 4.161368 4.117271 4.911182 
0 0.181843588 1.31190467 4.082785 4.334454 4.6424051 3.49276 3.475671 3.856794 
5.130334 5.387389826 5.52867222 3.879096 3.727541 4.5409021 4.587711 4.596597 5.483416 
4.677607 5.507855872 4.84309867 3.864511 4.374748 4.8789172 4.389166 4.754348 4.488174 
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0.00 3.65 6.53 0.6 0.41 0.6 1.02 14.29058 
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0.54 4.95 7.84 1.14 0.34 1.01 0.54 26.00272 
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0.00 7.35 94.13 0 0 0 0.13 14.43578 
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                                                            Patient Information Sheet 
1. Study Title 
Indicators of Prostate disease. 
      
2. Invitation Paragraph 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
For further advice you may contact Patient advice and liaison services 
(PALS) and Independent Complaints Advocacy Services (ICAS) through 
your local hospital or by phoning NHS direct line: 08454647 or by visiting their 
website: http://www.pals.nhs.uk/ .  Contact details for ICAS: telephone 
08454561082, e-mail: dhmail@dh.gsi.gov.uk; fax : 02072105454 or write : 
Veronica Fraser, Head of Complaints and Public Enquires & Customer 
Service Centre, Department of Health, Richmond House, 79 Whitehall, 
London, SW1A 2NS. You can seek further advice from INVOLVE by visiting 
their website: http://www.invo.org.uk 
 
3. What is the purpose of the study? 
The natural course of prostate disease is unpredictable. Some people have 
prostate problems but without any signs and symptoms. Others show 
symptoms. However, prostate diseases can progress from one stage to the 
other without noticeable symptoms. There are little or no factors to 
discriminate between ‘good’ and ‘bad’ prostate disease.  This study examines 
the expression of several types of disease markers (indicators) which are 
involved in prostate disease development and progression. Knowledge of 
these indicators will help improve diagnosis and treatment of prostate 
diseases. Those who have raised PSA and or enlarged prostate, which are 
indicators of prostate problem are invited to participate in this study. 
4. Why have I been chosen? 
 
As you are aware, your clinician has informed you that a biopsy is going to be 
taken from your prostate as you have been shown to have a raised PSA and / 
or an enlarged prostate. If you consent to taking part, urine and blood samples 
will be collected before your biopsy. Once your biopsy has been examined, 
any remaining tissue will be allocated to the study. 
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5. Do I have to take part? 
 
It is up to you to decide whether or not you wish to take part. If you decide to 
take part, you are still free to withdraw at any time without any reason. This 
will not affect the standard of care you receive. 
 
6. What happens to me if I take part? 
 
If you decide to take part, you will be asked to sign a consent form for this 
study. Before your biopsy is taken, you will be asked to give a urine sample 
and a blood sample will also be collected by the hospital phlebotomist. When 
the biopsy has been looked at for your diagnosis, part of the remaining tissue 
will be allocated for this study. 
 
7. What do I have to do? 
 
We ask you to carefully read this information and take your time in deciding if 
you want to be part of this study. If you agree to take part, you’ll be asked to 
sign a consent form and give a urine sample and a blood sample. When the 
routine biopsy is taken the normal procedure is performed and part of any 
remaining tissue is allocated for this study. 
 
8. What is the drug or procedure that is being tested? 
No drug or procedure is being tested. 
 
9. What are side effects of taking part? 
 
There are no risks associated with collection of urine and blood samples. The 
biopsy has no additional side effects apart from those normally associated 
with the clinical care operation. 
10.  What are the possible disadvantages and risks of taking part? 
There are no possible disadvantages or risks associated with taking part in this 
study. 
11. What are the possible benefits of taking part? 
There is no direct benefit to you but this study may help improve diagnosis 
and future treatment of prostate disease. However, results of this study will be 
made available to you through your Clinician in the Bedford Hospital. 
 
12. What happens when the research study stops? 
All tissue allocated for this study will be destroyed and the results will form the 
bases of a scientific thesis and may generate scientific publications. 
 
13. What if something goes wrong? 
 Molecular Profiling of Prostate Cancer Patients. PhD thesis E.O. Nna, Cranfield University. 
 
286 
If you are harmed by taking part in this research, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain about any aspects of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanism may be available to you. 
 
14. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot 
be recognised. All samples will be analysed anonymously. 
 
15. Who is organising and funding the research? 
The research is being organised and funded by Cranfield University. 
 
16. Who have reviewed the study? 
 Cranfield health local ethics committee, Bedford Hospital NHS trust research 
and development unit and Hertfordshire research ethics committee  
17. Contact for further information:  
Dr. M Wasil 
 Department of Research and Development 
Bedford Hospital, Kempston Road, 
Bedford, MK42 9DJ. 
Tel: 01234 355122 Ext. 5855 
Mohammad.Wasil@bedfordhospital.nhs.uk                                                                                      
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 Outline of methodology and Subject materials. 
STUDY PROTOCOL:  Hormonal modulation of putative tumour markers in Prostate cancer and microarray 
based sensor for prostate cancer diagnosis. 
Twelve different tumour markers are under investigation in this study. These are androgen receptor (AR), 
oestrogen receptors(ER-α, ER-β1 and ER-β2); minichromosome maintenance proteins (MCM 2 and MCM 5); p53 
and Bcl-2, prostate specific kallikreins (PSA and hK2); E-cadherin and CD44.   
Sample Collection: 100 patients will be involved. Patients who have endorsed the consent form will be asked to 
give blood and urine samples. 10ml of venous blood will be collected into a plain tube (without anticoagulant) from 
each patient by a nurse. The patient will be given a sterile universal container to void 20ml of urine. Both urine 
and blood samples will be collected in the Urologic clinic before prostate biopsy. The consultant Urologist (Dr H 
Sharma) will collect the prostate biopsies as part of normal patient clinical care. The biopsies are usually sent to 
Histopathology laboratory. Surplus tissue will be assigned to this study.30mg of each surplus tissue will be placed 
into a 2ml sterile eppendorf tube for RNA extraction. Power analysis for sample size was done using both 
NCSS/PASS 2000 software and Origins Lab 2007 software. Each sample will be assigned a serial number in a 
log book. And from each formalin fixed paraffin embedded block (prepared by the histopathology laboratory), 12 
slides of 4µm thick section per slide will be cut and labelled at the histopathology laboratory. Tissue blocks that do 
not have enough tissue to be kept in the archive after sample collection will be excluded. The slides, urine, blood 
and tissue in eppendorf tubes will be transported to Cranfield University molecular biology laboratory for analysis. 
See the chart on page three. 
 
 
 
Analysis: 12 slides from each tissue block will be used for immunohistochemistry to assess protein expression for 
each marker. 30mg tissue in the 2ml eppendorf tube (containing RNA stabilizing buffer) will be used for total RNA 
isolation using RNeasy Mini kit (QIAGEN, UK).Isolated RNA will be used for cDNA  synthesis using AMV first –
strand cDNA synthesis kit (Invitrogen, UK). Real time quantitative Polymerase chain reaction (PCR) will be 
performed using ABI sequence detection system (7900HT model), using TaqMan primer and probe sets as well 
as SYBER green 1 kits to assess gene expression of selected markers. Urine samples will be spurn, decanted 
into 20ml headspace vial and capped, and exfoliated cell sediments collected for RNA extraction using same 
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technique for the 30mg tissue sample. The decanted urine will be analysed using headspace sampling GC-MS for 
metabolic volatiles. Clotted 10ml blood samples will be spurn and serum harvested. The serum will be tested for 
PSA and h K2 using both microarray based sensor and Enzyme linked immunosorbent assay (ELISA). 
Results: Results from laboratory assays will be statistically analysed and used in writing up PhD thesis and will 
also be published in peer-reviewed journal. 
Anonymity: No patient-identifiable information is required at any stage of this work. No genetic testing will be 
done. The log book for sample collection and results of laboratory analysis will be stored in a pass word protected 
computer.                                    Sample Collection and Analysis flow chart. 
  Consented Patient 
                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood (10ml) 
10ml 
Urine spurn, decanted into 
vials and cell sediments 
collected 
Cell sediments 
Spurn and serum 
collected 
Tissue-30mg in 2ml tube 
(with RNA buffer) & 12 Slides 
from Histopathology lab 
 
Microarray 
sensor 
RNA extraction using 
Rneasy mini kit 
12 slides for 
IHC of markers 
RNA quality check 
20ml urine 
ELISA: PSA, h 
K2 
Decanted Urine for GC-
MS 
c DNA synthesis 
using AMV-first 
strand synthesis 
kit 
Real time quantitative PCR 
for KLK3, KLK2, ERα, ERβ, 
GUS, ABL, MCM2, MCM5, 
AR, p53, BCL-2; CD44 & E-
cadherin. 
Metabolic profiling 
Statistical analysis, including other data such as patients’ age, Gleason score 
and TNM staging. Correlation of tumour markers with disease progression. 
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Centre: Bedford Hospital NHS trust 
REC Reference Number: 08/H0311/90 
Patient identification Number for this study:........................ 
    
 
         CONSENT FORM 
 
Title of Project: Hormonal modulation of putative markers in prostate cancer and 
microarray based sensor for prostate cancer diagnosis. 
 
Name of Researchers: Emmanuel Nna & Yildiz Uludaq. 
 
                                                                                                                             (Please initial 
box) 
1. I confirm that I have read and understood the information sheet dated 12/06/08, 
version 01/08 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from Cranfield 
University, from regulatory authorities or from NHS trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have access to 
my records. 
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree to take part in the above study. 
 
................................                        .........................            ........................................... 
Name of patient                                 Date                              Signature 
 
 
.............................                         ..............................          .......................................... 
Researcher   Date   Signature 
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Letter of invitation 
 
 
 
Dear Participant, 
 
We invite you to participate in a study on prostate disease. This study looks at some indicators of 
prostate disease development and progression. Our aim for the study is to examine the link between 
the development of prostate disease and the production of these indicators, also known as disease 
markers. Results from this study may help improve diagnosis, treatment and management of prostate 
disease in the future. 
As you are aware, your clinician has informed you that a biopsy is going to be taken from your 
prostate as you have been shown to have a raised PSA and / or an enlarged prostate. The biopsy is 
part of your clinical care and will be used by the hospital laboratory to find out if you have prostate 
problem. The left over tissue will be used for this study. If you consent to taking part, urine and blood 
samples will be collected from you before your biopsy. 
 
More details of this study and your participation are contained in an information sheet also given to 
you. Please take time to read the information carefully and discuss with friends, relatives and your GP 
if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part. There is a letter for your GP, informing him or her 
about your participation in this study. Please kindly give the letter to you GP. Summary of results from 
this study will be made available to you and your GP. 
You are also given a consent form. If you decide to take part in this study, you will be asked to sign a 
consent form for this study. Before the Urologist takes your biopsy, you will be asked to give a urine 
sample and a blood sample, which will be collected by a nurse. 
We thank you for taking time to read this. 
 
Yours Sincerely, 
 
Emmanuel Nna                              
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Lettter to General Practioner 
 
 
            
                                                                               Cranfield Health 
           Building 52, 
            
                                                                                         Cranfield University 
  Bedfordshire, 
  MK43 0AL. 
          15-08-08. 
Dear GP, 
 
Hertfordshire REC Reference Number: 08/H0311/90 
 
Study Title:  Indicators of Prostate Disease 
 
Your patient, MR…………………… …… is invited to participate in a study on ‘indicators of prostate 
disease’. The study examines disease markers that can be used to identify ‘bad’ prostate disease. As 
you are aware, your patient has raised serum PSA level and or enlarged prostate gland and has been 
scheduled to undergo prostate biopsy. If he consents to this study, blood and urine samples will be 
collected from him before clinical biopsy. 
Find enclosed a copy of patient information sheet, patient invitation letter and consent form, which are 
also given to your patient. 
Results of this study will be made available to you and your patient through the collaborating clinician 
at the Bedford hospital (Dr.H Sharma). The results of this research will also be used in writing a PhD 
thesis, which will be published on line in the Cranfield University website: www.cranfield.ac.uk   
If you have any concern, please do not hesitate to contact me on phone: 01234 75 5561 or e-mail: 
e.o.nna.s05@cranfield.ac.uk . 
Yours Sincerely, 
Emmanuel Nna   
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